<rows>
  <row term_id="302006" id="349595" title="Laufey Amundadottir Ph.D. " langcode="en" field_short_title="Laufey Amundadottir Ph.D. " field_page_description="Laufey Amundadottir Ph.D., biographical sketch and research interests" field_feature_card_description="Laufey Amundadottir Ph.D., biographical sketch and research interests" field_list_description="Laufey Amundadottir Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-05-02" field_pretty_url="amundadottir-laufey" field_browser_title="Laufey Amundadottir Ph.D., biographical sketch and research interests" field_card_title="Laufey Amundadottir Ph.D. " field_email_address="amundadottirl@mail.nih.gov" field_first_name="Laufey" field_last_name="Amundadottir" field_phone_number="240-760-6454" field_org_name_1="National Cancer Institute" field_org_name_2="Laboratory of Translational Genomics" field_campus="301" field_office_location="ATC Room 134E">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=amundadottir%20l&amp;authorOption=exact&amp;pi=0013594683">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=290&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302640#Amundadottir-Lab" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302640" sys_dependentvariantid="1418" sys_relationshipid="7329921" sys_folderid="" sys_variantid="1418" sys_contentid="302640#amundadottir-lab">Amundadottir Lab Members</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" sys_contentid="302432" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422" sys_relationshipid="7329909">Laboratory of Translational Genomics</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Amundadottir received a Ph.D. in cell biology in 1995 from Georgetown University in Washington, D.C. She conducted her postdoctoral training with Dr. Phil Leder in the Department of Genetics at Harvard Medical School in Boston, Massachusetts, then joined deCODE Genetics in Iceland in 1998 as the head of the Division of Cancer Genetics, where she led genome-wide linkage and association efforts in various cancers. Dr. Amundadottir joined the NCI in 2007 as a senior scientist and became a tenure-track investigator in the Laboratory of Translational Genomics in 2008. She was awarded scientific tenure by the NIH and promoted to senior investigator in 2017. Her work focuses on genome-wide association studies (GWAS) and other gene mapping approaches to identify germline variants associated with risk of pancreatic cancer and the functional approaches required to understand the biological mechanisms by which they influence risk of pancreatic cancer.</p>
<h2 id="research">Research Interests</h2>
<p class="first-graf">Major advances have occurred in the last few years in our understanding of the genetics of common diseases. Genome-wide association studies, which assess hundreds of thousands of single nucleotide polymorphisms (SNPs) in large cohort and case-control studies, have provided new insights into the inherited factors that contribute to risk of developing cancer. These efforts have led to the discovery of thousands of chromosomal loci that significantly associate with one or more complex diseases or traits, including cancer. However, for most of the identified loci, the elucidation of the functional basis underlying disease risk is in the very early stages. This interface between gene mapping approaches and the function of risk variants is of special interest to my laboratory.</p>
<h4>Gene Mapping in Pancreatic Cancer</h4>
<p class="first-graf">Dr. Amundadottir co-leads PanScan, a GWAS of pancreatic cancer conducted within the framework of the NCI-sponsored Cohort Consortium. Collaborative efforts are conducted&nbsp;with the Pancreatic Cancer Case Control Consortium (PanC4), the PANcreatic Disease ReseArch (PANDoRA) consortium, the European Study on Pancreatic Cancer Genetics and Epidemology (PanGen-EU), and Chinese and Japanese pancreatic cancer GWAS efforts. The aim of these large international studies is to identify genetic factors that contribute to the risk of pancreatic cancer. Four GWAS phases have already been performed in close to 12,000 case and 17,000 control subjects from over 30 cohort and case-control studies from the U.S., Europe and Asia. This work has resulted in the discovery of fourteen common susceptibility loci for pancreatic cancer on chromosomes 1q32.1 (<i>NR5A2, </i>two independent loci), 2p14 (<i>ETAA1</i>), 3q28 (<i>TP63</i>), 5p15.33 (three independent risk loci in the <i>TERT-CLPTM1L</i> region), 7p14.1 (<i>SUGCT</i>), 7q23.2 (<i>LINC-PINT</i>), 8q24.1 (<em>MYC/PVT1</em> region, two independent loci), 9q34.2 (<i>ABO</i>), 13q12.2 (<i>PDX1</i>), 13q22.1 (nongenic), 16q23.1 (<i>BCAR1/CTRB1/CTRB2</i>), 17q24.3 (<i>LINC00673</i>) and 22q12.1 (<i>ZNRF3</i>). Further GWAS phases, as well as studies that aim at uncovering less common and rare pancreatic cancer risk variants, are underway.</p>
<h4>Functional Characterization of Pancreatic Cancer Risk Loci</h4>
<p>My laboratory conducts fine-mapping of risk loci identified in PanScan and collaborative gene mapping efforts, as well as wet-lab studies to uncover functional variants at each locus and understand the mechanism by which they influence risk of pancreatic cancer. This work involves genomic and epigenomic approaches, with a focus on genome-wide expression quantitative trait locus (eQTL) analyses to investigate the genetics of gene expression in normal and tumor derived pancreatic tissue samples and correlate to pancreatic cancer risk alleles as well as Transcriptome Wide Association Studies (TWAS) for gene mapping. These transcriptome and epigenome datasets are&nbsp;generated in our laboratory and supplemented with&nbsp;publicly available datasets. Furthermore, my laboratory focuses on targeted functional analyses in specific pancreatic cancer susceptibility loci. This work includes analysis of gene expression in the vicinity of risk variants, investigation of transcriptional regulation and gene/protein function with the aim of connecting pancreatic cancer risk variants to target genes and molecular phenotypes to explain the underlying biology of the risk at each locus.</p>
<h4>Consortia</h4>
<p>Co-Leader of <a href="http://epi.grants.cancer.gov/PanScan/">PanScan</a></p>
<p><a href="#top">Back to Top</a></p>
</div>
</div>]]></body>
    <field_image_promotional>349595</field_image_promotional>
  </row>
  <row term_id="302006" id="349632" title="Jay H. Lubin, Ph.D." langcode="en" field_short_title="Jay H. Lubin, Ph.D." field_page_description="Jay H. Lubin, Ph.D., biographical sketch and research interests" field_feature_card_description="Jay H. Lubin, Ph.D., biographical sketch and research interests" field_list_description="Jay H. Lubin, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2017-07-19" field_pretty_url="lubin-jay" field_browser_title="Jay H. Lubin, Ph.D., biographical sketch and research interests" field_card_title="Jay H. Lubin, Ph.D." field_email_address="lubinj@mail.nih.gov" field_first_name="Jay" field_last_name="Lubin" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=lubin%20j&amp;authorOption=exact&amp;pi=0010141428">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_relationshipid="7252454" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Lubin received a Ph.D. in biostatistics from the University of Washington. He joined the NCI as a Staff Fellow in 1978. Dr. Lubin received the PHS Special Recognition Award in 1993, and was elected a Fellow of the American Statistical Association in 1994. He has served on numerous expert committees of the National Academy of Sciences and the National Council for Radiation Protection and Measurements. In 1999, Dr. Lubin was selected DCEG Mentor of the Year by the training fellows in the Division, and in 2005 was given the DCEG Exemplary Service Award for his outstanding contributions to biostatistics, radiation epidemiology, statistical software development, mentoring, and national and international advisory committees. He retired from government service in 2011, continuing his work as a volunteer. Dr. Lubin was named Scientist Emeritus in 2012.</p>
<h2 class="first-graf">Research Interests</h2>
<p>Throughout his career, Dr. Jay Lubin has applied his expertise in the development of statistical methods for designing and analyzing complex epidemiologic studies. In particular, he was a driving force in a series of seminal investigations that have elucidated the effects of tobacco, radon, arsenic, pesticides, and other environmental exposures on the incidence of lung cancer and other malignancies such as thyroid cancer and leukemia. His impact on statistical and epidemiological research has led to significant advances in cancer risk assessment, public health, and public policy.</p>
</div>
</div>]]></body>
    <field_image_promotional>349632</field_image_promotional>
  </row>
  <row term_id="302006" id="349644" title="Nathaniel Rothman, M.D., M.P.H., M.H.S. " langcode="en" field_short_title="Nathaniel Rothman, M.D., M.P.H., M.H.S. " field_page_description="Nathaniel Rothman, M.D., M.P.H., M.H.S., biographical sketch and research interests " field_feature_card_description="Nathaniel Rothman, M.D., M.P.H., M.H.S., biographical sketch and research interests " field_list_description="Nathaniel Rothman, M.D., M.P.H., M.H.S., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-01-30" field_pretty_url="rothman-nathaniel" field_browser_title="Nathaniel Rothman, M.D., M.P.H., M.H.S., biographical sketch and research interests " field_card_title="Nathaniel Rothman, M.D., M.P.H., M.H.S. " field_email_address="rothmann@mail.nih.gov" field_first_name="Nathaniel" field_last_name="Rothman" field_phone_number="240-276-7169" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E134">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=rothman%20n&amp;authorOption=exact&amp;pi=0010040355">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7252623" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="biography"><a id="Biography"></a>Biography</h2>
<p class="first-graf">Dr. Rothman received an A.B. in biochemistry and molecular biology at Harvard College and a M.D. at Northwestern University. At the Johns Hopkins University, he received training in internal medicine, occupational and environmental medicine, and epidemiology. Dr. Rothman joined the NCI in 1990. His research focuses on using biologic markers of exposure, early biologic effect, and genetic susceptibility in epidemiologic studies of occupational and environmental causes of cancer. He is the author of more than 700 publications.</p>
<h2 id="research"><a id="Research-Interests"></a>Research Interests</h2>
<h3>Molecular Epidemiology Studies of Occupational and Environmental Causes of Cancer</h3>
<p>Dr. Rothman and colleagues use biomarkers of exposure, early biologic effect, genetic susceptibility, and disease to investigate the carcinogenic potential and mechanism of action of proven or suspected occupational and environmental compounds; to evaluate the influence of inter-individual variation in metabolism on the formation of important early biologic markers, such as cytogenetic aberrations and immunologic alterations; and to assess the risk of premalignant conditions and cancer associated with exposure to occupational and environmental agents. They apply state-of-the-art genomics technologies in their studies including epigenetics, transcriptomics, proteomics, metabolomics and whole genome sequencing, and conduct genome-wide association studies (GWAS).</p>
<h3>Benzene and Other Workplace Chemical Exposures</h3>
<p>Benzene is an established human leukemogen, and it may also cause non-Hodgkin lymphoma and other cancers. However, its mechanism of action is uncertain, and its ability to cause cancer at low levels of exposure is unknown. Dr. Rothman carried out a study of healthy workers exposed to high levels of benzene in China to identify mechanistically-based biomarkers that reflect early biologic effects of benzene. They observed an increased frequency of cytogenetic and genetic alterations in peripheral white blood cells (e.g., t8;21, del(5q), del(7q), AML 1/ETO fused transcript). These markers are relevant for leukemia and support the hypothesis that benzene's mechanism of action is mediated through chromosomal damage. An important unanswered question concerns the biologic effect of low exposure levels in the occupational setting and from environmental sources experienced by the general population. In a follow up study, he and his colleagues have applied sensitive, targeted and broad agnostic panels of biomarkers to study the biologic effects of relatively low-level exposure to benzene and reported associations with cytogenetic alterations in cultured myeloid progenitor cells, hematotoxicity, and mRNA changes. Dr. Rothman and colleagues have conducted similarly designed cross-sectional molecular epidemiology studies in healthy workers exposed to TCE and formaldehyde. They are also evaluating the relationship between benzene and myeloid and lymphoid tumors in a large retrospective cohort study in China, two prospective studies in Shanghai, and a large-scale hospital-based case-control study of lymphoid and myeloid neoplasms among Chinese in East Asia (AsiaLymph). In addition, they are evaluating genetic susceptibility for benzene hematotoxicity, lymphoid malignancies in the InterLymph Consortium, and lymphoid and myeloid neoplasms in the AsiaLymph study.</p>
<h3>Aromatic Amines</h3>
<p>Dr. Rothman and colleagues found that among workers in India exposed to the aromatic diamine benzidine, N acetylated benzidine was the predominant DNA adduct in exfoliated urothelial cells. This finding documented that acetylation activates rather than detoxifies benzidine in humans, in contrast to the deactivation role of acetylation for aromatic monoamines, such as 4 aminobiphenyl. He also showed that urine pH, which is influenced primarily by the diet, had a profound influence on DNA adducts levels. This finding is consistent with previous in vitro results that acidic urine hydrolyzes glucuronidated aromatic amines, which enables free compounds to bind DNA. This research indicates that gene-environment interactions can be highly exposure specific, and that nongenetic sources of susceptibility may interact with xenobiotic exposures and play an important role in determining an individual's cancer risk. He has pursued these findings in two large case-control studies of bladder cancer, one in Spain and one in Northern New England, as well as in a large-scale GWAS of bladder cancer and nested case-control studies of white blood cell epigenetic alterations and bladder cancer.</p>
<h3>Organochlorines</h3>
<p class="first-graf">The reasons for the steady increase in the incidence of non-Hodgkin lymphoma since the late 1940s remain mostly unknown. To evaluate exposure to organochlorines (OC), which are ubiquitous environmental contaminants and suspected human carcinogens, on the risk of non-Hodgkin lymphoma, Dr. Rothman has conducted three nested case-control studies of prospective cohorts &ndash; in Maryland, Norway, and Eastern Asia. He reported that that PCB levels were associated with subsequent risk of non-Hodgkin lymphoma in the first two studies, which had study subjects with relatively high levels of PCBs. He has also found suggestive evidence that other OCs may be associated with risk of NHL as well. Dr. Rothman and his colleagues are following up these findings in a large-scale study of NHL in Asia that will be able to study NHL subtype-specific OC effects.</p>
<h3>Polycyclic Aromatic Hydrocarbons (PAHs), Nitro-PAHs, and Other Related Chemical Species</h3>
<p>Dr. Rothman and colleagues are investigating the role of PAHs, nitro-PAHs, and related compounds in studies of populations exposed to a variety of combustion-derived particulates including coal, diesel exhaust, and carbon black. They are using cross-sectional molecular epidemiology studies of healthy populations with occupational or environmental exposures to these compounds to provide mechanistic insight. They are also using case-control and nested case-control studies to directly evaluate the carcinogenicity of these compounds using questionnaires linked to extensive exposure databases and biological monitoring in prospective studies.</p>
</div>
</div>]]></body>
    <field_image_promotional>349644</field_image_promotional>
  </row>
  <row term_id="302006" id="349653" title="Wen-Yi Huang, Ph.D., M.S.P.H." langcode="en" field_short_title="Wen-Yi Huang, Ph.D., M.S.P.H." field_page_description="Wen-Yi Huang, Ph.D., M.S.P.H., biographical sketch and research interests " field_feature_card_description="Wen-Yi Huang, Ph.D., M.S.P.H., biographical sketch and research interests " field_list_description="Wen-Yi Huang, Ph.D., M.S.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2015-07-20" field_pretty_url="huang-wen-yi" field_browser_title="Wen-Yi Huang, Ph.D., M.S.P.H., biographical sketch and research interests " field_card_title="Wen-Yi Huang, Ph.D., M.S.P.H." field_email_address="huangw@mail.nih.gov" field_first_name="Wen-Yi" field_last_name="Huang" field_phone_number="240-276-7277" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E606">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=huang+wy&amp;authorOption=exact&amp;pi=%200010846558">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7252761" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Huang received a Ph.D. in epidemiology from the University of North Carolina at Chapel Hill in 1998, with concentrations on gene-environment interactions and etiologic heterogeneity of breast cancer, defined by molecular markers. She completed two years of postdoctoral research in the Epidemiology Department at Glaxo Wellcome, and joined NCI as a staff scientist in DCEG in 2000. Since joining NCI, Dr. Huang has received the NCI DCEG Award for Outstanding Research Paper by a Staff Scientist in 2003, the NIH Award of Merit in 2014, and the NCI DCEG Distinguished Scientific Service Award in 2018.</p>
<h2 id="research">Research Interests</h2>
<p>Dr. Huang provides scientific consultations for nationwide research on cancer etiology and early markers in the NCI Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; she attends steering, review, and management meetings for the Trial and participates in cohort consortium and data pooling efforts. As a cancer epidemiologist, her studies focus on cancer risk related to genetic, epigenetic, and other molecular markers in DNA repair, metabolic, infection, and inflammation pathways, with primary interests on colorectal and prostate tumors.</p>
</div>
</div>]]></body>
    <field_image_promotional>349653</field_image_promotional>
  </row>
  <row term_id="302006" id="349667" title="Anil Chaturvedi, Ph.D." langcode="en" field_short_title="Anil Chaturvedi, Ph.D." field_page_description="Anil Chaturvedi, Ph.D., biographical sketch and research interests" field_feature_card_description="Anil Chaturvedi, Ph.D., biographical sketch and research interests" field_list_description="Anil Chaturvedi, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="chaturvedi-anil" field_browser_title="Anil Chaturvedi, Ph.D., biographical sketch and research interests" field_card_title="Anil Chaturvedi, Ph.D." field_email_address="chaturva@mail.nih.gov" field_first_name="Anil" field_last_name="Chaturvedi" field_phone_number="240-276-7193" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E238">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Chaturvedi+ak&amp;authorOption=exact&amp;pi=0012075327">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_dependentvariantid="1422" sys_dependentid="302430" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276768" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2>Biography</h2>
<p>Dr. Chaturvedi earned a degree in veterinary medicine (1999) from the Andhra Pradesh Agricultural University, India and an M.P.H. (2002) and Ph.D. (2004) in epidemiology from Tulane University. He joined IIB as a postdoctoral fellow in 2005, became a research fellow in 2007, was appointed as a tenure-track investigator in 2009, and was awarded scientific tenure and promoted to senior investigator in November 2016. He joined the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1041183" sys_dependentvariantid="1418" sys_dependentid="1041183" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276769" sys_variantid="1418" sys_contentid="1041183">Clinical Epidemiology Unit</a> of the Clinical Genetics Branch in 2017.</p>
<h2 id="research">Research Interests</h2>
<p>Dr. Chaturvedi studies the molecular epidemiology of two common cancers&mdash;head and neck cancers and lung cancers. His work addresses research questions on etiology and natural history that have high potential for translation into efforts for screening and early detection of head and neck cancers and lung cancers.</p>
<h3>Head and Neck Cancers</h3>
<p>Head and neck cancers encompass cancers at several anatomic sites, including:</p>
<ul>
<li>Oral cavity (lip, oral tongue, gum, floor of mouth, hard palate, and buccal mucosa and other parts of the mouth)</li>
<li>Oropharynx (base of tongue, tonsil, soft palate and uvula, pharyngeal wall, and Waldeyer ring)</li>
<li>Other parts of the pharynx (nasopharynx and hypopharynx)</li>
<li>Larynx</li>
</ul>
<p>Head and neck cancer overall is the eighth most common cancer worldwide, with an estimated annual burden of 686,000 incident cases and 376,000 deaths. Tobacco in the form of smoking and chewing, betel-quid chewing, and alcohol use are established risk factors for all head and neck cancer subsites. Other emerging risk factors for head and neck cancer include poor oral hygiene and low fruit and vegetable consumption. Importantly, research over the past 15 years has identified HPV infection as an etiologic agent for oropharyngeal cancers. It is currently believed that oral cavity and larynx cancers are rarely (&lt;5%) caused by HPV infection.</p>
<p>Given the recent recognition of HPV&rsquo;s etiologic role in oropharyngeal cancer, Dr. Chaturvedi&rsquo;s work addresses the epidemiology of HPV-positive oropharyngeal cancer as well as the epidemiology and natural history of oral HPV infections. He also studies the unique anatomic, histopathologic, and molecular characteristics of HPV-positive oropharyngeal cancers to understand the reasons underlying the vastly improved survival outcomes for these patients. He addresses these questions through population-based studies in the U.S.</p>
<p>Cancers of the oral cavity are ideal candidates for early detection and secondary prevention given the amenability for visual inspection and specimen collection and the availability of recognized precursor lesions, defined clinically and histologically. Yet, there are currently no guidelines for screening, treatment, or follow-up of patients with oral cancer precursor lesions due to several gaps in the current knowledge base. Dr. Chaturvedi is using a combination of retrospective and prospective cohort studies to address key questions pertaining to the natural history of oral cancer precursor lesions, epidemiologic and molecular predictors of progression of precursor lesions to cancer, methods for screening of oral cancer precursors, and the development of oral cancer risk stratification tools.</p>
<h3>Lung Cancers</h3>
<p>Lung cancer is the most common cancer, with an estimated 1.6 million annual incident cases worldwide and 230,000 cases in the United States. Cigarette smoking is the predominant risk factor for lung cancer, accounting for 80-90% of all lung cancers. Yet, smoking is neither necessary nor sufficient for lung cancer, underscoring the role of additional factors in lung carcinogenesis.</p>
<p>Dr. Chaturvedi studies the role of chronic inflammation in the etiology of lung cancer, through the identification of the inflammation mediators and pathways involved in lung carcinogenesis. He also studies the association of chronic inflammation with smoking, the primary lung cancer risk factor, to identify smoking-dependent and smoking-independent components of inflammation involved in lung carcinogenesis. Much of this work is conducted through the measurement of circulating immune/inflammation marker levels in case-control studies nested within large prospective cohorts.</p>
<p>Dr. Chaturvedi also conducts research on the development, validation, and application of lung cancer risk stratification tools, in collaboration with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349618" inlinetype="rxhyperlink" sys_relationshipid="7276766" sys_siteid="475" rxinlineslot="103" sys_dependentid="349618" sys_dependentvariantid="1965" sys_variantid="1965" sys_contentid="349618">Dr. Hormuzd Katki</a>. In 2011, the landmark National Lung Screening Trial (NLST) showed that, compared with chest radiography, three annual screens with low-dose computed tomography (LDCT) resulted in a 20% reduction in lung cancer mortality among 55-74 year-old smokers with at least 30 pack-years of smoking and no more than 15 years since quitting smoking. Based on these results, LDCT screening is currently recommended for smokers that meet the NLST entry criteria. In the U.S., there are currently 9 million smokers who meet the recommendations for LDCT screening, 20 million smokers in the recommended age range (55-80 years), and 94 million ever smokers of all ages. Given these numbers, as well as the costs and potential harms of LDCT screening, there is a growing recognition in the field to target screening to the highest risk smokers.</p>
<p>Dr. Chaturvedi conducts research on the potential utility of lung cancer risk prediction tools to improve the population-level effectiveness of LDCT screening in the United States. He specifically addresses questions regarding which smokers should be targeted for LDCT screening and how screen-positive individuals should be clinically managed. Additionally, he studies minimally invasive lung cancer biomarkers for improved risk stratification.</p>
</div>
</div>]]></body>
    <field_image_promotional>349667</field_image_promotional>
  </row>
  <row term_id="302006" id="349670" title="Sanford M. Dawsey, M.D. Biography" langcode="en" field_short_title="Sanford M. Dawsey, M.D. Biography" field_page_description="Sanford M. Dawsey, M.D., biographical sketch and research interests " field_feature_card_description="Sanford M. Dawsey, M.D., biographical sketch and research interests " field_list_description="Sanford M. Dawsey, M.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-23" field_pretty_url="dawsey-sanford" field_browser_title="Sanford M. Dawsey, M.D., biographical sketch and research interests " field_card_title="Sanford M. Dawsey, M.D. Biography" field_email_address="dawseys@mail.nih.gov" field_first_name="Sanford" field_last_name="Dawsey" field_phone_number="240-276-7194" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E302">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=dawsey%20s&amp;authorOption=exact&amp;pi=%200010131853">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_relationshipid="7252747" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422">Metabolic Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Dawsey received his M.D. degree from Stanford Medical School in 1976, completed his residency in pathology at the University of Colorado in 1981, and completed a fellowship in cytology at the University of California, Los Angeles, in 1987. He served as a staff pathologist at the McCormick Hospital in Chiang Mai, Thailand from 1982 to 1984 and at Saint Joseph Hospital in Denver, Colorado from 1984 to 1986.&nbsp;Dr. Dawsey&nbsp;joined NCI in 1987 and received tenure in 1995. He joined DCEG in 2005, and serves as a senior investigator in the Metabolic Epidemiology Branch. In 2011, Dr. Dawsey received the NIH Ruth L. Kirschstein Mentoring Award for "exemplary performance while demonstrating significant leadership, skill, and ability in serving as a mentor." In 2018, he received the 2018 DCEG Exemplary Service Award in honor of his outstanding research on esophageal and gastric cancer.&nbsp;</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Prevention and control of esophageal and gastric cancers</li>
<li>Etiologic studies of esophageal and gastric cancers, especially in high-risk populations</li>
<li>Developing clinically useful techniques for the early detection and treatment of esophageal and gastric cancers</li>
<li>Member of the <a href="http://dceg.cancer.gov/neb/research/ugcrg">DCEG Upper Gastrointestinal Cancers Research Group</a></li>
<li>Member of the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1090903" sys_contentid="1090903" inlinetype="rxhyperlink" sys_relationshipid="7252748" sys_dependentvariantid="1418" sys_dependentid="1090903" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">African Esophageal Cancer Consortium (AfrECC)</a></li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349670</field_image_promotional>
  </row>
  <row term_id="302006" id="349673" title="Lee Moore, Ph.D., M.P.H. " langcode="en" field_short_title="Lee Moore, Ph.D., M.P.H. " field_page_description="Lee Moore, Ph.D., M.P.H., biographical sketch and research interests" field_feature_card_description="Lee Moore, Ph.D., M.P.H., biographical sketch and research interests" field_list_description="Lee Moore, Ph.D., M.P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-06" field_pretty_url="moore-lee" field_browser_title="Lee Moore, Ph.D., M.P.H., biographical sketch and research interests" field_card_title="Lee Moore, Ph.D., M.P.H. " field_email_address="moorele@mail.nih.gov" field_first_name="Lee" field_last_name="Moore" field_phone_number="240-276-7281" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E614">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=moore%20l&amp;authorOption=exact&amp;pi=0011068308">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7252606">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Moore received a Ph.D. in environmental health science and an M.P.H. in industrial hygiene from the University of California at Berkeley. She completed postdoctoral studies at the University of California San Francisco's Cancer Center, joined the NCI as a tenure-track investigator in the Occupational and Environmental Epidemiology Branch in 2001, and became a staff scientist in 2011. Dr. Moore provides scientific support to OEEB molecular epidemiology studies.</p>
<h2>Research Interests</h2>
<ul>
<li>Molecular epidemiology and cancer risk</li>
<li>Molecular epidemiology of environmental arsenic exposure</li>
<li>Molecular epidemiology of renal cell carcinoma</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349673</field_image_promotional>
  </row>
  <row term_id="302006" id="349676" title="Sam Mbulaiteye, M.D. Biography" langcode="en" field_short_title="Sam Mbulaiteye, M.D. Biography" field_page_description="Sam Mbulaiteye, MBChB, M.Phil., M.Med., biographical sketch and research interests " field_feature_card_description="Sam Mbulaiteye, MBChB, M.Phil., M.Med., biographical sketch and research interests " field_list_description="Sam Mbulaiteye, MBChB, M.Phil., M.Med., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-03-12" field_pretty_url="mbulaiteye-sam" field_browser_title="Sam Mbulaiteye, MBChB, M.Phil., M.Med., biographical sketch and research interests " field_card_title="Sam Mbulaiteye, M.D. Biography" field_email_address="mbulaits@mail.nih.gov" field_first_name="Sam" field_last_name="Mbulaiteye" field_phone_number="240-276-7108" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E118">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=mbulaiteye%20s&amp;authorOption=exact&amp;pi=0010748167">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=63&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302590" sys_dependentvariantid="1422" sys_relationshipid="7328571" sys_variantid="1422">Infections and Immunoepidemiology Branch</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<div class="callout-box right">
<h3>Spotlight on Investigator</h3>
<div sys_relationshipid="7328574" sys_dependentid="606686" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2086" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=726267&amp;sys_siteid=475&amp;sys_contentid=606686&amp;sys_command=preview" alt="Sam Mbulaiteye"><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Read more about <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1955&amp;sys_contentid=375466" sys_contentid="375466" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="375466" sys_dependentvariantid="1955" sys_relationshipid="7328572" sys_variantid="1955">Dr. Mbulaiteye</a> in the November 2011 <i>Linkage</i> newsletter.</p>
</div>
<p class="first-graf">Dr. Mbulaiteye is a senior investigator in the Infections and Immunoepidemiology Branch (IIB). He conducts research to understand the etiology of Burkitt lymphoma (BL), a&nbsp;cancer that occurs worldwide but has its highest incidence recorded in populations of sub-Saharan Africa.</p>
<p class="first-graf">Dr. Mbulaiteye&nbsp;received physician training at Makerere University, Kampala (1990) with advanced training in epidemiology and biostatistics (M.Phil.) from the University of Cambridge, U.K. (1994), and specialist training in internal medicine (M.Med.) from Makerere University (1996). His early research focused on measuring the impact of HIV on cancer in patients at the Uganda Cancer Institute (1994-1997) and investigating population trends of HIV in a general population in rural southwest Uganda while at the Uganda Virus Research Institute/ U.K. Medical Research Council HIV program. Dr. Mbulaiteye joined IIB in December 2000 to focus his work on KS and BL as a research fellow, and was awarded NIH scientific tenure and appointed senior investigator in 2013.</p>
<p class="first-graf">Dr. Mbulaiteye is an active member of the NIH and NCI community, and has served on various search and technical committees. He is currently a member of DCEG Genotyping Review Committee. He is the Co-Editor-in-Chief, <em>Infectious Agents and Cancer</em>, Editorial Board Member for AIDS, <em>International Journal of Cancer</em>, and <em>Frontiers in Cancer Epidemiology and Prevention</em>. He is a member of the African Organization for Research and Training in Cancer (AORTIC), the Darwin College Society, the Cambridge Commonwealth Trust, and the World Federation of Scientists.</p>
<p class="first-graf">Dr. Mbulaiteye has been invited to organize scientific sessions about Burkitt lymphoma at the last four biennial meetings held by AORTIC (Cairo 2011, Durban 2013, Marrakech 2015, and Kigali 2017).</p>
<h2 id="research">Research Interests</h2>
<h3 id="research">Burkitt Lymphoma (BL)</h3>
<div class="callout-box right">
<h3>NIH Director's Seminar</h3>
<div sys_relationshipid="7328575" sys_dependentid="914514" rxinlineslot="105" contenteditable="false" sys_dependentvariantid="2086" rxselectedtext="" rxanchortext="" unselectable="on" inlinetype="rxvariant" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable">
          <figure class="image-left-medium centered-set">        <div class="centered-element">                      <img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=401214&amp;sys_siteid=475&amp;sys_contentid=914514&amp;sys_command=preview" alt="Sam Mbulaiteye"><!--Comment--></img>
                                                </div>
              </figure>
       </div>
<p>Watch Dr. Mbulaiteye discuss his research at the 2015 NIH Director&rsquo;s Seminar Series.</p>
<p><b>Video</b>: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1090683" sys_contentid="1090683" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1090683" sys_dependentvariantid="1410" sys_relationshipid="7328573" sys_variantid="1410">Burkitt lymphoma: A model of polymicrobial carcinogenesis and global oncology</a></p>
</div>
<p id="research">A major focus of Dr. Mbulaiteye&rsquo;s research is to characterize the epidemiology of Burkitt lymphoma (BL). In western countries, where BL occurs sporadically, Dr. Mbulaiteye has used registry-based datasets to investigate age-specific incidence rates for BL and adduce evidence for disease heterogeneity. The results from these studies suggest that that the etiology of sporadic BL may vary with age. In sub-Saharan Africa, where BL is the most common childhood tumor, Dr. Mbulaiteye seeks to quantify the association between markers of current or past malarial&nbsp;infection (parasite prevalence, load, and genotype, antibodies to malaria virulent antigens, and history of clinical malaria), and markers of Epstein-Barr virus (EBV) infection (antibodies or EBV variants) with BL. In addition, Dr. Mbulaiteye is investigating the role of systemic magnesium as a geographical co-factor associated with poor control of EBV and BL risk.</p>
<p id="research">To achieve these goals, Dr. Mbulaiteye implemented a case-control study of BL called the <a href="https://emblem.cancer.gov/">Epidemiology of Burkitt Lymphoma in East-African Children and Minors</a> (EMBLEM) in six rural regions in Uganda, Tanzania, and Kenya. This study addresses a major constraint that was hampering Dr. Mulaiteye&rsquo;s BL research: lack of access to high-quality data and annotated samples from BL patients, due either to depletion or unsuitability of historic samples for use with current proteomic and molecular technologies. The primary scientific goals of EMBLEM are to investigate the molecular characterization of BL and associations of BL with: a) malaria resistance genes, assuming the Mendelian randomization (MR) principle; b) EBV genetic variants; and c) germline variants in a genome-wide association study (GWAS).</p>
<h3 id="research">HIV/AIDS and Cancer</h3>
<p>Dr. Mbulaiteye was the first to use record-linkage methods to investigate the association between HIV and cancer in a low- and middle-income country (LMIC) with his study conducted in Uganda in 2005. He has since extended these methods to Nigeria and India. Dr. Mbulaiteye continues to support and advise other investigators who wish to use these methods to generate new data about the impact of HIV and cancer in LMICs.</p>
</div>
</div>]]></body>
    <field_image_promotional>349676</field_image_promotional>
  </row>
  <row term_id="302006" id="349692" title="Rashmi Sinha, Ph.D." langcode="en" field_short_title="Rashmi Sinha, Ph.D." field_page_description="Rashmi Sinha, Ph.D., biographical sketch and research interests" field_feature_card_description="Rashmi Sinha, Ph.D., biographical sketch and research interests" field_list_description="Rashmi Sinha, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2018-03-09" field_pretty_url="sinha-rashmi" field_browser_title="Rashmi Sinha, Ph.D., biographical sketch and research interests" field_card_title="Rashmi Sinha, Ph.D." field_email_address="sinhar@mail.nih.gov" field_first_name="Rashmi" field_last_name="Sinha" field_phone_number="240-276-7208" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E336">
    <body><![CDATA[<div class="rxbodyfield"><!--  - - - - - - - - - - - - - - - - - - - - /about/directory bio main content begins  - - - - - - - - - - - - - - - - - - - -  -->
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=sinha%20r&amp;authorOption=exact&amp;pi=%200010087897">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_relationshipid="7252813" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Sinha received a B.S. with honors and M.SC. in biochemistry from the University of Stirling in Scotland, and a Ph.D. in nutritional sciences from the University of Maryland. She began work at the NCI in the Laboratory of Cellular Carcinogenesis and Tumor Promotion in 1987, was selected as a Cancer Prevention Research Fellow in 1990, and later joined the Division of Cancer Epidemiology and Genetics in 1992. Dr. Sinha was promoted to senior investigator in 2001 and co-principal investigator of the NIH-AARP Diet and Health Study. She served for many years as Deputy Chief of the Nutritional Epidemiology Branch.</p>
<p>Dr. Sinha was awarded a fellowship from the Japanese Foundation for Cancer Research in 2001 and 1997, Sigma Xi Distinguished Lectureship 2005; and in 2007 was invited to present at the prestigious 38th International Princess Takamatsu Symposium, Tokyo, Japan. She has received the NIH Award of Merit, Technology Transfer Award, DCEG Special Appreciation Award, and several performance awards. Dr. Sinha was one of the founding members of the steering committee of the Molecular Epidemiology Group of the American Association for Cancer Research from 1997-1998, and of the Nutritional Epidemiology Research Group of the American Society of Nutritional Sciences from 1998-2000. She was a member of the working group for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans, (Volumes 92, 114, 116), and was a reviewer for the American Institute for Cancer Research/World Cancer Research Fund report <em>Food, Nutrition, Physical Activity, and Prevention of Cancer</em> (2007 and 1997 editions). As an expert in the field of nutritional epidemiology, Dr. Sinha regularly chairs international committees and sessions at national meetings, as well as organizes meetings, symposia, and workshops. She was the president of the 8th International Conference on Carcinogens and Mutagenic&ndash;substituted Aryl Compounds and edited a special issue of <em>Mutation Research &ndash; Fundamental and Molecular Mechanisms</em> in 2002. She serves on the Editorial Board of <em>Cancer Epidemiology, Biomarkers and Prevention</em>, and the journal of the Japanese Cancer Association, <em>Cancer Science</em>.</p>
<h2 id="research">Research Interests</h2>
<p>Dr. Sinha conducts interdisciplinary research to elucidate the dietary exposures and biological mechanisms associated with cancer risk, including the role of the microbiome.</p>
<h3>Diet and Cancer</h3>
<p class="first-graf">Only a small number of dietary components are convincingly linked causally to cancer, even though diet is thought to be important in the etiology of human cancers. The goal of our research is to explain the complex role of diet in cancer etiology, using an interdisciplinary approach that integrates biological mechanisms with epidemiologic studies. An aim of the Metabolic Epidemiology Branch is to improve dietary exposure assessment using questionnaires and novel biochemical measures to elucidate dietary exposures and biological mechanisms associated with cancer risk, including the role of genetic susceptibility. Dr. Sinha is particularly interested in examining the role of meat, poultry, and fish in relation to cancer risk. She also studies non-nutritive constituents of diet, e.g., <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302637" sys_dependentvariantid="1418" sys_dependentid="302637" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252815" sys_variantid="1418" sys_contentid="302637">carcinogens formed during the cooking process</a> and chemopreventive properties of coffee.</p>
<h3>Dietary Cohort in Asian Populations</h3>
<p>Asia is undergoing marked changes in diet, lifestyle, and chronic disease patterns. Dietary characteristics unique to Asia may be of particular interest. In high-income societies, over one-third of cancers are believed to be attributable to potentially modifiable, lifestyle-related exposures, such as diet, physical activity, and obesity. However, the relationship between diet and cancer risk within Asians are largely unexplored, despite the startling prevalence of diet-related conditions that may affect cancer and chronic disease risk, such as insulin resistance and hyperlipidemia. Dr. Sinha is actively involved in dietary studies in the Asian Cohort Consortium.</p>
<h3>Role of Gut Microflora and Health</h3>
<p>An evolving hypothesis is that dysbiosis, which is maladaptation of the commensal human microbial community, may contribute to disease development. Furthermore, cancer may be caused or prevented from an interplay between diet, gut bacteria, and microbial metabolites. To date, there are few well-conducted epidemiologic studies evaluating the role of the human microbiota and its related metabolites in cancer development.</p>
<p class="first-graf">Dr. Sinha&rsquo;s vision is to advance epidemiologic research on the microbiome in both extra- and intramural programs. She has taken a four-pronged approach to achieve this vision: (1) conducting methods studies to develop best practices including methods for collecting specimens, developing quality control standards, extracting and sequencing DNA, comparing different bioinformatics pipelines, and conducting statistical analyses; (2) incorporating fecal and oral collection into new or existing cohorts; (3) evaluating associations of cancer risk factors, such as body mass index and diet, with the microbiome and metabolome; and (4) conducting etiologic studies.</p>
<p class="first-graf">Learn more about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303730" sys_dependentvariantid="1418" sys_dependentid="303730" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252814" sys_variantid="1418" sys_contentid="303730">human microbiome and cancer</a>.</p>
</div>
<!--  - - - - - - - - - - - - - - - - - - - - /about/directory bio main content ends  - - - - - - - - - - - - - - - - - - - -  --></div>]]></body>
    <field_image_promotional>349692</field_image_promotional>
  </row>
  <row term_id="302006" id="638988" title="Steven C. Moore, Ph.D., M.P.H." langcode="en" field_short_title="Steven C. Moore, Ph.D., M.P.H." field_page_description="Steven C. Moore, Ph.D., M.P.H., biographical sketch and research interests" field_feature_card_description="Steven C. Moore, Ph.D., M.P.H., biographical sketch and research interests" field_list_description="Steven C. Moore, Ph.D., M.P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2013-09-20" field_date_reviewed="2013-09-20" field_date_updated="2013-09-20" field_pretty_url="Moore-Steven" field_browser_title="Steven C. Moore, Ph.D., M.P.H., biographical sketch and research interests" field_card_title="Steven C. Moore, Ph.D., M.P.H." field_email_address="moorest@mail.nih.gov" field_first_name="Steven" field_last_name="Moore" field_phone_number="240-276-7196" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E306">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=moore+sc&amp;authorOption=exact&amp;pi=0012245242">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7276872" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Steven Moore earned his Ph.D. in cancer epidemiology from Yale University School of Public Health.&nbsp;He joined the Nutritional Epidemiology Branch of the NCI Division of Cancer Epidemiology and Genetics as a predoctoral fellow in 2005 and became a research fellow in 2009. Dr. Moore was appointed as an Earl Stadtman Tenure-Track Investigator in 2013. In the newly formed <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7276871" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a>, Dr. Moore investigates the role of physical activity and obesity in the development of cancer. He has received a number of awards for his work in this area, including a DCEG Fellowship Achievement Award, as well as the Karen Hornbostel Memorial Award from the American College of Sports Medicine.</p>
<h2 id="research">Research Interests</h2>
<h4>Physical Activity, Obesity, and Cancer</h4>
<p>Dr. Moore&rsquo;s research focuses on the role of obesity-related factors on cancer risk, including waist circumference, sedentary behavior, and physical activity. He is exploring these questions in large population-based studies, such as the NIH-AARP Diet and Health Study cohort, and within the NCI Cohort Consortium, a group which has pooled data from nearly two million individuals. Dr. Moore seeks to establish the reduction in cancer rates that would occur if all people were more physically active, including for rare cancers and specific cancer subtypes. &nbsp;</p>
<h4>Metabolomics and Cancer</h4>
<p>Dr. Moore is a pioneer in the field of metabolomics, which applies novel high-throughput technology to analyze small-molecule metabolites in biospecimens, like blood or urine, as a way to understand how molecular pathways may influence cancer risk. In studying the metabolomics of energy balance, he has been instrumental in uncovering biomarkers for body mass index and diet. Dr. Moore is leading studies to identify metabolites and metabolic pathways involved in breast cancer and is a lead collaborator on studies of colorectal and pancreatic cancer.</p>
<p>Dr. Moore is chair of the Consortium of Metabolomics Studies (<a href="http://epi.grants.cancer.gov/comets/">COMETS</a>), an international consortium of prospective cohort studies that uses metabolomics to identify risk factors for chronic disease.</p>
</div>
</div>]]></body>
    <field_image_promotional>638988</field_image_promotional>
  </row>
  <row term_id="302006" id="919003" title="Stella Koutros, Ph.D.,  M.P.H." langcode="en" field_short_title="Stella Koutros, Ph.D.,  M.P.H." field_page_description="Stella Koutros, Ph.D., biographical sketch and research interests " field_feature_card_description="Stella Koutros, Ph.D., biographical sketch and research interests " field_list_description="Stella Koutros, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-03-23" field_date_reviewed="2015-03-23" field_date_updated="2019-02-06" field_pretty_url="koutros-stella" field_browser_title="Stella Koutros, Ph.D., biographical sketch and research interests " field_card_title="Stella Koutros, Ph.D.,  M.P.H." field_email_address="KoutrosS@mail.nih.gov" field_first_name="Stella" field_last_name="Koutros" field_phone_number="240-276-7165" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E616">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Koutros%20s&amp;authorOption=exact&amp;pi=0012452376">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7252774">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Koutros received her M.P.H. and Ph.D. in epidemiology from Yale University. She completed her doctoral work through the Yale-NCI partnership training program in cancer epidemiology, conducting research in the Occupational and Environmental Epidemiology Branch (OEEB). In 2008, upon completion of her doctorate, she became a fellow in OEEB; she was appointed to the position of tenure-track investigator in 2015.</p>
<h2 class="dceg-bio-content"><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Koutros&rsquo;s research involves the design and conduct of epidemiologic investigations to evaluate occupational exposures as risk factors for cancer. She employs state-of-the-art exposure assessment methods and molecular studies within highly exposed populations to identify the etiology and clarify the biological mechanisms underlying chemical-induced carcinogenesis. Areas of interest include exposures occurring in the workplace and those contributing to the etiology of bladder cancer.</p>
<h3>Occupation and Industry-based Exposures</h3>
<p>Dr. Koutros leads several efforts in large occupation and industry-based cohort studies studying the impact of high levels of exposure to several important chemicals that have large public health and regulatory concerns. Specific areas of interest include:</p>
<ul>
<li>Pesticide exposures as risk factors for cancer. Areas of focus include exposure to specific organophosphate insecticides and risk for aggressive prostate cancer and bladder cancer as well as the interaction between agricultural pesticide use and genetic susceptibility on cancer risk.</li>
<li>Acrylonitrile and cancer mortality. Areas of focus include suggested elevated risks for cancers of the lung and bladder among acrylonitrile-exposed workers.</li>
<li>Diesel exhaust and cancer mortality in a cohort of workers exposed to diesel exhaust at eight U.S. non-metal mining facilities.</li>
</ul>
<h3>Bladder Cancer</h3>
<p>Occupational exposures are a leading risk factor for bladder cancer, second only to smoking. Dr. Koutros is currently leading efforts within large case-control studies of bladder cancer to identify important occupational exposures that might influence risk. Dr. Koutros and her collaborators are examining potential gene-environment interactions as well as incorporating important somatic variation and bladder tumor marker data to integrate exposure, germline genetic variation, and somatic changes to gain insights into the etiology of bladder carcinogenesis.</p>
<p></p>
</div>
</div>]]></body>
    <field_image_promotional>919003</field_image_promotional>
  </row>
  <row term_id="302006" id="939611" title="Vladimir Drozdovitch, Ph.D." langcode="en" field_short_title="Vladimir Drozdovitch, Ph.D." field_page_description="Vladimir Drozdovitch, Ph.D., biographical sketch and research interests " field_feature_card_description="Vladimir Drozdovitch, Ph.D., biographical sketch and research interests " field_list_description="Vladimir Drozdovitch, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-04-29" field_date_reviewed="2015-04-29" field_date_updated="2015-04-29" field_pretty_url="vladimir-drozdovitch" field_browser_title="Vladimir Drozdovitch, Ph.D., biographical sketch and research interests " field_card_title="Vladimir Drozdovitch, Ph.D." field_email_address="drozdovv@mail.nih.gov" field_first_name="Vladimir" field_last_name="Drozdovitch" field_phone_number="240-276-7399" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E548">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=Drozdovitch+V&amp;authorOption=exact&amp;pi=0013072004">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7252824" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<p>Dr. Vladimir Drozdovitch is a radiation physicist and part of the Dosimetry Unit and Chernobyl Research Unit in the Radiation Epidemiology Branch (REB). Dr. Drozdovitch received an M.S. in nuclear physics from the Belarusian State University in Minsk, Belarus, and a Ph.D. in nuclear physics from the Belarusian Academy of Sciences. Previously, he was scientist at the Research Institute for Radiation Medicine in Minsk and the International Agency for Research on Cancer (IARC) in Lyon, France. He joined the Radiation Epidemiology Branch as a visiting fellow in 2006 and became a staff scientist in 2014.</p>
<h2 id="Research">Research Interests</h2>
<p>Dr. Drozdovitch&rsquo;s main scientific interests include radiation dosimetry and dose reconstruction methods and analysis of uncertainties associated with radiation doses. Within the REB, he leads the dosimetry calculation effort for studies of the Chernobyl accident, leads efforts to estimate historical doses from nuclear medicine in a nationwide cohort of the U.S. Radiologic Technologists (USRT), and is involved in studies to evaluate exposure and risk from radioactive fallout from nuclear weapons testing.</p>
<h2>Studies related to the Chernobyl accident</h2>
<p>In the Chernobyl-related cohort study of thyroid cancer and other diseases, conducted jointly with the Ministries of Health of Ukraine and Belarus, Dr. Drozdovitch is responsible for conducting and overseeing the dosimetry for the thyroid screening studies, the Belarusian <i>in utero</i> cohort, and the study of Ukrainian clean-up workers, including a case-control study of thyroid cancer and an investigation into germline mutations in the offspring of those workers. He assesses uncertainties in the doses by accounting for shared and unshared errors and collaborates with statisticians on the incorporation of uncertainties into the risk estimates. He also continues to conduct and support characterization of uncertainties in dosimetry for the IARC case-control study of thyroid cancer in Belarus and Russia.</p>
<h2>USRT study</h2>
<p>Dr. Drozdovitch is the lead dosimetrist on the nuclear medicine component of the USRT cohort. These technologists currently receive some of the highest occupational radiation doses of any medical workers. He has collected historical data, reviewed current practice standards and developed cutting edge methods to reconstruct doses from radioisotope diagnostic procedures.</p>
<h2>Fallout studies</h2>
<p>Dr. Drozdovitch has been a key researcher in the dosimetry effort for a study of thyroid nodules among persons in Kazakhstan who were exposed to radioactive fallout resulting from atmospheric nuclear weapons tests carried out at the Semipalatinsk Nuclear Test Site between 1949 and 1962. Information to estimate doses is based, in large part, on the analysis of historical behavior and food consumption. As part of a multi-disciplinary team, Dr. Drozdovitch set up and conducted focus-group sessions in Kazakhstan and incorporated those data in a complex 2-dimentional Monte Carlo dosimetry system. He also provides dosimetry support to the INSERM (France) case-control study of thyroid cancer in persons exposed to fallout resulting from atmospheric nuclear weapons tests conducted in French Polynesia between 1966 and 1974.</p>
<h2>Assessment of uncertainties in doses</h2>
<p>Dr. Drozdovitch has successfully worked to evaluate the uncertainties in exposure assessment, which involves the separation of shared and unshared errors, and of the errors related to stochastic variability and to lack of knowledge. He has initiated studies to evaluate uncertainties due to human factors in dosimetry for clean-up workers in Ukraine and estimate the reliability of questionnaire based dose reconstruction in Belarusian thyroid screening cohort.</p>
</div>
</div>]]></body>
    <field_image_promotional>939611</field_image_promotional>
  </row>
  <row term_id="302006" id="1059112" title="Amanda Black, Ph.D., M.P.H." langcode="en" field_short_title="Amanda Black, Ph.D., M.P.H." field_page_description="Amanda Black, Ph.D., biographical sketch and research interests  " field_feature_card_description="Amanda Black, Ph.D., biographical sketch and research interests  " field_list_description="Amanda Black, Ph.D., biographical sketch and research interests  &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-08-10" field_date_reviewed="2016-08-10" field_date_updated="2017-08-02" field_pretty_url="black-amanda" field_browser_title="Amanda Black, Ph.D., biographical sketch and research interests  " field_card_title="Amanda Black, Ph.D., M.P.H." field_email_address="blacka@mail.nih.gov" field_first_name="Amanda" field_last_name="Black" field_phone_number="240-276-7411" field_org_name_1="National Cancer Institute" field_org_name_2="Office of the Director" field_campus="300" field_office_location="Room 7E424">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Black%20A&amp;authorOption=exact&amp;pi=0013326415">Scientific Publications</a></li>
<li><a href="https://dceg2.cancer.gov/cgi-bin/Personnel.pl?1=OD">Office of the Director</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>In the Office of the Director, Dr. Amanda Black oversees management of the vast biological specimen resources of the Division and supports the planning of the new prospective multi-center cohort study that will serve as an important Division-wide resource. She is also a member of the Prostate, Lung, Colon, Ovary (PLCO) Prospective Cohort Study leadership team.<br /><br />Dr. Black received her undergraduate degree in biomedical science (2001), Master of Medical Laboratory Science (2002), and Ph.D. in epidemiology and public health (2005) from Queen&rsquo;s University, Belfast, U.K. In 2006, Dr. Black was selected for the NCI Cancer Prevention Fellowship. During her fellowship, Dr. Black was awarded a Master of Public Health (2008) by the University of Manchester, U.K. Dr. Black's Cancer Prevention Fellowship was in the Early Detection Research Group of the NCI Division of Cancer Prevention, where she worked on the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO). In 2009, she joined DCEG as a Staff Scientist.</p>
</div>
</div>]]></body>
    <field_image_promotional>1059112</field_image_promotional>
  </row>
  <row term_id="302006" id="1100176" title="Megan Frone,  M.S., C.G.C." langcode="en" field_short_title="Megan Frone,  M.S., C.G.C." field_page_description="Megan Frone, M.G.C., biographical sketch and research interests" field_feature_card_description="Megan Frone, M.G.C., biographical sketch and research interests" field_list_description="Megan Frone, M.G.C., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-11-13" field_date_reviewed="2017-11-13" field_date_updated="2017-11-13" field_pretty_url="frone-megan" field_browser_title="Megan Frone, M.G.C., biographical sketch and research interests" field_card_title="Megan Frone,  M.S., C.G.C." field_email_address="megan.frone@nih.gov" field_first_name="Megan" field_last_name="Frone" field_phone_number="240-276-5968" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E542">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research Interests">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Frone%2C%20Megan%5BFull%20Author%20Name%5D%20OR%20%28Frone%5BAll%20Fields%5D%20AND%20MN%5BAuthor%5D%29%20OR%20Farley%2C%20Megan%20N%5BFull%20Author%20Name%5D%20OR%20Farley%20MN%5BAuthor%5D&amp;cmd=DetailsSearch">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_dependentvariantid="1422" sys_dependentid="302430" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252556" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Megan Frone received her B.S. in biology (concentration in cell and molecular biology) from SUNY Binghamton University in 2008. In 2010, she earned a Masters in genetic counseling from Virginia Commonwealth University, where she also completed the Virginia Leadership Education in Neurodevelopmental Disabilities program. Ms. Frone has been a board-certified clinical genetic counselor since 2011. Prior to joining the Clinical Genetics Branch (CGB), she worked as an adult and pediatric cancer genetics counselor at UT Southwestern Medical Center in Dallas, Texas. She also counseled at the inborn errors of metabolism, Down Syndrome specialty, and general pediatrics genetics clinics of Children&rsquo;s Health, Dallas.</p>
<p>Ms. Frone provides genetic education and counseling to participants in CGB clinical studies, as well as conducts research in these areas across many of the branch&rsquo;s protocols; she is the lead genetic counselor for the <a href="https://lfs.cancer.gov/">Li-Fraumeni Syndrome study</a>. In collaboration with DCEG investigators, she develops and implements genetic variant curation, reviews pathogenicity of variants, and helps to identify clinically relevant findings from whole exome sequencing and gene discovery studies in patients with hereditary cancer, and for the Childhood Cancer Survivor Study (CCSS).</p>
<h2><a id="Research Interests"></a>Research Interests</h2>
<ul>
<li>Pediatric cancers</li>
<li>Secondary cancer risks in childhood cancer survivors</li>
<li>Bioinformatics and genetic variant curation</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>1100176</field_image_promotional>
  </row>
  <row term_id="302006" id="1113558" title="Payal Khincha, M.B.B.S., M.S.H.S." langcode="en" field_short_title="Payal Khincha, M.B.B.S., M.S.H.S." field_page_description="Payal Khincha, M.B.B.S., M.S.H.S. - biographical sketch and research interests" field_feature_card_description="Payal Khincha, M.B.B.S., M.S.H.S. - biographical sketch and research interests" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2018-04-20" field_date_reviewed="2018-04-20" field_date_updated="2018-04-20" field_pretty_url="khincha-payal" field_browser_title="Payal Khincha, M.B.B.S., M.S.H.S. - biographical sketch and research interests" field_card_title="Payal Khincha, M.B.B.S., M.S.H.S." field_email_address="payal.khincha@nih.gov" field_first_name="Payal" field_last_name="Khincha" field_phone_number="240.276.7267" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E540">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul>
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=khincha%20p&amp;authorOption=exact&amp;pi=0014348093">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_dependentvariantid="1422" sys_dependentid="302430" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7328566" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Payal Khincha first came to the Clinical Genetics Branch (CGB) as a special volunteer and clinical collaborator in July 2012 as part of the research component of a clinical fellowship in pediatric hematology-oncology at the Children&rsquo;s National Medical Center (CNMC), Washington, D.C. In 2014, she formally joined CGB as a clinical fellow. In 2017, she became a staff clinician, and in 2018, the principal investigator on the NCI&rsquo;s longitudinal family study on <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303694" sys_dependentvariantid="1418" sys_dependentid="303694" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7328567" sys_variantid="1418" sys_contentid="303694">Li-Fraumeni Syndrome</a>. Dr. Khincha received her primary medical degree (MBBS) in 2005 from Kempegowda Institute of Medical Sciences, Bangalore, India, and completed her residency training in pediatrics in 2010 at Maimonides Medical Center, Brooklyn, New York, and CNMC, Washington D.C. She is board certified in pediatrics and pediatric hematology-oncology.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Khincha&rsquo;s research interests lie in understanding inherited cancer predisposition syndromes, particularly those that can affect children.</p>
<h3>Dyskeratosis Congenita and Telomere Biology</h3>
<p>During her tenure as a clinical collaborator, Dr. Khincha worked with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=44&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349621" sys_dependentvariantid="1965" sys_dependentid="349621" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7328568" sys_variantid="1965" sys_contentid="349621">Sharon A. Savage, M.D.</a>, Chief, CGB, focusing her research on the diagnostic methods and clinical management of dyskeratosis congenita (DC), a cancer-prone inherited bone marrow failure syndrome and telomere biology disorder (TBD). As clinical fellow, she continued this work, reporting on novel phenotypes and treatment of effects of DC, while developing expertise in the TBD spectrum and telomere measurement methods. Dr. Khincha is also embarking on a deep phenotyping and genotype-phenotype project in DC, and is currently working on collaborative international studies of a novel vascular phenotype in DC/TBDs within the Clinical Care Consortium for Telomere Associated Ailments.</p>
<h3>Li-Fraumeni Syndrome</h3>
<p>Li-Fraumeni syndrome (LFS) is a highly-penetrant autosomal dominant cancer predisposition syndrome associated with a wide range of cancer types that occur at younger-than-expected ages. The NCI&rsquo;s longitudinal study on the <a href="https://lfs.cancer.gov/">clinical, genetic, and epidemiologic study of LFS</a> opened in 2011 under the leadership of Dr. Savage, in order to further characterize the clinical and molecular consequences of this disorder, and develop a cancer screening program for <em>TP53</em> mutation carriers. The team also assisted in the creation of an international LFS research consortium. During her NCI tenure, Dr. Khincha has been involved with the LFS Study in clinical evaluations and genetics of LFS families, quickly building her expertise in this area, taking on leadership roles in the study, and collaborating with experts in the consortium. Her LFS research focusses on developing an effective cancer surveillance protocol for these families, genotype-phenotype analyses, understanding the genetics and biological basis for cancer development in LFS, and evaluating the effects of cancer treatment on subsequent cancer risks.</p>
</div>
</div>]]></body>
    <field_image_promotional>1113558</field_image_promotional>
  </row>
  <row term_id="302006" id="1121710" title="Marie-Josphe Horner, Ph.D." langcode="en" field_short_title="Marie-Josphe Horner, Ph.D." field_page_description="Marie-Josphe Horner, Ph.D., biographical sketch and research interests" field_feature_card_description="Marie-Josphe Horner, Ph.D., biographical sketch and research interests" field_list_description="Marie-Josphe Horner, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2018-08-09" field_date_reviewed="2018-08-09" field_date_updated="2018-08-09" field_pretty_url="horner-marie-josephe" field_browser_title="Marie-Josphe Horner, Ph.D., biographical sketch and research interests" field_card_title="Marie-Josphe Horner, Ph.D." field_email_address="mariejosephe.horner@nih.gov" field_first_name="Marie-Josphe" field_last_name="horner" field_phone_number="(240) 276-7183 " field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E-236">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul>
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Horner%2C%20Marie%20Josephe%5BFull%20Author%20Name%5D&amp;cmd=DetailsSearch">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=47&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_dependentvariantid="1422" sys_dependentid="302590" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252504" sys_variantid="1422" sys_contentid="302590">Infections and Immunoepidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Marie-Jos&egrave;phe Horner received a B.Sc. in biology from McGill University, Quebec, Canada, and M.S.P.H. and Ph.D. degrees in epidemiology from the Universities of South Carolina and North Carolina at Chapel Hill, respectively. Her doctoral research focused on characterizing the cancer burden among people living with HIV and receiving antiretroviral therapy in sub-Saharan Africa. This research was conducted through the Malawi HIV-Cancer Match Study, which she implemented in-country as an NIH Fogarty Scholar.</p>
<p>Dr. Horner first joined the NCI in 2006 as an epidemiologist with the Surveillance, Epidemiology, and End Results (SEER) Program, for which she received an NIH Merit Award in 2009. In 2011, she joined the Laboratory of Translational Genomics, where she supported genome-wide association studies. After earning her Ph.D., she returned to the NCI in 2018 as a staff scientist in the Infections and Immunoepidemiology Branch.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Horner supports research activities within the NCI&rsquo;s <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303678" sys_dependentvariantid="1418" sys_dependentid="303678" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252505" sys_variantid="1418" sys_contentid="303678">HIV/AIDS Cancer Match Study</a>. Her research focuses on descriptive epidemiology of the evolving cancer burden among domestic HIV populations. Dr. Horner's&nbsp;interests include integrating new data sources for public health surveillance, study design, and analytic solutions for missing data.</p>
</div>
</div>]]></body>
    <field_image_promotional>1121710</field_image_promotional>
  </row>
  <row term_id="302006" id="349609" title="Mark Schiffman, M.D., M.P.H. " langcode="en" field_short_title="Mark Schiffman, M.D., M.P.H. " field_page_description="Mark Schiffman, M.D., M.P.H., biographical sketch and research interests " field_feature_card_description="Mark Schiffman, M.D., M.P.H., biographical sketch and research interests " field_list_description="Mark Schiffman, M.D., M.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-16" field_pretty_url="schiffman-mark" field_browser_title="Mark Schiffman, M.D., M.P.H., biographical sketch and research interests " field_card_title="Mark Schiffman, M.D., M.P.H. " field_email_address="schiffmm@mail.nih.gov" field_first_name="Mark " field_last_name="Schiffman" field_phone_number="240-276-7259" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E544">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=schiffman%20m&amp;authorOption=exact&amp;pi=0010100614">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_relationshipid="7276261" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2>Biography</h2>
<div class="callout-box right">
<h3>Research in Action</h3>
<p><img alt="" class="left" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=546657" sys_dependentid="546657" sys_dependentvariantid="1482" sys_relationshipid="7276263" sys_siteid="475" />Mark Schiffman uses molecular epidemiology to predict and prevent cervical cancer.</p>
<p><b>Video:</b> <a href="https://www.youtube.com/watch?v=lhQRUAEngVk&amp;feature=youtu.be" target="_blank" rel="noopener noreferrer">Taking the Long View</a></p>
</div>
<p class="first-graf">Dr. Schiffman received an M.D. from the University of Pennsylvania and an M.P.H. in epidemiology from The Johns Hopkins School of Hygiene and Public Health. He joined the NCI as a Staff Fellow in 1983 and, in 1996, was appointed Chief of the Interdisciplinary Studies Section in the Environmental Epidemiology Branch (which later became the HPV Research Group in the Hormonal and Reproductive Epidemiology Branch). He joined the Clinical Genetics Branch in October 2009 to study intensively why HPV is such a powerful carcinogenic exposure, akin to an acquired genetic trait with high penetrance for a cancer phenotype.</p>
<p>Dr. Schiffman received a Fulbright Scholarship in 1977 to carry out epidemiologic studies in Senegal. He has received numerous awards for his work in molecular epidemiology, including the ACS Medal of Honor and the AACR Prevent Cancer Foundation Award.</p>
<h2 id="research">Research Interests</h2>
<p>The main studies in which Dr. Schiffman played a major role in the past 5 years, listed chronologically, include: The Portland Kaiser Cohort; the Taiwan Cohort Study; the Guanacaste Natural History Study; the ASCUS-LSIL Triage Study (ALTS); the Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED/Biopsy); the Costa Rica Vaccine Trial (CVT); the Persistence and Progression (PaP) Study; and Nigeria Project Itoju. These studies overall have related HPV status to outcome for more than 100,000 women. Two were extremely large randomized trials. The two oldest cohorts have accrued more than 15 years of follow-up time. Through a natural progression of studies, he has pursued three main scientific themes: 1) HPV Natural History and Cervical Carcinogenesis; 2) Translational Studies of HPV Testing, Cytology, Colposcopy, and Vaccines; and 3) Risk Prediction and Cervical Cancer Prevention.</p>
<p>With regard to natural history, he has worked extensively with his major laboratory collaborator, Dr. Robert Burk (Albert Einstein, through a collaborative research agreement) on HPV phylogeny, investigating HPV at the levels of individual infections, women&rsquo;s experience with HPV during their lifetimes, and populations. His work has helped promulgate a multi-stage causal model of HPV and cervical carcinogenesis based on a few distinct steps: acute infection with carcinogenic HPV type(s), detectable viral persistence (rather than clearance) linked to development of cervical precancer (CIN3), and invasion.</p>
<p>The natural history studies gave rise to translational research on HPV tests, serology, cytology, colposcopy, histology, and vaccines. He has helped to show that HPV testing is useful along the entire course of cervical cancer prevention, and must be integrated now with HPV vaccination. As co-Project Officer and Medical Monitor of the independent NCI Vaccine Trial, he has been heavily involved with virtually all aspects of that project.</p>
<p>The availability of improved cervical cancer risk tests and vaccines led to an active interest in risk prediction and cervical cancer prevention. These efforts rest on a universal base of quantifiable science (risk prediction) but reach into the realm of policy, which is deeply affected by setting. Thus, prevention work in the wealthy mainstream of the U.S. is much different than international work in low-resource settings; Dr. Schiffman has worked especially in Nigeria and Senegal. The high sensitivity of HPV DNA testing makes the test amenable to one or two screens in a lifetime.</p>
<p>In terms of HPV genomics, Dr. Schiffman and his laboratory and epidemiologist collaborators are using whole genome sequencing and genotype-phenotype analyses to understand the uniquely high carcinogenicity of HPV16 compared with closely related HPV types. Also, as a major new area, he is exploring the association between methylation of CpG sites in the HPV genome (particularly in L2 and L1) and diagnosis of CIN3, as compared with viral clearance. As part of the vaccine trial analysis, he and his collaborators will investigate whether HPV genetic variants explain partial cross-protection by comparing selected ?9- and ?7-containing samples from the Cervarix and Havrix (control) vaccine arms for variant status. Regarding clinical management, he and colleagues are conducting analyses of the impact of vaccination on frequency of cytologic abnormalities, colposcopic referrals, and biopsies.</p>
</div>
</div>]]></body>
    <field_image_promotional>349609</field_image_promotional>
  </row>
  <row term_id="302006" id="349631" title="Douglas Stewart, M.D. " langcode="en" field_short_title="Douglas Stewart, M.D. " field_page_description="Douglas Stewart, M.D., biographical sketch and research interests " field_feature_card_description="Douglas Stewart, M.D., biographical sketch and research interests " field_list_description="Douglas Stewart, M.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="stewart-douglas" field_browser_title="Douglas Stewart, M.D., biographical sketch and research interests " field_card_title="Douglas Stewart, M.D. " field_email_address="drstewart@mail.nih.gov" field_first_name="Douglas" field_last_name="Stewart" field_phone_number="240-276-7238" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E450">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research</a>&nbsp;</li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;searchTxtAuth=stewart%20dr&amp;authorOption=exact&amp;pi=0012006729">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_relationshipid="7276153" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<div class="callout-box right">
<h3>Pleuropulmonary Blastoma (PPB) Cancer Study</h3>
<div sys_dependentvariantid="2086" sys_dependentid="881987" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7276171">
<figure class="image-left-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302225&amp;sys_siteid=475&amp;sys_contentid=881987&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
This study is recruiting children and family members with PPB or related tumors and conditions.&nbsp;Learn more at the <a href="http://ppb.cancer.gov/">PPB Cancer Study website</a>.</div>
<p class="first-graf">Dr. Stewart received his M.D. from the University of Pennsylvania School of Medicine in 1998. He completed a residency in internal medicine at the Hospital of the University of Pennsylvania in 2001 and training in medical genetics at the Children&rsquo;s Hospital of Philadelphia in 2004. He is board-certified in both internal medicine and clinical genetics. He had post-doctoral training in genetics in the laboratory of Richard Spielman at Penn from 2002-2004. In 2004 he joined the National Human Genome Research Institute as part of the Physician Scientist Development Program to investigate the monogenic tumor predisposition syndrome neurofibromatosis type 1 (NF1). In recognition for his work in NF1, he was named one of NIH&rsquo;s first Earl Stadtman Investigators when he joined the National Cancer Institute&rsquo;s Clinical Genetics Branch in the summer of 2010. His major research interests are the adult manifestations of RAS-pathway disorders (especially NF1 and Legius syndrome), next generation sequencing of NF1-associated tumors and the characterization of novel features of NF1. Dr Stewart was responsible for the early detailed characterization of the chromosome 9q sub-telomeric deletion syndrome (now Kleefstra syndrome) and the recognition (with Eric Legius, Leuven Belgium) of glomus tumors as part of the NF1 tumor spectrum. Dr. Stewart is also study director/principal investigator for the <a href="http://ppb.cancer.gov/">Pleuropulmonary Blastoma (PPB) <i>DICER1</i> Cancer Study</a>.&nbsp;</p>
<h2 id="research">Research</h2>
<p class="first-graf">Dr. Stewart is continuing data analysis from two protocols from his time at NHGRI: "Variation in Gene Expression in Neurofibromatosis Type 1" (05-HG-0152) which seeks to identify genetic modifiers of NF1 and "Natural history and biology of dermal neurofibromas in neurofibromatosis type 1" (06-HG-0134), which uses novel methods to characterize neurofibroma growth in NF1. He is developing new protocols investigating whole-genome sequencing of benign and malignant tumors in NF1 and the genetics of radiation sensitivity.</p>
</div>
<p>Dr. Stewart is recruiting participants for the <a href="http://ppb.cancer.gov/">PPB Cancer Study</a>, an observational study of children with PPB and their families. The study will help researchers define the tumor types and risks associated with the <em>DICER1</em> syndrome. Dr. Stewart hopes to identify other genes that may play a role in this syndrome. He also would like to understand why some mutation carriers develop cancer while others remain healthy.</p>
</div>]]></body>
    <field_image_promotional>349631</field_image_promotional>
  </row>
  <row term_id="302006" id="349664" title="Robert N. Hoover, M.D., Sc.D." langcode="en" field_short_title="Robert N. Hoover, M.D., Sc.D." field_page_description="Robert N. Hoover, M.D., Sc.D., biographical sketch and research interests " field_feature_card_description="Robert N. Hoover, M.D., Sc.D., biographical sketch and research interests " field_list_description="Robert N. Hoover, M.D., Sc.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-03-18" field_pretty_url="hoover-robert" field_browser_title="Robert N. Hoover, M.D., Sc.D., biographical sketch and research interests " field_card_title="Robert N. Hoover, M.D., Sc.D." field_email_address="hooverr@epndce.nci.nih.gov" field_first_name="Robert" field_last_name="Hoover" field_phone_number="240-276-7412" field_org_name_1="National Cancer Institute" field_org_name_2="Epidemiology and Biostatistics Program" field_campus="300" field_office_location="Room 7E584">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=hoover%20r&amp;authorOption=exact&amp;pi=0010147289">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302673" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302673" sys_dependentvariantid="1422" sys_relationshipid="7291038" sys_variantid="1422" sys_contentid="302673">Epidemiology and Biostatistics Program</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Robert N. Hoover graduated from the University of Notre Dame (B.A.), Loyola University of Chicago (M.D.), and the Harvard School of Public Health (S.M.Hyg., Sc.D.). As Director of the Epidemiology and Biostatistics Program of the National Cancer Institute (NCI), he has established ongoing programs of research in various areas of cancer epidemiology, including descriptive studies, field studies in high-risk areas identified on the NCI cancer maps, occupational exposures, radiation, studies of medicinal agents, diet and nutrition, viral studies, general environmental exposures, tobacco use and lifestyle factors, immunoepidemiology, genetic susceptibility, and gene-environment interactions. A special focus of his work has been in the area of hormonal carcinogenesis. Dr. Hoover is widely recognized as one of the nation's leading cancer epidemiologists. In recognition of his outstanding scientific achievements, he has received several honors, including the Abraham Lilienfeld Award from the American College of Epidemiology, the John Snow Award from the American Public Health Association, the American Association of Cancer Research-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention, the Distinguished Service Medal from the U.S. Public Health Service, the Gorgas Medal from the Association of Military Surgeons of the United States, the&nbsp;Cutter Lecture on Preventive Medicine at the Harvard School of Public Health, and the Robert S. Gordon Award Lecture at the National Institutes of Health for distinguished achievements in epidemiology.</p>
<h2>DES Follow-up Study</h2>
<p class="first-graf">Since 1992, Dr. Hoover, other NCI investigators, and collaborators from five field study centers have been actively following diethylstilbestrol (DES) -exposed and -unexposed mothers, daughters and sons, and granddaughters for adverse health effects resulting from this exposure. As DES-exposed offspring are currently reaching the age when cancer rates begin to rise, it is important to continue to monitor long-term risk of cancer and other adverse health outcomes in this unique population. The study also provides a model for assessing a number of hypotheses that address concerns about prenatal hormonal influences on disease risk, both an intriguing area of science and an increasingly controversial environmental issue that affects a substantial proportion of the population.<br /><br />To date the study has identified excess female breast cancer after age 40 that shows a dose-response effect, as well as increased risk for high-grade lesions of the cervix and vagina. Concern over other hormone-related cancers remains; though to date analyses have been limited due to small numbers of cases. In the sons, investigators observed an excess risk for urogenital anomalies and infertility, and a likely excess of testicular cancer. To examine the effects in the third generation (the daughters of the prenatally exposed daughters), investigators assembled a small cohort in 2000. Given their average age, there have been few relevant disease outcomes. However, investigators noted an elevated risk for infertility&mdash;though not statistically significant, this outcome was also seen in DES-daughters. In addition, there were three cases of ovarian cancer in the granddaughters, even though substantially less than one had been expected. While both of these observations remain difficult to interpret, they have added some urgency to expand the cohort and continue to follow-up. <a href="http://www.desfollowupstudy.org/index.asp">More on the DES Follow-up Study</a>.</p>
</div>
<!--  /about/staff-bios/hoover-robert main content begins   -->
<div class="callout-box center">
<h3>Hoover Discusses DES</h3>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=350301" sys_dependentvariantid="1418" sys_dependentid="350301" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7291039" sys_variantid="1418" sys_contentid="350301">Dr. Robert Hoover talks about his research on diethylstilbestrol (DES), its history and the long-term health effects.</a></p>
</div>
</div>]]></body>
    <field_image_promotional>349664</field_image_promotional>
  </row>
  <row term_id="302006" id="349677" title="Mark H. Greene, M.D. " langcode="en" field_short_title="Mark H. Greene, M.D. " field_page_description="Mark H. Greene, M.D., biographical sketch and research interests " field_feature_card_description="Mark H. Greene, M.D., biographical sketch and research interests " field_list_description="Mark H. Greene, M.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-12" field_pretty_url="greene-mark" field_browser_title="Mark H. Greene, M.D., biographical sketch and research interests " field_card_title="Mark H. Greene, M.D. " field_email_address="greenem@mail.nih.gov" field_first_name="Mark" field_last_name="Greene" field_phone_number="240-276-7242" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location=" Room 6E456">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=greene%20mh&amp;authorOption=exact&amp;pi=0010047978">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_relationshipid="7252572" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Greene received a B.A. (English) from Yale College, an M.D. from Tufts University, and completed his training in Internal Medicine at the Massachusetts General Hospital in Boston. He spent three years with the Epidemic Intelligence Service of the U.S. Centers for Disease Control and Prevention, and then came to the National Cancer Institute in 1975 as a Staff Fellow in the Environmental Epidemiology Branch. Dr. Greene completed his medical oncology fellowship at the Medicine Branch, NCI, and is board-certified in both Internal Medicine and Medical Oncology. In 1977, he became a Senior Investigator and, subsequently, Coordinator of Family Studies within the Environmental Epidemiology Branch (EEB). In 1984, Dr. Greene was appointed Deputy Branch Chief of EEB. In 1985, he left government service to enter the private practice of medical oncology and hematology in Sun City, Arizona. In 1991, he joined the faculty of Mayo Clinic Scottsdale as a Professor of Oncology in the Mayo Medical School. While at Mayo, he was a participating investigator with a variety of cooperative oncology groups, including NCCTG, ECOG and NSABP. Dr. Greene became the Principal Investigator for the Mayo Cancer Center&rsquo;s Familial Cancer Program in 1994. In the fall of 1999, he returned to NCI as the Branch Chief of the newly-created Clinical Genetics Branch. Dr. Greene served as Branch Chief until 2013, and continues to direct studies as a senior investigator within the branch. His major research interests are familial/hereditary cancers, genetic determinants of outcomes following cancer treatment, as well as intervention studies (cancer screening, surgical risk reduction and chemoprevention) in genetically at-risk populations, genetic modifiers of cancer risk, and leveraging alert clinical observations into novel etiologic insights.</p>
<h2 id="research">Research Interests</h2>
<p class="first-graf">With the discovery of many of the genes underlying the hereditary components of the common adult malignancies (<cite>i.e.</cite>, <cite>BRCA1/2</cite> in hereditary breast/ovarian cancer, the mismatch repair genes in HNPCC, the <cite>CDKN2A</cite> gene in hereditary melanoma, <cite>etc.</cite>), the molecular biology of familial cancer has challenged our ability to manage germline mutation carriers in an effective, evidence-based fashion. Clinicians and patients alike are have worked together to take advantage of these molecular breakthroughs, and the past decade has witnessed major improvements in evidence-based approaches to the management of high-risk individuals, but important questions remain. The Clinical Genetics Branch focuses its resources on acquiring the data needed to address these issues, both for rare, highly-penetrant genes and common, lower penetrance genes, which contribute to the development of cancer in humans.</p>
<h3>The National Ovarian Cancer Prevention and Early Detection Study (GOG-0199)</h3>
<p>This is Dr. Greene&rsquo;s major research initiative. GOG-0199 is a two-arm, prospective, nonrandomized natural history study of women at increased genetic risk of ovarian cancer. It is a unique collaborative undertaking between NCI&rsquo;s Intramural Research Program (DCEG Clinical Genetics Branch), Extramural Research Program (DCP CCOP Program; DCTD CTEP Program), the Gynecologic Oncology Group (GOG), and the NCI-sponsored Cancer Genetics Network (CGN). He is comparing women who elect risk-reducing salpingo-oophorectomy (RRSO) to those who choose to participate in a pilot study of a novel ovarian cancer screening strategy (the &ldquo;Risk of Ovarian Cancer Algorithm,&rdquo; aka &lsquo;ROCA&rsquo;). The study closed to accrual in November 2007, after 5 years&rsquo; prospective follow-up, having enrolled 1000 women in the RRSO arm and 1600 women in the screening arm. Final data form retrieval, data QC and analytic database construction are underway, to permit analysis of Primary Study Endpoints, which include comparisons of the cancer incidence, medical decision-making, quality of life, and performance characteristics of the ROCA algorithm between the two study arms. The <i>BRCA</i> mutation status of all subjects has been defined (mutation-negative/family history-positive women were eligible for this study), and central review of the surgical specimens from all baseline risk-reducing salpingo-oophorectomies has been completed. We have also assembled a meticulously-annotated biospecimen repository to support diverse translational research endpoints.</p>
<p>The current translational research focus for GOG-0199 relates to our active membership in CIMBA (Consortium of Investigators of Modifiers of <i>BRCA1/2</i>), an international consortium of 30 research groups which has assembled a collection of 30,000 <i>BRCA</i> mutation carriers to conduct adequately-powered analyses of candidate genetic modifiers and related genomic research. He has co-authored 31 publications through this collaboration. Ongoing analyses include (1) performance characteristics of the ROCA screening algorithm (GOG + CGN); (2) histopathology of 1,000 RRSO surgical specimens (both ovaries and fallopian tubes); (3) factors influencing the choice between RRSO and screening among high-risk women; and (4) baseline quality-of-life profiles of women electing RRSO and screening.</p>
<h3>Hereditary Breast/Ovarian Cancer (HBOC)</h3>
<p class="first-graf">This syndrome has been under active investigation within the Division for the past 40 years. The long-term clinical follow-up of a cohort of 60 HBOC families, 33 of which have deleterious <cite>BRCA1/2</cite> mutations, has provided a basis for ongoing CGB research targeting HBOC. Currently, enrollment of new subjects into active clinical research protocols has ended, with the exceptions of our behavioral studies targeting the needs of young (less than 30 years old) <cite>BRCA 1/2</cite> mutation carriers (NCI Protocol 09-C-N074). Analysis of data collected under prior HBOC-related projects (Protocols 01-C-0009; 02-C-0212; 02-C-0268) continues. Combining DNA samples and clinical data from the various HBOC studies (Hereditary Breast/Ovarian Cancer protocol, HBOC Breast Imaging protocol, and GOG-0199), we have contributed &gt; 1,100 subjects to the collaborative analyses being conducted by the Consortium of Investigators of Modifiers of <cite>BRCA1/2</cite> (CIMBA). Nearly 35 publications have resulted from this effort to date. <b>This protocol has closed to new patient accrual</b>, but translational analyses continue, utilizing the carefully-annotated biospecimens which have been collected from these study populations.&nbsp;</p>
<h3>Familial Testicular Cancer (FTC)</h3>
<p class="first-graf">The mapping of a familial testicular cancer susceptibility gene to chromosome Xq27, and the initiation of a major new DCEG testicular cancer case-control study resulted in CGB re-activating DCEG's Familial Testicular Cancer Study. We joined the International Testicular Cancer Linkage Consortium (ITCLC), and contributed DNA and clinical data from our multiple-case families to the FTC cancer susceptibility gene mapping and positional cloning effort. Standard linkage analysis failed to corroborate the Xq27 locus finding, and further suggested that the genetic basis for FTC may represent the combined effects of multiple low-penetrance genes, rather than a classical, single highly-penetrant gene. We are bringing selected testicular cancer families to the NIH Clinical Center for more detailed etiologic studies [NCI Protocol 02-C-0178]. CGB is taking the lead in performing an expert, central pathology review comparing familial with sporadic testicular cancers, and quantitatively analyzing the occurrence of malignancies other than testicular cancer in the ITCLC family set [NCI Protocol 04-C-N076]. The relationship between testicular microlithiasis and FTC risk is the current clinical focus of this project. We are also leveraging the biospecimens collected from multiple-case family members and their relatives to pursue in greater depth the recent genomewide association study results, which have identified a number of genes involved in testicular embryogenesis and fertility as strong candidate risk factors. We have demonstrated that the same genes implicated as genetic modifiers of sporadic testicular cancer risk also contribute to the risk of familial testicular cancer, and have contributed our DNA samples to an international GWAS meta-analysis which has identified 5 new genomic regions as important modifiers of testicular cancer risk.</p>
<h3>Myotonic Dystrophy (DM)</h3>
<p class="first-graf">Based on the clinical impression developed by neurologists responsible for the management of DM that their patients were developing more cancer than expected, we have become involved in trying to answer the question &ldquo;Is myotonic dystrophy a cancer susceptibility disorder?&rdquo; Initial results of our first quantitative analysis &ndash; based upon data obtained from population-based diagnosis and cancer registries, in collaboration with investigators in Sweden and Denmark &ndash; the answer appears to be &ldquo;yes.&rdquo; We have identified a highly-significant, two-fold increase in the risk of all cancers combined &ndash; an excess accounted for by cancers of the colon, endometrium, ovary and brain &ndash; among DM patients. Subsequent reports have suggested that persons with Type 1 DM are twice as likely as those with Type 2 to report a personal history of cancer, that there is no clear correlation between trinucleotide repeat length in DM1, and that the cumulative burden of cancer among DM patients is substantial. Additional work is ongoing to refine and clarify this novel observation.</p>
<h3>Genetic Polymorphisms as Determinants of Outcomes of Cancer Therapy</h3>
<p class="first-graf">DCEG has a long and distinguished history of investigating the relationship between treatments administered to patients to control an initial cancer, and the risk of subsequently developing a second cancer. This represents a unique situation in which one can study the consequences of human exposure to well defined chemical carcinogens and ionizing radiation. The opportunity exists to move these studies into the genetic arena, by investigating the relationship between common polymorphisms in genes affecting the bioavailability of chemical carcinogens and various outcomes of clinical interest. Such studies could identify population sub-groups which are at particular risk of second cancers, thrombotic events, acute myelosuppression, response to treatment or even survival. Information of this kind could have a significant impact on clinical decision-making. CGB's first foray into this arena - a study of <b>genetic polymorphisms in the genes related to tamoxifen and estrogen bioavailability and the risk of breast cancer as a result of tamoxifen exposure</b> &ndash; and it provided interesting leads related to <cite>CYP2D6</cite>, a gene involved in the metabolism of tamoxifen, and breast cancer risk.</p>
<p class="first-graf">Our ongoing study of <b>genetic polymorphisms in genes from the IGF signaling pathway</b> represents another variation on the theme of common variants within less penetrant genes as modifiers of cancer risk is Elevated levels of IGF1, a cytokine with both mitogenic and anti-apoptotic effects, have been associated with increased risks of a variety of different cancers. In collaboration with NCI&rsquo;s Core Genotyping Facility and investigators from DCEG&rsquo;s Biostatistics and Occupational/Environmental Epidemiology Branches, genetic variations in 8 genes within this signaling pathway have been identified, and are now being analyzed as determinants of advanced colorectal adenoma risk among participants of the Prostate, Lung, Colon and Ovarian Cancer screening trial. Circulating levels of IGF1, IGF2 and IGF-BP3 are also being evaluated in this nested case-control study. The first report from this project documents an increased risk of advanced colorectal adenoma in persons with the highest circulating levels of IGF1.&nbsp;</p>
<h3>Behavioral, Counseling and Psychosocial Implications Related to Being at Increased Genetic Risk of Developing Cancer</h3>
<p>Dr. Greene has implemented a strategy of actively seeking opportunities to investigate the genetic counseling, behavioral and psychosocial implications of being at increased genetic risk of cancer, since the Branch&rsquo;s inception. This is accomplished through selective incorporation of such research into our new and ongoing clinical research projects. Many of our staff (medical and pediatric oncologists, clinical geneticist, oncology genetic counselor, cancer genetics research nurse, and a marriage and family therapist) have unique training, interests and perspectives relative to this research domain, which is further supplemented by collaborations with senior behavioral research colleagues from other NIH divisions, and post-doctoral fellows (including NCI Cancer Prevention Fellows), Division of Cancer Control and Population Studies (DCCPS) and the National Human Genome Research Institute (NHGRI). Since CGB began operations 12 years ago, this activity has yielded nearly 50 publications. Projects that currently fall within this domain include (1) the ongoing development of the CEGRM (Colored Ecogenetics Relationship Map), a novel counseling tool aimed at identifying sources of social support; (2) a series of analyses focused on the lives of young <i>BRCA1/2</i> mutation carriers; (3) analyses of surgical decision-making and the influence of test ambiguity on screening behavior among <i>BRCA</i> mutation carriers; (4) a comprehensive set of psychosocial/behavioral analyses, both cross-sectional and longitudinal, among GOG-0199 study participants; and (5) initiation of data collection in our newest clinical research protocol, which targets the Li-Fraumeni syndrome.</p>
</div>
</div>]]></body>
    <field_image_promotional>349677</field_image_promotional>
  </row>
  <row term_id="302006" id="639592" title="Lisa Mirabello, Ph.D., M.S." langcode="en" field_short_title="Lisa Mirabello, Ph.D., M.S." field_page_description="Lisa Mirabello, Ph.D., biographical sketch and research interests " field_feature_card_description="Lisa Mirabello, Ph.D., biographical sketch and research interests " field_list_description="Lisa Mirabello, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2013-09-20" field_date_reviewed="2013-09-20" field_date_updated="2013-09-20" field_pretty_url="mirabello-lisa" field_browser_title="Lisa Mirabello, Ph.D., biographical sketch and research interests " field_card_title="Lisa Mirabello, Ph.D., M.S." field_email_address="Mirabellol@mail.nih.gov" field_first_name="Lisa" field_last_name="Mirabello" field_phone_number="240-276-7258" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E524">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=mirabello+l&amp;authorOption=exact&amp;pi=0013514277">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_siteid="475" sys_relationshipid="7276846" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Lisa Mirabello earned her Ph.D. in biomedical sciences with a focus on molecular population genetics and infectious disease from the University at Albany School of Public Health, State University of New York in 2007. She joined the Clinical Genetics Branch of the NCI Division of Cancer Epidemiology and Genetics as a postdoctoral Cancer Genetics Research Fellow in 2007 and was promoted to a Research Fellow in 2010. In 2013, Dr. Mirabello was appointed as an Earl Stadtman Tenure-Track Investigator in the Clinical Genetics Branch. Her research program is focused on genetic susceptibility to pediatric cancer and the genomics of HPV carcinogenicity. Dr. Mirabello has received a number of awards for her work in this area, including five DCEG Intramural Research Awards and three NCI Director&rsquo;s Intramural Innovation Awards.</p>
<h2 id="research">Research Interests</h2>
<h4>Pediatric Cancer Genomics-Osteosarcoma</h4>
<p>Osteosarcoma is the most common primary, malignant bone tumor among children and adolescents. Osteosarcoma etiology has remained poorly characterized, and metastatic disease has a poor prognosis. Dr. Mirabello is using epidemiologic studies to examine incidence patterns and identify risk groups for this rare cancer. She is using whole-genome approaches, including large genome-wide association studies and whole-exome sequencing, to comprehensively explore the relationship between genetic variation and susceptibility to osteosarcoma. Dr. Mirabello and her colleagues have completed the first international, multi-institution genome-wide association studies (GWAS) of osteosarcoma risk. She continues to conduct large genomic epidemiologic studies of osteosarcoma, and other pediatric cancers, to broadly seek novel germline genetic markers of disease risk.</p>
<p>Metastasis is responsible for approximately 90% of cancer deaths. Dr. Mirabello is interested in discovering genes and biological pathways, which could potentially lead to new strategies for early detection and treatment. She conducted the first GWAS of osteosarcoma metastasis, and with functional studies, identified a novel locus strongly linked to metastatic disease. Her work is focused on determining the role of germline genetic variation in metastatic disease and identifying genetic markers of adverse patient outcomes.</p>
<p><strong>Carcinogenic HPV Genomics</strong></p>
<p>Thirteen human papillomavirus (HPV) types cause virtually all cases of cervical cancer and a large proportion of other anogenital and oropharyngeal cancers. HPV is a common, sexually-transmitted infection, but only a small fraction of infected women progress to developing cervical precancer or cancer. Little is known about why only certain infections progress. There is huge variability in risk conferred by the different carcinogenic HPV types and, remarkably, strong differences even between closely related variant lineages within each type.</p>
<p>Dr. Mirabello is studying a large number of whole-genome sequences of carcinogenic HPV types from precancer/cancer cases and controls to understand the viral genetic basis of HPV carcinogenesis using a novel high-throughput HPV next-generation sequencing assay. HPV type 16 causes approximately half of all cervical cancers worldwide and causes most other HPV-related cancers. A primary focus of this HPV genomics project is to evaluate why HPV16 is so much more carcinogenic than closely related HPV types, and to evaluate HPV16 variants related to within type risk differences. Dr. Mirabello has evaluated HPV whole-genome sequences from over 15,000 high-risk HPV-positive women with benign infections or cervical precancer/cancer and has made several novel observations regarding HPV epidemiology and the uniquely high carcinogenicity of HPV16.</p>
</div>
</div>]]></body>
    <field_image_promotional>639592</field_image_promotional>
  </row>
  <row term_id="302006" id="802306" title="Britton Trabert, Ph.D., M.S. - Biography" langcode="en" field_short_title="Britton Trabert, Ph.D., M.S. - Biography" field_page_description="Britton Trabert, Ph.D., M.S., biographical sketch and research interests " field_feature_card_description="Britton Trabert, Ph.D., M.S., biographical sketch and research interests " field_list_description="Britton Trabert, Ph.D., M.S., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2014-07-10" field_date_reviewed="2014-07-10" field_date_updated="2014-07-10" field_pretty_url="Trabert-Britton" field_browser_title="Britton Trabert, Ph.D., M.S., biographical sketch and research interests " field_card_title="Britton Trabert, Ph.D., M.S. - Biography" field_email_address="britton.trabert@nih.gov" field_first_name="Britton" field_last_name="Trabert" field_phone_number="240-276-7331" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E422">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Trabert%20B&amp;authorOption=exact">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7252495" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<p>Dr. Britton Trabert earned her M.S.P.H. in epidemiology from Emory University, her M.S. in biostatistics from the University of Michigan, and her Ph.D. in epidemiology from the University of Washington with a focus in reproductive epidemiology and women&rsquo;s health. She joined the NCI Division of Cancer Epidemiology and Genetics (DCEG) as a Sallie Rosen Kaplan Postdoctoral Fellow in 2009, was promoted to research fellow in 2011, and was appointed as an Earl Stadtman Tenure-Track Investigator in 2014. Her research interests concentrate on the epidemiology of hormonally-related malignancies, specifically two areas: 1) the epidemiology of ovarian cancer and 2) the hormonal etiology of female cancers. Dr. Trabert has received numerous awards for her work, including the NCI Director&rsquo;s Innovation Award and NIH Fellows Award for Research Excellence.</p>
<h2 id="Research">Research Interests</h2>
<h3><b>Ovarian Cancer Epidemiology</b></h3>
<p>Until recently, scientists theorized that ovarian cancer arose from 1) microtrauma to the ovarian epithelium (outer layer) resulting from uninterrupted ovulation and 2) exposure to high levels of gonadotropin&mdash;a hormone secreted by the pituitary gland that stimulates the ovaries. Over the last decade, the understanding of the origin of ovarian cancer has changed dramatically. Morphologic and molecular studies now suggest that many high-grade serous tumors&mdash;the most common and lethal subtype&mdash;develop in the fimbria of the fallopian tubes before proliferating on the surface of the ovary. Dr. Trabert recently examined trends in fallopian tube cancers using the North American Association of Central Cancer Registries (NAACCR) demonstrating that changes in diagnostic practice have already begun.</p>
<p>This change in the understanding of the origin of many ovarian cancers indicates that the etiology is likely quite heterogeneous. However, scientists suspect that inflammation may be a common mechanistic thread. Dr. Trabert&rsquo;s research focuses on clarifying the role of both systemic and local (tubal) inflammation in ovarian carcinogenesis by histologic subtype. She has published and continues to lead studies within the Ovarian Cancer Cohort Consortium to understand the role of anti-inflammatory medications, particularly low-dose aspirin, in reducing ovarian cancer risk. In addition, she recently spearheaded a study examining the role of sexually transmitted diseases that are associated with chronic pelvic inflammation, such as Chlamydia, and ovarian carcinogenesis.</p>
<p>Dr. Trabert also led molecular studies to better understand circulating markers of inflammation and ovarian cancer within the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. She recently expanded this research by leading an analysis to evaluate associations between ovarian cancer risk and novel inflammatory markers: metabolites of arachidonic acid and linoleic acid.</p>
<h3>Hormonal Etiology of Female Cancers</h3>
<p>As evidenced by associations with menopausal hormone therapy and oral contraceptive use, hormonal factors play an important role in ovarian, endometrial, and breast cancers. However, the underlying carcinogenic mechanisms are not well understood. Surprisingly little is known about the role of endogenous hormones in ovarian and endometrial carcinogenesis, and although the role of circulating estrogens/estrogen metabolites in breast cancer etiology is established, few studies on circulating androgens and/or progesterone are available.</p>
<p>Dr. Trabert recently led a nested case-control study analysis within the Women&rsquo;s Health Initiative Observational Study (WHIOS) to evaluate the role of estrogen metabolism in ovarian and endometrial cancers. To further understand the <a href="https://dceg.cancer.gov/research/who-we-study/cohorts/bone-density-fit-study">role of endogenous hormones and cancer risk</a>, she has been a key player in the development of two novel hormone assays with colleagues at the Frederick National Laboratory for Cancer Research. These assays measure androgens and androgen metabolites, and progesterone and progesterone metabolites. Androgens and progesterone are precursors of estrogen metabolites. Experimental data suggest that androgen and estrogen exposures to the endometrial and ovarian epithelium promote tumor growth while progesterone exposure mitigates risk. Combined with the existing capacity to measure estrogens and estrogen metabolites, the ability to measure multiple androgen and progesterone metabolites will help advance our understanding of the <a href="https://dceg.cancer.gov/research/cancer-types/ovary/serum-sex-steroids-metabolites-ovarian-endometrial-cancer-whios">hormonal etiology of cancers</a> that occur in both men and women. Dr. Trabert is using these assays to analyze androgen/androgen metabolites and ovarian and endometrial cancer in WHIOS and a similar study of breast cancer within the Bone Density and Cancer Risk Follow-up Study of Women in the Fracture Intervention Trial (BFIT). In addition, she is leading novel investigations relating progesterone/progesterone metabolites to breast, ovarian, endometrial, and colorectal cancers in BFIT.</p>
<p>Dr. Trabert has contributed significantly to improving scientific understanding of the relationship between exogenous hormone use and cancer risk. Using the NIH-AARP Diet and Health study, she provided the strongest evidence to date that the use of estrogen plus progestin mitigates the increased risk of endometrial cancer observed with estrogen-only menopausal hormone therapy. More recently, Dr. Trabert and collaborators analyzed data from NIH-AARP to investigate whether the relationship between oral contraceptive use and risks for ovarian, endometrial, breast, and colorectal cancers change depending on health behaviors in the years leading up to and during menopause (for example, smoking, alcohol use, body mass index, and physical activity). In a separate study, they conducted a broad examination of oral contraceptive use and risk of many different cancers within NIH-AARP.</p>
<p>Dr. Trabert&rsquo;s research also focuses on <a href="https://dceg.cancer.gov/research/who-we-study/cohorts/infertility-treated-women-follow-up-study">cancer risk related to fertility treatment</a>, which can involve high doses of ovulation-inducing medications and in vitro fertilization (IVF) procedures. To evaluate the potential impact on cancer risk in women undergoing fertility treatment, she is leading a country-wide retrospective medical record linkage study in Israel.</p>
</div>
</div>]]></body>
    <field_image_promotional>802306</field_image_promotional>
  </row>
  <row term_id="302006" id="1052540" title="Meredith Shiels, Ph.D., biography and research interests" langcode="en" field_short_title="Meredith Shiels, Ph.D., biography and research interests" field_page_description="Meredith Shiels, Ph.D., biographical sketch and research interests" field_feature_card_description="Meredith Shiels, Ph.D., biographical sketch and research interests" field_list_description="Meredith Shiels, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-06-13" field_date_reviewed="2016-06-13" field_date_updated="2019-03-14" field_pretty_url="Shiels-Meredith" field_browser_title="Meredith Shiels, Ph.D., biographical sketch and research interests" field_card_title="Meredith Shiels, Ph.D., biography and research interests" field_email_address="shielsms@mail.nih.gov" field_first_name="Meredith" field_last_name="Shiels" field_phone_number="240-276-7182" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E218">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Shiels%20m&amp;authorOption=exact&amp;pi=0014316391">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=57&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_variantid="1422" sys_dependentvariantid="1422" sys_dependentid="302590" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7282604">Infections and Immunoepidemiology Branch</a></li>
<li>Study Website: <a href="http://hivmatch.cancer.gov/sites.html">HIV/AIDS Cancer Match Study</a></li>
</ul>
<h3><a id="Biography"></a>Biography</h3>
<p>Dr. Meredith Shiels earned her M.H.S. and Ph.D. in cancer epidemiology from the Johns Hopkins Bloomberg School of Public Health. She joined the Infections and Immunoepidemiology Branch (IIB) as a Cancer Research Training Award postdoctoral fellow in 2009. She was awarded the Sallie Rosen Kaplan Fellowship for Women Scientists in Cancer Research that same year, and was promoted to research fellow in 2011.&nbsp;In 2016, Dr. Shiels became a tenure-track investigator in IIB.</p>
<h3><a id="Research Interests"></a>Research Interests</h3>
<p>Dr. Shiels uses innovative approaches to confront high-impact public health questions with population-based data resources and descriptive analyses. She combines multiple population-based data resources, quantifies the contribution of risk factors to time trends, and disaggregates cancer incidence and mortality rates to reveal underlying patterns and explanatory mechanisms. Currently, her research program focuses on 1) quantifying cancer risk and burden in people living with HIV; 2) estimating the impact of risk factors on changing cancer rates over time; and 3) understanding rising rates of premature mortality in the United States.</p>
<h3>Cancer Risk and Burden in the HIV-infected Population</h3>
<p>Cancer is a significant comorbidity among people living with HIV and understanding the shifting landscape of cancer risk and burden has public health implications for prevention and the allocation of both research and resources. Dr. Shiels&rsquo; work among HIV-infected people quantifies the evolving epidemiology of cancer; provides insight into cancer etiology; and examines the association between HIV and cancer progression. Dr. Shiels is the co-principal investigator of the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303678" sys_contentid="303678" inlinetype="rxhyperlink" sys_variantid="1418" sys_dependentvariantid="1418" sys_dependentid="303678" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7282606">HIV/AIDS Cancer Match Study</a>, a data linkage study of population-based HIV and cancer registries in the United States. Her recent work has projected future cancer rates and burden among U.S. adults with HIV, showing a decline in the number of cases of Kaposi sarcoma and non-Hodgkin lymphoma and an increase in the number of lung and prostate cancers.</p>
<h3><strong>The Impact of Risk Factors on Trends in Cancer Rates</strong></h3>
<p>Dr. Shiels&rsquo; research program characterizes the extent to which candidate risk factors are driving observed temporal increases or decreases in cancer incidence rates. As cancer registries generally do not collect risk factor data, she uses linked databases and statistical modeling to disaggregate rates based on etiology, which is important for targeted prevention efforts. In recent studies, Dr. Shiels estimated the role of hepatitis C and hepatitis B viruses in rising rates of hepatocellular carcinoma, and the impact of the increasing prevalence of overweight and obesity on rising rates of papillary thyroid cancers.</p>
<h3>Investigating Premature Mortality Rates in the United States</h3>
<p>Dr. Shiels has additionally applied her expertise in interrogating large, population-based data to address specific public health questions related to the underlying drivers of premature mortality (deaths among 25-64-year-olds) rates in the United States, with a focus on the evolving drug overdose epidemic, which is a main contributor to rising premature mortality rates in some groups. Her recent studies have used U.S. national death certificate data to systematically assess and compare trends in premature, youth and infant mortality rates for each major cause of death by race/ethnicity and sex and to examine trends in premature overall and drug overdose death rates across measures of county-level socioeconomic status. She also has&nbsp;examined drug overdose death rates by race/ethnicity and specific contributing drug.</p>
</div>
</div>]]></body>
    <field_image_promotional>1052540</field_image_promotional>
  </row>
  <row term_id="302006" id="1088176" title="Mitchell Machiela, Sc.D., M.P.H." langcode="en" field_short_title="Mitchell Machiela, Sc.D., M.P.H." field_page_description="Mitchell Machiela, Sc.D., M.P.H., biographical sketch and research interests " field_feature_card_description="Mitchell Machiela, Sc.D., M.P.H., biographical sketch and research interests " field_list_description="Mitchell Machiela, Sc.D., M.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-06-22" field_date_reviewed="2017-06-22" field_date_updated="2017-06-22" field_pretty_url="machiela-mitchell" field_browser_title="Mitchell Machiela, Sc.D., M.P.H., biographical sketch and research interests " field_card_title="Mitchell Machiela, Sc.D., M.P.H." field_email_address="machielamj@mail.nih.gov" field_first_name="Mitchell" field_last_name="Machiela" field_phone_number="240-760-6518" field_org_name_1="National Cancer Institute" field_org_name_2="Integrative Tumor Epidemiology Branch" field_campus="300" field_office_location="Room 7E108">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=machiela%20m&amp;authorOption=exact&amp;pi=2001068726">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_contentid="302506" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302506" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7316740" sys_variantid="1422">Integrative Tumor Epidemiology Branch</a></li>
</ul>
<h2><a id="biography"></a>Biography</h2>
<p>Dr. Machiela received his M.P.H. in epidemiology from the University of Michigan and his Sc.D. in epidemiology from the Harvard T.H. Chan School of Public Health. He joined the Laboratory of Translational Genomics as a postdoctoral fellow in 2012, and transitioned to the Laboratory of Genetic Susceptibility in 2015. In 2016, he was promoted to research fellow. He was appointed to the position of Earl Stadtman Tenure-Track Investigator in 2017. Dr. Machiela has received numerous awards for his work, including two DCEG Fellowship Achievement Awards and two awards for the DCEG Outstanding Research Paper by a Fellow.</p>
<h2><a id="research"></a>Research Interests</h2>
<p>Dr. Machiela&rsquo;s research is focused on elucidating the role of germline variation and somatic mosaicism in cancer risk. He is leading studies of large-scale genetic mosaicism to investigate the causes of acquired mosaic alterations and their impact on cancer risk. He also conducts and analyzes genetic association studies to elucidate the underlying genetic architecture of different cancers (e.g. pediatric and common adult cancers).</p>
<h3>Genetic Mosaicism</h3>
<p>Genetic mosaicism results from an acquired DNA mutation that is present in some of the body's cells but not in others. A person with mosaicism has a mixture of normal and mutated cells. Dr. Machiela has published findings that estimate the frequency and distribution of mosaicism in existing genotyped collections of blood and buccal DNA. He is utilizing an unparalleled set of genotype data &ndash; 200,000 DCEG samples, 500,000 genotyped samples from the UK Biobank, and a merged international mosaicism consortium of over 1 million samples &ndash; to expand the size and scope of his research on mosaicism and cancer risk.</p>
<p>Relatively little is known of the mechanisms that initiate and select for mosaic alterations. Results from previous work suggests inherited germline variation (e.g. at <em>TCL1A</em>) or environmental exposures (e.g. smoking) may predispose to mosaicism. Dr. Machiela is utilizing genotyped samples from the UK Biobank and other datasets to examine endogenous and exogenous factors influencing acquisition of detectible mosaicism.</p>
<p>Acquired mosaic alterations have abundant potential to inform cancer etiology and drive oncogenic change. Dr. Machiela has found evidence to suggest that mosaicism increases cancer risk for hematologic malignancies and select solid tumor subtypes. He will continue to examine the influence of mosaicism on cancer risk in various populations and tissue types.</p>
<h3>Genetic Architecture of Cancer</h3>
<p>Dr. Machiela and colleagues have published several genome-wide association studies (GWAS) of common adult cancers. He is working to better understand the genomic architecture of cancer by performing genetic association studies in pediatric cancers, expanding association studies to incorporate whole-exome/genome sequencing data, and combining data on germline and somatic variation to better understand cancer genetic etiology and improve risk prediction.</p>
<p>Pediatric cancers like Ewing sarcoma (ES) provide a unique opportunity to study a homogenous tumor with potentially larger genetic contribution to risk. Dr. Machiela is leading a <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1121560" sys_contentid="1121560" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="1121560" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7316741" sys_variantid="1418">GWAS on ES to identify susceptibility regions and elucidate the underlying genetic architecture of ES</a>.</p>
<p>Dr. Machiela is the creator of a web-based tool, <a href="https://ldlink.nci.nih.gov/">LDlink</a>, which interactively explores linkage disequilibrium across 1000 Genomes population groups. LDlink is tailored for investigators interested in mapping disease susceptibility loci by generating output linking correlated alleles and highlighting putative functional variants. He is also the creator of <a href="https://authorarranger.nci.nih.gov/#/">AuthorArranger,</a> an online&nbsp;tool that&nbsp;helps researchers and consortia create and format title pages for journal submission.</p>
<p></p>
<p></p>
</div>
</div>]]></body>
    <field_image_promotional>1088176</field_image_promotional>
  </row>
  <row term_id="302006" id="1123256" title="Lene H.S. Veiga, Ph.D." langcode="en" field_short_title="Lene H.S. Veiga, Ph.D." field_page_description="Lene Veiga, Ph.D., biographical sketch and research interests " field_feature_card_description="Lene Veiga, Ph.D., biographical sketch and research interests " field_list_description="Lene Veiga, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2018-08-21" field_date_reviewed="2018-08-21" field_date_updated="2018-08-21" field_pretty_url="veiga-lene" field_browser_title="Lene Veiga, Ph.D., biographical sketch and research interests " field_card_title="Lene H.S. Veiga, Ph.D." field_email_address="veigal@mail.nih.gov" field_first_name="Lene" field_last_name="Veiga" field_phone_number="240-276-7877" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E532">
    <body><![CDATA[<div class="rxbodyfield"><a id="Top"></a>
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=veiga%20l&amp;authorOption=exact&amp;pi=0013703087">Scientific Publications</a></li>
<li><a href="https://dceg.cancer.gov/about/organization/programs-ebp/reb">Radiation Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Veiga received her M.H.S. in environmental biophysics from the Federal University of Rio de Janeiro in Brazil and a Ph.D. in cancer epidemiology from the National School of Public Health in Brazil. She worked for many years as a Research Scientist at the Brazilian Institute of Radiation Protection and Dosimetry. From 2008-2010, Dr. Veiga was a postdoctoral visiting scientist in the Radiation Epidemiology Branch (REB). After returning to Brazil, she continued to collaborate with NCI on several REB studies as a Senior Research Scientist at the Brazilian Institute of Radiation Protection and Dosimetry. From 2017-2018, Dr. Veiga was an ORISE contract worker for REB, and she was appointed as a Staff Scientist in August 2018.</p>
<h2 id="research"><a id="Research Interests"></a>Research Interests</h2>
<p>Dr. Veiga has more than thirty years of experience in the field of radiation protection and environmental and medical radiation research, with specialized expertise in radiation epidemiology and second cancers. She currently supports a number of initiatives in medical radiation, including the ongoing Pediatric CT Scans Cohorts in the UK and Canada, the Kaiser Breast Cancer Survivors Cohort, the pooled analysis of brain tumors after radiotherapy for childhood cancer, and nested case-control studies within the Childhood Cancer Survivors Study.</p>
</div>
</div>]]></body>
    <field_image_promotional>1123256</field_image_promotional>
  </row>
  <row term_id="302006" id="1125018" title="Clara Bodelon, Ph.D., M.S." langcode="en" field_short_title="Clara Bodelon, Ph.D., M.S." field_page_description="Clara Bodelon, Ph.D., M.S., Biography and research interests" field_feature_card_description="Clara Bodelon, Ph.D., M.S., Biography and research interests" field_list_description="Clara Bodelon, Ph.D., M.S., Biography and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2018-09-27" field_date_reviewed="2018-09-27" field_date_updated="2018-09-27" field_pretty_url="bodelon-clara" field_browser_title="Clara Bodelon, Ph.D., M.S., Biography and research interests" field_card_title="Clara Bodelon, Ph.D., M.S." field_email_address="bodelonc@mail.nih.gov" field_first_name="Clara" field_last_name="Bodelon" field_phone_number="240-276-7327" field_org_name_1="National Cancer Institute" field_org_name_2="Integrative Tumor Epidemiology Branch" field_campus="300" field_office_location="Room 7E238">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=bodelon%20c&amp;authorOption=exact&amp;pi=2000629061">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302506" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252392" sys_variantid="1422" sys_contentid="302506">Integrative Tumor Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Bodelon received her Ph.D. in mathematics from Boston University and then went on to get her M.S. in epidemiology from the University of Washington. Dr. Bodelon joined DCEG as a postdoctoral fellow and was awarded the Sallie Rosen Kaplan Cancer Research Training Fellowship. She was promoted to a research fellow in 2015 and became a staff scientist in the Integrative Tumor Epidemiology Branch (ITEB) in 2018.</p>
<p>Dr. Bodelon has been the recipient of multiple awards, including two Intramural Research Awards, two DCEG Fellows Awards for Research Excellence, two NIH Fellows Awards for Research Excellence, two AACR Scholar-in-Training Awards, and a Division award for the most outstanding research paper by a fellow.</p>
<h2 class="first-graf"><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Bodelon conducts integrative analyses of genomic and molecular data to characterize breast cancers. She supports several ongoing projects aimed at informing mechanisms that may underlie relationships of key breast cancer risk factors (e.g., mammographic breast density and terminal duct lobular unit [TDLU] involution) to breast cancer risk and progression. She also supports collaborative initiatives to investigate early molecular changes in the normal breast.</p>
</div>
</div>]]></body>
    <field_image_promotional>1125018</field_image_promotional>
  </row>
  <row term_id="302006" id="1134633" title="Jonas S. Almeida, Ph.D." langcode="en" field_short_title="Jonas S. Almeida, Ph.D." field_page_description="Biographical sketch and research interests of Jonas S. Almeida, Ph.D." field_feature_card_description="Biographical sketch and research interests of Jonas S. Almeida, Ph.D." field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2019-01-08" field_date_reviewed="2019-01-08" field_date_updated="2019-01-08" field_pretty_url="almeida-jonas" field_browser_title="Jonas S. Almeida, Ph.D. - biography" field_card_title="Jonas S. Almeida, Ph.D." field_email_address="jonas.dealmeida@nih.gov" field_first_name="Jonas" field_last_name="Almeida" field_phone_number="240-276-7977" field_org_name_1="National Cancer Institute" field_org_name_2="Office of the Director" field_campus="300" field_office_location="Room 7E542">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/42473640">Scientific Publications</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Jonas Almeida leads a multidisciplinary research program that combines systems biology, computational statistics, and software engineering for biomedical applications. The primary focus of his research is to accelerate the investigation of epidemiologic and genetic causes of cancer by developing innovative methods to advance the computational research infrastructure for conducting precision prevention studies of cancer.</p>
<p>Dr. Almeida seeks to identify and deliver consumer-facing architectures for precision medicine and prevention that employ cloud computing, web applications, and machine learning. He explores this interrelated computational ecosystem by developing portable software solutions that can migrate between data sources &ndash; from consumer genomics to wearable sensing devices, and between different contexts of application from patients to caregivers.</p>
<p>As Chief Data Scientist for the NCI Division of Cancer Epidemiology and Genetics (DCEG), Dr. Almeida has the dual responsibilities of 1) leading efforts for the integrated creation, management, and analysis of data-intensive knowledge bases, establishing cost-effective scalable researcher-facing analytic infrastructure, and defining new infrastructure to extract, manage, and analyze data in a scalable way to support epidemiological research within the Division; and 2) conducting independent research to advance real-time analytics of cancer &ldquo;Big Data&rdquo;. He provides support for the data and technology infrastructure used by the new prospective multi-center cohort study that will serve as an important Division-wide resource.</p>
<p>Dr. Almeida received his Ph.D. in Biological Engineering from the University Nova of Lisbon, Portugal in 1995. After a postdoctoral fellowship in computational statistics and machine learning at the University of Tennessee and Oak Ridge National Laboratory, he became an Assistant Professor in Chemistry at the University of Lisbon in 1996, followed by an appointment as an Associate Professor of Biostatistics at the Medical University of South Carolina in 2001 and as a tenured Professor of Bioinformatics in the Division of Applied Mathematics of the University of Texas MD Anderson Cancer Center in 2006. In 2008, MD Anderson awarded Dr. Almeida the endowed Abell-Hanger Distinguished Professorship in Bioinformatics. In 2011, he was recruited to be the inaugural Director of a new Division of Informatics and tenured Professor in the Department of Pathology of the University of Alabama at Birmingham. In 2015, he joined Stony Brook University as a tenured Professor and Chief Technology Officer. Dr. Almeida was appointed Chief Data Scientist of DCEG in 2019.</p>
</div>
</div>]]></body>
    <field_image_promotional>1134633</field_image_promotional>
  </row>
  <row term_id="302006" id="349597" title="Michael B. Cook, Ph.D." langcode="en" field_short_title="Michael B. Cook, Ph.D." field_page_description="Michael B. Cook, Ph.D., biographical sketch and research interests" field_feature_card_description="Michael B. Cook, Ph.D., biographical sketch and research interests" field_list_description="Michael B. Cook, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="cook-michael-b" field_browser_title="Michael B. Cook, Ph.D., biographical sketch and research interests" field_card_title="Michael B. Cook, Ph.D." field_email_address="michael.cook@nih.gov" field_first_name="Michael" field_last_name="Cook" field_phone_number="240-276-7298" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E430">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Cook%20MB&amp;authorOption=exact&amp;pi=0013132602">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7276202" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<div class="callout-box right">
<h3>Spotlight on Investigator</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1108385" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7276203">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=401212&amp;sys_siteid=475&amp;sys_contentid=1108385&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Read <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1097633" sys_dependentvariantid="1424" sys_dependentid="1097633" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276204" sys_variantid="1424" sys_contentid="1097633">Esophageal Adenocarcinoma: Disease Detectives Study Etiology, Biomarkers, and Risk</a> in the Fall 2017 <em>Linkage</em> newsletter.</p>
</div>
<p>Dr. Michael B. Cook earned his B.Sc. in genetics at the University of Nottingham, England, and, subsequently, a Ph.D. in epidemiology at the University of Leeds, England. He joined the Division of Cancer Epidemiology and Genetics as a postdoctoral fellow in 2007, was promoted to research fellow in 2008, and was appointed as a tenure-track investigator in 2011. Dr. Cook&rsquo;s research program is focused on the epidemiology of esophageal adenocarcinoma and prostate cancer. He investigates the role of excess adiposity, sex steroid hormones and reproductive factors on cancer pathogenesis, and biomarkers for diagnosis and prognosis. The overarching goal of Dr. Cook&rsquo;s research is to understand pathogenesis with potential utility for clinical management.</p>
<h2 id="research">Research Interests</h2>
<h4><strong>Esophageal Adenocarcinoma</strong></h4>
<p>Esophageal adenocarcinoma incidence has dramatically increased in the United States accompanied with a 5-year survival of less than 20%. Despite its widely-accepted pathogenesis of gastroesophageal reflux &rarr; Barrett&rsquo;s esophagus &rarr; esophageal adenocarcinoma, many etiologic questions remain and predictive biomarkers are needed to optimize prevention and diagnosis. Dr. Cook utilizes both classical and molecular epidemiologic approaches in his studies of esophageal adenocarcinoma. Specifically, he seeks to elucidate: 1) the pathogenesis and progression of this disease; 2) how excess adiposity is associated with an increased risk of this malignancy; 3) why Barrett&rsquo;s esophagus and esophageal adenocarcinoma are more prevalent in men compared with women; and 4) biomarkers for diagnosis and risk prediction. Dr. Cook is pursuing studies of sex steroid hormones, systemic inflammation, microRNAs, and other circulating and tissue-based markers in his pursuit of answers to these questions.</p>
<h4>Prostate Cancer</h4>
<p>Prostate cancer is predominantly an indolent cancer with a variable and unpredictable prognosis. Therefore, the main goals of Dr. Cook&rsquo;s prostate cancer research program are to study clinically-relevant disease&mdash;defined as aggressive, progressive, and fatal forms&mdash;to elucidate etiology and discover prognostic biomarkers. The specific aims of Dr. Cook&rsquo;s prostate cancer research program are to: 1) describe and understand the basis of racial differences; 2) elucidate the role of excess adiposity; 3) understand the etiologic roles of sex steroid hormones and reproductive factors; and 4) discover and validate tissue biomarkers to aid prediction of progression. Dr. Cook is conducting studies using age-period-cohort models, and latent class trajectory models to aid our understanding of racial differences, incidence rates and excess adiposity in relation to clinically-relevant disease. In addition, Dr. Cook is using large datasets to study endogenous and exogenous hormones as well as reproductive factors to assess these exposures in relation to prostate cancer risk. Finally, he is assessing whether computational pathology of prostate biopsy or radical prostatectomy samples may improve diagnostic and prognostic algorithms of prostate cancer.</p>
</div>
</div>]]></body>
    <field_image_promotional>349597</field_image_promotional>
  </row>
  <row term_id="302006" id="349605" title="Aime R. Kreimer, Ph.D." langcode="en" field_short_title="Aime R. Kreimer, Ph.D." field_page_description="Aime R. Kreimer, Ph.D., biographical sketch and research interests" field_feature_card_description="Aime R. Kreimer, Ph.D., biographical sketch and research interests" field_list_description="Aime R. Kreimer, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-02-25" field_pretty_url="kreimer-aimee" field_browser_title="Aime R. Kreimer, Ph.D., biographical sketch and research interests" field_card_title="Aime R. Kreimer, Ph.D." field_email_address="kreimera@mail.nih.gov" field_first_name="Aime" field_last_name="Kreimer" field_phone_number="240-276-7102" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E104">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=kreimer&amp;authorOption=exact&amp;pi=0011507933">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=56&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302590" sys_dependentvariantid="1422" sys_relationshipid="7280047" sys_variantid="1422">Infections and Immunoepidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<div class="callout-box right">
<h3>Spotlight on Investigator</h3>
<div sys_dependentvariantid="2086" sys_dependentid="902547" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7280051">
<figure class="image-left-medium centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=726267&amp;sys_siteid=475&amp;sys_contentid=902547&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p><b>Video:</b><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=900878" sys_contentid="900878" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="900878" sys_dependentvariantid="1410" sys_relationshipid="7280049" sys_variantid="1410">Aim&eacute;e Kreimer discusses her research on HPV and cancer</a><br />(Posted January 2015)</p>
</div>
<p class="first-graf">Dr. Kreimer is a senior investigator in the Infections and Immunoepidemiology Branch (IIB). She focuses her research on the etiology and prevention of <a href="/Rhythmyx/assembler/render?sys_contentid=419301&amp;sys_revision=13&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="419301" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="7280052">human papillomavirus (HPV) and cancers </a>at multiple sites, including the head and neck and anogenital region.&nbsp;Dr. Kreimer&nbsp;has particular interests in translational research, cancer etiology related to the natural history of HPV infection at multiple anatomic sites, and cancer prevention. She received a Ph.D. in infectious disease epidemiology from the Johns Hopkins Bloomberg School of Public Health in 2003.&nbsp;Dr. Kreimer&nbsp;conducted postdoctoral research at the International Agency for Research on Cancer in Lyon, France and the National Cancer Institute, NIH.</p>
<h2 id="research">Research Interests</h2>
<p id="research">Dr. Kreimer&rsquo;s scientific interests lay in the evaluation of:</p>
<ul>
<li>The performance of prophylactic HPV vaccines, with a particular focus on single-dose efficacy;</li>
<li>Understanding the natural history of HPV infections at multiple anatomic sites; and,</li>
<li>HPV 16 E6 seropositivity as a possible biomarker for HPV-driven cancers.</li>
</ul>
<p>HPV type 16 (HPV 16) infection is one of the most important human carcinogens, causing ~300,000 cancer deaths per year worldwide, the majority of which are due to cervical cancer in low-income countries. It is well established that persistent infection with HPV 16, 18, or other carcinogenic HPV genotypes is the necessary, but not sufficient, cause of cervical cancer. Infection with HPV 16 is an established risk factor for some cancers at additional anatomic sites, including cancers of the anus, oropharynx, vagina, vulva, and penis. Of note, whereas HPV type 16 causes about 50 percent of cervical cancers, at other anatomic sites, it causes upwards of 90 percent of the non-cervical HPV-driven cancers.</p>
<p>The advent of the HPV prophylactic vaccine has the potential to dramatically reduce the burden of HPV-associated cancers. Despite this success, many important research questions remain. For example, how long will the vaccine protect at the cervix? How many doses are truly needed to provide durable protection? Since the vaccine should confer immunity on all mucosal surfaces where HPV causes cancer, does the HPV vaccine provide durable protection against infections at non-cervical anatomic sites where HPV causes cancer?</p>
<p>Dr. Kreimer is co-principal investigator of the Costa Rica HPV Vaccine Trial long-term follow-up study (CVT LTFU), a study that started as a randomized controlled trial of the bivalent HPV vaccine, in collaboration with Agencia Costarricense de Investigaciones Biom&eacute;dicas (ACIB), and transitioned to an epidemiologic cohort study for the long-term follow-up phase. Using data from this study, Dr. Kreimer and colleagues were the first to demonstrate that that vaccine efficacy against incident persistent HPV 16/18 infection was comparably high among women who received three, two, or even a single dose of vaccine four years after HPV vaccination.&nbsp;They recently updated their findings and showed that a single dose continues to provide robust protection up to seven years after HPV vaccination. Her team has also documented that the bivalent vaccine strongly protects against HPV infections at essentially all non-cervical anatomic sites where HPV causes cancer in a woman (i.e., the anus, vulva, and oral region), and that the level of protection was comparably high to that observed at the cervix among the same women. The CVT LTFU field effort recently completed; women were followed for a median of 11 years following the initial vaccination. While our data on single-dose protection of the bivalent HPV are compelling, their post-hoc nature make the data inadequate to justify a formal change in current multi-dose HPV vaccine recommendations. A new trial was needed to rigorously evaluate the effectiveness and potential public health impact of a single-dose strategy.</p>
<p>Dr. Kreimer and her NCI team, again in collaboration with ACIB, implemented the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1102867" sys_contentid="1102867" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1102867" sys_dependentvariantid="1418" sys_relationshipid="7280048" sys_variantid="1418">ESCUDDO study (Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano)</a>, a large, randomized, controlled, noninferiority efficacy trial designed to formally investigate the protection afforded by a single dose of the bivalent Cervarix<sup>&reg;</sup> and nonavalent GARDASIL<sup>&reg;</sup>9 HPV vaccines in Costa Rica. The main goals of the trial are to evaluate whether, in adolescent girls, one dose or two doses of these vaccines confers strong, durable protection against persistent HPV16/18 infections. Virologic endpoints are necessary in the evaluation of a one-dose schedule, as one-dose antibody levels are inferior to those of two doses, and presently, the minimum antibody level required for protection is unknown. Separately for each vaccine, one dose will be tested for noninferiority against the two-dose regimen. Analyses will also be conducted to estimate the vaccine efficacy versus no vaccination using a concurrent population survey of comparable, unvaccinated age-matched females in the same region, who will be tested for HPV DNA and then immediately vaccinated. Immunogenicity induced by these different vaccine dose schedules and vaccine products will be compared. Study results are expected in 2025 and are intended to provide definitive results for recommending bodies, if warranted.</p>
<p>Despite the great potential of HPV vaccination, the current birth cohorts (individuals in their 30s, 40s, 50s, etc.) will not experience the protection afforded by prophylactic HPV vaccines. Therefore, screening will remain an important tool in our fight against cancer for decades as these individuals age into cancer-susceptible phases of life. Thus, continued research into possible biomarkers of HPV-driven cancers is necessary. Dr. Kreimer and colleagues from the International Agency for Research on Cancer (IARC) and the German Cancer Research Center (DKFZ) discovered that the HPV 16 E6 antibody marker predicts risk of oropharyngeal cancer years before cancer development. They validated their discovery in an independent U.S.-based NCI cohort, the Prostate, Lung, Colon, and Ovary (PLCO) Screening Trial. Based on these findings, Dr. Kreimer and team formed the HPV Cancer Cohort Consortium (HPVC3) involving nine prospective cohort studies from Europe, North America and Australia. The main aim of HPVC3 is to evaluate HPV antibodies and risk of HPV-driven cancers, with a focus on oropharyngeal and anal cancer, but also including penile, cervical, vaginal and vulvar cancer. Blood was collected up to 40 years prior to cancer diagnosis in this pooled effort. Dr. Kreimer also investigates HPV 16-E6 seroprevalence and kinetics in people without cancer.</p>
</div>
</div>]]></body>
    <field_image_promotional>349605</field_image_promotional>
  </row>
  <row term_id="302006" id="349616" title="Lindsay M. Morton, Ph.D." langcode="en" field_short_title="Lindsay M. Morton, Ph.D." field_page_description="Lindsay M. Morton, Ph.D., biographical sketch and reserch interests" field_feature_card_description="Lindsay M. Morton, Ph.D., biographical sketch and reserch interests" field_list_description="Lindsay M. Morton, Ph.D., biographical sketch and reserch interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="morton-lindsay" field_browser_title="Lindsay M. Morton, Ph.D., biographical sketch and reserch interests" field_card_title="Lindsay M. Morton, Ph.D." field_email_address="mortonli@mail.nih.gov" field_first_name="Lindsay" field_last_name="Morton" field_phone_number="240-276-7377" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E454">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=morton+lm&amp;authorOption=exact&amp;pi=0011657276">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7276849" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Morton received a B.A. from Dartmouth College and a Ph.D. in epidemiology from Yale University with a focus on cancer epidemiology. She joined DCEG in 2004 as a postdoctoral fellow with a concentration in molecular epidemiology. During her doctoral and postdoctoral training, she focused her research on understanding the causes of lymphoid neoplasms.</p>
<p>In 2008, Dr. Morton joined the Radiation Epidemiology Branch (REB) as a tenure-track investigator. She expanded her research to the study of multiple primary cancers, evaluating the carcinogenic effects of radiotherapy and chemotherapy, as well as other environmental and genetic risk factors for second cancers. In 2015, Dr. Morton was awarded scientific tenure by NIH and became a senior investigator.</p>
<p>Dr. Morton has been recognized for her research contributions with an NCI Career Development Innovation Award, an NIH Merit Award, and an NCI Director&rsquo;s Award. In addition, she received the DCEG Mentoring Award in recognition of her strong commitment to training junior scientists.</p>
<h2 id="research">Research Interests</h2>
<p>In recent decades, new treatments and early detection have dramatically improved survival following a cancer diagnosis. However, new malignancies, or &ldquo;second cancers,&rdquo; are a leading cause of morbidity and mortality among survivors. The overarching goal of Dr. Morton&rsquo;s research program is to quantify the risk of second cancers in different groups of cancer survivors, and to elucidate the causes of second cancers. The results from her studies can be used to better understand the biology of cancer and to inform clinical practice (e.g., treatment risks and benefits and long-term follow-up of cancer survivors).</p>
<h3>Genetic Susceptibility to Second Cancers</h3>
<p>With rapid advances in technology in the last decade, scientists have dramatically increased their understanding of cancer predisposition, finding inherited genetic markers that are associated with risk for a particular disease. Dr. Morton is leading DCEG efforts to identify genetic variants associated with the development of second cancers, either independent of treatment exposures or that act jointly with specific treatments. Key studies in this collaboration are the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302605" sys_dependentvariantid="1418" sys_dependentid="302605" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276850" sys_variantid="1418" sys_contentid="302605">Childhood Cancer Survivor Study</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303648" sys_dependentvariantid="1418" sys_dependentid="303648" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276851" sys_variantid="1418" sys_contentid="303648">NCI&rsquo;s Long-Term Follow-Up Study of Retinoblastoma Survivors</a>, both of which have the rare combination of detailed medical record data, long-term follow-up of childhood cancer survivors with information on occurrence of second cancers, and available DNA.</p>
<h3>Treatment-Related Second Cancers</h3>
Primary cancer treatments are an important focus of second cancers research. Dr. Morton has an interest in the role of both radiotherapy and chemotherapy in second primary gastrointestinal malignancies, having recently completed a <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302397" sys_dependentvariantid="1418" sys_dependentid="302397" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276852" sys_variantid="1418" sys_contentid="302397">multi-center international study of second primary gastrointestinal (GI) cancers</a> occurring among survivors of Hodgkin lymphoma and cancers of the breast, cervix, and testis. Dr. Morton also expanded on her long-standing interest in hematopoietic malignancies by investigating treatment-related myelodysplasia and leukemia following radiotherapy and chemotherapy. This research focuses on quantifying the risk of myelodysplasia and leukemia in patients treated in the modern era, in which known cytotoxic chemotherapies have been increasingly used. Finally, Dr. Morton is leading several studies aimed at identifying second cancer risks in high-risk populations, such as recipients of solid organ and hematopoietic stem cell transplants.</div>
</div>]]></body>
    <field_image_promotional>349616</field_image_promotional>
  </row>
  <row term_id="302006" id="349618" title="Hormuzd A. Katki, Ph.D." langcode="en" field_short_title="Hormuzd A. Katki, Ph.D." field_page_description="Hormuzd Katki, Ph.D., biographical sketch and research interests" field_feature_card_description="Hormuzd Katki, Ph.D., biographical sketch and research interests" field_list_description="Hormuzd Katki, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2018-06-25" field_pretty_url="katki-hormuzd" field_browser_title="Hormuzd Katki, Ph.D., biographical sketch and research interests" field_card_title="Hormuzd A. Katki, Ph.D." field_email_address="HK33Q@nih.gov" field_first_name="Hormuzd" field_last_name="Katki" field_phone_number="240-276-7423" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E592">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=katki%20h&amp;authorOption=exact&amp;pi=0010039269">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422" sys_relationshipid="7276773" sys_siteid="475" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Hormuzd A. Katki received a B.S. in math from the University of Chicago and an M.S. in statistics from Carnegie-Mellon University. He received a Ph.D in biostatistics from Johns Hopkins University in 2006, where he received the Margaret Merrell Award for research by a biostatistics doctoral student. Dr. Katki joined NCI in 1999, became a principal investigator in 2009, and was appointed senior investigator upon receiving NIH scientific tenure in 2015.&nbsp;</p>
<h2 id="research">Research Interests</h2>
<p>Dr. Katki&rsquo;s research focuses on understanding how epidemiologic findings could be used for cancer screening and prevention. &nbsp;&nbsp;He is particularly interested in developing individualized risk-based approaches to cancer screening. His methodologic research focuses on estimating individual absolute risk, strategies for risk-based screening and management, and metrics for evaluating risk models and biomarkers.&nbsp; Dr. Katki is interested in mentoring both statisticians interested in cancer research, and also epidemiologists who want to use state-of-the-art quantitative and computational methods. If you are interested in a fellowship with Dr. Katki, please see our <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302382" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="302382" sys_dependentvariantid="1418" sys_relationshipid="7276772" sys_siteid="475" sys_variantid="1418" sys_contentid="302382">research training opportunities</a>.</p>
<h4>Lung Cancer Screening</h4>
<p>In spite of the definitive <a href="https://www.cancer.gov/types/lung/research/nlst">National Lung Screening Trial (NLST)</a> and USPSTF guidelines recommending screening, CT lung-cancer screening is still not widespread.&nbsp; This is partly due to the inefficiency of screening.&nbsp; To make screening more efficient, Dr. Katki conducts research on using risk calculations to better identify those who benefit the most from lung screening and to propose risk-based management options during the course of screening.</p>
<p>Dr. Katki developed validated individualized risk models for lung cancer incidence (<a href="https://analysistools.nci.nih.gov/lungCancerRiskAssessment/">LCRAT: Lung Cancer Risk Assessment Tool</a>) and mortality (<a href="https://analysistools.nci.nih.gov/lungCancerRiskAssessment/">LCDRAT: Lung Cancer Death Risk Assessment Tool</a>).&nbsp; Using these models to select ever-smokers at highest risk should improve screening effectiveness and efficiency versus current USPSTF guidelines.&nbsp; To empower doctors and patients with risk information needed to decide about undergoing screening, Dr. Katki collaborates with Dr. William Klein to improve the NCI lung cancer screening risk tool, the <a href="https://analysistools.nci.nih.gov/lungCancerScreening/">Risk-based NLST Outcomes Tool (RNOT)</a>.</p>
<p>The R package <a href="http://dceg.cancer.gov/tools/risk-assessment/lcmodels">lcmodels</a> estimates risk from 9 published lung cancer models: LCRAT, LCDRAT, Bach, PLCO<sub>M2012</sub>, Spitz, Hoggart, LLP, LLPi, and Pittsburgh.&nbsp; The R package <a href="https://dceg.cancer.gov/tools/risk-assessment/lcrisks">lcrisks</a> provides the risk calculators that are used by RNOT.</p>
<p>Dr. Katki is conducting research on a Markov model for updating individual lung cancer risk with CT image findings during the course of screening.&nbsp; This model may be useful to extend screening intervals for those at sufficiently low risk of developing lung cancer.</p>
<h4>Risk Models for Epidemiology</h4>
<p>Dr. Katki is interested in developing models for individualized risk estimation.</p>
<p>Dr. Katki has developed risk models for screening data, where some disease is already present at baseline (left-censored), some disease occurs between consecutive visits (interval censored), and some disease is unknown if it was prevalent or incident.&nbsp; These models, the logistic-Weibull and logistic-Cox models, can be accessed as part of R package <a href="https://dceg.cancer.gov/tools/analysis/pimixture/PIMixture">PImixture</a>.&nbsp; The models allow sampling weights.</p>
<p>He has helped develop methods and software for calculating absolute risk for case-cohort studies, or case-control studies nested within cohorts (also known as &ldquo;two-phase sampling&rdquo;) which is in the R package <a href="https://dceg.cancer.gov/tools/analysis/nested-cohort">NestedCohort</a>.</p>
<p>He has proposed <a href="http://www.ncbi.nlm.nih.gov/pubmed/22865328">a hybrid risk regression model called &ldquo;LEXPIT&rdquo;</a> that allows for both additive and multiplicative effects in logistic regression, and allows sampling weights.&nbsp; LEXPIT is in the R package <a href="https://cran.r-project.org/web/packages/blm/index.html">blm</a>.</p>
<p>Dr. Katki is conducting research on improving the external validity of epidemiologic cohort analyses by including data from nationally representative surveys.</p>
<p>Dr. Katki is also helping with research to develop individualized models of years of life gained by screening to select people for screening.&nbsp; Years of life gained is a measure of the benefit of screening, and as such is more relevant than simply using risk to select people for screening.</p>
<h4>Metrics for evaluating diagnostic tests and risk prediction models</h4>
<p>Dr. Katki is interested all aspects of evaluating the potential of new biomarkers for clinical use.</p>
<p>In particular, he has done research quantify <em>risk stratification</em>, the ability of a test or model to separate those at high-risk from those at low-risk.&nbsp; His metric Mean Risk Stratification (MRS) is the average change in a person&rsquo;s risk that is revealed by using a risk model or test. &nbsp;MRS better compares tests across populations with different disease prevalence by interpreting AUC in the context of prevalence.&nbsp; He has used MRS to compare the risk stratification from cervical screening tests and risk models to identify who in a family carries a mutation in <em>BRCA1/2</em>.&nbsp; The MRS webtool is part of the <a href="https://analysistools.nci.nih.gov/biomarkerTools/">Biomarker Tools Suite</a>.</p>
<p>Dr. Katki has developed methods for calculating diagnostic accuracy and agreement statistics under verification bias, when one test is conducted on only a subsample of specimens, in R package <a href="http://cran.r-project.org/web/packages/CompareTests/index.html">CompareTests</a>.</p>
<h4>Cervical Cancer Screening and HPV-related cancers</h4>
<p>Dr. Katki he led a team that calculated cervical cancer risks, using the logistic-Weibull model, for women using data on 1.4 million women at Kaiser Permanente Northern California (KPNC). These risks enabled guidelines to ensure &ldquo;<a href="https://www.ncbi.nlm.nih.gov/pubmed/27323876">equal management of women at equal risk of cancer</a>&rdquo;. The resulting 2012 American Society for Colposcopy and Cervical Pathology Consensus Guidelines and the eight reports with the supporting data were published in a 2013 supplement of the <a href="http://journals.lww.com/jlgtd/toc/2013/04001"><em>Journal of Lower Genital Tract Disease</em></a> .&nbsp;</p>
<p>He developed the &ldquo;Risk Bar&rdquo; for the <a href="http://www.asccp.org/store-detail2/asccp-mobile-app">risk-based App for the Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors</a>, based on woman&rsquo;s history of HPV, Pap smear, and biopsy results.&nbsp;</p>
<p>Dr. Katki collaborates with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/chaturvedi-anil">Dr. Anil Chaturvedi</a> on oral HPV and oropharyngeal cancer, conducting research on natural history with an eye towards future prevention.</p>
<h4>Population-based mutation screening</h4>
<p>Dr. Katki is developing risk-based approaches to help propose risk-based screening programs for genetic mutations, such as for <em>BRCA1</em> and <em>BRCA2</em>.</p>
<br />
<h2>Software</h2>
<h4>Webtools</h4>
<ul>
<li><a href="http://www.asccp.org/store-detail2/asccp-mobile-app">Official risk-based App for US Cervical Cancer Screening Guidelines</a></li>
<li>Individualized risk models for lung cancer: <a href="https://analysistools.nci.nih.gov/lungCancerRiskAssessment/">Lung Cancer Risk Assessment Tool (LCRAT) and Lung Cancer Death Risk Assessment Tool (LCDRAT)</a></li>
<li>NCI lung cancer screening risk tool: <a href="https://analysistools.nci.nih.gov/lungCancerScreening/">Risk-based NLST Outcomes Tool (RNOT)</a></li>
<li><a href="https://analysistools.nci.nih.gov/biomarkerTools/">NCI Biomarker Tools Suite</a> for calculating Mean Risk Stratification (MRS)</li>
</ul>
<h4>R Software</h4>
<ul>
<li>R package <a href="https://cran.r-project.org/web/packages/CompareTests/index.html">CompareTests</a> to correct for verification bias in diagnostic accuracy and agreement</li>
<li>R package <a href="https://cran.r-project.org/web/packages/NestedCohort/index.html">NestedCohort</a> for survival analysis for case-cohort studies or case-control studies nested in cohorts.</li>
<li>R package <a href="https://cran.r-project.org/web/packages/blm/index.html">blm</a> for the LEXPIT binary risk regression model that handles both logistic and additive effects.</li>
<li>R package <a href="http://dceg.cancer.gov/tools/risk-assessment/lcmodels">lcmodels</a> to calculate risks from 9 published lung cancer risk models</li>
<li>R package <a href="https://dceg.cancer.gov/tools/risk-assessment/lcrisks">lcrisks</a> to calculate risks from LCRAT, LCDRAT, and a model risk for false-positive lung CT screen</li>
<li>R package <a href="https://dceg.cancer.gov/tools/analysis/pimixture/PIMixture">PImixture</a> to calculate risks from screening program data using the logistic-Weibull and logistic-Cox models.</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349618</field_image_promotional>
  </row>
  <row term_id="302006" id="349619" title="Demetrius Albanes, M.D. " langcode="en" field_short_title="Demetrius Albanes, M.D. " field_page_description="Demetrius Albanes, M.D., Biographical sketch and research interests" field_feature_card_description="Biographical sketch and research interests of Demetrius Albanes, M.D." field_list_description="Demetrius Albanes, M.D. - Biographical sketch and research interests of " field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-08" field_pretty_url="albanes-demetrius" field_browser_title="Demetrius Albanes, M.D., Biographical sketch and research interests" field_card_title="Demetrius Albanes, M.D. " field_email_address="albanesd@mail.nih.gov" field_first_name="Demetrius" field_last_name="Albanes" field_phone_number="240-276-7212" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E342">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=albanes%20d&amp;authorOption=exact&amp;pi=0010765397">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7252362" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Albanes received a B.S. in biology from the State University of New York at Stony Brook and his M.D. degree from the Medical College of Wisconsin. Dr. Albanes entered the Epidemic Intelligence Service of the Centers for Disease Control (CDC) through which he began working in the cancer prevention program of the NCI in 1982. Thereafter, Dr. Albanes completed a Preventive Medicine residency with the CDC and continued his research in the Cancer Prevention Studies Branch of NCI from 1984 to 1990, when he received scientific tenure. He joined the Division of Cancer Epidemiology and Genetics in 2000 as a senior investigator in the Nutritional Epidemiology Branch, and served as Chief of the DCEG Office of Education until 2008. Dr. Albanes is principal investigator of the landmark <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303743" sys_dependentvariantid="1418" sys_dependentid="303743" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252363" sys_variantid="1418" sys_contentid="303743">Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Study</a> and serves as chair of the NIH Committee on Scientific Conduct and Ethics.</p>
<p><a href="#top">Back to Top</a></p>
<h2><a id="Research"></a>Research Interests</h2>
<p>Dr. Albanes conducts a molecular epidemiologic program that is focused on prostate and other cancers in relation to micronutrients (particularly vitamins D, E, and A), vitamin supplementation, and metabolite profiles through biochemical, genetic, and mechanistic investigations. His recent prospective metabolomics studies have discovered novel serologic profiles for prostate cancer, glioma, and vitamin supplementation and serum status. Dr. Albanes has also highlighted the importance of hyperinsulinemia, a hyperthyroid state, higher vitamin D and A status, and lower vitamin E status in elevated prostate cancer risk. This high-incidence malignancy is of essentially unknown etiology other than being more frequent in men with a first-degree family history of the disease, in African-Americans, and being associated with over 100 common genetic variants.</p>
<p><a href="#top">Back to Top</a></p>
<h3>Micronutrients and Cancer</h3>
<p>Our ATBC Study found 18% higher lung cancer incidence in men supplemented with 20 mg beta-carotene daily for 5-8 years, and 32% lower prostate cancer incidence in those receiving 50 IU vitamin E. We did not confirm the latter finding in the Selenium and Vitamin E Cancer Prevention Trial (SELECT), but rather showed 17% higher prostate cancer incidence in men receiving 400 IU vitamin E daily. The latter findings indicated that supplementation with supra-physiological vitamin dosages could have deleterious health outcomes and highlighted the importance of large controlled trials in cancer epidemiological research. By contrast, that a low, physiological dose of vitamin E may prevent prostate cancer remains an active hypothesis that we have pursued through cohort, nested case-control, genetic, and experimental investigations.</p>
<p>We are comprehensively investigating the role of vitamin D in cancer because the epidemiological data have been inconsistent and there has been a widespread presumption of the beneficial effects of supplementation. Our studies include prospective nested case-control studies measuring the accepted biomarker of vitamin D status, 25-hydroxy-vitamin D (25(OH)D), and its major carrier protein, vitamin D binding protein (DBP); genetic analyses; and ChIP-Seq cell culture experiments testing biological mechanisms. Based in part on our research, there is a growing consensus in the field that, 1) men with higher vitamin D status are at increased risk of prostate cancer, 2) a beneficial, preventive association exists for colorectal cancer, and, 3) null associations exist for most other organ sites, including breast cancer. Many of these biochemical associations are supported by our analyses of vitamin D genetic variants/polygenic scores based on our genome-wide association study (GWAS) findings for the 25(OH)D phenotype. We have also shown that serum DBP both modifies vitamin D risk associations (e.g., for prostate and pancreatic cancer) and directly affects risk (e.g., inverse association in prostate cancer in black men). Cell culture ChIP-Seq experiments we are conducting in collaboration with our DCEG Laboratory of Translational Genomics are examining the effects of vitamins D (and E) on prostate cancer growth, VDR-AR-RXR nuclear receptor interactions, and gene transcription sites. We are also studying the role of vitamin D in cancer survival, finding that higher serum 25(OH)D years prior to diagnosis predicts improved survival of prostate, and possibly renal, gastric, pancreatic and liver cancers.</p>
<p><a href="#top">Back to Top</a></p>
<h3><a id="Metabolomic-Profiling"></a>Metabolomic Profiling of Cancer Risk</h3>
<p>Identifying effective serologic biomarkers of cancer risk and early detection are critical to its prevention and reduction of mortality. Metabolomic profiling of blood represents a relatively new agnostic, "broad-spectrum" approach for examining potential metabolic biomarkers of risk. We initiated a program to investigate prospectively serum metabolites associated with cancer risk, and found strong inverse associations between energy and lipid metabolites and aggressive prostate cancer, including for inositol-1-phosphate, glycerophospholipids and fatty acids, as well as TCA cycle compounds alpha-ketoglutarate and citrate. Prostate cancer survival appears related to androgen and endocannabinoid metabolism. We showed a very different profile for risk of glioma, with 2-oxoarginine, cysteine, chenodeoxycholate and argininate being the strongest metabolite signals (inversely related), along with several xanthine metabolites related to caffeine metabolism being elevated in cases. The observed patterns provide new potential leads regarding the molecular basis relevant to etiologic or sub-clinical biomarkers for prostate cancer and glioma that we are pursuing in the <a href="https://epi.grants.cancer.gov/comets/">Consortium of Metabolomics Studies</a> (COMETS).</p>
<p><a href="#top">Back to Top</a></p>
<h3><a id="Metabolomic-and-Genetic"></a>Metabolomic and Genetic Studies of Vitamin Status</h3>
<p>Within the ATBC Study, we conducted a serum metabolomic profile of response to beta-carotene supplementation that revealed dysregulation of xenobiotic metabolism. We have observed a number of lipid metabolites associated with serum vitamin D, including for example, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), and the omega-3 essential fatty acids eicosapentaenoate (EPA) and docosahexaenoate (DHA), and found several metabolites associated with serum vitamin A (retinol), including N-acetyltryptophan), myo-inositol and inositol metabolism, which is of great interest given that we had found inositol 1-phosphate strongly associated with aggressive prostate cancer in the study described above. Such findings provide new biological clues relevant to the role of vitamins in human carcinogenesis.</p>
<p>We participate in large international cancer consortia that have identified hundreds of low-penetrance genetic variants associated with risk, and applied these GWAS data to serum vitamin status (including supplementation). For example, we identified four genes associated with vitamin D status&mdash;<em>GC</em>, <em>CYP2R1</em>, <em>DHCR7</em>, and <em>CYP24B1&mdash;</em>which collectively explained ~5 percent of vitamin D variance, and found their genetic vitamin D score was associated with prostate cancer risk in the same causal direction as our serum studies have shown. These Mendelian randomization studies provide an unbiased confirmation of our biochemical data.</p>
<p><a href="#top">Back to Top</a></p>
</div>
</div>]]></body>
    <field_image_promotional>349619</field_image_promotional>
  </row>
  <row term_id="302006" id="349643" title="Jackie Lavigne Ph.D., M.P.H." langcode="en" field_short_title="Jackie Lavigne Ph.D., M.P.H." field_page_description="Jackie Lavigne Ph.D., M.P.H., biographical sketch" field_feature_card_description="Jackie Lavigne Ph.D., M.P.H., biographical sketch" field_list_description="Jackie Lavigne Ph.D., M.P.H., biographical sketch&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-05-02" field_pretty_url="lavigne-jackie" field_browser_title="Jackie Lavigne Ph.D., M.P.H., biographical sketch" field_card_title="Jackie Lavigne Ph.D., M.P.H." field_email_address="lavignej@mail.nih.gov" field_first_name="Jackie" field_last_name="Lavigne" field_phone_number="240-276-7237" field_org_name_1="National Cancer Institute" field_org_name_2="Office of Education" field_campus="300" field_office_location="Room 7E450">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<h2>Biography</h2>
<div class="callout-box right">
<h3>Summer Interns Featured in Video</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1065400" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7329162">
<figure class="image-left-small centered-set">
<div class="centered-element"><img alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=800245&amp;sys_siteid=475&amp;sys_contentid=1065400&amp;sys_command=edit" /><!--Comment--></div>
</figure>
</div>
<p>DCEG <!--2016--> summer interns describe what they learned and valued most about their time in the Division.</p>
<p><b>Watch:</b> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1430&amp;sys_contentid=1064855" sys_contentid="1064855" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1430" rxinlineslot="103" sys_dependentid="1064855" sys_variantid="1430" sys_relationshipid="7329161">DCEG Summer Interns</a></p>
</div>
<p>Dr. Lavigne received her bachelor's degree from Colby College in Waterville, ME. She then earned a Ph.D. in molecular toxicology and an M.P.H with a concentration in epidemiology and biostatistics from the Johns Hopkins Bloomberg School of Public Health in Baltimore, MD. She completed her postdoctoral training in the National Cancer Institute (NCI)'s Cancer Prevention Fellowship Program (CPFP), conducting research on the role of insulin-like growth factors in diet-related cancer. Subsequently, she joined NCI's Center for Cancer Research as a Scientific Program Specialist, became Associate Director of CPFP in 2006, and has served as the Chief of the Office of Education in the NCI&rsquo;s Division of Cancer Epidemiology and Genetics since 2008. In this role, she oversees the division&rsquo;s fellowship training program, which was awarded the inaugural Alexander D. Langmuir Award for Training Program Excellence and Innovation by the North American Congress of Epidemiology in 2011. She is experienced in mentoring, coaching, and training junior scientists and received the NCI&rsquo;s Outstanding Mentor Award in 2008. &nbsp;In addition, she received the NCI&rsquo;s Leading Diversity Award in 2015 for her work with trainee populations underrepresented in the sciences. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1042858" sys_contentid="1042858" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" rxinlineslot="103" sys_dependentid="1042858" sys_variantid="1418" sys_relationshipid="7329159">In 2016, Dr. Lavigne was recognized in <em>Cancer</em> for her contributions to promote diversity at NCI and beyond</a>. She also received a 2016 Distinguished Alumna Award from the Johns Hopkins Bloomberg School of Public Health.</p>
</div>
</div>]]></body>
    <field_image_promotional>349643</field_image_promotional>
  </row>
  <row term_id="302006" id="349657" title="Philip S. Rosenberg, Ph.D. " langcode="en" field_short_title="Philip S. Rosenberg, Ph.D. " field_page_description="Philip S. Rosenberg, Ph.D., biographical sketch and research interests " field_feature_card_description="Philip S. Rosenberg, Ph.D., biographical sketch and research interests " field_list_description="Philip S. Rosenberg, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2013-08-12" field_pretty_url="rosenberg-philip" field_browser_title="Philip S. Rosenberg, Ph.D., biographical sketch and research interests " field_card_title="Philip S. Rosenberg, Ph.D. " field_email_address="rosenbep@mail.nih.gov" field_first_name="Philip" field_last_name="Rosenberg" field_phone_number="240-276-7312" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E130">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=Rosenberg+PS&amp;authorOption=exact&amp;pi=0010194752">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_relationshipid="7276651" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Philip Rosenberg received a Ph.D. in biostatistics from Yale University. He joined the NCI as a Staff Fellow in 1988, and became a Senior Investigator within the Biostatistics Branch in 1997. Dr. Rosenberg&rsquo;s research focuses on advancing medical science by testing clinical, epidemiological, and biological hypotheses using state-of-the-art statistical methods. Dr. Rosenberg has received numerous awards for his work in biostatistics, including the Howard W. Temin Award for his contribution to the development of statistical methods to monitor trends in the HIV. He has received NIH Merit Awards for his collaborative work on inherited bone marrow failure syndromes, as well as for pioneering methods and software tools to identify candidate genes and pathways.</p>
<h2 id="research">Research Interests</h2>
<h4>Risk Models for Inherited Bone Marrow Failure Syndromes</h4>
<p>Dr. Rosenberg has a special interest in rare cancers arising in the inherited bone marrow failure syndromes, including Fanconi anemia (a disorder of DNA repair), severe congenital neutropenia (a disorder characterized by very low numbers of neutrophils, a type of white blood cell that ingests harmful foreign particles, especially bacteria), and dyskeratosis congenita (a disorder of telomere maintenance).</p>
<p>Dr. Rosenberg has developed and validated &lsquo;competing risks&rsquo; models for Fanconi anemia and severe congenital neutropenia. He and his colleagues continue to assess risks of solid tumors and acute myeloid leukemia for these syndromes in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=26&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303691" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7276650" sys_dependentvariantid="1418" sys_dependentid="303691" rxinlineslot="103" sys_variantid="1418" sys_contentid="303691"></a>. Dr. Rosenberg has also expanded his work and is developing statistical models for other cancer predisposition syndromes, such as Dyskeratosis Congenita.</p>
<h4>Descriptive Epidemiology Studies</h4>
<p>Dr. Rosenberg is a co-principal investigator on a series of descriptive studies of breast cancer. Among these studies, he focuses on identifying secular trends in prognosis, underlying causes of racial disparity, and etiological heterogeneity of breast tumors. Dr. Rosenberg&rsquo;s novel statistical methods were also used to establish etiological heterogeneity within an array of different cancers, including hairy cell leukemia, Burkitt Lymphoma, and non-cardia gastric cancers.</p>
<p>Dr. Rosenberg also works on developing new methods for cancer surveillance research, including novel methods based on the age-period-cohort model, proportional hazards models for comparative age-period-cohort analysis, and methods to forecast the future burden of cancer.</p>
<p><span>Read about Dr. Rosenberg's&nbsp;collaboration in&nbsp;</span><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=968240" sys_dependentvariantid="1418" sys_dependentid="968240" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7276656" sys_variantid="1418" sys_contentid="968240"></a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=968240" sys_dependentvariantid="1418" sys_dependentid="968240" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7276657" sys_variantid="1418" sys_contentid="968240">innovative age-period-cohort modeling</a><span>.</span></p>
<h4>Genetic and Environmental Epidemiology</h4>
<p>Dr. Rosenberg develops statistical approaches to analyze candidate genes and pathways. He is a collaborator on the population-based Shanghai Biliary Tract Cancer Study, the Central and Eastern European Renal Cancer Study, and the Second Multicenter Hemophilia Cohort Study. For these studies, Dr. Rosenberg helps develop cutting-edge analytical methods and software tools to analyze SNPs in candidate genes and pathways and their associations to cancer. Some of the pathways that he and his colleagues are exploring include vitamin D metabolism, cell differentiation, apoptosis, and lipid peroxidation.</p>
</div>
</div>]]></body>
    <field_image_promotional>349657</field_image_promotional>
  </row>
  <row term_id="302006" id="349661" title="Laura Beane Freeman, Ph.D. " langcode="en" field_short_title="Laura Beane Freeman, Ph.D. " field_page_description="Laura Beane Freeman, Ph.D., biographical sketch and research interests" field_feature_card_description="Laura Beane Freeman, Ph.D., biographical sketch and research interests" field_list_description="Laura Beane Freeman, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-01-30" field_pretty_url="beane-freeman-laura" field_browser_title="Laura Beane Freeman, Ph.D., biographical sketch and research interests" field_card_title="Laura Beane Freeman, Ph.D. " field_email_address="freemala@mail.nih.gov" field_first_name="Laura" field_last_name="Beane Freeman" field_phone_number="240-276-7439" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E136">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=beane-freeman%20l&amp;authorOption=exact&amp;pi=0011507917">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7276810" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="biography"><a id="Biography"></a>Biography</h2>
<p>Dr. Beane Freeman received her doctorate in epidemiology from the University of Iowa in 2003 and completed postdoctoral training in the Occupational and Environmental Epidemiology Branch (OEEB). In 2009 she was appointed to the tenure track, and was awarded scientific tenure by the NIH in 2017. She is the NCI Principal Investigator of the Agricultural Health Study, the Early Life Exposures in Agriculture Study and the NCI Formaldehyde Industries cohort. Dr. Beane Freeman has received numerous awards recognizing her work, including two NCI Director&rsquo;s Innovation Awards, and the DCEG Mentoring Award. In 2016, Dr. Beane Freeman was elected to the Management Group of the International Epidemiology in Occupational Health (EPICOH) society.</p>
<h2 id="research"><a id="Research-Interests"></a>Research Interests</h2>
<p>The focus of Dr. Beane Freeman&rsquo;s work includes investigating cancer risk associated with a number of occupational and environmental exposures. Specifically, she conducts research related to the agricultural environment, including pesticides; industrial chemical exposures such as formaldehyde; and drinking water contaminants, such as disinfection by-products.</p>
<h3>Agricultural Exposures</h3>
<p>Studies around the world have observed that farmers and other agricultural workers are at elevated risk of several specific cancers, despite lower overall mortality and, in particular, cancer mortality. In this occupational group, excess risks are observed for Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, multiple myeloma, and cancers of the brain, skin, lip, stomach, and prostate. Exposures suspected of contributing to the excesses include pesticides, viruses, mycotoxins, well-water contaminants, and a variety of other agents encountered in the agricultural environment.</p>
<p>The <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303742" sys_contentid="303742" inlinetype="rxhyperlink" sys_variantid="1418" sys_relationshipid="7276811" sys_dependentvariantid="1418" sys_dependentid="303742" rxinlineslot="103" sys_siteid="475">Agricultural Health Study</a> is a collaboration of the NCI, the National Institute of Environmental Health Sciences, the National Institute for Occupational Safety and Health, and the Environmental Protection Agency to evaluate agricultural exposures that may be related to cancer and other health outcomes. This prospective cohort study of approximately 90,000 participants includes licensed private pesticide applicators and their spouses in Iowa and North Carolina, and commercial applicators in Iowa.</p>
<p>In addition to pesticides, Dr. Beane Freeman is investigating other exposures within the agricultural environment such as exposure to livestock and poultry, diesel exhaust and endotoxins and other bioaerosols. There is increasing evidence that early life exposures may influence disease risk in adulthood. Therefore, she has initiated a study of offspring of the AHS participants to investigate how their childhood farm exposures may affect their health in later life. Finally, she is actively collaborating within the AGRICOH consortium, a collection of agricultural cohorts around the world, to replicate and extend a number of findings in the AHS.</p>
<h3>Formaldehyde</h3>
<p>Dr. Beane Freeman&rsquo;s research on formaldehyde exposure and cancer risk has focused on (1) whether occupational exposure to formaldehyde increases the risk of cancer at a number of sites, specifically the respiratory tract and lymphohematopoietic malignancies, and (2) the biologic plausibility of formaldehyde carcinogenicity, particularly at sites distant from the respiratory tract. She conducts this work within the NCI Cohort of Workers in Formaldehyde Industries, the largest study of occupationally exposed workers, including over 25,000 participants. The most recent follow-up on this study added another 10 years of mortality data, allowing sufficient person years to explore effects at different time periods and offered further insight into temporality of potential associations between formaldehyde and leukemia and other lymphohematopoietic malignancies.</p>
<h3>Drinking Water Contaminants</h3>
<p class="first-graf">Water disinfection&mdash;a public health triumph&mdash;reduces morbidity and mortality due to infectious disease. However, by-products resulting from the chemical reactions of disinfectants and organic matter in the water have been linked to increased risk of bladder cancer. This important public health concern raises many interesting and unresolved scientific questions related to the specific etiologic agents in the chemical mixture, as well as risks associated with route of exposure and overall exposure. To address these gaps, Dr. Beane Freeman leads ongoing&nbsp;investigations of bladder cancer risk using the most comprehensive exposure assessment of disinfection by-products to date.</p>
</div>
</div>]]></body>
    <field_image_promotional>349661</field_image_promotional>
  </row>
  <row term_id="302006" id="349682" title="Barry I. Graubard, Ph.D. " langcode="en" field_short_title="Barry I. Graubard, Ph.D. " field_page_description="Barry I. Graubard, Ph.D., biographical sketch and research interests" field_feature_card_description="Barry I. Graubard, Ph.D., biographical sketch and research interests" field_list_description="Barry I. Graubard, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2018-05-08" field_pretty_url="graubard-barry" field_browser_title="Barry I. Graubard, Ph.D., biographical sketch and research interests" field_card_title="Barry I. Graubard, Ph.D. " field_email_address="graubarb@mail.nih.gov" field_first_name="Barry" field_last_name="Graubard" field_phone_number="240-276-7316" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E140">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=graubard%20bi&amp;authorOption=exact&amp;pi=0010126479">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422" sys_relationshipid="7252419" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Graubard received a Ph.D. in mathematics from the University of Maryland in 1991. He began his career as a mathematical statistician at the National Center for Health Statistics in 1977, and held research positions at the Alcohol Drug Abuse and Mental Health Administration and the National Institute of Child Health and Human Development. Dr. Graubard joined the NCI in 1990. He received the American Statistical Association and Biometric Society Snedecor Award for Applied Statistical Research in 1990, and he is a Fellow of the American Statistical Association and of the Statistics Section of the American Association for the Advancement of Science.</p>
<h2 id="research">Research Interests</h2>
<h3>Background</h3>
<p>Dr. Graubard&rsquo;s research interests are primarily in the development and application of statistical methods to efficiently design and analyze studies that make valid inferences to well-defined target populations. These types of studies often collect data using complex sample designs that randomly sample individuals using stratified and multistage cluster sampling. National cross-sectional health surveys and population-based study designs such as case-control studies that sample population controls from the population at risk becoming diseased and case-cohort or nested cohort studies that subsample from a cohort can use complex sample designs. In addition, national health surveys link the participants to vital statistics or electronic medical records to form population representative cohorts to study disease etiology.&nbsp; When analyzing data from these types of studies attention needs to be given to the complex sample design because the sample weights that reflect the differential rates of selection of study participants and the stratification and clustering of the sampling that are used efficient data collection can affect the estimation of prevalence, incidence and risk factor associations of diseases and the variances in analyses. A large part of Dr. Graubard&rsquo;s research involves the integration of survey methods to develop statistical methods for efficiently using complex sample designs in cancer surveillance and epidemiology.</p>
<h3>Areas of Statistical Methods Research</h3>
<ul>
<li>Augmenting existing samples to address new hypotheses.</li>
<li>Combining surveys with cohorts, vital statistics, cancer registries and electronic medical records to improve population representativeness of inferences. &nbsp;</li>
<li>Developing and evaluating disease and mortality absolute risk models with probability and nonprobability samples.</li>
<li>Inferring health and risk factor disparities between advantaged and disadvantaged groups using national surveys.</li>
<li>Conducting efficient inferences for genetic data from complex samples.</li>
<li>Protecting anonymity of participant&rsquo;s measurements in complex samples.</li>
<li>Estimation and inference of family aggregation of phenotypes from network sampling in national surveys.</li>
</ul>
<h3>Collaborative Epidemiological and Surveillance Studies</h3>
<p>Dr. Graubard collaborates with epidemiologists and other public health researchers on the designs and analyses of a wide range of epidemiologic studies. &nbsp;A large number of these collaborations use the National Health and Nutrition and Examination Survey (NHANES), National Health Interview Survey (NHIS) and the Behavior Risk Factor Survey (BRFS).&nbsp; For instance, Dr. Graubard with his collaborators have used NHANES to study prevalence of human papillomavirus (HPV) and its oncologic subtypes and factors related to increased risk of prevalent HPV, prevalence of monoclonal gammopathy of undetermined significance (MGUS), an associated precursor to multiple myeloma (MM), &nbsp;dietary consumption of food and beverages and nutrition-related biomarkers in relation to development of obesity and chronic disease incidence and all-cause and cause-specific mortality for cancer cardiovascular and other diseases. In addition, they have used the NHIS to study trends in alcohol consumption among the elderly population, trends in race/ethnic disparity in cancer screening, and with NHANES and BRFFS to study trends in physical activity among the elderly.</p>
</div>
</div>]]></body>
    <field_image_promotional>349682</field_image_promotional>
  </row>
  <row term_id="302006" id="966087" title="Michael Dean, Ph.D." langcode="en" field_short_title="Michael Dean, Ph.D." field_page_description="Michael Dean, Ph.D., biographical sketch and research interests " field_feature_card_description="Michael Dean, Ph.D., biographical sketch and research interests " field_list_description="Michael Dean, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-06-10" field_date_reviewed="2015-06-10" field_date_updated="2015-06-10" field_pretty_url="dean-michael" field_browser_title="Michael Dean, Ph.D., biographical sketch and research interests " field_card_title="Michael Dean, Ph.D." field_email_address="deanm@mail.nih.gov" field_first_name="Michael" field_last_name="Dean" field_phone_number="240-760-6484" field_org_name_1="National Cancer Institute" field_org_name_2="Laboratory of Translational Genomics" field_campus="301" field_office_location="ATC Room 134D">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=Dean+M&amp;authorOption=exact&amp;pi=0010042043">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422" sys_relationshipid="7252542" sys_variantid="1422" sys_contentid="302432">Laboratory of Translational Genomics</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<p>Dr. Michael Dean is a senior investigator in the Laboratory of Translational Genomics. He obtained his Ph.D. from the Biochemistry Department at the Boston University School of Medicine. He performed his postdoctoral studies at the National Cancer Institute, Center for Cancer Research (CCR), on the <i>MET</i> oncogene and cystic fibrosis gene. He is a member of the American Society of Human Genetics, Centre d'Etude du Polymorphisme Humaine (CEPH), the Human Genome Organization (HUGO), and an adjunct faculty member at Hood College. Before joining DCEG in 2015, Dr. Dean led the Human Genetics Section of the Cancer and Inflammation Program within CCR.</p>
<h2 id="Research Interests">Research Interests</h2>
<p>Dr. Dean is broadly interested in inherited (germline) genetic variation, somatic mutations in tumors, and the combined effect of both on cancer risk, progression, and response to therapy. While part of CCR, Dr. Dean participated in cloning genes (<i>PTCH</i>, <i>VHL</i>) involved in inherited cancers; characterized common variants associated with cancer; and sequenced the genomes of tumors to identify genes commonly altered. In the LTG, Dr. Dean is continuing his work on unlocking the mechanisms through which genetic alterations affect cancer risk. By evaluating the genetic factors of tumor as well as host, Dr. Dean is determining new biomarkers for early detection and treatment. He also&nbsp;continues his investigations into the genetic components of cancer health disparities in the U.S. and in Latin America.</p>
<h3>Association to Function</h3>
<p>Genome-wide association studies have been completed on most major cancer types and have revealed many chromosome regions that influence cancer risk. We have focused on a region including the <i>MSMB</i> and <i>NCOA4</i> genes associated with prostate cancer, and demonstrated complex regulation of expression and splicing of these genes. We are also studying variations associated with renal cancer risk to understand their function.</p>
<h3>Tumor Genomes</h3>
<p>All cancer is genetic in the sense that all tumors have genetic alterations not present in normal tissue of the person with cancer. We have sequenced the exome (coding portion of the genome) of tumors from the bladder, cervical, kidney, prostate, and adrenal gland. These data have identified potential markers for early diagnosis and targets of therapy, and many somatic mutations of the genes involved in histone modification and chromatin remodeling. We will continue to explore these areas focusing on samples from the many large cohorts that DCEG has assembled. By studying samples with detailed epidemiological data, we hope to better apply genetics and genomics to understanding cancer.</p>
<h3>Global Health and Cancer</h3>
<p>Cancer is increasingly a global health problem. We have established studies of cervical and breast cancer in Guatemala, Nicaragua, Mexico and Venezuela, which are yielding important genetic differences as well as potential environmental factors.</p>
<p>For common cancers among adults, we are investigating the reasons behind the very high rates of cervical cancer in the region. We apply a molecular and genomic approach to this question, analyzing cancer tissue, blood samples, and standard epidemiological information on cases as well as genome sequencing. &nbsp;</p>
</div>
</div>]]></body>
    <field_image_promotional>966087</field_image_promotional>
  </row>
  <row term_id="302006" id="974564" title="Wei Hu, Ph.D." langcode="en" field_short_title="Wei Hu, Ph.D." field_page_description="Wei Hu, Ph.D., biographical sketch and research interests" field_feature_card_description="Wei Hu, Ph.D., biographical sketch and research interests" field_list_description="Wei Hu, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-07-08" field_date_reviewed="2015-07-08" field_date_updated="2015-07-08" field_pretty_url="hu-wei" field_browser_title="Wei Hu, Ph.D., biographical sketch and research interests" field_card_title="Wei Hu, Ph.D." field_email_address="huw2@mail.nih.gov" field_first_name="Wei" field_last_name="Hu" field_phone_number="240-276-7295" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E648  ">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<h2>Biography</h2>
<p class="first-graf">Dr. Hu received his Ph.D. from the University of Science and Technology, Beijing in 2005 in safety technology and engineering, with a specialization in environmental and occupational safety. His dissertation topic was environmental exposure and human health. He completed two years of postdoctoral research in the Occupational and Environmental Epidemiology Branch (OEEB), and became a staff scientist in 2012. Dr. Hu provides scientific support to OEEB molecular epidemiology studies of chemical exposures and their association with lung cancer, lymphoma, and biomarkers.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Lung cancer, household air pollution from solid fuels, genetic susceptibility, and occupational and environmental exposure to other particulates</li>
<li>Molecular epidemiology studies of known or suspected occupational hematopoietic carcinogens</li>
<li>Molecular epidemiology studies of lymphoma</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>974564</field_image_promotional>
  </row>
  <row term_id="302006" id="1057578" title="Paul S. Albert, Ph.D." langcode="en" field_short_title="Paul S. Albert, Ph.D." field_page_description="Paul S. Albert, Ph.D., biographical sketch and research interests" field_feature_card_description="Paul S. Albert, Ph.D., biographical sketch and research interests" field_list_description="Paul S. Albert, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-07-29" field_date_reviewed="2016-07-29" field_date_updated="2018-05-15" field_pretty_url="albert-paul" field_browser_title="Paul S. Albert, Ph.D., biographical sketch and research interests" field_card_title="Paul S. Albert, Ph.D." field_email_address="albertp@mail.nih.gov" field_first_name="Paul" field_last_name="Albert" field_phone_number="240-276-7593" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E-146">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research%20Interests">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1JQU5gcjnedYgl/bibliography/54989946/public/?sort=date&amp;direction=ascending">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276275" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<div class="callout-box right">
<div sys_dependentvariantid="2086" sys_dependentid="1058281" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7276280">
<figure class="image-left-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=401214&amp;sys_siteid=475&amp;sys_contentid=1058281&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Video: <a href="https://www.youtube.com/watch?v=9940ZC1kYQ0">Watch BB Chief Paul Albert talk about his choice to pursue biostatistics</a></p>
</div>
<p>Dr. Paul Albert was appointed senior investigator and chief of the Biostatistics Branch in 2016. Prior to joining the Division, he&nbsp;was senior investigator and chief of the Biostatistics and Bioinformatics Branch in the Division of Epidemiology, Statistics, and Prevention in the&nbsp;<em>Eunice Kennedy Shriver </em>National Institute of Child Health and Human Development. Dr. Albert&nbsp;came to the NIH in 1998, first as a staff fellow in the National Institute of Neurological Disorders and Stroke in the Biometry and Field Studies Branch, later as a mathematical statistician in the National Heart Lung and Blood Institute, and the Division of Cancer Treatment and Diagnosis. He received his Ph.D. in biostatistics from the Johns Hopkins University.</p>
<h2><a id="Research Interests"></a>Research Interests</h2>
<p>Dr. Albert's research interests primarily focus on complex modeling of correlated outcomes in biomedical sciences, including the analysis of longitudinal data, diagnostic testing, and data from biomarker studies.</p>
<p>In addition, Dr. Albert's recent methodological research interests include the joint modeling of longitudinal and survival data, the analysis of high-dimensional chemical mixture models, and the analysis of circadian rhythms.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1JQU5gcjnedYgl/bibliography/54989946/public/?sort=date&amp;direction=ascending">Browse Dr. Albert's recent publications</a>.</p>
</div>
</div>]]></body>
    <field_image_promotional>1057578</field_image_promotional>
  </row>
  <row term_id="302006" id="1122124" title="Danielle Karyadi, Ph.D." langcode="en" field_short_title="Danielle Karyadi, Ph.D." field_page_description="Danielle Karyadi, Ph.D., biographical sketch and research interests" field_feature_card_description="Danielle Karyadi, Ph.D., biographical sketch and research interests" field_list_description="Danielle Karyadi, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2018-08-10" field_date_reviewed="2018-08-10" field_date_updated="2018-08-10" field_pretty_url="karyadi-danielle" field_browser_title="Danielle Karyadi, Ph.D., biographical sketch and research interests" field_card_title="Danielle Karyadi, Ph.D." field_email_address="karyadid@mail.nih.gov" field_first_name="Danielle" field_last_name="Karyadi" field_phone_number="240-276-5897" field_org_name_1="National Cancer Institute" field_org_name_2="Laboratory of Genetic Susceptibility" field_campus="300" field_office_location="Room 7E560">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul>
<li><a href="#Biography">Biography</a></li>
<li><a href="#ResearchInterests">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/danielle.karyadi.1/bibliography/56227840/public/?sort=date&amp;direction=descending">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=966088" sys_dependentvariantid="1422" sys_dependentid="966088" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252431" sys_variantid="1422" sys_contentid="966088">Laboratory of Genetic Susceptibility</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Karyadi received her Ph.D. in molecular genetics from the University of California, San Diego and was a postdoctoral fellow at the Fred Hutchinson Cancer Research Center. Prior to joining DCEG, Dr. Karyadi was a staff scientist at the National Human Genome Research Institute where her most recent work utilized whole exome and whole genome sequencing to identify germline cancer susceptibility variants as well as somatic mutation signatures in aggressive prostate cancer tumors.</p>
<h2><a id="ResearchInterests"></a>Research Interests</h2>
<p>Dr. Karyadi is interested in identifying genetic variants that modulate cancer susceptibility, tumor progression or risk of secondary malignancies. She has expertise in family-based and case-control analyses utilizing a variety of approaches from genome-wide association studies or haplotype-based analysis of single nucleotide polymorphism chip genotypes to implementing bioinformatic pipelines of high-throughput sequencing for variant identification and annotation.</p>
</div>
</div>]]></body>
    <field_image_promotional>1122124</field_image_promotional>
  </row>
  <row term_id="302006" id="349621" title="Sharon A. Savage, M.D. " langcode="en" field_short_title="Sharon A. Savage, M.D. " field_page_description="Sharon A. Savage, M.D., biographical sketch and research interests" field_feature_card_description="Sharon A. Savage, M.D., biographical sketch and research interests" field_list_description="Sharon A. Savage, M.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-16" field_pretty_url="savage-sharon" field_browser_title="Sharon A. Savage, M.D., biographical sketch and research interests" field_card_title="Sharon A. Savage, M.D. " field_email_address="savagesh@mail.nih.gov" field_first_name="Sharon" field_last_name="Savage" field_phone_number="240-276-7241" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E454">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=savage%20s&amp;authorOption=exact&amp;pi=0011058327">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" sys_contentid="302430" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_relationshipid="7276751">Clinical Genetics Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Savage joined the Clinical Genetics Branch, DCEG, NCI in 2006 as a tenure-track investigator. She was awarded scientific tenure by the NIH and appointed senior investigator in 2012. In 2013, she was promoted to Branch Chief, and&nbsp;in 2018, she became the Clinical Director for DCEG.&nbsp;Dr. Savage&nbsp;received her M.D. from the University of Vermont College of Medicine, completed residency training in Pediatrics at Children&rsquo;s National Medical Center, in Washington DC, and a fellowship in Pediatric Hematology/Oncology at the NCI Pediatric Oncology Branch and Johns Hopkins University. She is board-certified in both Pediatrics and Pediatric Hematology-Oncology.&nbsp;</p>
<p class="first-graf">Dr. Savage is an elected member of the American Society for Clinical Investigation. Her current research is focused on the genetic and molecular epidemiology of telomere biology, pediatric cancer etiology, and inherited cancer predisposition syndromes.</p>
<h2 id="research">Research Interests</h2>
<h3>Telomere Molecular Epidemiology</h3>
<div class="callout-box right">
<h3>Video: Telomere Biology and Cancer Risk</h3>
<div sys_dependentvariantid="2066" sys_dependentid="1072225" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7276878">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302271&amp;sys_siteid=475&amp;sys_contentid=1072225&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Watch as investigators and families they study discuss dyskeratosis congenita, a rare and complex inherited cancer predisposition syndrome.</p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1072158" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="1072158" sys_relationshipid="7276879" sys_variantid="1410" sys_contentid="1072158">Highlights from Telomere Biology and Cancer Risk (3:25)</a></p>
<p><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1071885" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="1071885" sys_relationshipid="7276880" sys_variantid="1410" sys_contentid="1071885">Telomere Biology and Cancer Risk (full length) (19:45)</a></p>
</div>
<p>Telomeres, specialized structures consisting of long DNA nucleotide repeats and a protein complex, are designed to protect the ends of chromosomes and are critical to chromosome stability. Each time a cell divides, the telomeres lose a small amount of DNA and become shorter. Eventually, telomeres become critically short, causing cellular senescence or cellular crisis, which result in apoptosis, genomic instability or a reduction in cellular lifespan. If cells bypass natural processes and continue to divide despite the presence of genomic instability, cancer can develop. Dr. Savage investigates the connection between telomere biology and cancer through studies of the association between telomere length and cancer risk, the telomere biology disorder dyskeratosis congenita, and the&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=511115" sys_contentid="511115" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="511115" rxinlineslot="103" sys_relationshipid="7276748">genetic contribution to telomere biology</a>.</p>
<h3>Understanding Cancer Etiology - Osteosarcoma</h3>
<p>Osteosarcoma is the most common primary malignant bone tumor and typically occurs during the adolescent growth spurt. Patients with localized osteosarcoma at diagnosis have a 60 to 80% long-term survival rate; metastatic disease carries a much poorer prognosis. In order to better understand the etiology of this disease, Dr. Savage conducts <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303547" sys_contentid="303547" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303547" rxinlineslot="103" sys_relationshipid="7276749">epidemiologic and genetic studies of osteosarcoma</a>.</p>
<h3><strong>Li-Fraumeni Syndrome</strong></h3>
<div class="callout-box right">
<div sys_dependentvariantid="2086" sys_dependentid="1041083" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7276881">
<figure class="image-left-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=568389&amp;sys_siteid=475&amp;sys_contentid=1041083&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Watch Dr. Savage present her research at the 2016 NIH Rare Disease Day symposium</p>
<p><strong>Video:</strong> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1090641" sys_dependentvariantid="1410" sys_dependentid="1090641" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276882" sys_variantid="1410" sys_contentid="1090641">Bench to Bedside Update: Telomeres in Li-Fraumeni Syndrome</a></p>
</div>
<p>Li-Fraumeni syndrome (LFS) is a highly-penetrant autosomal dominant cancer predisposition syndrome associated with a wide range of cancer types which occur at younger-than-expected ages. It was first described in 1969 and germline mutations in <i>TP53</i> were recognized as the primary cause in 1990. Dr. Savage and her colleagues have initiated a new <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303694" sys_contentid="303694" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303694" rxinlineslot="103" sys_relationshipid="7276750">clinical, genetic, and epidemiologic study of LFS</a> in order to further characterize the clinical and molecular consequences of this disorder, and to develop a cancer screening program for <i>TP53</i> mutation carriers (<a href="http://www.lfs.cancer.gov">www.lfs.cancer.gov</a>). They also assisted in the creation of an international LFS research consortium.</p>
</div>
</div>]]></body>
    <field_image_promotional>349621</field_image_promotional>
  </row>
  <row term_id="302006" id="349622" title="Mitchell H. Gail, M.D. Ph.D " langcode="en" field_short_title="Mitchell H. Gail, M.D. Ph.D " field_page_description="Mitchell H. Gail, M.D. Ph.D., biographical sketch and research interests" field_feature_card_description="Mitchell H. Gail, M.D. Ph.D., biographical sketch and research interests" field_list_description="Mitchell H. Gail, M.D. Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2018-05-08" field_pretty_url="gail-mitchell" field_browser_title="Mitchell H. Gail, M.D. Ph.D., biographical sketch and research interests" field_card_title="Mitchell H. Gail, M.D. Ph.D " field_email_address="gailm@mail.nih.gov" field_first_name="Mitchell" field_last_name="Gail" field_phone_number="240-276-7315" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E138">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="#software">Software</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=gail%20m&amp;authorOption=exact&amp;pi=0010153525">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422" sys_relationshipid="7291030" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<div class="callout-box right">
<h3><b>Gail Presents Gordon Lecture</b></h3>
<p><img alt="" class="left" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=658301" sys_dependentid="658301" sys_dependentvariantid="1482" sys_relationshipid="7291032" sys_siteid="475" />Watch Dr. Gail deliver the prestigious 2013 Robert S. Gordon Lecture in Epidemiology.</p>
<p>Video: <a href="http://videocast.nih.gov/summary.asp?Live=12305" target="_blank" rel="noopener noreferrer">Using risk models for breast cancer prevention</a></p>
</div>
<p class="first-graf">Dr. Gail received an M.D. from Harvard Medical School in 1968 and a Ph.D. in statistics from George Washington University in 1977. He joined NCI in 1969, and served as chief of the Biostatistics Branch from 1994 to 2008. Dr. Gail is a Fellow and former President of the American Statistical Association, a Fellow of the American Association for the Advancement of Science, an elected member of the American Society for Clinical Investigation, and an elected member of the National Academy of Medicine of the National Academy of Sciences. He has received the Spiegelman Gold Medal for Health Statistics, the Snedecor Award for applied statistical research, the Howard Temin Award for AIDS Research, the NIH Director's Award, the PHS Distinguished Service Medal, the Nathan Mantel Lifetime Achievement Award, the&nbsp;NIH Robert S. Gordon, Jr. Lecture in Epidemiology, and the AACR - American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention.<o:p></o:p></p>
<h2>Research Interests</h2>
<ul>
<li>Developing statistical methods for epidemiologic studies, including intervention trials, and genetic and other molecular epidemiologic studies</li>
<li>Modeling absolute risk of disease, including breast cancer risk projection</li>
</ul>
<h2 id="software">Software</h2>
<ul class="grey-bullets">
<li><a href="http://www.cancer.gov/bcrisktool/">Breast Cancer Risk Assessment Tool</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=939444" inlinetype="rxhyperlink" sys_relationshipid="7291029" sys_siteid="475" rxinlineslot="103" sys_dependentid="939444" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="939444">Breast Cancer Risk Assessment R Package</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302422" inlinetype="rxhyperlink" sys_relationshipid="7291024" rxinlineslot="103" sys_dependentid="302422" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="302422">Asian Pacific Islander American Women Breast Cancer SAS Macro</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=25&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302532" inlinetype="rxhyperlink" sys_relationshipid="7291025" rxinlineslot="103" sys_dependentid="302532" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="302532">Breast Cancer Risk Assessment SAS Macro</a> (Gail Model)</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302385" inlinetype="rxhyperlink" sys_relationshipid="7291026" rxinlineslot="103" sys_dependentid="302385" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="302385">Breast Cancer with Mammographic Density Risk Assessment SAS Macro</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302400" inlinetype="rxhyperlink" sys_relationshipid="7291027" rxinlineslot="103" sys_dependentid="302400" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="302400">CARE Mode SAS Macro: Breast Cancer Risk Assessment for African American Women</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1110245" sys_dependentvariantid="1418" sys_dependentid="1110245" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7291031" sys_variantid="1418" sys_contentid="1110245">Sample Size Calculations for Case Conrol Studies - R Package</a></li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349622</field_image_promotional>
  </row>
  <row term_id="302006" id="349625" title="Nilanjan Chatterjee, Ph.D." langcode="en" field_short_title="Nilanjan Chatterjee, Ph.D." field_page_description="Nilanjan Chatterjee, Ph.D. - Special Volunteer, biographical sketch and research interests " field_feature_card_description="Nilanjan Chatterjee, Ph.D. - Special Volunteer, biographical sketch and research interests " field_list_description="Nilanjan Chatterjee, Ph.D. - Special Volunteer, biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2014-04-14" field_pretty_url="chatterjee-nilanjan" field_browser_title="Nilanjan Chatterjee, Ph.D. - Special Volunteer, biographical sketch and research interests " field_card_title="Nilanjan Chatterjee, Ph.D." field_email_address="chattern@mail.nih.gov" field_first_name="Nilanjan" field_last_name="Chatterjee" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=chatterjee%20n&amp;authorOption=exact&amp;pi=0010012280">Scientific Publications</a></li>
<li><a href="#software">Software</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_relationshipid="7252533" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Chatterjee received his Bachelor&rsquo;s and Master&rsquo;s degree from the Indian Statistical Institute, Calcutta and a Ph.D. in statistics from the University of Washington, Seattle in 1999. He served as Chief of the Biostatistics Branch of the Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI) for almost eight years. Dr. Chatterjee now serves as a Bloomberg Distinguished Professor at the Johns Hopkins University with joint appointments at the Bloomberg School of Public Health (Biostatistics) and the School of Medicine (Oncology). He remains a Special Volunteer with DCEG.</p>
<p class="first-graf">Dr. Chatterjee's research focuses on a diverse set of quantitative issues that arise in design, analysis, interpretation and public health translation of modern molecular and genetic epidemiologic studies. He has made methodological contributions in cutting-edge topics such as analysis of genetic associations and gene-environment interactions, modeling etiologic heterogeneity by disease subtypes and development of models for risk prediction. He has played key roles in design and analysis of genome-wide association studies of various cancers with a particular emphasis on smoking related sites, such as lung and bladder. He is an active mentor for a number of Fellows and junior investigators and provides guidance for many ongoing projects in various areas such as risk-modeling, gene-environment interaction, design and analysis of studies that use next-generation sequencing. He is an elected Fellow of the American Statistical Association (2008), an elected member of the American Epidemiologic Society (2012) and is the recipient of numerous national and international awards, including the Mortimer Spiegelman Award (2010) for outstanding contribution to public health statistics, the Snedecor Award (2011) for significant contribution to theory of Biometry and the notable COPSS President&rsquo;s award (2011) jointly sponsored by five major statistical societies to recognize the outstanding contribution by a young statistician.</p>
<h2 id="software">Software</h2>
<ul class="grey-bullets">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=753548" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="753548" rxinlineslot="103" sys_relationshipid="7252532" sys_variantid="1418" sys_contentid="753548">CBRM</a> - An R package for testing Calibration of Binary Risk Model using different goodness-of-fit statistics</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302535" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302535" rxinlineslot="103" sys_relationshipid="7252527" sys_variantid="1418" sys_contentid="302535">CGEN</a> - An R package for genetic analysis of case-control data.</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302455" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302455" rxinlineslot="103" sys_relationshipid="7252528" sys_variantid="1418" sys_contentid="302455">KinCohort</a> - A MATLAB software package for likelihood-based analysis of kin-cohort data.</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302523" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302523" rxinlineslot="103" sys_relationshipid="7252529" sys_variantid="1418" sys_contentid="302523">MultAssoc</a> - A MATLAB software package for test of association of a disease with a group of SNPs after accounting for their interaction with another group of SNPs or environmental exposures.</li>
<li><a href="http://www.stat.sinica.edu.tw/yhchen/download.htm">SAS macro for haplotype analysis of case-control studies</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302487" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302487" rxinlineslot="103" sys_relationshipid="7252530" sys_variantid="1418" sys_contentid="302487">Integrated Power Calculation Tool</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302635" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="302635" rxinlineslot="103" sys_relationshipid="7252531" sys_variantid="1418" sys_contentid="302635">ASSET</a> - An R package for subset-based association analysis of heterogeneous traits and subtypes.</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349625</field_image_promotional>
  </row>
  <row term_id="302006" id="349634" title="Choonsik Lee, Ph.D. " langcode="en" field_short_title="Choonsik Lee, Ph.D. " field_page_description="Choonsik Lee, Ph.D., biographical sketch and research interests" field_feature_card_description="Choonsik Lee, Ph.D., biographical sketch and research interests" field_list_description="Choonsik Lee, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="lee-choonsik" field_browser_title="Choonsik Lee, Ph.D., biographical sketch and research interests" field_card_title="Choonsik Lee, Ph.D. " field_email_address="leechoonsik@mail.nih.gov" field_first_name="Choonsik" field_last_name="Lee" field_phone_number="240-276-7374" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E448">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=lee+c&amp;authorOption=exact&amp;pi=0014327747">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7276138" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<div class="callout-box right">
<h3>Spotlight on Investigator</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1101763" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7276139">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=401210&amp;sys_siteid=475&amp;sys_contentid=1101763&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>Read "<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=18&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1087876" sys_dependentvariantid="1424" sys_dependentid="1087876" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276140" sys_variantid="1424" sys_contentid="1087876">Applying 3-Dimensional Printing for Radiation Exposure Assessment</a>" in the summer 2017 issue of <em>Linkage</em> newsletter.</p>
</div>
<p>Dr. Lee received a Ph.D. degree in health physics in 2002 from Hanyang University in South Korea. He subsequently joined the Innovative Technology Center for Radiation Safety in South Korea as a postdoctoral fellow, and later completed extensive training in computational medical physics as a postdoctoral researcher at the University of Florida. Dr. Lee joined the Radiation Epidemiology Branch (REB) as a tenure-track investigator in 2009, and was awarded scientific tenure and promoted to senior investigator in September 2016 and named Head of REB&rsquo;s Dosimetry Unit. Dr. Lee is a full member on two task groups of the International Commission on Radiological Protection (ICRP). He also serves on the editorial board of <em>Radiation Protection Dosimetry</em>.</p>
<h2><a id="Research"></a>Research Interests</h2>
<p>Dr. Lee develops methods and tools to estimate radiation dose from medical exposures, including treatment and diagnostic tests, in order to generate reliable data for use in epidemiological studies of ionizing radiation and cancer risk.</p>
<h3>Computational Human Phantoms</h3>
<p>There are two broad approaches to determine organ doses to portions of the human body exposed to ionizing radiation: measurement and calculation. Although measurement can provide dose estimates in actual radiation exposure settings, it is not practical to perform a large number of measurements for all study subjects in epidemiologic studies, because the process is usually time-consuming, expensive, and inflexible.</p>
<p>Alternatively, organ doses can be calculated using a computer simulation of the human body (called a computational human phantom) and radiation exposure scenarios combined with Monte Carlo radiation transport techniques. Dr. Lee has developed a series of computational human phantoms that are crucial for realistic, individualized dose reconstruction. His pediatric series of phantoms has been adopted by the ICRP as the international reference model. To estimate more accurate doses, Dr. Lee, in collaboration with the University of Florida, has expanded the computational phantoms include non-reference body sizes utilizing a library of body dimensions representative of the U.S. population.</p>
<h3>Dosimetry for Therapeutic Radiation Procedures</h3>
<p>Quantitative estimation of the risk of developing second cancers related to radiotherapy relies on the quality of the dose estimates to normal tissues. However, there are substantial difficulties in reconstructing organ doses for a large cohort of patients treated years ago. Dr. Lee initiated a research consortium with several universities and clinical centers to develop new dose reconstruction methods for external x-ray radiotherapy using Monte Carlo simulation of radiotherapy machines coupled with his computational human phantoms. He calls this combination the National Cancer Institute dosimetry system for Radiation Treatment (NCIRT). Dr. Lee is applying NCIRT to multiple epidemiological studies of second cancers in radiotherapy patients in collaboration with REB epidemiologists as well as the research consortium. He is also extending NCIRT to include dosimetry methods for proton therapy patients.</p>
<h3>Dosimetry for Diagnostic Radiation Procedures</h3>
<p>Approximately 10 percent of all computed tomography (CT) examinations in the U.S. are performed on pediatric patients, who are at higher risk of radiation-related cancer compared to adults. In order for radiologists to weigh the benefit-harm of conducting such exams, they need a better understanding of the nature and magnitude of the associated health risks. To generate the necessary data to inform such decisions, Dr. Lee has been developing the <a href="https://ncidose.nci.nih.gov/">National Cancer Institute dosimetry system for Computed Tomography (NCICT)</a>, based on Monte Carlo simulation combined with computational human phantoms. To validate the organ dose calculated from NCICT, he compared it with data collected from experiments using physical anthropomorphic phantoms and radiation dosimeters. The software itself has been tested by more than 100 beta testers and utilized for multiple epidemiological studies of CT risk. NCICT is being made available to the scientific community in conjunction with the NCI Technology Transfer Center. Dr. Lee is also developing dosimetry methods and tools for other diagnostic radiation procedures including radiography, fluoroscopically-guided interventional procedures, and nuclear medicine practices.</p>
</div>
</div>]]></body>
    <field_image_promotional>349634</field_image_promotional>
  </row>
  <row term_id="302006" id="349652" title="Gretchen Gierach, Ph.D, M.P.H." langcode="en" field_short_title="Gretchen Gierach, Ph.D, M.P.H." field_page_description="Gretchen Gierach, Ph.D., M.P.H., biographical sketch and research interests" field_feature_card_description="Gretchen Gierach, Ph.D., M.P.H., biographical sketch and research interests" field_list_description="Gretchen Gierach, Ph.D., M.P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="gierach-gretchen" field_browser_title="Gretchen Gierach, Ph.D., M.P.H., biographical sketch and research interests" field_card_title="Gretchen Gierach, Ph.D, M.P.H." field_email_address="gierachg@mail.nih.gov" field_first_name="Gretchen" field_last_name="Gierach" field_phone_number="240-276-7299" field_org_name_1="National Cancer Institute" field_org_name_2="Integrative Tumor Epidemiology Branch" field_campus="300" field_office_location="Room 7E102">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=gierach%20g&amp;authorOption=exact&amp;pi=%20%200012662891">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_dependentvariantid="1422" sys_dependentid="302506" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252413" sys_variantid="1422" sys_contentid="302506">Integrative Tumor&nbsp;Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Gierach earned both her M.P.H. (2004) and Ph.D. (2006) degrees in epidemiology from the University of Pittsburgh with a focus in cancer epidemiology and women&rsquo;s health. She joined the Division of Cancer Epidemiology and Genetics (DCEG) as a NCI Cancer Prevention Fellow in 2006, became a tenure-track investigator in 2010, was awarded tenure in 2017, and became Deputy Chief of the Integrative Tumor Epidemiology Branch in 2018. Dr. Gierach has been awarded the DCEG Molecular Epidemiology Research Funding Award, the NCI Merit Award in Cancer Prevention Research Training, and an Award to Advance Research on Cancers in Women from the NCI Office of Science Planning and Assessment and the NIH Office of Research on Women&rsquo;s Health. Dr. Gierach serves as chair of the Division&rsquo;s Breast Cancer Working Group and co-chair of the DCEG Hormone Laboratory Advisory Committee.</p>
<h2>Research Interests</h2>
<p>I am interested in the study of the etiology of hormonally-related female cancers, particularly in the molecular mechanisms underlying breast carcinogenesis. My interdisciplinary research program has a special emphasis on the molecular epidemiology of mammographic density, one of the strongest risk factors for breast cancer.</p>
<h3>Molecular Epidemiologic Studies of Mammographic Density and Breast Cancer Risk</h3>
<p>The tissue composition of the breast is reflected mammographically by the pattern of distribution of fibroglandular and fatty tissue. A higher component of fat results in lower mammographic density. Conversely, a higher proportion of fibroglandular tissue results in greater density. Studies have consistently demonstrated that high mammographic density is a strong breast cancer risk factor. Therefore, understanding factors that affect mammographic density and their underlying mechanisms are important, yet understudied, research questions.</p>
<p>The <a href="http://dceg.cancer.gov/research/cancer-types/breast-cancer/radiology-evaluation-study-tissues-stamp-project">BREAST Stamp Project</a> aims to characterize the radiologic, histologic, and molecular features of dense breast tissue and to understand how the microenvironment of dense breasts promotes neoplastic transformation of the breast epithelium. Data relating mammographic density to molecular markers of breast cancer are limited. To correlate mammographic density to molecular profiles of breast tissues, we are currently leveraging the resources of the <a href="http://dceg.cancer.gov/research/cancer-types/breast-cancer/breast-cancer-case-control-study-poland">Breast Cancer Case-Control Study in Poland</a>, a population-based case-control study conducted in L&oacute;dz and Warsaw from 2000-2003. We have collected mammograms for density assessment from a subset of the study&rsquo;s cancer cases, along with breast tissues that were snap frozen and analyzed using mRNA profiling.</p>
<p>Epidemiologic risk factors strongly associated with mammographic density, such as age and body mass index, explain only about 20% to 30% of the variation in density. The remaining variation in mammographic density is thought to be, in part, genetically determined. We are therefore conducting several investigations designed to address the role of genes in mammographic density. In collaboration with DCEG&rsquo;s Clinical Genetics Branch, we are examining whether mammographic density and computer-extracted mammographic texture pattern features differ by <em>BRCA1/2</em> mutation status.</p>
<p>In addition to addressing how molecular epidemiologic factors may influence mammographic density and its associated breast cancer risk, I am also addressing other ways in which density may relate to breast carcinogenesis. In light of emerging evidence indicating that reductions in mammographic density may predict response to tamoxifen treatment, my colleagues and I&nbsp;initiated a study within Kaiser Permanente Northwest to determine whether breast cancer patients who experience large reductions in density following tamoxifen treatment have an improved prognosis. We have also launched the <a href="http://dceg.cancer.gov/research/cancer-types/breast-cancer/ultrasound-study-tamoxifen">Ultrasound Study of Tamoxifen</a>, in which we are using novel ultrasound tomography methods to assess changes in volumetric breast density within the first year of tamoxifen therapy. These studies may provide support for future investigations evaluating change in mammographic density as a &ldquo;biosensor&rdquo; of factors that increase or decrease breast cancer risk.</p>
</div>
</div>]]></body>
    <field_image_promotional>349652</field_image_promotional>
  </row>
  <row term_id="302006" id="349659" title="Charles E. Matthews, Ph.D. " langcode="en" field_short_title="Charles E. Matthews, Ph.D. " field_page_description="Charles E. Matthews, Ph.D., biographical sketch and research interests " field_feature_card_description="Charles E. Matthews, Ph.D., biographical sketch and research interests " field_list_description="Charles E. Matthews, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="matthews-charles" field_browser_title="Charles E. Matthews, Ph.D., biographical sketch and research interests " field_card_title="Charles E. Matthews, Ph.D. " field_email_address="matthewsce@mail.nih.gov" field_first_name="Charles" field_last_name="Matthews" field_phone_number="240-276-7211" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E444">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Program</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=matthews%20c&amp;authorOption=exact&amp;pi=0014348093">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7276783" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Charles E. Matthews, Ph.D. is a physical activity epidemiologist and investigator in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7276782" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a>, Division of Cancer Epidemiology and Genetics, National Cancer Institute. He received a M.S. in exercise science from the University of South Carolina, Columbia, and a Ph.D. in epidemiology from the University of Massachusetts, Amherst. Dr. Matthews held academic appointments in the Department of Epidemiology and Biostatistics at the University of South Carolina and the Vanderbilt University School of Medicine prior to joining DCEG in 2009 as a tenure-track investigator. Dr. Matthews was awarded scientific tenure by NIH in 2016. He is a Fellow of the American College of Sports Medicine (ACSM) and an Associate Editor for the ACSM journal, Medicine and Science in Sports and Exercise.</p>
<h2 id="research">Research Program</h2>
<p class="first-graf">Dr. Matthews studies the relationship between physical activity behaviors and the development of cancer in humans. Physical activity behaviors reflect the continuum of human movement that influences energy expenditure and energy balance, and these behaviors range from purely sedentary (e.g., sitting) to physically active pursuits (e.g., light, moderate-vigorous intensity activities). In his etiologic studies, Dr. Matthews&rsquo; seeks to understand how the full spectrum of physical activity behaviors influences cancer risk, the dose-response relations between active and sedentary behaviors and cancer, and the biological mechanisms underlying these relationships. In his methodological research, Dr. Matthews is working to develop better methods for measuring physical activity behaviors in population-based studies that may help identify new cancer associations and better define the optimal types and amount of physical activity that are associated with reduced risk. This knowledge is critical to the development of evidence-based public health guidelines for physical activity and cancer prevention and control.</p>
<p><i>Cancer Etiology Research</i><br />Dr. Matthews and colleagues conduct research that adds to the evidence-base relating both physically active and sedentary behaviors to risk for developing cancer, as well as prognosis following a cancer diagnosis. For colon, post-menopausal breast, and endometrial cancers, research has shown the benefits of moderate-to-vigorous physical activity to reduce risk. However, our understanding of amount of activity required to achieve risk reduction, the potential benefits of lower intensity activities and the adverse effects of sedentary behaviors remains limited. For all other cancer sites where the evidence is less clear, his research seeks to test the hypothesis that physical activity is associated with reduced risk for these outcomes. In addition, recently he has begun to test the hypothesis that high levels of sedentary behavior (&ldquo;too much sitting&rdquo;) is associated with increased risk for certain cancers, independent of the effect of moderate-to-vigorous physical activity. Using an integrative epidemiology framework as a guide, Dr. Matthews&rsquo; mechanistic research attempts to expand current understanding of the biological mechanisms linking physical activity behaviors and energy balance to cancer risk. He is exploring the metabolic effects that habitual patterns of physical activity and/or prolonged sedentary time may impart in adults, and future work will also evaluate potential gene-environment interactions between physical activity behaviors and cancer risk. This discovery work has the potential to enhance our understanding of the biological mechanisms mediating the effects of physical activity and energy balance on cancer risk.</p>
<p><i>Methodological Research</i><br />Dr. Matthews&rsquo; methodological research addresses the need for better tools to assess physical activity behaviors in large population-based studies. Self-reported information about active and sedentary behaviors from questionnaires that rely on long-term recall/averaging are known to be prone to measurement error. Errors in these exposure assessments may limit our ability to find important physical activity-cancer associations, and to describe the true dose-response relationships for the associations that we can detect. Dr. Matthews&rsquo; work in this area includes the description of the measurement error structure of existing self-report instruments and the development and testing of new tools for measuring physically active and sedentary behaviors in population-based studies. He is also working to develop infrastructure to support advanced activity monitoring technology in large cancer etiology studies.</p>
</div>
</div>]]></body>
    <field_image_promotional>349659</field_image_promotional>
  </row>
  <row term_id="302006" id="349668" title="Nicolas Wentzensen, M.D., Ph.D., M.S." langcode="en" field_short_title="Nicolas Wentzensen, M.D., Ph.D., M.S." field_page_description="Nicolas Wentzensen, M.D., Ph.D., M.S., biographical sketch and research interests " field_feature_card_description="Nicolas Wentzensen, M.D., Ph.D., M.S., biographical sketch and research interests " field_list_description="Nicolas Wentzensen, M.D., Ph.D., M.S., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2019-04-24" field_date_updated="2019-04-24" field_pretty_url="wentzensen-nicolas" field_browser_title="Nicolas Wentzensen, M.D., Ph.D., M.S., biographical sketch and research interests " field_card_title="Nicolas Wentzensen, M.D., Ph.D., M.S." field_email_address="wentzenn@mail.nih.gov" field_first_name="Nicolas" field_last_name="Wentzensen" field_phone_number="240-276-7303" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E-448">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=wentzensen%20n&amp;authorOption=exact&amp;pi=0013454301">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_relationshipid="7317425" sys_siteid="475" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2>Biography</h2>
<p>Dr. Wentzensen received an M.D. from the University of Heidelberg in 2000. He trained in general surgery and conducted research in surgical oncology in the Department of Surgery, University of Heidelberg. Dr. Wentzensen earned his Ph.D. in Applied Tumor Biology at the Institute of Pathology, University of Heidelberg. During this time, he conducted research in molecular biology, molecular pathology, and molecular epidemiology of cervical cancer. He built a research group focusing on cervical cancer biomarker discovery and validation and established a diagnostic laboratory for cervical cancer screening. In 2007 he earned a Master of Science in Epidemiology at the University of Mainz. Dr. Wentzensen joined DCEG as a visiting fellow in 2007, became a tenure-track investigator in 2009, and was awarded scientific tenure by the NIH and appointed senior investigator in 2013. In 2015 he joined the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_relationshipid="7317423" sys_siteid="475" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a>&nbsp;as Deputy Chief and head of the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1041183" inlinetype="rxhyperlink" sys_relationshipid="7317424" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="1041183" rxinlineslot="103" sys_variantid="1418" sys_contentid="1041183">Clinical Epidemiology Unit</a> within the branch.</p>
<p>Dr. Wentzensen&rsquo;s research is focused on etiologic heterogeneity and biomarker discovery of gynecological cancers, mainly cervical and ovarian. His research has been highly recognized internationally. His medical doctorate thesis on human papillomavirus integration was awarded summa cum laude. He has received multiple research awards from the University of Heidelberg and several awards for presentations at international scientific meetings, including an AACR scholar-in-training award. Since joining DCEG, Dr. Wentzensen has won two intramural research awards, an NCI Director&rsquo;s Intramural Innovation Award, an NIH Award of Merit and a Research Highlights Award. He was selected as an expert for the Cochrane Gynaecological Cancer Review Group (Section &lsquo;Prevention of Cervical Cancer&rsquo;) and the Society of Gynecologic Oncologists Future Strategies of Cervical Cancer Prevention Meeting, and he serves on a standing U.S. Food and Drug Administration panel for Microbiology Devices.</p>
<p>Dr. Wentzensen has played an important role in recent updates of <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915715/">cervical cancer screening and management guidelines</a>, including the Practice Improvement of Cervical Screening and Management effort sponsored by the American Cancer Society, the&nbsp;Society of Lower Genital Tract Disorders (ASCCP), and the American Society for Clinical Pathology, as well as the ASCCP cervical cancer management guidelines effort. For his contributions to these efforts, he was awarded a Meritorious Scientific Award at the biennial ASCCP meeting in 2014. In 2018, he received the ASCCP Distinguished Scientific Award, the Society's highest honor. Dr. Wentzensen serves as a senior editor for <em>Cancer Epidemiology, Biomarkers and Prevention</em>.</p>
<h2 id="research">Research Interests</h2>
<p class="first-graf">I am leading a research program focused on the molecular etiology and prevention of cervical and other human papillomavirus (HPV)-related cancers, and ovarian and endometrial cancers. I also have special expertise in the p16/Rb pathway, human papillomavirus biology, gene methylation, and molecular profiling of cancers. A strong focus of my work is on moving etiologic discoveries into clinical or public health practice. Several of my studies have the potential to directly affect public health decisions and clinical practice.</p>
<p class="first-graf">I am currently working on several established DCEG studies, and have initiated new field efforts to analyze the etiology of cervical precancers and to improve colposcopy-biopsy protocols. I am also leading consortial efforts to study the etiologic heterogeneity of ovarian cancers.</p>
<h3><strong>Cervical Cancer and Other HPV-related Cancers</strong></h3>
<p class="first-graf">In the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303575" inlinetype="rxhyperlink" sys_relationshipid="7317418" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303575" rxinlineslot="103" sys_variantid="1418" sys_contentid="303575">Study to Understand Cervical Cancer Early Endpoints and Determinants</a>, my goal is to comprehensively assess biomarkers of risk for progressive cervical neoplasia, and thus develop a new set of biomarkers that can distinguish those at highest risk of cervical cancer from those with benign infection. In the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303576" inlinetype="rxhyperlink" sys_relationshipid="7317419" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303576" rxinlineslot="103" sys_variantid="1418" sys_contentid="303576">Biopsy Study to Improve Detection of Cervical Precancer</a>, my goals are to study cervical disease on the lesion level, to optimize criteria for biopsy placement, and to analyze the incremental benefit of taking multiple biopsies. In the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303577" inlinetype="rxhyperlink" sys_relationshipid="7317420" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303577" rxinlineslot="103" sys_variantid="1418" sys_contentid="303577">Cervical Cancer Screening Among HIV-Infected Women in India</a> and the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303538" inlinetype="rxhyperlink" sys_relationshipid="7317421" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303538" rxinlineslot="103" sys_variantid="1418" sys_contentid="303538">Anal Precancer and Cancer in HIV-Positive Men (Anal Cancer Screening Study)</a>, I am focusing on evaluation of biomarkers and colposcopy/anoscopy to improve detection of HPV-related diseases in HIV-infected populations.</p>
<p class="first-graf">Based on my long experience with cellular and humoral immune responses against tumor-associated and viral antigens, I am evaluating novel serologic assays to detect HPV antibodies as markers of exposure and protection together with other investigators in HREB and the Infections and Immunoepidemiology Branch (IIB) in several DCEG-based studies (Costa Rica Natural History Cohort, Costa Rica Vaccine Trial, ASCUS-LSIL-Triage-Study).</p>
<h3><strong>Ovarian Cancer</strong></h3>
<p class="first-graf">The etiology of ovarian cancer is complex and poorly understood, in part because risk factor associations may differ by histological type, grade and other factors. My focus on ovarian cancers is to understand etiologic heterogeneity by studying risk factor associations and circulating biomarkers in histologic subtypes. I am particularly interested in the role of inflammation in ovarian carcinogenesis, since it could lead to new interventions to prevent or control inflammation.</p>
<p class="first-graf">Together with extramural researchers, I have established the Ovarian Cancer Cohort Consortium (OC3) to allow well-powered studies of risk factors and biomarkers by histologic subtypes. I am conducting tissue based profiling studies in the Ovarian Cancer Case-Control Study in Poland to help improve the understanding of etiologic heterogeneity and to identify cells of origin of ovarian cancers based on molecular profiles of normal reproductive tissues.</p>
<p class="first-graf">In collaboration with investigators in the Biostatistics Branch, we are extending our analyses to cases from the Surveillance, Epidemiology, and End Results Residual Tissue Repository (SEER RTR). I am analyzing several <i>a priori</i> markers and pathways, such as mismatch repair deficiency, <i>p53</i> and p16/Rb alterations, and telomere length alterations. We seek to identify markers that can be integrated with standardized histological typing and grading to improve the classification of ovarian tumors for epidemiologic studies. We also want to identify markers for early detection that can be translated into clinical or screening applications. In collaboration with investigators in the Clinical Genetics Branch and with outside clinical partners, we are evaluating novel techniques for sampling of endometrial and ovarian epithelium, as well as fallopian tubes.</p>
<h3>Endometrial Cancer</h3>
<p>My main focus on endometrial cancer research is to characterize cancer precursors and to develop early detection biomarkers. In a study to <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303581" inlinetype="rxhyperlink" sys_relationshipid="7317422" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303581" rxinlineslot="103" sys_variantid="1418" sys_contentid="303581">evaluate biomarkers in samples collected using endometrial brushings and intravaginal tampons</a>, my colleagues and I identified several candidate markers that showed good performance to identify women with endometrial cancer. I am now conducting a large prospective study to evaluate methylation and mutation markers to identify endometrial cancers and cancer precursors.</p>
</div>
</div>]]></body>
    <field_image_promotional>349668</field_image_promotional>
  </row>
  <row term_id="302006" id="349689" title="Thomas R. O'Brien, M.D., M.P.H." langcode="en" field_short_title="Thomas R. O'Brien, M.D., M.P.H." field_page_description="Thomas R. O'Brien, M.D., M.P.H., biographical sketch and research interests " field_feature_card_description="Thomas R. O'Brien, M.D., M.P.H., biographical sketch and research interests " field_list_description="Thomas R. O'Brien, M.D., M.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-15" field_pretty_url="obrien-thomas" field_browser_title="Thomas R. O'Brien, M.D., M.P.H., biographical sketch and research interests " field_card_title="Thomas R. O'Brien, M.D., M.P.H." field_email_address="obrient@mail.nih.gov" field_first_name="Thomas" field_last_name="O'Brien" field_phone_number="240-276-7104" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E108">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research">Research Interests</a></li>
<li><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=o%27brien%20tr&amp;authorOption=exact&amp;pi=0010060635">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=56&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302590" sys_dependentvariantid="1422" sys_relationshipid="7280135" sys_variantid="1422">Infections and Immunoepidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p class="first-graf">Dr. O'Brien received undergraduate and medical degrees from the University of Michigan, and an M.P.H. from the Harvard School of Public Health. He was an Epidemic Intelligence Service Officer and Medical Epidemiologist with the Centers for Disease Control and Prevention before joining the NIH Intramural Research Program in 1992. His primary research interests have involved studies on the transmission and natural history of oncogenic viruses, including human immunodeficiency virus type 1, hepatitis B virus and hepatitis C virus (HCV).</p>
<h2><a id="Research"></a>Research Interests</h2>
<p>Dr. O&rsquo;Brien&rsquo;s research program targets viruses that cause cancer, especially hepatitis C virus, through interdisciplinary studies that emphasize human genetics. He focuses on studies that may translate into clinical or public health benefits. Dr. O&rsquo;Brien organized a trans-disciplinary group of investigators to refine understanding of the genetic basis for spontaneous HCV clearance and response to treatment for chronic hepatitis C. This collaboration led to the discovery of interferon lambda 4 (<em>IFNL4</em>), a novel gene that appears to underlie observed differences in HCV clearance (Prokunina-Olsson et al, <em>Nature Genetics</em>, 2013). His current work focuses on <a href="/Rhythmyx/assembler/render?sys_contentid=1140233&amp;sys_revision=1&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1140233" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="7280136">hepatitis viruses</a>, hepatocellular carcinoma and <a href="/Rhythmyx/assembler/render?sys_contentid=1140677&amp;sys_revision=1&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1140677" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="7280137">phenotypic expressions of the <em>IFNL4</em> genotype</a>.</p>
</div>
</div>]]></body>
    <field_image_promotional>349689</field_image_promotional>
  </row>
  <row term_id="302006" id="917441" title="Jonathan Hofmann, Ph.D., M.P.H." langcode="en" field_short_title="Jonathan Hofmann, Ph.D., M.P.H." field_page_description="Jonathan Hofmann, Ph.D., M.P.H., biographical sketch and research interests" field_feature_card_description="Jonathan Hofmann, Ph.D., M.P.H., biographical sketch and research interests" field_list_description="Jonathan Hofmann, Ph.D., M.P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-03-18" field_date_reviewed="2015-03-18" field_date_updated="2019-01-30" field_pretty_url="hofmann-jonathan" field_browser_title="Jonathan Hofmann, Ph.D., M.P.H., biographical sketch and research interests" field_card_title="Jonathan Hofmann, Ph.D., M.P.H." field_email_address="hofmannjn@mail.nih.gov" field_first_name="Jonathan" field_last_name="Hofmann" field_phone_number="240-276-7168" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology" field_campus="300" field_office_location="Room 6E604">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Hofmann%20j&amp;authorOption=exact&amp;pi=0014323772">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7252423" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="Biography"><a id="Biography"></a>Biography</h2>
<p>Dr. Hofmann received his Ph.D. in epidemiology from the University of Washington, where he conducted a longitudinal molecular epidemiologic study of organophosphate-exposed agricultural pesticide handlers for his dissertation research. After completing his doctoral degree in 2008, Dr. Hofmann joined the Occupational and Environmental Epidemiology Branch (OEEB) as a postdoctoral fellow. He became a research fellow in 2011 and was appointed to the position of tenure-track investigator in 2015.&nbsp;He has received several awards recognizing his research, including the NCI Director&rsquo;s Intramural Innovation Award, the AACR Scholar-in-Training Award, and Fellows Awards for Research Excellence from both the National Institutes of Health and the Division of Cancer Epidemiology and Genetics.</p>
<h2 id="Research Interests"><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Hofmann's research is focused on evaluating the role of agricultural exposures in the etiology of multiple myeloma and other cancers, and on understanding the biological mechanisms that influence the development and progression of multiple myeloma. He is also investigating the etiology of renal cell carcinoma using both classical and molecular epidemiologic approaches.</p>
<h3>Investigating the Effects of Agricultural Exposures on Cancer Risk</h3>
<p>Agricultural exposures including pesticides, endotoxins, and diesel exhaust have been associated with risk of various cancers, although the biological mechanisms underlying these associations are generally not well understood. To better understand the biologic plausibility and potential mechanisms of action through which these exposures influence cancer risk. Dr. Hofmann serves as the principal investigator of the Biomarkers of Exposure and Effect in Agriculture (BEEA) study. In this molecular epidemiologic subcohort within the Agricultural Health Study, biospecimens (including blood, urine, buccal cells, and house dust) and updated information on pesticide use and other agricultural exposures were collected from over 1,600 pesticide applicators in Iowa and North Carolina.&nbsp;</p>
<p class="first-graf">Within BEEA, Dr. Hofmann is investigating the relationships between agricultural exposures and intermediate biomarkers related to multiple myeloma and other cancers.</p>
<h3>Etiologic Studies of Multiple Myeloma</h3>
<div sys_dependentvariantid="2066" sys_dependentid="1136069" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7252425">
<figure class="image-right-medium centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=401210&amp;sys_siteid=475&amp;sys_contentid=1136069&amp;sys_command=edit" alt="Illustration shows a bone cut away to reveal the red marrow where plasma cells are made, with insets showing both normal plasma cells and antibodies, and multiple myeloma cells (abnormal plasma cells). " /><!--Comment--> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_authtype=0&amp;sys_variantid=1518&amp;sys_context=0&amp;sys_folderid=401210&amp;sys_siteid=475&amp;sys_contentid=1136069&amp;sys_command=edit" target="_blank" class="article-image-enlarge no-resize" rel="noopener noreferrer" sys_variantid="1518" sys_contentid="1136069">Enlarge</a></div>
</figure>
</div>
<p>The etiology of multiple myeloma, an aggressive plasma cell malignancy, remains poorly understood. A unique feature of multiple myeloma is that it is consistently preceded by a condition called monoclonal gammopathy of undetermined significance (MGUS).</p>
<p>Dr. Hofmann is conducting molecular and genetic epidemiologic studies of multiple myeloma and its precursor MGUS, with a particular emphasis on elucidating the biological mechanisms through which obesity and immune dysregulation contribute to multiple myeloma development and progression from MGUS to multiple myeloma.&nbsp;</p>
<h3>Etiologic and Health Disparities Research on Renal Cell Carcinoma</h3>
<p>Dr. Hofmann&rsquo;s research on renal cell carcinoma focuses on understanding factors that contribute to the racial disparities in this malignancy. He serves as the co-principal investigator of the U.S. Renal Cell Cancer Study, a population-based case-control study of blacks and whites in Detroit and Chicago. Dr. Hofmann is also conducting investigations of renal cell carcinoma risk in relation to occupational and environmental exposures including pesticides and per- and polyfluoroalkyl substances (PFAS).&nbsp;</p>
</div>
</div>]]></body>
    <field_image_promotional>917441</field_image_promotional>
  </row>
  <row term_id="302006" id="939428" title="Cari Kitahara, Ph.D." langcode="en" field_short_title="Cari Kitahara, Ph.D." field_page_description="Cari Kitahara, Ph.D., biographical sketch and research interests" field_feature_card_description="Cari Kitahara, Ph.D., biographical sketch and research interests" field_list_description="Cari Kitahara, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-04-27" field_date_reviewed="2015-04-27" field_date_updated="2015-04-27" field_pretty_url="kitahara-cari" field_browser_title="Cari Kitahara, Ph.D., biographical sketch and research interests" field_card_title="Cari Kitahara, Ph.D." field_email_address="meinholdc@mail.nih.gov" field_phone_number="240-276-7406" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E536">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Kitahara+Meinhold&amp;authorOption=or&amp;pi=0013349291">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7252437" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<p>Dr. Kitahara earned her Ph.D. in cancer epidemiology from the Johns Hopkins Bloomberg School of Public Health. She joined the Radiation Epidemiology Branch in 2008 as a predoctoral fellow and became a research fellow in 2011. In 2015, she was appointed to the position of tenure-track investigator.&nbsp;Dr. Kitahara&rsquo;s research focuses on low-dose radiation exposure and cancer risks in medical workers and the etiology of radiosensitive cancers, particularly thyroid cancer and glioma. She has received numerous awards for her work, including the DCEG Fellows Award for Research Excellence and the Outstanding Achievement in Science Seminar Series Award.&nbsp;Dr. Kitahara has a B.S. degree from the University of Michigan in biology and anthropology (2005) and an M.H.S. degree from the Johns Hopkins Bloomberg School of Public Health (2008).</p>
<h2 id="Research Interests">Research Interests</h2>
<h3>Occupational Radiation Exposure and Cancer</h3>
<p>Everyone receives some degree of exposure to ionizing radiation&mdash;a known carcinogen&mdash;from both natural and man-made sources. Epidemiologists face many challenges when seeking to quantify the relationship between low levels of radiation and health risks in the general population. Occupational groups, such as radiologic technologists, are routinely monitored for radiation exposure as part of worker-safety measures, and thus provide a unique setting for studying associations between radiation and cancer. Dr. Kitahara is particularly interested in cancer risks associated with occupational exposure to low-dose radiation from emerging medical practices and procedures. Much of her current work focuses on nuclear medicine procedures (i.e., those involving radionuclides). Some of these procedures, including those that emit higher gamma radiation energy (e.g., positron emission tomography [PET]), are being performed with increasing frequency over time, potentially yielding greater cumulative exposure to the technologists who perform them. Findings from these studies can inform current radiation protection practices for medical radiation workers and, more broadly, improve our understanding of the impact of low-dose radiation exposure on the risk of cancer in the general population.</p>
<h3>Etiology of Radiosensitive Cancers</h3>
<p>A broader understanding of the etiology of radiation-associated cancers, including potential effect modifiers, is important for the study of radiation and cancer. Exposure to ionizing radiation during childhood is one of the few established risk factors for thyroid cancer and glioma; the thyroid and brain are two of the most radiosensitive organs. The relatively low incidence of these two malignancies makes them difficult to study. Of the few epidemiologic studies of non-ionizing radiation in relation to thyroid cancer and glioma, most are based on small numbers of incident cases or are case-control in design. Dr. Kitahara&rsquo;s research utilizes data from large prospective studies to address long-standing and new hypotheses regarding the influence of certain exposures (e.g., obesity, diet, smoking, and hormone use) across the life course on the risk of these two malignancies. Some examples of this work include a large pooled analysis of five prospective NCI studies on lifestyle-related factors and thyroid cancer risk. She has expanded this effort to include 22 prospective studies from the NCI Cohort Consortium. These studies, based in &nbsp;North America, Asia, and Europe, allow her to evaluate associations for anthropometric factors and other potential thyroid cancer risk factors by histological subtype. Using data from the GliomaScan consortium, Dr. Kitahara and colleagues evaluated the association for height and history of diabetes, as well as genetic polymorphisms, in relation to glioma risk. Dr. Kitahara has also worked with colleagues at the Institute of Preventive Medicine in Copenhagen, Denmark, to evaluate measured height and weight in childhood in relation to risk of thyroid cancer and glioma in adulthood./p&gt;</p>
</div>
</div>]]></body>
    <field_image_promotional>939428</field_image_promotional>
  </row>
  <row term_id="302006" id="974527" title="Gabriella Andreotti, M.P.H., Ph.D." langcode="en" field_short_title="Gabriella Andreotti, M.P.H., Ph.D." field_page_description="Gabriella Andreotti, M.P.H., Ph.D., Biographical sketch and research interests: genetic and molecular mechanisms of occupational and environmental exposures related to carcinogenicity" field_feature_card_description="Gabriella Andreotti, M.P.H., Ph.D., Biographical sketch and research interests" field_list_description="Gabriella Andreotti, M.P.H., Ph.D. - Biographical sketch and research interests: genetic and molecular mechanisms of occupational and environmental exposures related to carcinogenicity." field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-07-07" field_date_reviewed="2015-07-07" field_date_updated="2015-07-07" field_pretty_url="andreotti-gabriella" field_browser_title="Gabriella Andreotti, M.P.H., Ph.D., Biographical sketch and research interests" field_card_title="Gabriella Andreotti, M.P.H., Ph.D." field_email_address="andreotg@mail.nih.gov" field_first_name="Gabriella" field_last_name="Andreotti" field_phone_number="240-276-7284" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E622">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Andreotti%20g&amp;authorOption=exact&amp;pi=0011670499">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_relationshipid="7252380" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p class="first-graf">Dr. Andreotti received her M.P.H. and Ph.D. in epidemiology from George Washington University, during which she conducted research on the genetic susceptibility of biliary tract cancers. Upon completion of her doctorate she became a postdoctoral fellow in the Occupational and Environmental Epidemiology Branch (OEEB), and in 2010 was appointed to the position of staff scientist. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1054762" sys_contentid="1054762" inlinetype="rxhyperlink" sys_relationshipid="7252382" sys_dependentvariantid="1418" sys_dependentid="1054762" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">In 2016 she was the first staff scientist elected to serve as a Woman Scientist Advisor for the Division</a>.&nbsp;</p>
<h2 class="first-graf"><a id="Research-Interests"></a>Research Interests</h2>
<p class="first-graf">Dr. Andreotti provides coordination and management support to the Agricultural Health Study, a large cohort of pesticide applicators and their spouses in Iowa and North Carolina. Dr. Andreotti&rsquo;s research interests include the genetic and molecular mechanisms of occupational and environmental exposures related to carcinogenicity. She has conducted gene-environment interaction studies of pesticide use and prostate cancer, as well as various other molecular studies of pesticide use. She also has examined the effects of lifestyle factors, including smoking, alcohol, and body mass index, on multiple myeloma and pancreatic cancer.</p>
</div>
</div>]]></body>
    <field_image_promotional>974527</field_image_promotional>
  </row>
  <row term_id="302006" id="1004366" title="Montserrat Garca-Closas, M.D., Dr.P.H." langcode="en" field_short_title="Montserrat Garca-Closas, M.D., Dr.P.H." field_page_description="Montserrat Garca-Closas, M.D., Dr.P.H., biographical sketch and research interests " field_feature_card_description="Montserrat Garca-Closas, M.D., Dr.P.H., biographical sketch and research interests " field_list_description="Montserrat Garca-Closas, M.D., Dr.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-09-21" field_date_reviewed="2015-09-21" field_date_updated="2015-09-21" field_pretty_url="garcia-closas-montserrat" field_browser_title="Montserrat Garca-Closas, M.D., Dr.P.H., biographical sketch and research interests " field_card_title="Montserrat Garca-Closas, M.D., Dr.P.H." field_email_address="montserrat.garcia-closas@nih.gov" field_first_name="Montserrat" field_last_name="Garca-Closas" field_phone_number="240-276-7150" field_org_name_1="National Cancer Institute" field_org_name_2="Office of the Director" field_campus="300" field_office_location="Room 7E404">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=garcia-closas+m&amp;authorOption=exact&amp;pi=0010035562&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
</ul>
<h3 id="Biography">Biography</h3>
<p>Dr. Montserrat Garc&iacute;a-Closas investigates the causes of cancer with the aim of improving risk assessment tools that can aid the development of targeted screening and risk reduction strategies for personalized prevention. She carries out a multidisciplinary research program on the molecular epidemiology of breast and bladder cancers, and has made important contributions to the understanding of genetic susceptibility and etiologic heterogeneity of these malignancies.</p>
<p>As Deputy Director for the NCI Division of Cancer Epidemiology and Genetics (DCEG) she focuses not only on her own research interests, but also on the management of the broad scientific program of the Division. She was appointed Acting Chief of the Integrative Tumor Epidemiology Branch in 2016.</p>
<p>Dr. Garc&iacute;a-Closas received her M.D. from the University of Barcelona, Spain, a Master of Public Health in quantitative methods, and a Doctorate of Public Health in epidemiology from the Harvard School of Public Health. She joined DCEG in 1996 as a postdoctoral fellow, became a tenure-track investigator in 1999 and a tenured senior investigator in 2007. From 2008-2010, she was a visiting scientist at the Department of Oncology and Strangeways Laboratory, Cambridge University, U.K. In 2010, she became a Professor of Epidemiology at the Division of Genetic and Epidemiology of the Institute of Cancer Research (ICR), University of London, U.K.</p>
<p>She is the recipient of several awards including two NIH Merit Awards, an NCI Intramural Research Award, and an NCI Mentor of Merit Award. She has also served in numerous expert committees including the American Association for Cancer Research (AACR) Molecular Epidemiology Working Group (MEG), the U.K. MEG and the Advisory Committee on NHS Breast Cancer Screening, England. She is a founder member of several large consortia, served as the Chair of the Coordinating Committee for the International Consortium of Case-Control Studies of Bladder Cancer from 2005-2011, and co-Chairs the Pathology and Survival Working Group of the Breast Cancer Association Consortium (BCAC), a major breast cancer consortium.</p>
<h3 id="Research Interests">Research Interests</h3>
<p>Dr. Garc&iacute;a-Closas employs a multidisciplinary approach to identify biomarkers of breast and bladder cancer risk in combination with questionnaire-based information collected from large epidemiological studies. Specific areas of interest include:</p>
<ul>
<li>Molecular characterization of tumors to identify exposure signatures and subtype-specific causes of cancer</li>
<li>Identification of biomarkers of risk, including genetic and epigenetic changes</li>
<li>Integration of biomarkers and other risk factors into cancer risk prediction models, and evaluation of their utility in risk stratification to inform personal and public health decisions</li>
</ul>
<h3>Breast Cancer</h3>
<p>In the study of breast cancer etiology, Dr. Garc&iacute;a-Closas is co-leader of large-scale molecular pathology studies within BCAC. She has contributed to the development of one of the largest, centralized collection of breast tumor tissue with detailed data on risk factors and clinical outcomes. This resource has revealed important tumor markers that delineate the etiologic heterogeneity of breast cancer. At the ICR, she co-led the Breakthrough Generations Study, a large prospective cohort study of over 110,000 women in the U.K. aimed at evaluating risk factors for breast cancer.</p>
<p>As an investigator in the ongoing international genotyping project, OncoArray, Dr. Garc&iacute;a-Closas seeks to identify inherited susceptibility loci associated with specific subtypes of breast cancer. OncoArray uses a custom microarray chip of 500,000 single nucleotide polymorphisms (SNPs) in over 100,000 breast cancer cases drawn from multiple studies from around the world.</p>
<p>In addition, she is one of the lead investigators in a large-scale project embedded in BCAC that will be characterizing thousands of breast tumors using targeted DNA sequencing and immunohistochemistry and <em>in-situ</em> hybridization analysis. Through the study of how genetic and environmental risk factors, tumor features and clinical progression interrelate, this effort will provide critical information for the development and validation of integrated risk and prognostic models.</p>
<p>To identify novel biomarkers, Dr. Garc&iacute;a-Closas is also conducting an epigenetic-wide association study (EWAS) of breast cancer using pre-diagnostic DNA samples from the Prostate, Lung, Colorectal and Ovarian (PLCO) Study.&nbsp;</p>
<p>The ultimate goal of this research is to facilitate the development and implementation of targeted prevention and screening strategies for different types of breast cancer.</p>
<h3>Bladder Cancer</h3>
<p>Dr. Garc&iacute;a-Closas investigates the combined effects of genetic and environmental risk factors for bladder cancer. She published the definitive study of the interaction between smoking history and the <em>NAT2</em> genotype, which is one of the few consistent gene-environment interactions described to date. She has made important contributions to the discovery of novel susceptibility loci for bladder cancer using genome-wide association studies (GWAS), an area where she continues to collaborate. In addition, she is engaged in an EWAS of bladder cancer in the PLCO Study to identify additional biomarkers of risk.</p>
</div>
</div>]]></body>
    <field_image_promotional>1004366</field_image_promotional>
  </row>
  <row term_id="302006" id="1074440" title="Catherine Schairer, Ph.D." langcode="en" field_short_title="Catherine Schairer, Ph.D." field_page_description="Catherine Schairer, Ph.D., biographical sketch and research interests" field_feature_card_description="Catherine Schairer, Ph.D., biographical sketch and research interests" field_list_description="Catherine Schairer, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-03-01" field_date_reviewed="2017-03-01" field_date_updated="2017-03-01" field_pretty_url="schairer-catherine" field_browser_title="Catherine Schairer, Ph.D., biographical sketch and research interests" field_card_title="Catherine Schairer, Ph.D." field_email_address="schairec@mail.nih.gov" field_first_name="Catherine" field_last_name="Schairer" field_phone_number="(240) 276-7425" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E340">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<p><a href="#Biography">Biography</a><br /><a href="#Research-Interests">Research Interests</a><br /><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=schairer%20c&amp;authorOption=exact&amp;pi=0010170704">Scientific Publications</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7252481" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></p>
<h3><a id="Biography"></a>Biography</h3>
<p>Dr. Catherine Schairer joined DCEG as a health statistician in 1982. She has a Master of Science degree in biostatistics from the University of California, Los Angeles, and a Ph.D. in epidemiology from Johns Hopkins University, Baltimore, Maryland. Dr. Schairer has a long-standing interest in breast cancer research.&nbsp;She is a co-principal investigator of the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303562" inlinetype="rxhyperlink" sys_relationshipid="7252482" sys_dependentvariantid="1418" sys_dependentid="303562" rxinlineslot="103" sys_siteid="475" sys_variantid="1418" sys_contentid="303562">Breast Cancer Detection Demonstration Project Follow-up study</a>, and recently led a case-control study of inflammatory breast cancer in North Africa.&nbsp;Dr. Schairer has served as Chair of the NCI Special Studies Institutional Review Board since 2011.</p>
<h3><a id="Research-Interests"></a>Research Interests</h3>
<ul class="dceg-blue-bullets-lrg">
<ul>
<li>Inflammatory breast cancer &ndash; etiology, trends in rates</li>
<li>Exogenous and endogenous hormones and breast cancer risk</li>
<li>Study design and epidemiologic methods</li>
<li>Research ethics</li>
</ul>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>1074440</field_image_promotional>
  </row>
  <row term_id="302006" id="1126519" title="Li C. Cheung, Ph.D." langcode="en" field_short_title="Li C. Cheung, Ph.D." field_page_description="Li C. Cheung, Ph.D., biographical sketch and research interests " field_feature_card_description="Li C. Cheung, Ph.D., biographical sketch and research interests " field_list_description="Li C. Cheung, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2018-10-15" field_date_reviewed="2018-10-15" field_date_updated="2018-10-15" field_pretty_url="cheung-li" field_browser_title="Li C. Cheung, Ph.D., biographical sketch and research interests " field_card_title="Li C. Cheung, Ph.D." field_email_address="li.cheung@nih.gov" field_first_name="Li" field_last_name="Cheung" field_phone_number="240-276-5812" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E612">
    <body><![CDATA[<div class="rxbodyfield"><a id="Top"></a>
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/li.cheung.1/bibliography/56765956/public/?sort=date&amp;direction=descending">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_contentid="302568" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7252535" sys_siteid="475" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422">Biostatistics Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Cheung received his B.S. (2002) in biomedical and electrical engineering from Duke University, and his M.S. (2011) and Ph.D. (2017) in statistics from George Washington University. For his doctoral dissertation, he worked with <a href="https://dceg.cancer.gov/about/staff-directory/biographies/A-J/katki-hormuzd">Hormuzd Katki, Ph.D.</a>, to formalize the risk models used&nbsp;to estimate risks for cervical cancer screening and management guidelines. Prior to joining the Biostatistics Branch (BB) as an ORISE fellow in 2016, he worked for 11 years as a statistician and SAS/R programmer at IMS, Inc., supporting human papillomavirus (HPV) research, lung cancer research, and studies within BB and the Radiation Epidemiology Branch. Dr. Cheung became a staff scientist in BB in 2018.</p>
<h2><a id="research"></a>Research Interests</h2>
<p>Dr. Cheung&rsquo;s research focus is on understanding how epidemiologic findings could be used for cancer screening and prevention, particularly in developing individualized risk-based approaches to cancer screening. He is assisting <a href="https://dceg.cancer.gov/about/staff-directory/biographies/K-N/schiffman-mark">Mark Schiffman, M.D., M.P.H.</a>, and colleagues on the&nbsp;continued development of cervical cancer management guidelines&nbsp;and on other cervical cancer research. He also collaborates with Dr. Katki and colleagues on lung cancer screening. Dr. Cheung is developing and validating an individualized model for the expected life-years gained from undergoing lung-cancer screening.</p>
</div>
</div>]]></body>
    <field_image_promotional>1126519</field_image_promotional>
  </row>
  <row term_id="302006" id="349601" title="Eric A. Engels, M.D., M.P.H. " langcode="en" field_short_title="Eric A. Engels, M.D., M.P.H. " field_page_description="Eric A. Engels, M.D., M.P.H., biographical sketch and research interests" field_feature_card_description="Eric A. Engels, M.D., M.P.H., biographical sketch and research interests" field_list_description="Eric A. Engels, M.D., M.P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-03-12" field_pretty_url="engels-eric" field_browser_title="Eric A. Engels, M.D., M.P.H., biographical sketch and research interests" field_card_title="Eric A. Engels, M.D., M.P.H. " field_email_address="engelse@exchange.nih.gov" field_first_name="Eric" field_last_name="Engels" field_phone_number="240-276-7186" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E226">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=engels%20e&amp;authorOption=exact&amp;pi=0010069431">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=56&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_relationshipid="7280131" sys_dependentvariantid="1422" sys_dependentid="302590" rxinlineslot="103" sys_siteid="475" sys_variantid="1422">Infections and Immunoepidemiology Branch</a></li>
<li>Study Website: <a href="http://hivmatch.cancer.gov/sites.html">HIV/AIDS Cancer Match Study</a></li>
<li>Study Website: <a href="http://transplantmatch.cancer.gov/sites.html">Transplant Cancer Match Study</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Engels earned a B.A. in mathematics from the University of Virginia in 1987 and an M.D. from Harvard Medical School in 1991. From 1991 to 1994, he trained in internal medicine at Brigham and Women's Hospital. Subsequently, Dr. Engels received clinical training in infectious diseases and an M.P.H. at Tufts University School of Medicine. He joined the NCI Viral Epidemiology Branch (later the Infections and Immunoepidemiology Branch (IIB)) in 1998 as a senior staff fellow, became an investigator in 2000, and was tenured in 2007. He was appointed Chief of IIB in 2017. Dr. Engels holds an adjunct faculty appointment in the Department of Epidemiology at the Johns Hopkins School of Public Health.</p>
<h2 id="research">Research Interests</h2>
<h3><strong>Immunosuppression and&nbsp;Infection in Cancer</strong></h3>
<p>A major focus of investigation concerns the epidemiology of cancer in immunosuppressed individuals. My research on HIV-related cancers utilizes data from our <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303678" inlinetype="rxhyperlink" sys_relationshipid="7280132" sys_dependentvariantid="1418" sys_dependentid="303678" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_variantid="1418" sys_contentid="303678">HIV/AIDS Cancer Match (HACM) Study</a>. This study links HIV and cancer registry data from 11 U.S. regions to identify cancers arising in over 880,000 people registered with HIV infection. The HACM Study allows my colleagues and me to address important research questions and examine patterns of cancer incidence that have direct public health relevance. We have used this resource to characterize trends in cancer risk among people with HIV over the entire course of the HIV epidemic. Our studies have documented substantial declines over time in cancers caused by viral infections, such as Kaposi sarcoma and non-Hodgkin lymphoma, as HIV treatment has improved. In contrast, there has been an increase in the burden of cancers not associated with immunosuppression, especially as the number of people living with HIV increases and as the HIV population ages.</p>
<p>My coworkers and I also conduct research on cancer in solid organ transplant recipients, another immunosuppressed population. We have conducted a computerized match of the U.S. transplant registry with 18 cancer registries. This <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303740" inlinetype="rxhyperlink" sys_relationshipid="7280133" sys_dependentvariantid="1418" sys_dependentid="303740" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_variantid="1418" sys_contentid="303740">Transplant Cancer Match Study</a> includes population-based cancer data on approximately half of the U.S. transplant population. Our research on cancer in transplant recipients is conducted in close collaboration with colleagues at the Health Resources and Services Administration, which oversees the U.S. transplant network. Using these data, we have described the overall spectrum of cancer risk in transplant recipients, and we are doing further research projects focused on specific cancers and transplant-related risk factors.</p>
<p>I am also interested in cancers associated with other immune-related conditions, including autoimmune diseases, allergic conditions, and immunosenescence. The incidence of some cancers is elevated in relation to immune activation or inflammation, and some immune-modulating medications used to treat these conditions may also increase cancer risk. Finally, we are studying how immunosuppressive medical conditions such as HIV infection and solid organ transplantation affect patient outcomes after a cancer diagnosis.</p>
<p></p>
</div>
</div>]]></body>
    <field_image_promotional>349601</field_image_promotional>
  </row>
  <row term_id="302006" id="349608" title="Neal D. Freedman, Ph.D., M.P.H." langcode="en" field_short_title="Neal D. Freedman, Ph.D., M.P.H." field_page_description="Neal D. Freedman, Ph.D., M.P.H., biographical sketch and research interests " field_feature_card_description="Neal D. Freedman, Ph.D., M.P.H., biographical sketch and research interests " field_list_description="Neal D. Freedman, Ph.D., M.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2018-04-18" field_pretty_url="freedman-neal" field_browser_title="Neal D. Freedman, Ph.D., M.P.H., biographical sketch and research interests " field_card_title="Neal D. Freedman, Ph.D., M.P.H." field_email_address="freedmanne@mail.nih.gov" field_first_name="Neal" field_last_name="Freedman" field_phone_number="240-276-7195" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E432">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=freedman%20n&amp;authorOption=exact&amp;pi=0011789029">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276817" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Freedman received his Ph.D. in biomedical sciences from the University of California, San Francisco in 2004 and an M.P.H. from the Harvard School of Public Health in 2005. He subsequently joined the Division of Cancer Epidemiology and Genetics as a Cancer Prevention Fellow, becoming a tenure-track investigator in 2009. Dr. Freedman was awarded scientific tenure by NIH in 2015, and is DCEG's principal investigator for the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=11&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303750" sys_dependentvariantid="1418" sys_dependentid="303750" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276818" sys_variantid="1418" sys_contentid="303750">Prostate, Lung, Colon, and Ovary (PLCO) Cohort Study</a>. He draws on his training in molecular biology and epidemiology to investigate the roles of tobacco, diet, and metabolic hormones in cancer risk.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Tobacco products in cancer and disease</li>
<li>Diet, energy balance, and liver cancer</li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302410" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302410" rxinlineslot="103" sys_relationshipid="7276815" sys_variantid="1418" sys_contentid="302410">Member of the DCEG Upper Gastrointestinal Cancers Research Group</a></li>
</ul>
<h2>Research</h2>
<div class="dceg-bio-content">
<h3>Tobacco products in cancer and disease</h3>
<p>It has long been known that tobacco causes many different types of cancer. Yet, the tobacco epidemic has changed substantially over the past 50 years. Thankfully, with concerted tobacco cessation and prevention efforts, the prevalence of smoking has decreased in the United States. Still, more than 15 percent of Americans continue to smoke cigarettes. In the past, many more men smoked than women, and they started smoking earlier. Currently, however, similar proportions of men and women smoke, and they typically start smoking at similar ages. There have also been many changes in the design and construction of cigarettes. New and emerging tobacco products are also gaining popularity, including electronic cigarettes and water pipes; yet whether these products cause cancer is unclear. We are working to determine the impact of such changes on cancer risks.</p>
<p>Read: "<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1955&amp;sys_contentid=645216" sys_dependentvariantid="1955" sys_dependentid="645216" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276819" sys_variantid="1955" sys_contentid="645216">The Changing Role of Tobacco in Cancer</a>", "<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1109033" sys_dependentvariantid="1424" sys_dependentid="1109033" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276820" sys_variantid="1424" sys_contentid="1109033">New study describes mortality risk associated with cigarette-, cigar-, or pipe-only use</a>", and "<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1067781" sys_dependentvariantid="1424" sys_dependentid="1067781" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276821" sys_variantid="1424" sys_contentid="1067781">Low-intensity smokers are at increased risk of earlier death</a>"</p>
<p>We are also working to understand the impact of trends in tobacco products and other factors on premature mortality and health disparities. Read: "<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1071619" sys_dependentvariantid="1424" sys_dependentid="1071619" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276822" sys_variantid="1424" sys_contentid="1071619">Study finds premature death rates diverge in the United States by race and ethnicity</a>"</p>
<h3>Coffee and other aspects of diet and energy balance in liver cancer</h3>
<p class="first-graf">Liver cancer is the second most common cause of cancer-related mortality worldwide. Strong risk factors have been identified including aflatoxin, alcohol, and chronic hepatitis B and C infection, but a substantial proportion of liver cancer cases in the United States lack these exposures. The liver is a major metabolic organ, important for the regulation of fatty acid, insulin, and glucose signaling. Diabetes and adiposity are consistent risk factors for liver cancer, suggesting an important role for energy balance. Diet may also be important, with proposed associations for coffee, red and white meat, fats, sugars, fruits and vegetables, and micronutrients. My work has investigated associations of dietary and environmental exposures with liver cancer, with a recent focus on coffee drinking. In epidemiologic studies, coffee has been consistently and inversely associated with liver cancer and diabetes. Emerging data also suggest that coffee drinking is inversely related to overall mortality. We are conducting epidemiologic and molecular studies to better understand these observed inverse associations.</p>
</div>
</div>
</div>]]></body>
    <field_image_promotional>349608</field_image_promotional>
  </row>
  <row term_id="302006" id="349623" title="Maria Teresa Landi, M.D., Ph.D." langcode="en" field_short_title="Maria Teresa Landi, M.D., Ph.D." field_page_description="Maria Teresa Landi, M.D., Ph.D., biographical sketch and research interests " field_feature_card_description="Maria Teresa Landi, M.D., Ph.D., biographical sketch and research interests " field_list_description="Maria Teresa Landi, M.D., Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-15" field_pretty_url="landi-maria" field_browser_title="Maria Teresa Landi, M.D., Ph.D., biographical sketch and research interests " field_card_title="Maria Teresa Landi, M.D., Ph.D." field_email_address="landim@mail.nih.gov" field_first_name="Maria" field_last_name="Landi" field_phone_number="240-276-7236" field_org_name_1="National Cancer Institute" field_org_name_2="Integrative Tumor Epidemiology Branch" field_campus="300" field_office_location="Room 7E106">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=landi%20mt&amp;authorOption=exact&amp;pi=0010011282">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302506" sys_dependentvariantid="1422" sys_relationshipid="7252581" sys_variantid="1422" sys_contentid="302506">Integrative Tumor Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Landi received an M.D. with honors from the University of Milan, Italy, and was trained in oncology and general medicine at the San Raffaele Hospital, University of Milan. She received a Ph.D. in occupational medicine and industrial hygiene, subgroup of molecular epidemiology, from an Italian University Consortium in 1993, and qualified for the associate professorship in occupational medicine and industrial hygiene in the Italian Universities in 1998. Dr. Landi received tenure at the Genetic Epidemiology Branch (GEB) in 2006. Dr. Landi is Associate Professor of Epidemiology at The Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, and Adjunct Professor of Epidemiology at the George Washington University, School of Public Health and Health Services, Washington, D.C.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>To study the genetic and environmental determinants of lung cancer using an integrative approach that allows the investigation of the process that begins with smoking initiation and persistence, continues with lung cancer development, and ends with progression to disseminated disease or response to therapy and survival.</li>
<li>To investigate the genetic and environmental determinants of cutaneous malignant melanoma in the general population and in high-risk families; in particular, to explore the relationship of UV radiation, pigmentation, and other host factors in the etiology of melanoma.</li>
<li>To examine the role of dioxins on cancer risk in highly exposed populations, by means of markers of exposure and early effect.</li>
<li>To explore new approaches using high-throughput techniques and genome-wide association studies in the etiology of complex diseases.</li>
<li>To understand lung cancer etiology in never smokers. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1135394" sys_dependentvariantid="1418" sys_dependentid="1135394" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252582" sys_variantid="1418" sys_contentid="1135394">See the Sherlock-<em>lung</em> study for more information</a>.</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349623</field_image_promotional>
  </row>
  <row term_id="302006" id="349630" title="Stephen J. Chanock, M.D." langcode="en" field_short_title="Stephen J. Chanock, M.D." field_page_description="Stephen J. Chanock, M.D., biographical sketch and research interests" field_feature_card_description="Stephen J. Chanock, M.D., biographical sketch and research interests" field_list_description="Stephen J. Chanock, M.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="chanock-stephen" field_browser_title="Stephen J. Chanock, M.D., biographical sketch and research interests" field_card_title="Stephen J. Chanock, M.D." field_email_address="chanocks@mail.nih.gov" field_first_name="Stephen" field_last_name="Chanock" field_phone_number="240-276-7150" field_org_name_1="National Cancer Institute" field_campus="300" field_office_location="Room 7E412">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=966088" sys_dependentvariantid="1422" sys_dependentid="966088" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276735" sys_variantid="1422" sys_contentid="966088">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=chanock%20s&amp;authorOption=exact&amp;pi=0010114442">Scientific Publications</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<p>Dr. Stephen Chanock is a leading expert in the discovery and characterization of cancer susceptibility regions in the human genome. He has received numerous awards for his scientific contributions to our understanding of common inherited genetic variants associated with cancer risk and outcomes.</p>
<p>Dr. Chanock received his M.D. from Harvard Medical School in 1983 and completed clinical training in pediatrics, pediatric infectious diseases, and pediatric hematology/oncology and research training in molecular genetics at Boston Children&rsquo;s Hospital and the Dana-Farber Cancer Institute, Boston. Since 1995, Dr. Chanock has served as the Medical Director for <a href="http://www.speciallove.org/index.php?option=com_content&amp;view=article&amp;id=46&amp;Itemid=67" target="_blank" rel="noopener noreferrer">Camp Fantastic</a>, a week-long recreational camp for pediatric cancer patients, which is a joint venture of the NCI and Special Love, Inc.</p>
<p>From 2001-2007, he was a tenured investigator in the Genomic Variation Section of the Pediatric Oncology Branch in the NCI Center for Cancer Research. He also served as co-chair of NCI's Genetics, Genomics and Proteomics Faculty for five years. In 2001, he was appointed as Chief of the Cancer Genomics Research Laboratory (formerly Core Genotyping Facility), and in 2007 as Chief of the Laboratory of Translational Genomics, both within the NCI Division of Cancer Epidemiology and Genetics (DCEG). Dr. Chanock co-led the Cancer Genetic Markers of Susceptibility project. From 2012 to 2013, he also served as Acting Co-Director of the NCI Center for Cancer Genomics. Dr. Chanock was appointed Director of DCEG in August 2013.&nbsp;</p>
<p>For more information on Dr. Chanock's research interests, please see the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=966088" sys_dependentvariantid="1422" sys_dependentid="966088" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276736" sys_variantid="1422" sys_contentid="966088">Laboratory of Genetic Susceptibility</a> page. Follow Dr. Chanock on Twitter <a href="https://twitter.com/NCIChanock">@NCIChanock</a>.</p>
<div class="callout-box center">
<h3>TCGA Invited Perspective</h3>
<p><img alt="" class="left" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=731568" sys_dependentid="731568" sys_dependentvariantid="1482" sys_relationshipid="7276737" sys_siteid="475" />Dr. Chanock discusses the role of The Cancer Genome Atlas in understanding how germline variation informs the landscape of somatic alterations in cancer.</p>
<p><b>Read:</b> <a href="http://cancergenome.nih.gov/researchhighlights/perspectives/Chanock_Perspective" target="_blank" rel="noopener noreferrer">Dr. Chanock's full post in the TCGA "Perspectives" blog</a></p>
</div>
<div class="callout-box center">
<h3>Jeffrey M. Trent Lecture in Cancer Research</h3>
<p>Watch Dr. Chanock discuss "<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=911031" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1410" rxinlineslot="103" sys_dependentid="911031" sys_relationshipid="7276738" sys_variantid="1410" sys_contentid="911031">The Complexity of Genetic Susceptibility to Cancer</a>".</p>
</div>
<div class="callout-box center">
<h3>Chanock and Fellows at Camp Fantastic</h3>
<p><img class="left" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=623831" inlinetype="rximage" rxinlineslot="104" sys_dependentid="623831" sys_dependentvariantid="1482" sys_relationshipid="7276739" sys_siteid="475" />Dr. Chanock serves as the medical director for <a href="http://www.speciallove.org/index.php?option=com_content&amp;view=article&amp;id=46&amp;Itemid=67" target="_blank" rel="noopener noreferrer">Camp Fantastic</a>. In 2016, he mentored DCEG fellows who volunteered as camp staff.</p>
<p>Read "<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1061699" inlinetype="rxhyperlink" rxinlineslot="103" sys_dependentid="1061699" sys_dependentvariantid="1418" sys_relationshipid="7276740" sys_siteid="475" sys_variantid="1418" sys_contentid="1061699">Camp Fantastic: Perspective from the Mountaintop</a>".</p>
</div>
</div>
</div>]]></body>
    <field_image_promotional>349630</field_image_promotional>
  </row>
  <row term_id="302006" id="349648" title="Rochelle E. Curtis, M.A. " langcode="en" field_short_title="Rochelle E. Curtis, M.A. " field_page_description="Rochelle E. Curtis, M.A., biographical sketch and research interests " field_feature_card_description="Rochelle E. Curtis, M.A., biographical sketch and research interests " field_list_description="Rochelle E. Curtis, M.A., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-06" field_pretty_url="curtis-rochelle" field_browser_title="Rochelle E. Curtis, M.A., biographical sketch and research interests " field_card_title="Rochelle E. Curtis, M.A. " field_email_address="rcurtis@mail.nih.gov" field_first_name="Rochelle" field_last_name="Curtis" field_phone_number="240-276-7384" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E516">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=curtis%20r&amp;authorOption=exact&amp;pi=0010037790">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7252745" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Rochelle E. Curtis is a Research Statistician at the Radiation Epidemiology Branch in the Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI). Ms. Curtis received her Bachelor of Arts in Mathematics from the University of Massachusetts in 1963, and a Master of Arts in Mathematical Statistics from the University of Maryland in 1979. She joined NCI&rsquo;s Biometry Branch, Division of Cancer Cause and Prevention in 1979, and moved to DCEG in 1983. Ms. Curtis is the lead editor on the NCI monograph published in 2006 entitled, New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973&ndash;2000 (available at http://seer.cancer.gov/publications). She has authored numerous other publications, and has received awards for her groundbreaking studies demonstrating an increased risk of secondary cancer following bone marrow transplantation; for contributions in evaluating risks associated with radiation-induced second cancers; and for epidemiologic investigations that have clarified and quantified the risk of leukemia following specific agents used to treat breast cancer.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Etiology of multiple primary cancers</li>
<li>Carcinogenic potential of anti-cancer drugs and radiation treatment</li>
<li>Risk of cancer following hematopoietic stem cell transplantation</li>
<li>Risk of cancer following treatment for breast cancer</li>
</ul>
<h3><a href="http://seer.cancer.gov/publications/mpmono/">New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000</a></h3>
<p class="first-graf">Ms. Curtis lead the development of a new NCI monograph published in 2006, which was the first to provide a comprehensive analysis of the risk of developing a new malignancy in the U.S. population. Many other studies have evaluated risk of subsequent cancers for individual cancer types or groups of cancers, usually related to the late effects of treatment, but this is the first report to provide a complete evaluation of subsequent cancer risk for most first primary cancer sites. The report utilized data from nine cancer registries participating in the Surveillance, Epidemiology, and End Results (SEER) Program from 1973 to 2000. The monograph is by far the largest study to date to assess risk of subsequent cancers and includes over 2 million cancer survivors over a nearly 30-year period, and over 185,000 subsequent primary cancers. More than 50 adult and 18 childhood cancers are included in the new report, including new data on less common cancer sites. Over 350 data tables present the risk of subsequent cancer by time since initial diagnosis, sex, age at initial diagnosis, and when appropriate, by treatment, and cancer cell type. Each chapter compares the findings with other studies, and discusses the results in terms of potential risk factors and mechanisms. Overall, cancer survivors were found to have a 14% increased risk of developing a subsequent primary cancer compared with that expected in the general population. Striking differences were seen by age, with a 6-fold increased risk observed for survivors of childhood cancer. In many cases, the patterns of excess risks that emerged suggested the effect of risk factors that are shared by the primary and subsequent cancers, or a carcinogenic effect of cancer therapies. The monograph provides a unique resource for clinicians, health professionals, and policy makers from which to evaluate the patterns of multiple cancers, and will be useful in advising cancer survivors on their long-term outcomes and the importance of medical supervision for prevention and early detection of new malignancies.</p>
<h3>Cancer Risk Following Hematopoietic Stem Cell Transplantation (HCT)</h3>
<p class="first-graf">Long-term survivors of allogeneic HCT are subject to the possible late effects of total-body irradiation combined with high-dose chemotherapy, and to the late complications of severe immune dysfunction. To quantify the risk of developing a new malignancy, a cohort of nearly 30,000 HCT recipients has been evaluated from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the Fred Hutchinson Cancer Research Center. Results to date have shown that transplant recipients have an increased risk of solid tumors that increases steeply over time; especially high risks were seen for the very young, underscoring the need for lifelong surveillance in this cohort. Recent results from this study show that the risk of non-squamous cell carcinoma cancers was strongly linked to radiation conditioning regimens received at a young age (and especially under 10 years of age), and that this risk increased with time since HCT (Blood 2009). In contrast, the risk of squamous cell cancers was related to chronic graft-versus-host disease (GVHD) and male gender (Blood 2005, 2009). In the first study to fully assess the joint effects and interactions of multiple factors on risk of post-transplant lymphoproliferative disorders (PTLD), Ms. Curtis and collaborators confirmed previous studies showing that the strongest risk factors were T-cell depletion through methods that selectively targeted T-cells and ATG given as prophylaxis of or treatment for GVHD (Blood 2009). In new findings, older age at transplantation (&gt;50 years) and the occurrence of a second transplant were strongly linked to increased risk of PTLD. A separate study conducted among recipients of autologous transplantation for lymphoma found that type and intensity of pre-transplant chemotherapy were important risk factors for the development of leukemic conditions (Blood 2003).</p>
</div>
<!--  - - - - - - - - - - - - - - - - - - - - /about/directory bio main content ends  - - - - - - - - - - - - - - - - - - - -  --></div>]]></body>
    <field_image_promotional>349648</field_image_promotional>
  </row>
  <row term_id="302006" id="349654" title="D. Michal Freedman, J.D., M.P.H., Ph.D." langcode="en" field_short_title="D. Michal Freedman, J.D., M.P.H., Ph.D." field_page_description="D. Michal Freedman, J.D., M.P.H., Ph.D., biographical sketch and research interests" field_feature_card_description="D. Michal Freedman, J.D., M.P.H., Ph.D., biographical sketch and research interests" field_list_description="D. Michal Freedman, J.D., M.P.H., Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-06" field_pretty_url="freedman-michal" field_browser_title="D. Michal Freedman, J.D., M.P.H., Ph.D., biographical sketch and research interests" field_card_title="D. Michal Freedman, J.D., M.P.H., Ph.D." field_email_address="freedmam@mail.nih.gov" field_first_name="Michal" field_last_name="Freedman" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=freedman%20d&amp;authorOption=exact&amp;pi=0010065801">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7252405" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Freedman received an M.P.H. in 1995 and a Ph.D. in 1998 from Johns Hopkins Public Health School. She had previously been awarded a J.D. from Yale Law School and practiced law for several private and public organizations. Dr. Freedman joined the NCI Epidemiology and Biostatistics Program in 1995 and the Radiation Epidemiology Branch in 1999. She was awarded the NCI Director's 2006 Intramural Innovation Award and the NIH Merit Award in 2007. Dr. Freedman's research focused on the effects of ultraviolet radiation and vitamin D on cancer risk. She also studied cancer among medical radiation workers. Dr. Freedman retired from government service in 2017.</p>
</div>
</div>]]></body>
    <field_image_promotional>349654</field_image_promotional>
  </row>
  <row term_id="302006" id="349662" title="Ludmila Prokunina-Olsson, Ph.D. " langcode="en" field_short_title="Ludmila Prokunina-Olsson, Ph.D. " field_page_description="Ludmila Prokunina-Olsson, Ph.D., biographical sketch and research interests" field_feature_card_description="Ludmila Prokunina-Olsson, Ph.D., biographical sketch and research interests" field_list_description="Ludmila Prokunina-Olsson, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-03-18" field_pretty_url="prokunina-olsson-ludmila" field_browser_title="Ludmila Prokunina-Olsson, Ph.D., biographical sketch and research interests" field_card_title="Ludmila Prokunina-Olsson, Ph.D. " field_email_address="prokuninal@mail.nih.gov" field_first_name="Ludmila" field_last_name="Prokunina-Olsson" field_phone_number="240-760-6531" field_org_name_1="National Cancer Institute" field_org_name_2="Laboratory of Translational Genomics" field_campus="301" field_office_location="ATC Room 134C">
    <body><![CDATA[<div class="rxbodyfield"><a id="Top"></a>
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=prokunina-olsson+l&amp;authorOption=exact&amp;pi=0012093092">Scientific Publications</a></li>
<li><a href="/Rhythmyx/assembler/render?sys_contentid=302640&amp;sys_revision=290&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=#Prokunina-Olsson-Lab" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302640" sys_dependentvariantid="1418" sys_folderid="" sys_relationshipid="7329920">Prokunina-Olsson Lab Members</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=30&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" sys_contentid="302432" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422" sys_relationshipid="7329914">Laboratory of Translational Genomics</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Prokunina-Olsson received an M.Sc. in Molecular Genetics from Moscow State University, Russia, and a Ph.D. in Medical Genetics from Uppsala University, Sweden. During 2005-2008 she was a visiting fellow with Dr. Francis Collins in the Genome Technology Branch of the National Human Genome Research Institute, NIH. Dr. Prokunina-Olsson joined the Laboratory of Translational Genomics of DCEG as a research fellow in June 2008, became a tenure-track investigator in April 2010, and was awarded NIH scientific tenure and promoted to senior investigator in December 2014. She became Acting Chief of LTG in February 2018 and was appointed as Chief in December 2018. Dr. Prokunina-Olsson has been recognized for her research contributions with an NCI Director&rsquo;s Merit Award, several NCI Innovation and Intramural Research Awards and several awards outside the NIH. She received the DCEG Outstanding Mentor Award in 2017.</p>
<h2 id="research"><a id="Research Interests"></a>Research Interests</h2>
<p class="first-graf">Recent genome-wide association studies (GWAS) have identified multiple common germline genetic susceptibility variants that may play a role in a variety of human diseases and outcomes. Dr. Prokunina-Olsson explores the connections between the GWAS-identified genetic susceptibility variants and molecular phenotypes of importance for cancer. Some of her findings resulted in translational and clinical applications.</p>
<h3>Genetics of Bladder Cancer</h3>
<p class="first-graf">Several GWAS for bladder cancer risk in individuals of European ancestry discovered 15 genomic regions with statistically significant associations. In addition to contribution to GWAS efforts, Dr. Prokunina-Olsson leads the post-GWAS analysis of these regions that includes genetic fine-mapping and functional molecular analysis of the candidate genetic variants and genes. In addition to bioinformatics tools, her lab uses a wide range of experimental tools to explore both coding and non-coding genetic variants, such as DNA and RNA sequencing, genotyping, RNA and protein expression, DNA-protein interaction analysis, genome editing, cell culture, epigenetic studies, etc. She is also exploring the regulation of somatic mutagenesis in bladder tumors by germline variants and environmental factors. So far, she has comprehensively explored and published results of her studies on five of 15 GWAS regions associated with bladder cancer risk; the work on other GWAS regions is ongoing.</p>
<h3>Genetics of Infection and Cancer</h3>
<p>Recently, Dr. Prokunina-Olsson&rsquo;s lab has discovered a novel human interferon, IFN-&lambda;4, by performing a follow-up of GWAS findings for clearance of hepatitis C virus (HCV) infection. Chronic HCV is a primary etiological factor for the development of chronic liver disease and liver cancer. Dr. Prokunina-Olsson leads the genetic and functional studies on IFN-&lambda;4 in relation to HCV and several other infections associated with cancer.</p>
</div>
<h3>Related News</h3>
<ul>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1135284" sys_contentid="1135284" inlinetype="rxhyperlink" sys_variantid="1424" sys_siteid="475" rxinlineslot="103" sys_dependentid="1135284" sys_dependentvariantid="1424" sys_relationshipid="7329919">Interferon Lambda Experts Meet at NIH to Discuss Disease Impact and Translational Potential</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1139938" sys_contentid="1139938" inlinetype="rxhyperlink" sys_variantid="1424" sys_siteid="475" rxinlineslot="103" sys_dependentid="1139938" sys_dependentvariantid="1424" sys_relationshipid="7329918">Laboratory of Translational Genomics Celebrates 10th Anniversary with Symposium</a></li>
<li><a href="https://www.cancer.gov/news-events/press-releases/2013/IFNL4affectsclearanceofhepatitisCvirus">Investigators discover new gene that affects clearance of hepatitis C virus</a></li>
<li><a href="https://www.cancer.gov/news-events/press-releases/2012/Geneticvariantmarkerforbladdercancer">NIH study suggests gene variation may shape bladder cancer treatment</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=841024" sys_contentid="841024" inlinetype="rxhyperlink" sys_variantid="1424" sys_siteid="475" rxinlineslot="103" sys_dependentid="841024" sys_dependentvariantid="1424" sys_relationshipid="7329916">Genetic marker identified for aggressive bladder cancer</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1062085" sys_contentid="1062085" inlinetype="rxhyperlink" sys_variantid="1424" sys_siteid="475" rxinlineslot="103" sys_dependentid="1062085" sys_dependentvariantid="1424" sys_relationshipid="7329917">Genetic and environmental factors influence APOBEC mutagenesis in tumors</a></li>
</ul>
</div>]]></body>
    <field_image_promotional>349662</field_image_promotional>
  </row>
  <row term_id="302006" id="349666" title="Martha S. Linet, M.D., M.P.H. " langcode="en" field_short_title="Martha S. Linet, M.D., M.P.H. " field_page_description="Martha S. Linet, M.D., M.P.H., biographical sketch and research interests " field_feature_card_description="Martha S. Linet, M.D., M.P.H., biographical sketch and research interests " field_list_description="Martha S. Linet, M.D., M.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-07" field_pretty_url="linet-martha" field_browser_title="Martha S. Linet, M.D., M.P.H., biographical sketch and research interests " field_card_title="Martha S. Linet, M.D., M.P.H. " field_email_address="linetm@mail.nih.gov" field_first_name="Martha" field_last_name="Linet" field_phone_number="240-276-7379" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E452">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=linet%20m&amp;authorOption=exact&amp;pi=0010139595">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=106&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7262263">Radiation Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Martha Linet, a physician epidemiologist, served as Chief of the Radiation Epidemiology Branch of the National Cancer Institute from 2002&ndash;2014. She joined NCI in 1987, and was previously an Associate Professor in the Department of Epidemiology at the Johns Hopkins School of Public Health. Dr. Linet led the collaborative NCI-Children&rsquo;s Oncology Group case-control study of extremely low-frequency residential magnetic fields and other environmental exposures and risk of childhood acute lymphoblastic leukemia, and was co-principal investigator of the multi-center NCI case-control study of cellular telephones and other risk factors for adult brain tumors. She is the long-standing Principal Investigator of the study of cancer and other radiation-related disease risks in U.S. radiologic technologists and the Co-Principal Investigator of the study of cancer risks in Chinese benzene workers. Dr. Linet currently is a member of the National Academy of Sciences Nuclear and Radiation Studies Board, the National Council on Radiation Protection and Measurements, and the Editorial Board of the American Journal of Epidemiology. During 2004-2005 Dr. Linet was President of the American College of Epidemiology. She also previously served as the NCI liaison to the Committee on Environmental Health of the American Academy of Pediatrics, the Advisory Group on Cancer and the Environment to the American Cancer Society, and the Standing Committee on Epidemiology of the International Commission on Non-Ionizing Radiation Protection. Dr. Linet authored The Leukemias: Epidemiologic Aspects, an internationally recognized text in the field. Among her honors are NIH Merit and Director&rsquo;s Awards and election to the Johns Hopkins Society of Scholars.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Assess and quantify cancer risks associated with ionizing and non-ionizing radiation</li>
<li>Identify etiologies of hematopoietic and lymphoproliferative malignancies and related disorders in adults and children</li>
<li>Evaluate and quantify risks of hematopoietic, lymphoproliferative and related disorders associated with occupational exposure to benzene</li>
<li>Study postulated risk factors for malignant lymphoma by subtype in pooled case-control studies conducted by the Interlymph consortium</li>
<li>Examine risk factors for brain cancer in adults and children</li>
</ul>
<h3>Radiation and Cancer; Etiology of Hematopoietic, Lymphoproliferative, and Primary Brain Cancers</h3>
<p class="first-graf">My research focuses on assessing and quantifying cancer risks linked with occupational, residential, and medical exposures to ionizing and non-ionizing radiation. In a series of investigations, my colleagues and I have examined a wide range of postulated risk factors for hematopoietic, lymphoproliferative, and primary brain neoplasms in adults and children.</p>
<h3>Ionizing Radiation Exposure and Cancer Risks in Radiologic Technologists</h3>
<p class="first-graf">In a collaborative investigation with the University of Minnesota, my colleagues and I have investigated mortality and cancer incidence among a nationwide cohort of 146,022 U.S. radiologic technologists certified 2 or more years during 1926-1982. Using work history questionnaire data provided by 90,000 of the technologists (77% women) during 1983-89 and followed up through 1998, we found no increase in total cancer mortality risks, but a 3-fold excess of breast cancer mortality among those first employed before 1940, modest increases in mortality from the combined grouping of acute myeloid, acute lymphoid, and chronic myeloid leukemia among those first employed prior to 1950, and a 40 percent higher circulatory disease mortality risk among those who first worked before 1940 compared with first working in 1960 or later. Mortality and incidence risks according to work history were similar for breast cancer, and for the combined category of leukemias other than chronic lymphocytic leukemia. Basal cell carcinoma incidence risks were more than 2-fold increased and cutaneous melanoma was also significantly elevated, the latter based on small numbers, for those who first worked before 1940 or before 1950, respectively.</p>
<p>Recently, we have reconstructed doses for individual workers and are currently analyzing incidence risks of cancers and other serious diseases according to individual technologist's occupational and personal radiation doses to specific organs. My colleagues and I are also studying the role of specific molecular and selected genetic factors thought to be directly or indirectly involved in radiation carcinogenesis.</p>
<h3>Non-ionizing Radiation, Extremely Low Frequency and Radiofrequency</h3>
<p class="first-graf">To address public health concerns about risk of childhood leukemia from exposures to extremely low frequency magnetic fields (50 or 60 Hertz), we conducted a large case control study with the Children's Oncology Group (a NCI funded clinical trials cooperative group) and found that neither high measured residential magnetic field levels (except possibly magnetic field levels greater than 0.4 microtesla) nor high wire code levels (a proxy measure for close distance of residence to power lines) were associated with significantly increased risks of childhood acute lymphoblastic leukemia. Exploratory analyses evaluating various alternative magnetic field exposure metrics, did not alter our conclusions. Childhood acute lymphoblastic leukemia risks were significantly elevated in offspring whose mothers reported use of an electric blanket during pregnancy, and children with postnatal use of electric blankets, hair dryers, video machines in arcades, and video games connected to televisions. However, patterns for duration or frequency of use of these appliances were inconsistent.</p>
<p>My colleagues and I conducted a large hospital-based case-control study and found that risks of gliomas, meningiomas, and acoustic neuromas were not associated with cumulative use, duration or minutes per day of use of hand-held cellular telephones. In a multi-center population-based study of non-Hodgkin lymphoma, we found that risks of lymphoma were not significantly associated with minutes per week, duration, cumulative lifetime or year of first use of cellular telephones.</p>
<p>Using data from 12 NCI SEER population-based cancer registries, we found that age-specific incidence rates of glioma remained generally constant in 2008, a period coinciding with substantial increase in mobile phone use from 0% to almost 100% of the U.S. population. Comparing observed rates of glioma with projected rates (by combining relatives risks from the two key case-control studies forming the basis of the classification of cell phone use as a possible carcinogen by the International Agency for the search on Cancer, and adjusting for age, registry, sex, data on cell phone use, and various latency periods), we found that projected rates would need to have been 40% higher than those observed in 2008 based on results from the Swedish study by Hardell and colleagues but predicted rates were consistent with observed rates based on results from the 2010 Interphone study.</p>
<h3>Nonionizing Radiation, Ultraviolet or Sunlight Exposures</h3>
<p class="first-graf">My colleagues and I conducted a methodological study to improve the effectiveness of questionnaires in assessing individual UV or sunlight exposures. Comparing assessment of time spent outdoors with an activity-based approach we found higher reproducibility for the activity-based approach during adult ages and over subjects' lifetimes then the time-based approach particularly for women. Currently, we are assessing the extent to which questionnaire-derived data on sunlight exposure and other postulated determinants predict vitamin D levels. We are also studying historical data from NASA (total ozone mapping spectrometer) satellites on UVR ambient exposure in conjunction with questionnaire data on personal exposure to sunlight to assess comprehensively the relationship of UVR with risks for basal cell and squamous cell skin carcinogenesis with USRT.</p>
<h3>Benzene Related Hematopoietic Disorders</h3>
<p class="first-graf">A cohort study of mortality and hematopoietic malignancy incidence risks was carried out among 75,000 benzene exposed workers employed between 1949 and 1987 in 12 cities in China. We found a three fold excess risk for non Hodgkin lymphoma (NHL), with risks rising with increasing duration of benzene exposure and associated with benzene exposure more than 10 years prior to diagnosis of NHL. In contrast, a three-fold excess of acute nonlymphocytic leukemia (ANLL) was linked with recent exposures; risk did not vary according to exposure duration. Significantly elevated risks were also seen for myelodysplastic syndromes and aplastic anemia, and there were non-significant excesses of acute lymphoid leukemia and chronic myeloid leukemia, but the numbers of cases were small. Underway is an investigation to extend follow-up of mortality risks foe an additional 12 years (1972-1999).</p>
<p>We are currently conducting a case-cohort study to quantify benzene dose-response risk of hematopoietic malignancies, benzene hematotoxicity, and lung cancer during 1972-1999, and also conducting a molecular and genetic case-control investigation of benzene hematotoxiticity.</p>
</div>
</div>]]></body>
    <field_image_promotional>349666</field_image_promotional>
  </row>
  <row term_id="302006" id="349669" title="William F. Anderson, M.D., M.P.H. " langcode="en" field_short_title="William F. Anderson, M.D., M.P.H. " field_page_description="William F. Anderson M.D., M.P.H., biographical sketch and research interests" field_feature_card_description="William F. Anderson M.D., M.P.H., biographical sketch and research interests" field_list_description="William F. Anderson M.D., M.P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2016-10-05" field_pretty_url="anderson-william" field_browser_title="William F. Anderson M.D., M.P.H., biographical sketch and research interests" field_card_title="William F. Anderson, M.D., M.P.H. " field_email_address="wanderso@mail.nih.gov" field_first_name="William" field_last_name="Anderson" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=anderson%20wf&amp;authorOption=exact&amp;pi=0010389987">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_relationshipid="7276658" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Anderson received his medical, clinical, and epidemiological training at Tulane University in New Orleans Louisiana.&nbsp; He is board certified in internal medicine, hematology, and medical oncology. After nearly 20 years as a community-based hematologist/medical oncologist in northeast Louisiana, he joined the NCI to develop a research program in cancer surveillance research with a special interest in breast cancer. Dr. Anderson supplemented standard descriptive epidemiology with biostatistical methods including age-period-cohort models, spline-based survival models, and incidence-based mortality. Using these combined techniques, he assessed cancer trends, heterogeneity, racial and geographic disparities in population-based cancer registries. Dr. Anderson retired from government service in 2017.</p>
<!-- /about/directory bio main content ends   --></div>
</div>]]></body>
    <field_image_promotional>349669</field_image_promotional>
  </row>
  <row term_id="302006" id="349684" title="Sonja Berndt, Pharm.D., Ph.D. " langcode="en" field_short_title="Sonja Berndt, Pharm.D., Ph.D. " field_page_description="Sonja Berndt, Pharm.D., Ph.D., biographical sketch and research interests " field_feature_card_description="Sonja Berndt, Pharm.D., Ph.D., biographical sketch and research interests " field_list_description="Sonja Berndt, Pharm.D., Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="berndt-sonja" field_browser_title="Sonja Berndt, Pharm.D., Ph.D., biographical sketch and research interests " field_card_title="Sonja Berndt, Pharm.D., Ph.D. " field_email_address="berndts@mail.nih.gov" field_first_name="Sonja" field_last_name="Berndt" field_phone_number="240-276-7166" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E126">
    <body><![CDATA[<div class="rxbodyfield"><!-- /about/staff-bios/ berndt-sonja bio main content begins   -->
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=Berndt+SI&amp;authorOption=exact&amp;pi=0011547497">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7276867" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="biography"><a id="Biography"></a>Biography</h2>
<p class="first-graf">Dr. Berndt received a Pharm.D. from the University of Michigan, and a Ph.D. in epidemiology from Johns Hopkins University. She joined DCEG in 2003 as a pre-doctoral fellow, becoming a post-doctoral fellow in 2006 within the Occupational and Environmental Epidemiology Branch. In 2009, Dr. Berndt was appointed to the position of tenure-track investigator. She was awarded scientific tenure and promoted to senior investigator in March 2017. She has received several awards for her work, including an NCI Intramural Research Award, NCI Director&rsquo;s Career Development Award, and several DCEG and NIH Fellowship Achievement awards for excellence in research.</p>
<h2 id="research"><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Berndt&rsquo;s research utilizes new analytic methods in genetic and molecular epidemiology to elucidate &nbsp;the etiology of cancer and anthropometric traits and explores the impact of modifiable risk factors on cancer risk and mortality. She co-leads several genome-wide association studies (GWAS) and the PLCO Prostate Cancer Progression (PCP) Study. She is a member of the InterLymph Consortium Coordinating Committee and serves as the principal investigator representing the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial for the Genetic Investigation of Anthropometric Traits (GIANT), Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL), African American Prostate Cancer (AAPC), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), and <em>Helicobacter pylori</em> Colorectal Cancer (HpCRC) consortia.</p>
<h3><strong>Lymphoid Malignancies</strong></h3>
<p>Genetic, environmental, and immune-related factors have been implicated in the etiology of non-Hodgkin lymphoma (NHL), but the complex etiology of this disease is not well understood. To elucidate the genetic underpinnings of common NHL subtypes, Dr. Berndt co-led a large multicenter genome-wide association study (GWAS) for NHL and identified over 30 new independent single nucleotide polymorphisms (SNPs) associated with specific subtypes of NHL, more than doubling the number of identified loci for NHL and discovering a key role for apoptosis in CLL susceptibility. She is currently expanding the GWAS to include additional rare and common lymphoid malignancies. The expanded GWAS will double the sample size for discovery and lead to further exploration of the genetic architecture of lymphoid malignancies. Her research also uses next generation sequencing and bioinformatic tools to fine-map discovered risk loci and molecular technologies to further understand potential biological mechanisms.</p>
<h3><strong>Prostate Cancer</strong>&nbsp;</h3>
<p>Both environmental and genetic factors are thought to contribute to the risk of prostate cancer. Over the past decade, through the work of Dr. Berndt and others, substantial progress has been made in identifying genetic loci associated with the risk of prostate cancer with over 150 loci discovered to date. Dr. Berndt&rsquo;s research seeks to understand the genetic architecture of prostate cancer susceptibility, explore potential effect modification by environmental and occupational risk factors, and examine how these factors may be used in risk prediction and screening for prostate cancer. Although prostate cancer is one of the most common cancers in the world, only a small proportion of men die from the disease. Understanding and predicting which men are likely to die from the disease is of clinical importance to prevent overtreatment. Dr. Berndt co-leads a study of prostate cancer progression within the PLCO Cancer Screening Trial, which seeks to identify environmental, lifestyle and molecular risk factors for disease progression.</p>
</div>
<h3 class="dceg-bio-content">Anthropometric Traits</h3>
<div class="dceg-bio-content">
<p class="first-graf">Although the biological mechanisms are not well understood, obesity and height are risk factors for several cancers. Both anthropometric traits have strong genetic components. Through the GIANT Consortium, Dr. Berndt and colleagues have identified hundreds of loci for height and adiposity-related traits (e.g., body mass index). This work has a had profound impact on our understanding of the genetic architecture of these traits as well as other diseases, but many questions remain. Dr. Berndt&rsquo;s research seeks to further understand the genetic underpinnings of anthropometric traits and to examine the impact of adiposity on cancer risk and mortality.</p>
</div>
</div>]]></body>
    <field_image_promotional>349684</field_image_promotional>
  </row>
  <row term_id="302006" id="832328" title="Linda M. Liao, Ph.D." langcode="en" field_short_title="Linda M. Liao, Ph.D." field_page_description="Linda M. Liao, Ph.D., biographical sketch and research interests " field_feature_card_description="Linda M. Liao, Ph.D., biographical sketch and research interests " field_list_description="Linda M. Liao, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2014-09-19" field_date_reviewed="2014-09-19" field_date_updated="2014-09-19" field_pretty_url="liao-linda" field_browser_title="Linda M. Liao, Ph.D., biographical sketch and research interests " field_card_title="Linda M. Liao, Ph.D." field_email_address="liaolm@mail.nih.gov" field_first_name="Linda" field_last_name="Liao" field_phone_number="240-276-7288" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E424">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Liao+LM&amp;authorOption=exact&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_relationshipid="7252584" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<p>Dr. Linda Liao received a B.S. in nutrition and food science in 2000 and an M.P.H. in epidemiology in 2002 from the University of California, Berkeley. In 2007, she received a Ph.D. in epidemiology from the University of Washington, where she studied the relationship between genetic variation in calcium- and vitamin D-related genes and colon cancer. In November 2007, Dr. Liao joined the Occupational and Environmental Epidemiology Branch as a Sallie Rosen Kaplan postdoctoral fellow and was promoted to research fellow in March 2011. In July 2014, she joined the Nutritional Epidemiology Branch as a staff scientist. Dr. Liao has received several awards for her work, including an NCI Director&rsquo;s Career Development Innovation award and an NIH Fellows Award for Research Excellence.</p>
<p>In the newly formed <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_relationshipid="7252583" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a>, Dr. Liao is responsible for all aspects of managing the NIH-AARP Diet and Health Study, a prospective cohort study of 500,000 people aged 50-71. This study serves as an important resource for investigators seeking to understand the relationship between diet and lifestyle and the etiology of various cancers.</p>
<h2 id="Research Interests">Research Interests</h2>
<p>Dr. Liao has a long-standing interest in how dietary factors and obesity affect the development of cancer. In addition, she is evaluating molecular markers in relation to upper gastrointestinal and kidney cancers.</p>
</div>
</div>]]></body>
    <field_image_promotional>832328</field_image_promotional>
  </row>
  <row term_id="302006" id="1016601" title="Maki Inoue-Choi, Ph.D., M.S., R.D." langcode="en" field_short_title="Maki Inoue-Choi, Ph.D., M.S., R.D." field_page_description="Maki Inoue-Choi, Ph.D., biographical sketch and research interests " field_feature_card_description="Maki Inoue-Choi, Ph.D., biographical sketch and research interests " field_list_description="Maki Inoue-Choi, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-10-26" field_date_reviewed="2015-10-26" field_date_updated="2015-10-26" field_pretty_url="inoue-choi-maki" field_browser_title="Maki Inoue-Choi, Ph.D., biographical sketch and research interests " field_card_title="Maki Inoue-Choi, Ph.D., M.S., R.D." field_email_address="maki.inoue-choi@nih.gov" field_first_name="Maki" field_last_name="Inoue-Choi" field_phone_number="240-276-6329" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E346">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Inoue+Choi&amp;authorOption=exact&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252579" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<p>Maki Inoue-Choi, Ph.D., M.S., R.D., received an M.S. in nutritional sciences from the University of Washington in 2004 and subsequently worked as a clinical dietitian in the University of Washington Medical Center. Before starting the graduate program, she was a clinical dietitian at the Osaka University Graduate School of Medicine and an instructor at the Doshisha Women&rsquo;s College in Japan. In 2012, she received a Ph.D. in epidemiology from the University of Minnesota, where she studied the role of nutrients in one-carbon metabolism and their interaction with genes in the etiology of breast cancer. After working as a research associate in the Division of Epidemiology &amp; Community Health of the University of Minnesota, School of Public Health, Dr. Inoue-Choi joined the Occupational and Environmental Epidemiology Branch of the Division of Cancer Epidemiology and Genetics as a postdoctoral fellow in 2013. She evaluated the extent to which chronic exposure to environmental chemicals, such as pesticides and fertilizers from drinking water, is associated with the risk of hormone-related cancers among women, and whether the exposure to these chemicals interacts with nutrients. In October 2015, Dr. Inoue-Choi joined the Nutritional Epidemiology Branch as a staff scientist. In the newly formed <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252578" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a>, she develops and coordinates multidisciplinary projects that quantify the cancer risks from both traditional and emerging tobacco products, and to elucidate the molecular mechanisms driving subsequent cancer risk.</p>
<p>Dr. Inoue-Choi has received several awards for her research, including the NIH Fellows Award for Research Excellence and the American Association for Cancer Research Scholar-in-Training Award.&nbsp;</p>
<h2 id="Research-Interests">Research Interests</h2>
<ul>
<li>Emerging tobacco products and cancer and chronic disease</li>
<li>Urinary biomarkers of tobacco exposure and cancer and chronic disease</li>
<li>Endocrine disrupting chemicals in diet and drinking water and hormone-related cancer</li>
<li>Molecular mechanisms of nutrient metabolism in relation to breast cancer</li>
<li>Diet and lifestyle among cancer survivors</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>1016601</field_image_promotional>
  </row>
  <row term_id="302006" id="1033589" title="Stephanie J. Weinstein, Ph.D." langcode="en" field_short_title="Stephanie J. Weinstein, Ph.D." field_page_description="Stephanie Weinstein, Ph.D., biographical sketch and research interests " field_feature_card_description="Stephanie Weinstein, Ph.D., biographical sketch and research interests " field_list_description="Stephanie Weinstein, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-01-06" field_date_reviewed="2016-01-06" field_date_updated="2016-01-06" field_pretty_url="weinstein-stephanie" field_browser_title="Stephanie Weinstein, Ph.D., biographical sketch and research interests " field_card_title="Stephanie J. Weinstein, Ph.D." field_email_address="weinstes@mail.nih.gov" field_first_name="Stephanie" field_last_name="Weinstein" field_phone_number="240-276-7209" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E426">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Weinstein+S&amp;authorOption=exact&amp;pi= 0010411027&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7252826" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Stephanie Weinstein received a B.S. in biology from Tufts University and M.S. and Ph.D. degrees in nutrition from Cornell University. Her doctoral dissertation focused on one-carbon metabolism and cervical cancer. Upon completion of her graduate work, Dr. Weinstein was a postdoctoral fellow in the Nutritional Epidemiology Branch (NEB), Division of Cancer Epidemiology and Genetics, NCI, for three years. After working for one year as a nutritionist in the U.S. Department of Agriculture&rsquo;s Center for Nutrition Policy and Promotion, she returned to NCI as a staff scientist in NEB in 2002, and continues her duties in the Metabolic Epidemiology Branch.</p>
<p>Since joining NCI, Dr. Weinstein received the NIH Fellows Award for Research Excellence and the NCI Staff Scientist/Staff Clinician Organization Travel Award.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Weinstein has published extensively on diet and cancer associations, with a focus on vitamin D, vitamin E, and one-carbon metabolism. In addition, she has served on the steering committee of several large collaborative/pooling projects, such as the Vitamin D Pooling Project of Rarer Cancers, the Circulating Biomarkers and Breast and Colorectal Cancer Consortium, and the Lung Cancer Cohort Consortium.</p>
<p>In addition, Dr. Weinstein manages the <a href="http://atbcstudy.cancer.gov/">Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study</a>, a prospective cohort study that began as a clinical trial. Between 1985 and 1988, nearly 30,000 male smokers in southwestern Finland, ages 50-69, were randomized to receive daily supplementation of alpha-tocopherol (vitamin E), beta-carotene, both, or a placebo. Supplementation continued for 5&ndash;8 years, until 1993. Since that time, post-intervention follow-up of the cohort has continued, with yearly mortality and cancer incidence outcome updates. The ATBC study serves as an important resource of risk factor data and biospecimens used to study biochemical, nutritional, genetic, and molecular hypotheses relevant to cancer etiology, survival, early detection, and prevention.</p>
</div>
</div>]]></body>
    <field_image_promotional>1033589</field_image_promotional>
  </row>
  <row term_id="302006" id="1080328" title="Rena Jones, Ph.D., M.S." langcode="en" field_short_title="Rena Jones, Ph.D., M.S." field_page_description="Rena R. Jones, Ph.D., M.S., biographical sketch and research interests" field_feature_card_description="Rena R. Jones, Ph.D., M.S., biographical sketch and research interests" field_list_description="Rena R. Jones, Ph.D., M.S., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-04-05" field_date_reviewed="2017-04-05" field_date_updated="2017-04-05" field_pretty_url="jones-rena" field_browser_title="Rena R. Jones, Ph.D., M.S., biographical sketch and research interests" field_card_title="Rena Jones, Ph.D., M.S." field_email_address="rena.jones@nih.gov" field_first_name="Rena" field_last_name="Jones" field_phone_number="240-276-7292" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E124">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul>
<li><a href="#Biography">Biography</a></li>
<li><a href="#ResearchInterests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=jones%20rr&amp;authorOption=exact&amp;pi=2001119361">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7252762">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Jones earned her M.S. and Ph.D. degrees in epidemiology from the University at Albany (State University of New York) School of Public Health. She joined the Occupational and Environmental Epidemiology Branch (OEEB) as a postdoctoral fellow in 2012, became a research fellow in 2014, and was appointed to the tenure-track in 2017. Dr. Jones&rsquo; work has been recognized with several awards, including the DCEG Fellows Award for Research Excellence, the DCEG Intramural Research Award, the NCI Director&rsquo;s Innovation Award, and the Sallie Rosen Kaplan Fellowship for Women Scientists in Cancer Research.</p>
<h2><a id="ResearchInterests"></a>Research Interests</h2>
<p>Dr. Jones&rsquo; research focuses on the investigation of cancer risk associated with environmental contaminants, especially air and water pollutants. Her work relies on the application of Geographic Information Systems (GIS)&nbsp;and novel approaches to assess environmental exposures, and identifying and clarifying how they may cause cancer.</p>
<h3>Outdoor Air</h3>
<p>Outdoor air pollution is a known lung carcinogen, but the specific pollutants driving cancer risk and etiologic mechanisms are not well understood. Along with OEEB Branch Chief <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349599" sys_contentid="349599" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" rxinlineslot="103" sys_dependentid="349599" sys_dependentvariantid="1965" sys_relationshipid="7252765">Debra Silverman, Sc.D.</a>, Dr. Jones is pursuing some of these questions in the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=9&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=976905" sys_contentid="976905" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" rxinlineslot="103" sys_dependentid="976905" sys_dependentvariantid="1418" sys_relationshipid="7252763"> Los Angeles Ultrafines Study</a>, such as whether ultrafine particles (UFP), primarily emitted from vehicle exhaust, are a cause of lung cancer. Estimation of participants&rsquo; exposures to air pollution in this study requires innovation in both data collection and modeling, and makes use of a state-of-the-art approach for retrospectively quantifying exposure to UFP and other pollutants.</p>
<p>Dr. Jones is also leading efforts to evaluate potential cancer risks associated with air pollutants from industrial sources, to which much of the general population is routinely exposed. She is pursuing etiologic hypotheses related to emissions of dioxins and furans as well as those arising from intensive animal agriculture.<o:p></o:p></p>
<h3>Drinking Water</h3>
<p><span style="color: black; background: white;">Drinking water is an important route of exposure to numerous compounds of public health concern, including agricultural contaminants, disinfection-byproducts (DBP), and biologically active substances. Cancer risks associated with these exposures&nbsp;are not well understood, especially because measurement data to estimate exposure in epidemiologic study populations is limited. Dr. Jones&rsquo; drinking water research aims to address issues relating to exposure characterization and to describing cancer risks associated with contaminants of emerging concern. </span>She has developed exposure metrics for nitrate in public water supplies, which she and collaborators are using to investigate nitrate associations with several cancers. Promising results from the Iowa Women&rsquo;s Health Study&nbsp;cohort have motivated an effort to apply similar techniques in the <a href="https://dceg.cancer.gov/research/who-we-study/cohorts/agricultural-health-study">Agricultural Health Study</a>.</p>
<p>Dr. Jones also has led multiple analyses of DBP in public drinking water, investigations that considered concomitant exposure to nitrate and other compounds. She is leading an effort evaluate the utility of bioassays in characterizing exposures to endocrine disrupting&nbsp;compounds in drinking water. She is also advancing research on environmentally persistent water contaminants, including per- and polyfluorinated compounds, and their relation to cancer.<o:p></o:p></p>
<h3>Exposure Assessment</h3>
<p>A fundamental underpinning of high quality environmental epidemiologic studies is accurate exposure assessment. The development of estimates that adequately reflect human exposure requires an understanding of exposure pathways, environmental transport and persistence, and individual exposure determinants, all of which have sources of uncertainty, especially in retrospective studies. Dr. Jones takes several approaches to improving long-term environmental exposure estimates, including optimizing the spatial accuracy of residential addresses and exposure sources, characterizing participant mobility and time spent in microenvironments, and incorporating information from surveys, regulatory monitoring data and other external datasets. Her work also focuses on characterizing exposure mixtures and validation studies to evaluate the quality of exposure estimates.</p>
<p>Dr. Jones is co-chair of the DCEG Geographic Analysis Working Group, which seeks to advance the use of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1087390" sys_contentid="1087390" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" rxinlineslot="103" sys_dependentid="1087390" sys_dependentvariantid="1418" sys_relationshipid="7252766">Geographic Information Systems (GIS)</a> and geospatial methods in epidemiologic studies of cancer.</p>
</div>
</div>]]></body>
    <field_image_promotional>1080328</field_image_promotional>
  </row>
  <row term_id="302006" id="1134872" title="Emily Vogtmann, Ph.D., M.P.H." langcode="en" field_short_title="Emily Vogtmann, Ph.D., M.P.H." field_page_description="Emily Vogtmann, Ph.D., Earl Stadtman investigator in DCEG - biography and research interests" field_feature_card_description="Emily Vogtmann, Ph.D., is an Earl Stadtman investigator in DCEG." field_list_description="Emily Vogtmann, Ph.D., is an Earl Stadtman investigator in DCEG.&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2019-01-11" field_date_reviewed="2019-01-11" field_date_updated="2019-01-11" field_pretty_url="vogtmann-emily" field_browser_title="Emily Vogtmann, Ph.D.- biography and research interests" field_card_title="Emily Vogtmann, Ph.D., M.P.H." field_email_address="emily.vogtmann@nih.gov" field_first_name="Emily" field_last_name="Vogtmann" field_phone_number="(240) 276-6701" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E428">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul>
<li><a href="#Biography">Biography</a></li>
<li><a href="#ResearchInterests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=vogtmann%20e&amp;authorOption=exact&amp;pi=2001270816">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_dependentvariantid="1422" sys_dependentid="1033171" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_folderid="" sys_relationshipid="7203819" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology&nbsp;Branch</a></li>
</ul>
<h3><a id="Biography"></a>Biography</h3>
<p>Dr. Vogtmann, received her B.S. in biochemistry and molecular biology and B.A. in Spanish from Michigan State University in 2005. She went on to receive an M.P.H. in international health epidemiology from the University of Michigan in 2009, where she investigated human papillomavirus and cervical cancer awareness and mortality trends in Mexico. Dr. Vogtmann completed a Ph.D. in epidemiology in 2013 at the University of Alabama at Birmingham. Her dissertation focused on cruciferous vegetable intake,&nbsp;<em>GST</em> polymorphisms, and colorectal cancer among men in Shanghai, China, completed in collaboration with the Shanghai Cancer Institute and Vanderbilt University Medical Center. Dr. Vogtmann joined DCEG as a Cancer Prevention Fellow in the Metabolic Epidemiology Branch in August 2013 and was promoted to Research Fellow in June 2016. She was appointed to the position of Earl Stadtman Tenure-Track Investigator in 2018. Dr. Vogtmann has received a number of awards for her work, including the NIH and DCEG Fellows&rsquo; Award for Research Excellence and the NCI Director&rsquo;s Innovation Award.</p>
<h3><a id="ResearchInterests"></a>Research Interests</h3>
<p>Dr. Vogtmann&rsquo;s research focuses on: 1) the association between the human microbiota and cancer risk; 2) how human microbiota may mediate associations between exposures and cancer risk; and 3) risk factors for head and neck and lower gastrointestinal cancers.</p>
<h3>Human microbiota and cancer risk</h3>
<p>Within the body, microbial cells&mdash;bacteria, viruses, fungi, etc.&mdash;outnumber human cells and are known to play both pathogenic and commensal roles. Nevertheless, the mechanistic contributions of the human microbiota to cancer and other diseases remain poorly characterized. Dr. Vogtmann applies cutting-edge microbial techniques in epidemiologic studies to investigate the role of the microbiota in cancer risk and progression. To perform this research, she currently utilizes oral wash specimens (originally collected as a source of DNA for study of the human genome) from multiple large cohort studies to determine the prospective association between the oral microbiota and cancer risk. She is also actively collaborating with investigators to include fecal collections in these large cohorts in order to be able to study the prospective association between the fecal microbiota with cancer risk. In addition to pursuing cancer risk analyses, she is evaluating methods to characterize the fungal component of the microbiota so its relationship to cancer risk can be considered.</p>
<h3>Associations between established cancer risk factors and the human microbiota</h3>
<p>In addition to direct effects, microbiota may also mediate relationships between various exposures and cancer risk. For example, tobacco products cause periodontal disease, a risk factor for oral cancer; alterations in the oral microbiota may mediate this association. Dr. Vogtmann investigates the effects of cancer risk factors, such as tobacco use, betel quid use, alcohol intake, and diet, on microbial communities.</p>
<h3>Risk factors for head and neck and lower gastrointestinal cancers</h3>
<p>In order to inform her studies of the microbiota as both a risk factor and a potential mediator for head and neck and lower gastrointestinal cancer, Dr. Vogtmann conducts studies to evaluate the impact of lifestyle factors on the risks of these cancers. She uses questionnaire data from prospective cohort studies, such as the Golestan Cohort Study and the NIH-AARP Diet and Health Study, to investigate cancer risk factors.</p>
</div>
</div>]]></body>
    <field_image_promotional>1134872</field_image_promotional>
  </row>
  <row term_id="302006" id="349594" title="Jianxin Shi, Ph.D " langcode="en" field_short_title="Jianxin Shi, Ph.D " field_page_description="Jianxin Shi, Ph.D., biographical sketch and research interests " field_feature_card_description="Jianxin Shi, Ph.D., biographical sketch and research interests " field_list_description="Jianxin Shi, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="shi-jianxin" field_browser_title="Jianxin Shi, Ph.D., biographical sketch and research interests " field_card_title="Jianxin Shi, Ph.D " field_email_address="Jianxin.Shi@nih.gov" field_first_name="Jianxin" field_last_name="Shi" field_phone_number="240-276-7419" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E122">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="#software">Software</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=shi%20j&amp;authorOption=exact&amp;pi=0014378909">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_relationshipid="7276793" sys_siteid="475" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Jianxin Shi received a B.S. in mathematics and an M.S. in computer science from Beijing University in 2002. He received his Ph.D. in statistics from Stanford University under the supervision of Professor David O. Siegmund in 2006. Prior to joining NCI, Dr. Shi spent two years as a postdoctoral research fellow and one year as research scientist in Health Research and Policy (HRP) in the Department of Psychiatric and Behavior Science at Stanford University, working on genome-wide association studies of breast cancer, schizophrenia, and recurrent depression. Dr. Shi joined the DCEG Biostatistics Branch as a tenure-track principal investigator in August 2009. He was awarded scientific tenure by the NIH in 2016.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Genetic epidemiology, genetic risk prediction, copy number variation analysis</li>
<li>Statistical analysis of microbiome data in epidemiological studies</li>
<li>Integrative genomic analysis of tumors, tumor evolution</li>
</ul>
<h2 id="software">Software</h2>
<ul class="grey-bullets">
<li>MEGSA</li>
<li>MicrobiomeGWAS</li>
<li>SummaryAUC</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349594</field_image_promotional>
  </row>
  <row term_id="302006" id="349600" title="Shelia Hoar Zahm, Sc.D. " langcode="en" field_short_title="Shelia Hoar Zahm, Sc.D. " field_page_description="Shelia Hoar Zahm, Sc.D., biographical sketch and research interests " field_feature_card_description="Shelia Hoar Zahm, Sc.D., biographical sketch and research interests " field_list_description="Shelia Hoar Zahm, Sc.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-23" field_pretty_url="zahm-shelia" field_browser_title="Shelia Hoar Zahm, Sc.D., biographical sketch and research interests " field_card_title="Shelia Hoar Zahm, Sc.D. " field_email_address="Zahms@mail.nih.gov" field_first_name="Shelia" field_last_name="Zahm" field_phone_number="301-502-2090" field_org_name_1="National Cancer Institute" field_org_name_2="Office of the Director" field_campus="300" field_office_location="Room 7E406">
    <body><![CDATA[<div class="rxbodyfield"><!--  - - - - - - - - - - - - - - - - - - - - /about/directory/zahm-sheila bio main content begins  - - - - - - - - - - - - - - - - - - - -  -->
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=zahm+s&amp;authorOption=exact&amp;PI=0010036969">Scientific Publications</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Zahm received a Sc.D. in epidemiology from the Harvard School of Public Health and joined NCI as a Staff Fellow in 1980. She was tenured in 1987 in the Occupational Studies Section, became Deputy Chief of the Occupational and Environmental Epidemiology Branch in 1996, and served as Deputy Director of the DCEG from 1998 to 2011. Dr Zahm has received the American Occupational Medical Association's Merit in Authorship Award for a paper on job-exposure matrices, the Harvard School of Public Health Alumni Award of Merit, the U.S. DHHS Secretary's Award for Distinguished Service, the NIH Merit Award and the PHS Special Recognition Award for her work on the relationship between pesticides and the risk of non-Hodgkin lymphoma, the NIH Director's Award for her program of research on cancer among migrant and seasonal farm workers, the NIH Director&rsquo;s Award for developing NIH biospecimen storage and tracking guidelines, the NIH Merit Award for implementation of the NIH Reform Act of 2006, two NIH Quality of Work Life Awards, the DCEG Mentoring Award, and the DCEG Exemplary Service Award. Dr. Zahm has served on the editorial board of several journals and on numerous national and international committees, including service as chair of the United Auto Workers/General Motors Occupational Health Advisory Board. Dr. Zahm was elected to the American Epidemiology Society in 1995 and is an adjunct faculty member at George Washington University. Her research interests include pesticides and cancer, the etiology of non-Hodgkin lymphoma, and occupational cancer among women.</p>
</div>
</div>]]></body>
    <field_image_promotional>349600</field_image_promotional>
  </row>
  <row term_id="302006" id="349612" title="Christian C. Abnet, Ph.D, M.P.H. " langcode="en" field_short_title="Christian C. Abnet, Ph.D, M.P.H. " field_page_description="Christian C. Abnet, Ph.D, M.P.H., Biographical sketch and research interests" field_feature_card_description="Biographical sketch and research interests of Christian C. Abnet, Ph.D, M.P.H." field_list_description="Biographical sketch and research interests of Christian C. Abnet, Ph.D, M.P.H." field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="abnet-christian" field_browser_title="Christian C. Abnet, Ph.D, M.P.H., biographical sketch and research interests" field_card_title="Christian C. Abnet, Ph.D, M.P.H. " field_email_address="abnetc@mail.nih.gov" field_first_name="Christian" field_last_name="Abnet" field_phone_number="240-276-7213" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E410">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=abnet%20c&amp;authorOption=exact&amp;pi=0010389577">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7275932" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<a id="Biography"></a>
<h2>Biography</h2>
<div class="callout-box right">
<h3>Christian Abnet Studies Tobacco and the Oral Microbiome</h3>
<p><img class="left" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=951079" sys_dependentvariantid="1482" sys_dependentid="951079" inlinetype="rximage" rxinlineslot="104" sys_siteid="475" sys_relationshipid="7275934" /><strong>Video</strong>: Watch Dr. Abnet discuss his research on <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1087221" sys_dependentvariantid="1410" sys_dependentid="1087221" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275935" sys_variantid="1410" sys_contentid="1087221">Tobacco and the Oral Microbiome</a>, as part of FDA's Tobacco Regulatory Science in Action, Spring 2014.</p>
</div>
<p class="first-graf">Dr. Christian Abnet earned a Ph.D. in environmental toxicology from the University of Wisconsin in 1998 and an M.P.H. in epidemiology from the University of Minnesota in 1999. He joined NCI as a Cancer Prevention Fellow in the Division of Cancer Prevention in 1998. Dr. Abnet became a tenure-track investigator in the Nutritional Epidemiology Branch (NEB) in 2005. In 2014, he was awarded scientific tenure by NIH and appointed Acting Chief of NEB. In 2015, he was named Chief of the newly established <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7275931" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a>.</p>
<h2 id="Research">Research Interests</h2>
<p>Dr. Abnet's work focuses on the etiology of esophageal and gastric cancer. His research interests are driven by a desire to meet the needs of populations in limited-resource settings who are at highest risk for these diseases.</p>
<h3>Etiologic Studies of Esophageal and Gastric Cancer</h3>
<p>Esophageal cancer presents one of the most uneven worldwide geographic distributions of all cancers with several regions of extraordinarily high incidence. There are two primary bands of high-incidence populations with one stretching across central Asia from China to Iran and a second spanning East to Southern Africa. Overall, gastric cancer patterns appear distinct from esophageal cancer, but populations with high rates of esophageal squamous cell carcinoma (ESCC) tend to have co-occurring high rates of gastric cardia adenocarcinoma. Tobacco smoking and excessive alcohol drinking account for most ESCC in the US and similar countries, but these factors play little or no role in high-incidence populations.</p>
<p>Dr. Abnet studies the complex pattern of incidence and differing etiologic factors for these two malignancies and the multiple risk factors across diverse populations that share high rates of ESCC and gastric cardia adenocarcinoma. Specifically, he examines the nutritional underpinnings of ESCC and upper gastrointestinal (UGI) cancer, with a focus on the role of vitamins D, C, and B; and tobacco, alcohol, and other harmful habits.</p>
<p>Dr. Abnet is a member of the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1090903" sys_dependentvariantid="1418" sys_dependentid="1090903" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7275933" sys_variantid="1418" sys_contentid="1090903">African Esophageal Cancer Consortium (AfrECC)</a>.</p>
<h3>Genetics and Genomics</h3>
<p>The advent of genome-wide association studies has allowed Dr. Abnet to pursue powerful genetic studies of these cancers in high- and low-incidence populations.&nbsp;In a first study of ESCC and gastric cardia adenocarcinoma in ethnic Chinese subjects, Dr. Abnet and colleagues found that a single locus encompassing the phospholipase C, epsilon 1 (<i>PLCE1</i>) gene was the top hit for both cancers. In the future, this team will complete additional work on susceptibility to gastric cancer in Chinese populations and complementary studies of ESCC and gastric cancer in Caucasians. This comprehensive examination across continents will provide the fullest possible understanding of the genetic contribution to the apparent etiologic differences.</p>
<h3>Oral Health and Oral Microbiome</h3>
<p>Dr. Abnet also carries out research into the bacterial milieu of the upper digestive tract. He has shown associations between oral health and UGI cancer risk in China, Finland, Iran, and India, and is now exploring potential underlying mechanisms between oral health and risk of UGI cancers overall.&nbsp;Dr. Abnet has completed one of the first large, prospective epidemiologic studies of the upper digestive tract microbiome and found associations with pre-neoplastic conditions in both the esophagus and stomach.&nbsp;He is employing the National Health and Nutrition Examination Survey (NHANES) study to assess the impact of tobacco on the oral microbiome.&nbsp;This study is the first to characterize the effects of tobacco on the oral microbiome in a nationally representative study population and allows for the examination of the association between the oral microbiome and tobacco related diseases. It is funded by the Food and Drug Administration&rsquo;s (FDA) Center for Tobacco Products through a trans-NIH&mdash;FDA collaboration coordinated by the <a href="https://prevention.nih.gov/tobacco-regulatory-science-program">NIH Tobacco Regulatory Science Program</a>.</p>
<p>&nbsp;</p>
</div>
</div>]]></body>
    <field_image_promotional>349612</field_image_promotional>
  </row>
  <row term_id="302006" id="349617" title="Kai Yu, Ph.D." langcode="en" field_short_title="Kai Yu, Ph.D." field_page_description="Kai Yu, Ph.D., biographical sketch and research interests" field_feature_card_description="Kai Yu, Ph.D., biographical sketch and research interests" field_list_description="Kai Yu, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2015-04-13" field_pretty_url="yu-kai" field_browser_title="Kai Yu, Ph.D., biographical sketch and research interests" field_card_title="Kai Yu, Ph.D." field_email_address="yuka@mail.nih.gov" field_first_name="Kai" field_last_name="Yu" field_phone_number="240-276-7433" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E630">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="#Software">Software</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=yu%20k&amp;authorOption=exact&amp;pi=0012376126">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_relationshipid="7252660" sys_siteid="475" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Yu received a Ph.D. in biostatistics from the University of Pittsburgh in 2000, and had postdoctoral training in statistical genetics at Stanford University. He joined NCI in 2005 as a tenure-track investigator, and was awarded scientific tenure by the NIH and appointed senior investigator in 2012. Dr. Yu's research addresses a wide variety of statistically and computationally challenging problems that have arisen in design and analysis of modern high-dimensional genetic and molecular epidemiologic studies. In 2009, he received an NIH Merit Award for developing creative statistical methods for genetic epidemiologic studies.</p>
<h2>Research Interests</h2>
<ul class="grey-bullets">
<li>Statistical methods for genetic and genomic studies</li>
<li>Tree-based models and applications in molecular epidemiology studies</li>
<li>Machine learning approaches for automated cervical screening and triage</li>
</ul>
<h2>Software:</h2>
<ul class="grey-bullets">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302598" inlinetype="rxhyperlink" sys_relationshipid="7252656" rxinlineslot="103" sys_dependentid="302598" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="302598">Extremely small P-value Evaluation for Resampling-based Test (EXPERT)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=6&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302485" inlinetype="rxhyperlink" sys_relationshipid="7252657" rxinlineslot="103" sys_dependentid="302485" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="302485">Bayesian model for Detecting Gene Environment interaction (BaDGE)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=725733" inlinetype="rxhyperlink" sys_relationshipid="7252659" sys_siteid="475" rxinlineslot="103" sys_dependentid="725733" sys_dependentvariantid="1418" sys_variantid="1418" sys_contentid="725733">Bayesian Subset Regression (BSR)</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302436" sys_dependentvariantid="1418" sys_dependentid="302436" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252661" sys_variantid="1418" sys_contentid="302436">Summary statistics-based genetic pathway analysis software (ARTP2)</a></li>
<li>Generalized Integration Model for combining summary statistics with individual-level data (GIM)</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349617</field_image_promotional>
  </row>
  <row term_id="302006" id="349620" title="Regina G. Ziegler, Ph.D., M.P.H. " langcode="en" field_short_title="Regina G. Ziegler, Ph.D., M.P.H. " field_page_description="Regina G. Ziegler, Ph.D., M.P.H. biographical sketch and research interests" field_feature_card_description="Biographical sketch and research interests of Regina G. Ziegler, Ph.D., M.P.H." field_list_description="Biographical sketch and research interests of Regina G. Ziegler, Ph.D., M.P.H.&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-21" field_pretty_url="ziegler-regina" field_browser_title="Regina G. Ziegler, Ph.D., M.P.H. - Biography" field_card_title="Regina G. Ziegler, Ph.D., M.P.H. " field_email_address="zieglerr@mail.nih.gov" field_first_name="Regina" field_last_name="Ziegler" field_org_name_1="National Cancer Institute" field_org_name_2="Epidemiology and Biostatistics Program" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=ziegler%20r&amp;authorOption=exact&amp;pi=0010158378">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302673" sys_contentid="302673" inlinetype="rxhyperlink" sys_relationshipid="7276887" sys_dependentvariantid="1422" sys_dependentid="302673" rxinlineslot="103" sys_siteid="475" sys_variantid="1422">Epidemiology and Biostatistics Program</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Ziegler is a special volunteer in the Epidemiology and Biostatistics Program of the National Cancer Institute. Her research on diet, nutrition, and cancer has emphasized both etiology and public health implications, and has integrated biochemical and molecular techniques. Dr. Ziegler received a B.A. in chemistry and English from Swarthmore College, a Ph.D. in biochemistry from the University of California at Berkeley, and a M.P.H. in epidemiology and public policy from the Harvard School of Public Health. She has developed and taught courses on public health nutrition, international nutrition, and global food resources at Yale, Harvard, and Tufts Universities. Dr. Ziegler helped establish the Nutritional Epidemiology Research Interest Section of the American Society of Nutritional Sciences and currently serves on the editorial boards of the Journal of the National Cancer Institute, the American Journal of Clinical Nutrition, and the Nutrition Action Healthletter. In 1996, she was awarded the NIH Merit Award for her research on the role of vegetables, fruits, and micronutrients in the etiology of cancer. Dr. Ziegler retired from federal service in October 2018.</p>
<h2 id="research">Research Interests</h2>
<h3>Multidisciplinary Studies of Diet, Nutrition, and Cancer</h3>
<h4>Vegetables, Fruits, and Carotenoids</h4>
<p class="first-graf">Previously, we demonstrated that diets high in vegetables, fruits, and carotenoids were strongly associated with reduced risk of lung and upper aerodigestive tract cancers. To explore the individual contributions of the major carotenoids, we conducted nested case control studies in the Honolulu Heart Program cohort. High serum levels of several carotenoids were associated with decreased risk of lung, oral pharyngeal, esophageal, and laryngeal cancer, with a-carotene the most predictive. Recently, in the Nurses and Health Professionals cohorts, using repeated dietary measures, we found that high vegetable and fruit intake was associated with only a modestly reduced risk of lung cancer in women and no risk reduction in men. Our analyses suggested that the strength of this widely accepted relationship might have been exaggerated because confounding by smoking has not always been adequately controlled. Since other recent publications have questioned whether vegetable intake can reduce the risk of colorectal cancer, we are exploring opportunities to continue to evaluate the importance of vegetables and fruits in cancer etiology, with emphasis on prospective studies, range and variety in intake, and accurate assessment of exposure. Initially, we will explore vegetable and fruit intake, circulating levels of individual carotenoids, and risk of colorectal polyps at various stages in the speculated progression to cancer, using data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.</p>
<p>Lycopene, a carotenoid concentrated in tomato products, has been linked to reduced risk of prostate cancer in several studies. In a case control study conducted among U.S. blacks and whites, we found that high circulating lycopene was protective in both races. In addition, circulating levels were lower in the blacks, which suggested that low lycopene might contribute to the substantially higher rates of prostate cancer among U.S. blacks. The protective influence of lycopene rich diets has been most consistently seen in U.S. studies, so we are now exploring the influence of high circulating lycopene in a cohort of Finnish men with distinct dietary patterns.</p>
<h4>One-Carbon Metabolism</h4>
<p class="first-graf">Disruption of one carbon metabolism can interfere with DNA synthesis, repair, and methylation and thus promote carcinogenesis. Efficient one carbon metabolism requires not only folate but also vitamins B2, B6, and B12 and optimal activity of multiple enzymes, such as methylene tetrahydrofolate reductase and methionine synthase. In a community based case control study of invasive cervical cancer in five areas in the U.S., we found that low serum and red blood cell folate were only modestly predictive of increased risk. However, elevated serum homocysteine was strongly and significantly predictive (RR's~2 3), which suggested that pervasive problems in one carbon metabolism might be involved. We are now assessing the contribution of B vitamin inadequacies and common polymorphisms in key one carbon metabolism genes. In addition, we will be evaluating the importance of one carbon metabolism in the etiology of brain and colorectal cancer. Dietary and vitamin supplement information are being analyzed in a multicenter case control study of brain cancer, and will be complemented by assays for genetic polymorphisms. In the PLCO cohort, 2,400 men and women were diagnosed with colorectal adenomatous polyps at baseline. The dietary information, serum, and DNA collected in this study will allow us to relate the role of one carbon metabolism to the speculated progression of colorectal cancer. Since folic acid fortification has already been shown to decrease homocysteine levels in populations with a variety of nutritional and genetic impairments, our results may indicate how targeted supplementation and/or fortification schemes may contribute to cancer prevention.</p>
<h4>Breast Cancer</h4>
<p class="first-graf">International variation in breast cancer incidence and migrant studies indicate that modifiable factors play a major role in breast cancer etiology, although the specific lifestyles and environmental exposures remain elusive. We designed a large, population-based case-control study of breast cancer in Asian-American women to take advantage of their diversity in diet and breast cancer risk. Childhood, adolescent, and adult exposures were assessed by interviewing both study participants and their mothers. To complement the extensive interview information, body size and shape were measured, and blood and urine samples were collected. Endogenous hormones, phytoestrogens, growth factors, micronutrients, and fatty acids have been or will be measured in selected specimens. We found a 6-fold gradient in breast cancer risk by migration history within our study population, comparable to the international differences in breast cancer incidence rates. Exposures during adult life substantially influenced risk. Furthermore, there was no evidence of an especially susceptible period during menarche or early reproductive life. Increased adiposity and weight gain in the decade preceding diagnosis were critical determinants of risk. Thus, excess weight may function as a late stage promoter in breast carcinogenesis, and weight maintenance or reduction as an adult may have a significant and rapid impact on breast cancer risk. We are currently exploring which endogenous hormones, hormone metabolites, growth factors, and dietary patterns are most correlated with migration history, and thus likely determinants of the 6-fold gradient in breast cancer incidence. Circulating estrogens were only weakly associated with Westernization, while circulating androgens were inversely associated in both pre- and postmenopausal women. Decreased intake of soy was associated with a doubling of breast cancer risk. We now want to examine the broader dietary patterns associated with soy intake; in particular, its relationship to vegetable, fruit, and grain consumption; the relative contributions of childhood and adult soy intake; and what specific isoflavones and lignans seem important. Since height was a strong and consistent predictor of risk in these Asian-American women, we are seeking biologic explanations, with emphasis initially on insulin-like growth factors.</p>
</div>
</div>]]></body>
    <field_image_promotional>349620</field_image_promotional>
  </row>
  <row term_id="302006" id="349640" title="Neelam Giri, M.D., M.B.B.S." langcode="en" field_short_title="Neelam Giri, M.D., M.B.B.S." field_page_description="Neelam Giri, M.D., M.B.B.S., biographical sketch and research interests " field_feature_card_description="Neelam Giri, M.D., M.B.B.S., biographical sketch and research interests " field_list_description="Neelam Giri, M.D., M.B.B.S., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-05-10" field_pretty_url="giri-neelam" field_browser_title="Neelam Giri, M.D., M.B.B.S., biographical sketch and research interests " field_card_title="Neelam Giri, M.D., M.B.B.S." field_email_address="girin@mail.nih.gov" field_first_name="Neelam" field_last_name="Giri" field_phone_number="240-276-7256" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E538">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=giri%20n&amp;authorOption=exact&amp;pi=0011561735">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_relationshipid="7341969" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Giri received her MBBS and MD degrees from the University of Bombay, India, where she also received her initial training in general pediatrics and in pediatric hematology/oncology at Tata Memorial Cancer Center. She underwent additional post-doctoral training at the Prince of Wales Children's Hospital in Sydney, Australia, the King Faisal Specialist Hospital in Riyadh, Saudi Arabia, and at the NCI Pediatric Oncology Branch. During her tenure at NCI, she also worked in the Stem Cell Biology Laboratory of the National Heart, Lung and Blood Institute, where her research interests included the biology of Diamond-Blackfan anemia. Prior to joining the NCI, Dr. Giri was a Staff Physician in the Blood and Bone Marrow Transplantation Unit of the Alfred I. duPont Hospital for Children in Wilmington, DE.</p>
<h2 id="research">Research Interests</h2>
<p class="first-graf">Dr. Giri provides sub-specialty clinical support to the DCEG Inherited Bone Marrow Failure Syndromes Program. She also conducts clinical and laboratory research focused on the various diseases which are being studied as part of this comprehensive protocol, including Fanconi's anemia, dyskeratosis congenita, Diamond-Blackfan anemia and Shwachman-Diamond syndrome.</p>
</div>
</div>]]></body>
    <field_image_promotional>349640</field_image_promotional>
  </row>
  <row term_id="302006" id="349642" title="Amy Berrington de Gonzlez, D.Phil." langcode="en" field_short_title="Amy Berrington de Gonzlez, D.Phil." field_page_description="Amy Berrington de Gonzlez, D.Phil., biographical sketch and research interests" field_feature_card_description="Amy Berrington de Gonzlez, D.Phil., biographical sketch and research interests" field_list_description="Amy Berrington de Gonzlez, D.Phil., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-03-18" field_pretty_url="berrington-amy" field_browser_title="Amy Berrington de Gonzlez, D.Phil., biographical sketch and research interests" field_card_title="Amy Berrington de Gonzlez, D.Phil." field_email_address="berringtona@mail.nih.gov" field_first_name="Amy " field_last_name="Berrington de Gonzlez" field_phone_number="240-276-7376" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E458">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Berrington%20de%20Gonzalez%20A&amp;authorOption=exact&amp;pi=0013703118">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=112&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7291512">Radiation Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<div class="callout-box right">
<h3>Berrington de Gonz&aacute;lez Presents at Director&rsquo;s Seminar</h3>
<p><img alt="" class="left" inlinetype="rximage" rxinlineslot="104" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=3&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=660716" sys_dependentid="660716" sys_dependentvariantid="1482" sys_relationshipid="7291513" sys_siteid="475" />Watch Dr. Berrington de Gonz&aacute;lez discuss her research at the 2013 NIH Director&rsquo;s Seminar Series.</p>
<p><b>Video</b>: <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1410&amp;sys_contentid=1090680" sys_dependentvariantid="1410" sys_dependentid="1090680" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7291514" sys_variantid="1410" sys_contentid="1090680">Medical radiation and cancer risk: Assessing the price of progress</a></p>
</div>
<p>Dr. Amy Berrington is the Branch Chief and senior investigator in the Radiation Epidemiology Branch. She is an internationally recognized expert in the potential cancer risks from medical radiation exposures. Dr. Berrington is co-PI of the UK Pediatric CT scans cohort, which was the first epidemiological study to suggest a direct link between CT scans and subsequent cancer risk. She also leads studies on the risk of second cancer after proton therapy and other emerging radiotherapy techniques. Dr. Berrington is currently a member of the NAS Nuclear and Radiation Studies Board and has participated in many national and international radiation committees. She is an elected member of the American Epidemiological Society and served on the editorial board for the American Journal of Epidemiology. Before joining the NCI in 2008 she held faculty positions at Oxford and Johns Hopkins University.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h2 id="research">Research Interests</h2>
<p class="first-graf">Radiation exposure to the US population from medical sources has increased six-fold in the last three decades. The overarching goal of Dr. Berrington's research is to quantify the potential cancer risks from this important source of radiation exposure in order to provide information for public health and clinical purposes. Her interdisciplinary training in epidemiology and biostatistics allow her to pursue this goal using both theoretical risk projection modeling and also by conducting epidemiological studies of medically exposed populations. The studies vary across the dose-spectrum from low-dose diagnostic and screening procedures to high-dose radiotherapy, with distinct opportunities and challenges in each area.</p>
<h3>Diagnostic and screening tests</h3>
<p class="first-graf">Dr. Berrington has conducted a series of risk projection studies to estimate the potential cancer risks from both diagnostic and screening examinations, including: cardiac stress tests, CT colonography and lung CT screening. To perform these studies she and other collaborators developed the NCI Radiation Risk Assessment Tool (RadRAT), which is interactive computer software that uses state of the art risk projection models to estimate lifetime cancer risks and incorporates Monte Carlo simulation methods to assess the impact of uncertainties in the assumptions and data. She recently became the NCI Principal Investigator for the UK Pediatric CT scans study, which is a retrospective cohort study of 250,000 children who had one or more CT scans as children or adolescents.</p>
<h3>Therapeutic radiation exposure</h3>
<p class="first-graf">As cancer treatment and screening has improved markedly the number of patients diagnosed with a second primary cancer has also increased. Studying the second cancer risks after radiotherapy provides both important clinical information and also insights into the long-term effects of high-dose fractionated radiation exposure. Furthermore, as treatments continue to evolve it is important to study the effects of newer treatments on second cancer rates. Dr. Berrington has conducted a number of studies using the SEER cancer registries to evaluate patterns of second cancers and the second cancer risks related to radiotherapy treatment. She is currently developing a cohort of breast cancer survivors using the electronic medical records from Kaiser Permanente Health Plans to study the late effects of various breast cancer treatments. She is also developing methods to project risks from high-doses of radiation exposure and conducting a pilot study to assess the feasibility of performing the first multi-center study of the second cancer risks from proton therapy and IMRT.</p>
</div>
</div>]]></body>
    <field_image_promotional>349642</field_image_promotional>
  </row>
  <row term_id="302006" id="349649" title="Joshua Sampson, Ph.D. " langcode="en" field_short_title="Joshua Sampson, Ph.D. " field_page_description="Joshua Sampson, Ph.D., biographical sketch and research interests " field_feature_card_description="Joshua Sampson, Ph.D., biographical sketch and research interests " field_list_description="Joshua Sampson, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="sampson-joshua" field_browser_title="Joshua Sampson, Ph.D., biographical sketch and research interests " field_card_title="Joshua Sampson, Ph.D. " field_email_address="sampsonjn@mail.nih.gov" field_first_name="Joshua" field_last_name="Sampson" field_phone_number="240-276-7418" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E594">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=sampson%20j&amp;authorOption=exact&amp;pi=0014378933">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=41&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_relationshipid="7276790" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2 a="" id="biography">Biography</h2>
<p class="first-graf">Joshua Sampson received a B.A. in mathematics and chemistry from Pomona College and an M.S. in biophysical chemistry from Stanford University. He then received his Ph.D. from the Biostatistics Department at the University of Washington in 2007 and spent two years as a postdoctoral fellow in the Yale School of Medicine. He joined the NCI in 2009 as a principal investigator, and was awarded scientific tenure and promoted to senior investigator in December 2016.</p>
<h2 a="" id="research">Research Interests</h2>
<h3><a id="High-Dim-Mediation"></a>High-Dimensional Mediation Analysis</h3>
<p>In epidemiology, a mediation model proposes that the exposure variable (E) of interest impacts a mediator variable M, that then influences (mediates) the outcome Y. The total causal effect of E on Y is then portioned into an indirect (through M) and a direct effect on Y. The goal of mediation analysis is thus to help clarify the true relationship between the exposure and outcome variables. One example is that Body Mass Index (BMI) (E) increases estrogen levels (M) which, in turn, increases the risk of ER+ breast cancer (Y). However, many studies now want to test whether a large panel of biomarkers&mdash;perhaps 100s of metabolites or 100,000s of gene expression levels&mdash;can mediate the relationship between an exposure and an outcome. My goal is to develop statistically powerful methods for identifying individual biomarkers that are mediators, identifying sets of biomarkers that are mediators, and quantifying the indirect effect through these mediators.</p>
<h3><a id="&quot;HPV"></a>HPV Vaccine Trials and HPV Epidemiology</h3>
<p>Cervical cancer affects more than half a million women annually, with 88 percent of mortality occurring in low-income nations. Human papillomavirus (HPV) vaccines were licensed and recommended in the early 2000s, in order to reduce HPV, a necessary cause of cervical carcinogenesis. While initially recommended as a three-dose regimen, there is strong evidence to suggest that a single dose of the vaccine is efficacious at preventing HPV infection. Therefore, the Division of Cancer Epidemiology and Genetics is leading observational studies to demonstrate the long-term efficacy of a single dose and, in collaboration with other groups, leading clinical trials to definitively establish the efficacy of a single dose. As part of this effort, my goal has been to develop new statistical methods for vaccine studies with rare events and no placebo-arm, to develop statistically defendable thresholds of non-inferiority, and to lead new trials showing high immunogenicity of a one-dose regimen.</p>
<h3><a id="Cancer-Epidemiology"></a>Cancer Epidemiology</h3>
<p>There is mounting evidence to show that increased physical activity can reduce the risk of cancer. My objective is to develop new methods to define the exact features of physical activity that are associated with the reduction of cancer risk, to understand the biological mechanisms mediating this relationship, and to quantify the error in measures of activity.</p>
<p><a href="#top">Back to Top</a></p>
</div>
</div>]]></body>
    <field_image_promotional>349649</field_image_promotional>
  </row>
  <row term_id="302006" id="349658" title="Alisa M. Goldstein, Ph.D. " langcode="en" field_short_title="Alisa M. Goldstein, Ph.D. " field_page_description="Alisa M. Goldstein, Ph.D., biographical sketch and research interests" field_feature_card_description="Alisa M. Goldstein, Ph.D., biographical sketch and research interests" field_list_description="Alisa M. Goldstein, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-23" field_pretty_url="goldstein-alisa" field_browser_title="Alisa M. Goldstein, Ph.D., biographical sketch and research interests" field_card_title="Alisa M. Goldstein, Ph.D. " field_email_address="goldstea@mail.nih.gov" field_first_name="Alisa" field_last_name="Goldstein" field_phone_number="240-276-7233" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E438">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=goldstein%20a&amp;authorOption=exact&amp;pi=0010047855">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_relationshipid="7252417" sys_siteid="475" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
</div>
<h2>Biography</h2>
<p class="first-graf">Dr. Goldstein received a Ph.D. in genetic epidemiology from the University of California at Los Angeles in 1988 and subsequently joined DCEG. She received NIH scientific tenure in 1997. Dr. Goldstein completed a fellowship in the NIH InterInstitute Medical Genetics Program, and is board certified in medical genetics. Her research focuses on genetic epidemiologic studies of several cancers, including melanoma and upper gastrointestinal (UGI) cancer. The main goal of her studies is to understand the role of genetic and environmental factors in the etiology of these cancers. Her studies combine epidemiologic, genetic, clinical, and molecular methodologies.</p>
<h2 id="research">Research Interests</h2>
<ul>
<li>Identification of genetic and environmental risk factors for cancer</li>
<li>Search for high-, moderate-, and/or low-risk cancer susceptibility genes using family-based, tumor-based, and case-control/cohort studies</li>
<li>For cancers with identified major susceptibility gene mutations, investigation of other genetic and environmental factors and their interactions in the expression of disease</li>
</ul>
</div>]]></body>
    <field_image_promotional>349658</field_image_promotional>
  </row>
  <row term_id="302006" id="349671" title="Jill Koshiol, Ph.D." langcode="en" field_short_title="Jill Koshiol, Ph.D." field_page_description="Jill Koshiol, Ph.D., biographical sketch and research interests" field_feature_card_description="Jill Koshiol, Ph.D., biographical sketch and research interests" field_list_description="Jill Koshiol, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-03-13" field_pretty_url="koshiol-jill" field_browser_title="Jill Koshiol, Ph.D., biographical sketch and research interests" field_card_title="Jill Koshiol, Ph.D." field_email_address="koshiolj@mail.nih.gov" field_first_name="Jill " field_last_name="Koshiol" field_phone_number="240-276-7178" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E212">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Koshiol%20J&amp;authorOption=exact&amp;pi=0012157919">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=56&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7281250" sys_dependentvariantid="1422" sys_dependentid="302590" rxinlineslot="103" sys_siteid="475">Infections and Immunoepidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Jill Koshiol received her Ph.D. in epidemiology from the University of North Carolina at Chapel Hill School of Public Health in 2005. Subsequently, she joined the Genetic Epidemiology Branch of the Division of Cancer Epidemiology and Genetics as a Cancer Prevention Fellow. Dr. Koshiol joined the Infections and Immunoepidemiology Branch as a research fellow in 2008 and became an Earl Stadtman Tenure-Track Investigator in 2010.</p>
<h2 id="research">Research Interests</h2>
<p>Dr. Koshiol has focused her research program on hepatobiliary cancers, which are linked to both infections and inflammation. Biliary tract cancers are rare in much of the world, but there are hotspots where these cancers constitute a major public health burden. Because these cancers are rare in the developed world, their etiology is poorly understood, even with respect to classic cancer risk factors. Biliary tract cancers have a multifactorial etiology, and inflammation is likely central in the carcinogenesis process. Dr. Koshiol&rsquo;s work is identifying previously unknown risk factors, such as aflatoxin. Identification of such determinants, as well as biomarkers, may lead to new opportunities for cancer prevention and early detection that can be translated into public health impact, particularly in high-risk areas.</p>
<p>Chile is one such high-risk area. Gallbladder cancer (GBC) is a leading cause of cancer death in Chilean women. To investigate the epidemiologic and molecular predictors of gallbladder dysplasia and cancer, Dr. Koshiol initiated the Chile Biliary Longitudinal Study (Chile BiLS). The very high rates of GBC and gallstones in Chile provide a unique opportunity to test several emerging hypotheses that are difficult to examine in other populations.</p>
<p>Dr. Koshiol is also the principal investigator for the Shanghai Biliary Tract Cancer Study and leads the Biliary Tract Cancer Pooling Project and the Cholecystectomy Risk Stratification (CRS) study. In addition, she collaborates on the REVEAL-HBV and -HCV studies of individuals with chronic hepatitis B and C infection. Using these studies and others, she plans to elucidate hepatobiliary cancer etiology and aid cancer prevention through the identification of cancer-related molecular pathways and targets.</p>
</div>
</div>]]></body>
    <field_image_promotional>349671</field_image_promotional>
  </row>
  <row term_id="302006" id="349680" title="Melissa Friesen, Ph.D. " langcode="en" field_short_title="Melissa Friesen, Ph.D. " field_page_description="Melissa Friesen, Ph.D., biographical sketch and research interests " field_feature_card_description="Melissa Friesen, Ph.D., biographical sketch and research interests " field_list_description="Melissa Friesen, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2015-07-10" field_pretty_url="friesen-melissa" field_browser_title="Melissa Friesen, Ph.D., biographical sketch and research interests " field_card_title="Melissa Friesen, Ph.D. " field_email_address="friesenmc@mail.nih.gov" field_first_name="Melissa" field_last_name="Friesen" field_phone_number="240-276-7278" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology" field_campus="300" field_office_location="Room 6E602">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=friesen+mc&amp;authorOption=exact&amp;pi=0014329888&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=53&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_relationshipid="7276215" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="biography"><a id="Biography"></a>Biography</h2>
<div class="callout-box right">
<h3>Friesen Develops New Method for Occupational Studies</h3>
<ul>
<li>Learn about the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1052505" inlinetype="rxhyperlink" sys_relationshipid="7276219" sys_siteid="475" rxinlineslot="103" sys_dependentid="1052505" sys_dependentvariantid="1424" sys_variantid="1424" sys_contentid="1052505">Standardized Occupational Coding for Computer-assisted Epidemiologic Research (SOCcer)</a> in the July 2016<i> Linkage</i> newsletter.</li>
<li><a href="https://soccer.nci.nih.gov/soccer/">Open the SOCcer application</a>.</li>
</ul>
</div>
<p class="first-graf">Dr. Friesen received a Ph.D. (2006) and M.Sc. (2001) in occupational hygiene from the University of British Columbia in Vancouver, Canada. She completed postdoctoral studies at Monash University in Melbourne, Australia, and at the University of California at Berkeley. She joined the NCI as a tenure-track investigator in the Occupational and Environmental Epidemiology Branch in June 2009, and was awarded NIH scientific tenure and promoted to senior investigator in 2017.</p>
<h2 id="research"><a id="Research-Interests"></a>Research Interests</h2>
<p class="first-graf">Dr. Friesen's research has focused on quantitative assessment strategies to minimize exposure misclassification in occupational epidemiologic studies. She has focused on improving exposure estimates, evaluating the robustness of exposure-response relationships to exposure assessment strategies, and using statistical models for both developing exposure metrics and evaluating their exposure-response relationships. By using more refined and more proximal exposure measures, her research has resulted in quantitative exposure-response relationships for several exposure-disease associations that have not previously been published.</p>
<h4>Decision Rule and Measurement-based Approaches</h4>
<p>In OEEB, Dr. Friesen focuses her research on&nbsp;developing transparent measurement- and decision rule-based methods to assess occupational exposure in case-control studies and population-based cohorts. Exposure assessment in these studies relies heavily on subject-reported information and the professional judgment of exposure assessors. She has demonstrated that decision-rule based approaches that link questionnaire response patterns to exposure decisions are comparable to the estimates from a traditional job-by-job expert review and can replicate the average rating from a team of experts. She has also developed a method to use data mining methods (e.g. classification trees, CT) to extract underlying (but not explicitly stated) decision rules from the relationship between exposure estimates derived from professional judgment and questionnaire responses. The resulting CT decision trees extract the valuable information from previous assessments and thus allow the decision rules to be used to estimate exposure in other studies with similar exposure information. As a result, exposure assessors can focus their attention on the exposure scenarios identified by the CT model as being difficult to assess and on scenarios that were not covered by the decision rules. To continue efficiently using teams of experts, she led the development of source-specific decision rules for estimating historical lead and benzene for US case-control studies. Developing decision rules removes the assessment from its much criticized &lsquo;black box&rsquo; and facilitates future exposure assessment efforts that can apply the rules. <o:p></o:p></p>
<p>A crucial component the decision rule exposure estimation process is to anchor the intensity estimates to a concentration scale. Dr. Friesen has extended the use of statistical models that are commonly used in industry-based studies to predict historical exposure to population-based studies using publicly available data from the literature and measurements collected during health and safety inspections. For example, she has developed a framework to combine subjective ratings of exposure from job exposure matrices (JEMs) and exposure measurements to better discriminate between time and job differences in exposure levels in population-based studies. In addition, she was the first to apply meta-regression models in summary statistics extracted from the published literature for both occupational and environmental exposures to identify determinants of exposure. She has now used this modeling approach to identify determinants of multiple exposures, including lead, benzene, and pesticides.<o:p></o:p></p>
<h4>Automated Methods to Process Free-text Responses</h4>
<p>Dr. Friesen also develops exposure assessment tools to facilitate the use of occupational risk factor data in epidemiologic studies by efficiently transforming the verbatim participants&rsquo; responses from occupational questionnaires into usable data. She led the development of an algorithm, <a href="http://soccer.nci.nih.gov">SOCcer (Standardized Occupation Coding for Computer-assisted Epidemiological Research</a>), to automatically code job descriptions into standardized occupation classification (SOC) codes. She also developed a keyword-based approach to use the verbatim responses to systematically extract variables representing exposure scenarios that can be used in decision rules.</p>
<h4>Gender Differences in Exposure</h4>
<p>During the Environmental Exposures and Women's Health seminar series held on October 5, 2010, Dr. Friesen discussed the importance of examining cancer risk separately in men and women. Specifically, she focused on sex differences in the accuracy of exposure assessment tools for epidemiologic studies. <a href="http://videocast.nih.gov/Summary.asp?File=16180&amp;start=4503">View Dr. Friesen's presentation, &ldquo;Women are not just small men&rdquo;</a>. In analyses pooling occupational responses from three OEEB studies, she found gender differences in the prevalence and frequency of work tasks. These differences would result in exposure misclassification if these work task differences are not considered and demonstrate the need for incorporating job modules to capture individual-level occupational information.&nbsp;More recently, she led the development of an algorithm to assess non-occupational pesticide exposure for the spouses of farmers in the Agricultural Health Study. The resulting algorithm estimates will be crucial for future evaluations of whether the health risks observed in the male farmers are also seen in women and evaluating risks for female-specific cancer sites.</p>
</div>
</div>]]></body>
    <field_image_promotional>349680</field_image_promotional>
  </row>
  <row term_id="302006" id="913119" title="Julia C. Gage, Ph.D., M.P.H." langcode="en" field_short_title="Julia C. Gage, Ph.D., M.P.H." field_page_description="Julia C. Gage, Ph.D., M.P.H., biographical sketch and research interests" field_feature_card_description="Julia C. Gage, Ph.D., M.P.H., biographical sketch and research interests" field_list_description="Julia C. Gage, Ph.D., M.P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-03-05" field_date_reviewed="2015-03-05" field_date_updated="2015-03-05" field_pretty_url="gage-julia" field_browser_title="Julia C. Gage, Ph.D., M.P.H., biographical sketch and research interests" field_card_title="Julia C. Gage, Ph.D., M.P.H." field_email_address="gagej@mail.nih.gov" field_first_name="Julia" field_last_name="Gage" field_phone_number="240-276-7264" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E546">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content"><a id="Top"></a>
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Gage+JC&amp;authorOption=exact&amp;pi=0012219572">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_relationshipid="7252411" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<p>Julia Gage, Ph.D., M.P.H, joined DCEG as a CRTA pre-doctoral fellow in 2005, while pursuing a Ph.D. in epidemiology at Johns Hopkins Bloomberg School of Public Health. After completing her Ph.D. in 2008, she worked as a postdoctoral fellow, first in the Hormonal and Reproductive Epidemiology Branch (HREB), and then in the Clinical Genetics Branch (CGB), under the guidance of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=913119" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="913119" sys_dependentvariantid="1965" sys_relationshipid="7252406" sys_variantid="1965" sys_contentid="913119">Mark Schiffman, M.D., M.P.H.</a>, senior investigator. Following her research fellowship, she became a staff scientist in 2014.</p>
<h2 id="Research-Interests">Research Interests</h2>
<p>Dr. Gage&rsquo;s research is focused on translating novel discoveries regarding the natural history of human papillomavirus (HPV) into improved screening and diagnosis for cervical precancer. In particular, she investigates improved targeting of underlying precancer through novel HPV tests, colposcopy and histopathology. Dr. Gage also pursues scientific investigations to bring new technologies for cervical cancer prevention to low medical resource settings. Recently, she expanded her work to include the adaptation of data routinely collected in clinical records for research.</p>
<h4>Screening and Diagnosis for Cervical Precancer</h4>
<p>Along with Dr. Schiffman and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349668" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349668" sys_dependentvariantid="1965" sys_relationshipid="7252407" sys_variantid="1965" sys_contentid="349668">Nicolas Wentzensen, M.D., Ph.D.</a>, senior investigator, HREB, Dr. Gage serves as co-investigator for multiple studies within the DCEG collaboration with Kaiser Permanente Northern California (KPNC). Dr. Gage is investigating novel biomarkers to triage HPV-positive screening results in the Persistence and Progression (PaP) cohort. She also serves as lead analyst for NCI in the New Mexico Cervical HPV Registry Project, a statewide registry of all data on cytology, HPV testing, pathology, and vaccination, used to study the impact of vaccination on screening.</p>
<p>To address these issues in low-resource settings, Dr. Gage contributes to the HPV primary screening intervention study in El Salvador. She is also collaborating on research to identify more effective treatment methods that are simple and inexpensive.</p>
<h4>Adapting Clinical Records for Research</h4>
<p>Working with Dr. Schiffman and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349618" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349618" sys_dependentvariantid="1965" sys_relationshipid="7252408" sys_variantid="1965" sys_contentid="349618">Hormuzd Katki, Ph.D.</a>, an investigator in the Biostatistics Branch, Dr. Gage has led recent analyses from the <a href="http://www.ncbi.nlm.nih.gov/pubmed/25038467">KPNC Management Guidelines cohort</a> of over 1 million women screened with HPV and cytology since 2003. The resulting publications have informed screening and clinical management. Recently, Dr. Gage&rsquo;s interest in the use of routine clinical records for epidemiologic research has led her beyond the study of HPV and cervical cancer. Under the guidance of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=15&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349606" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="349606" sys_dependentvariantid="1965" sys_relationshipid="7252409" sys_variantid="1965" sys_contentid="349606">Shahinaz Gadalla, M.D., Ph.D.</a>, also in CGB, Dr. Gage is coordinating with the United Kingdom Clinical Practice Research Datalink (CPRD) to access observational clinical data for millions of patients in primary care clinics across the country.</p>
</div>
</div>]]></body>
    <field_image_promotional>913119</field_image_promotional>
  </row>
  <row term_id="302006" id="974537" title="Bu-Tian Ji, M.D., Dr. P.H." langcode="en" field_short_title="Bu-Tian Ji, M.D., Dr. P.H." field_page_description="Bu-Tian Ji, M.D., Dr. P.H., biographical sketch and research interests" field_feature_card_description="Bu-Tian Ji, M.D., Dr. P.H., biographical sketch and research interests" field_list_description="Bu-Tian Ji, M.D., Dr. P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-07-07" field_date_reviewed="2015-07-07" field_date_updated="2015-07-07" field_pretty_url="ji-bu-tian" field_browser_title="Bu-Tian Ji, M.D., Dr. P.H., biographical sketch and research interests" field_card_title="Bu-Tian Ji, M.D., Dr. P.H." field_email_address="jib@mail.nih.gov" field_first_name="Bu-Tian" field_last_name="Ji" field_phone_number="240-276-7279" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="6E612">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Ji+BT&amp;authorOption=exact&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7252430" sys_variantid="1422" sys_contentid="302610">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Bu-Tian Ji received a Bachelor&rsquo;s degree in medicine in 1987 and an M.P.H. in epidemiology in 1990 from the Shanghai Medical University. In 1998, he received a Dr.P.H. in epidemiology from the Columbia University School of Public Health. He joined the Occupational and Environmental Epidemiology Branch (OEEB) as an IRTA/CRTA postdoctoral fellow in 1997 and became a staff scientist in 1999. Dr. Ji plays a leadership role in the Shanghai Women&rsquo;s Health Study, a large prospective cohort study, for which he oversees biological sample processing for all nested case-control studies. He is also involved in the Chinese Benzene Cohort Study and the Multi-center Case-Control Study of Lymphoid Neoplasms in Asia (AsiaLymph). He makes significant contributions to the questionnaire data management, data retrieval quality control, and case verification for lung cancer and hematopoietic disorders in the Chinese benzene study. In the AsiaLymph study, he evaluates the quality of the interview data and monitors the field study progress. As a cancer epidemiologist, his studies focus on cancer risk related to lifestyle factors, occupational exposures, and other environmental risk factors. Dr. Ji received the NCI DCEG Intramural Research Training Award in 1999. He has served as a reviewer for numerous scientific journals and has been an invited speaker for international conferences.</p>
<h2 id="research"><a id="Research-Interests"></a>Research Interests</h2>
<ul class="grey-bullets">
<li>Occupational exposure and cancer risk</li>
<li>Nightshift work and cancer risk</li>
<li>Physical activity and other lifestyle factors and cancer risk</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>974537</field_image_promotional>
  </row>
  <row term_id="302006" id="1048350" title="Hannah P. Yang, Ph.D., Sc.M." langcode="en" field_short_title="Hannah P. Yang, Ph.D., Sc.M." field_page_description="Hannah P. Yang, Ph.D., Sc.M., biographical sketch and research interests " field_feature_card_description="Hannah P. Yang, Ph.D., Sc.M., biographical sketch and research interests " field_list_description="Hannah P. Yang, Ph.D., Sc.M., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-05-12" field_date_reviewed="2016-05-12" field_date_updated="2016-05-12" field_pretty_url="yang-hannah" field_browser_title="Hannah P. Yang, Ph.D., Sc.M., biographical sketch and research interests " field_card_title="Hannah P. Yang, Ph.D., Sc.M." field_email_address="yanghan@mail.nih.gov " field_first_name="Hannah" field_last_name="Yang" field_phone_number="240-276-7337 " field_org_name_1="National Cancer Institute" field_org_name_2="Office of the Director" field_campus="300" field_office_location="Room 7E344">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=Yang+HP&amp;authorOption=exact&amp;pi=0013137609">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=39&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302541" inlinetype="rxhyperlink" sys_relationshipid="7252496" sys_dependentvariantid="1418" sys_dependentid="302541" rxinlineslot="103" sys_siteid="475" sys_variantid="1418" sys_contentid="302541">Office of the Director</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
In the Office of the Director, Dr. Hannah P. Yang oversees scientific review, site visits, annual and ad hoc reporting, executive search committees, budget formulation, and Division liaison activities to numerous NCI and NIH entities. She also supports the planning of a new prospective multi-center cohort study that will serve as an important Division-wide resource. <br /><br />Dr. Yang received her B.S. in biology and the history and sociology of science from the University of Pennsylvania, and her Sc.M. and Ph.D. in epidemiology from the Johns Hopkins Bloomberg School of Public Health. She joined DCEG as a pre-doctoral fellow in 2007 and completed her doctoral work through the Hopkins-DCEG partnership training program in cancer epidemiology. Upon completion of her doctorate, she became a postdoctoral fellow (2009-2011) and then a research fellow (2011-2012). She was appointed as a Staff Scientist in 2012. Dr. Yang has received several awards for her work, including DCEG awards for Outstanding Research Paper by a Staff Scientist (2013, 2015) and the CCR and DCEG award for Outstanding Poster at the Staff Scientist and Staff Clinician Retreat (2015).</div>
</div>]]></body>
    <field_image_promotional>1048350</field_image_promotional>
  </row>
  <row term_id="302006" id="1062759" title="Stephen W. Hartley, Ph.D." langcode="en" field_short_title="Stephen W. Hartley, Ph.D." field_page_description="Stephen W. Hartley, Ph.D., biographical sketch and research interests" field_feature_card_description="Stephen W. Hartley, Ph.D., biographical sketch and research interests" field_list_description="Stephen W. Hartley, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-09-26" field_date_reviewed="2016-09-26" field_date_updated="2016-09-26" field_pretty_url="hartley-stephen" field_browser_title="Stephen W. Hartley, Ph.D., biographical sketch and research interests" field_card_title="Stephen W. Hartley, Ph.D." field_email_address="stephen.hartley@nih.gov" field_first_name="Stephen" field_last_name="Hartley" field_phone_number="240-276-7355 " field_org_name_1="National Cancer Institute" field_org_name_2="Human Genetics Program" field_campus="300" field_office_location="Room 7E582">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a><br /><a href="#Research-Interests">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Hartley%20SW%5bAuthor%5d&amp;cmd=DetailsSearch">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302429" inlinetype="rxhyperlink" sys_relationshipid="7252754" sys_dependentvariantid="1422" sys_dependentid="302429" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302429">Human Genetics Program</a></li>
</ul>
<h3><a id="Biography"></a>Biography</h3>
<p>Dr. Hartley earned a Ph.D. in biostatistics from Boston University in 2012 after receiving his B.A. in computer science at Wesleyan University. Prior to joining DCEG, he was a postdoctoral fellow in the National Human Genome Research Institute (NHGRI) in the Comparative Genomics Analysis Unit of the Cancer Genetics and Comparative Genomics Branch. During his postdoctoral fellowship, Dr. Hartley designed and developed <em>QoRTs</em>, an RNA-Seq quality control, visualization, and data processing toolkit and <em>JunctionSeq</em>, a novel method&mdash;implemented as a bioconductor package&mdash;for identifying, assessing, and visualizing differential exon and splice junction usage in RNA-Seq data. In September 2016, he joined the DCEG Human Genetics Program as a staff scientist, working with DCEG investigators to implement the GENOMEL exome sequencing Cloud pilot and to analyze genomic data in pediatric cancers.</p>
<h3><a id="Research-Interests"></a>Research Interests</h3>
<ul>
<li>Design, application, and evaluation of new statistical and bioinformatic methods</li>
<li>Developing robust, efficient, and effective algorithms, software, and pipelines for the analysis of high-throughput sequencing data</li>
<li>Detecting, identifying, and assessing deleterious variants</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>1062759</field_image_promotional>
  </row>
  <row term_id="302006" id="1100757" title="Danping Liu, Ph.D." langcode="en" field_short_title="Danping Liu, Ph.D." field_page_description="Danping Liu, Ph.D., biographical sketch and research interests" field_feature_card_description="Danping Liu, Ph.D., biographical sketch and research interests" field_list_description="Danping Liu, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-11-28" field_date_reviewed="2017-11-28" field_date_updated="2017-11-28" field_pretty_url="liu-danping" field_browser_title="Danping Liu, Ph.D., biographical sketch and research interests" field_card_title="Danping Liu, Ph.D." field_email_address="danping.liu@nih.gov" field_first_name="danping" field_last_name="liu" field_phone_number="240-276-7760" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E630">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=((Liu%2C%20Danping%5BFull%20Author%20Name%5D%20NOT%20China%5BAffiliation%5D)%20NOT%20Liaoning%5BAffiliation%5D)%20NOT%20Australia%5BAffiliation%5D&amp;cmd=DetailsSearch">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" sys_dependentvariantid="1422" sys_dependentid="302568" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252450" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Liu received his Ph.D. in biostatistics from the University of Washington in 2010, and completed a two-year postdoctoral training at the National Alzheimer&rsquo;s Coordinating Center, University of Washington. Prior to joining NCI, he served as a tenure-track investigator at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Dr. Liu joined the Biostatistics Branch of the NCI Division of Cancer Epidemiology and Genetics in October 2017.</p>
<h2 id="research">Research Interests</h2>
<p>Dr. Liu is interested in developing new statistical methods to evaluate and combine biomarkers for use in risk prediction. Individualized disease risk prediction is particularly attractive to patients, health care providers and policy makers. At the population level, accurate prediction of disease helps target interventions and treatments to the most vulnerable groups. Biomarker research has attracted much attention in the diagnosis or prediction of disease outcomes, especially in studies of cancer. Particularly, Dr. Liu is interested in the following topics.</p>
<h3>Developing methods to incorporate longitudinal biomarkers into risk prediction</h3>
<p>It is important to incorporate longitudinal biomarkers into risk prediction of clinical endpoints, because additional information on pathology and critical time window is contained in the subject-specific trajectories of the biomarkers. Prediction accuracy could be substantially improved by incorporating the longitudinal information. Dr. Liu has been working on methods for effectively combining longitudinal biomarkers in predicting disease outcomes. In cancer risk prediction, a unique challenge is to account for the timing of, and cancer staging at, diagnosis. Dr. Liu is interested in risk prediction under a survival model framework, where the staging at diagnosis can be used to estimate the lag between cancer onset and diagnosis. While properly accounting for the timing and staging information, Dr. Liu is developing statistical methods to make formal inference on how the risk prediction accuracy of a biomarker changes over time.</p>
<h3>Developing model selection techniques for combining high-dimensional longitudinal biomarkers</h3>
<p>Including more biomarkers into a prediction model does not always improve prediction accuracy. Selection of markers is a crucial step, especially when the number of candidate markers is large. Marker selection involves several aspects: selecting markers with high classification power, selecting the important time points for making observations, and selecting subgroups of patients for enhanced prediction. Dr. Liu is interested in developing model selection techniques for longitudinal risk prediction.</p>
<h3>Missing data problems in biomarker evaluation and combination</h3>
<p>Incomplete observations are common in most longitudinal studies, but this problem has not been studied in the context of biomarker combination. Both the biomarker and the outcome could be missing due to loss of follow-up. The absence might be informative if the dropout process depends on a subject&rsquo;s unobserved characteristics. For example, the subjects who develop cancer sooner have a shorter follow-up and hence fewer biomarker observations. Dr. Liu&rsquo;s interest lies in developing efficient and robust techniques to correct for the bias that results from ignoring the missing data.</p>
</div>
</div>]]></body>
    <field_image_promotional>1100757</field_image_promotional>
  </row>
  <row term_id="302006" id="1116390" title="Monica Sierra, Ph.D., M.S.P.H." langcode="en" field_short_title="Monica Sierra, Ph.D., M.S.P.H." field_page_description="Monica Sierra, Ph.D., biographical sketch and research interests " field_feature_card_description="Monica Sierra, Ph.D., biographical sketch and research interests " field_list_description="Monica Sierra, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2018-05-25" field_date_reviewed="2018-05-25" field_date_updated="2018-05-25" field_pretty_url="sierra-monica" field_browser_title="Monica Sierra, Ph.D., biographical sketch and research interests " field_card_title="Monica Sierra, Ph.D., M.S.P.H." field_email_address="monica.sierra@nih.gov" field_first_name="Monica" field_last_name="Sierra" field_phone_number="240.276.7065" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E206">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<p><a href="#Biography">Biography</a><br /><a href="#Research-Interests">Research Interests</a><br /><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1HAFH-lTne3IoM/bibliography/55020665/public/?sort=date&amp;direction=descending">Scientific Publications</a><br /> <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=47&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_dependentvariantid="1422" sys_dependentid="302590" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252638" sys_variantid="1422" sys_contentid="302590">Infections and Immunoepidemiology Branch</a></p>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Sierra received her M.S.P.H. and Ph.D. degrees in epidemiology from the University of Texas Health Science Center School of Public Health. As a postdoctoral fellow at the University of Alberta, Canada, she received the Outstanding Contributions in Collaborative Research Award for her focus on community-based studies of <em>H. pylori</em> infection with the Canadian North <em>Helicobacter pylori</em> (CAN<em>Help</em>) Working Group. Dr. Sierra was awarded the Marie-Curie COFUND Actions postdoctoral fellowship from the International Agency for Research on Cancer (IARC), Lyon, France and received an IARC Outstanding Contribution Award. At the Section of Cancer Surveillance, IARC, she evaluated cancer patterns and trends in Central and South America. Prior to joining DCEG, Dr. Sierra worked at the Task Force for Global Health, Inc., contributing to the development of the cancer epidemiology curriculum for the Field Epidemiology Training Program of the Centers for Disease Control and Prevention.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Sierra has broad expertise in global health, cancer surveillance systems in low- and middle-income countries, and cancer control and prevention. She currently supports the human papillomavirus (HPV) vaccine trials in Costa Rica. Prophylactic vaccines for HPV are being introduced in many countries for the prevention of cervical cancer, the second leading cause of cancer-related death in women worldwide. These vaccines have the potential to significantly impact the future burden of cervical cancer, particularly in underserved populations where screening is non-existent or limited in scale.</p>
</div>
</div>]]></body>
    <field_image_promotional>1116390</field_image_promotional>
  </row>
  <row term_id="302006" id="1136015" title="Pabitra Josse, M.S." langcode="en" field_short_title="Pabitra Josse, M.S." field_page_description="Pabitra Josse, M.S., biographical sketch and research interests" field_list_description="Pabitra Josse, M.S. focuses her research on characterizing occupational exposure in epidemiologic studies of cancer. " field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2019-01-28" field_date_reviewed="2019-01-28" field_date_updated="2019-01-28" field_pretty_url="josse-pabitra" field_browser_title="Pabitra Josse, M.S., biographial sketch and research interests" field_card_title="Pabitra Josse, M.S." field_email_address="pabitra.josse@nih.gov" field_first_name="Pabitra" field_last_name="Josse" field_phone_number="240-276-5098" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E550">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<p><a href="#Biography">Biography</a><br /><a href="#Research-Interests">Research Interests</a><br /><a href="https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/57631293/?sort=date&amp;direction=descending">Scientific Publications</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=43&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7234141" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475" sys_folderid="">Occupational and Environmental Epidemiology Branch</a></p>
<h2><a id="Biography"></a>Biography</h2>
<p>Ms. Josse received an M.S.&nbsp;in environmental health from Colorado State University. She joined the Occupational and Environmental Epidemiology Branch (OEEB) in 2017 as an occupational exposure assessment specialist. Ms. Josse&rsquo;s research focuses on characterizing occupational exposure in epidemiologic studies of cancer. Before joining NCI, Ms. Josse worked at Westat as a senior study director, providing study management and exposure characterization for occupational and environmental exposures in epidemiologic studies.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<ul>
<li>Identifying, extracting, and synthesizing exposure-related information from the published and grey literature for use in reconstructing occupational exposures.</li>
<li>Developing novel retrospective exposure assessment methods to efficiently evaluate and estimate historical workplace exposures in epidemiologic studies of cancer.</li>
<li>Designing and implementing field sampling strategies for prospective studies to characterize exposures and identify key exposure determinants.</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>1136015</field_image_promotional>
  </row>
  <row term_id="302006" id="349596" title="Steven L. Simon, Ph.D. " langcode="en" field_short_title="Steven L. Simon, Ph.D. " field_page_description="Steven L. Simon, Ph.D., biographical sketch and research interests" field_feature_card_description="Steven L. Simon, Ph.D., biographical sketch and research interests" field_list_description="Steven L. Simon, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2018-11-27" field_pretty_url="simon-steven" field_browser_title="Steven L. Simon, Ph.D., biographical sketch and research interests" field_card_title="Steven L. Simon, Ph.D. " field_email_address="ssimon@mail.nih.gov" field_first_name="Steven" field_last_name="Simon" field_phone_number="240-276-7371" field_org_name_1="National Cancer Institute" field_org_name_2="Epidemiology &amp; Biostatistics Program" field_campus="300" field_office_location="Room 7E588">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=simon%20s&amp;authorOption=exact&amp;pi=0010383062">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302673" sys_contentid="302673" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302673" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252810" sys_variantid="1422">Epidemiology and Biostatistics Program</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Steven Simon received a B.S. in physics from the University of Texas, an M.S. in radiological physics from the University of Texas Health Sciences Center in Dallas, and a Ph.D. in radiological health sciences from Colorado State University. Prior to joining NCI, he was on the research faculty at the University of Utah, the academic faculty at the University of North Carolina-Chapel Hill, served as a medical physicist for the University of New Mexico at Los Alamos National Laboratory, as a senior staff officer at the National Research Council, and as director of the Marshall Islands Nationwide Radiological Study. He joined the NCI in 2000. Dr. Simon is a recognized expert in dose reconstruction methods for epidemiologic studies involving all types and sources of radiation exposure.</p>
<p>Dr. Simon received NIH Merit Awards in 2004, 2009, 2011, 2014, and 2018&nbsp;for his research into applications&nbsp;of radiation dosimetry to epidemiological research. In 2010, he received the Division of Cancer Epidemiology and Genetics Exemplary Service Award for his deployment to the U.S. Embassy in Tokyo during the Fukushima nuclear crisis, where he served as a DHHS technical expert in radiation dose and risk. In 2018, he received the U.S. Department of Health and Human Services (HHS) Assistant Secretary for Health&rsquo;s Award for Superior Service for &ldquo;Contributions to four Special Exposure Cohort (SEC) Administrative Review Panels for the Energy Employees Occupational Illness Compensation Program Act (EEOICPA) of 2000.&rdquo;&nbsp;</p>
<p>Dr. Simon has worldwide experience in monitoring nuclear test sites for residual radioactivity (including test sites in the Marshall Islands, Johnston Island, French Polynesia, and Algeria) and at assessing historical radiation doses from nuclear weapons fallout (including Nevada, New Mexico, Kazakhstan, Marshall Islands, and global fallout). He has provided advice over many years to national and international organizations on issues related to environmental contamination from nuclear testing and the related radiation exposures.</p>
<p>Dr. Simon has been a member of the National Council on Radiation Protection and Measurements for more than 14 years and is currently a&nbsp;Scientific Vice President and Chair&nbsp;of the NCRP&rsquo;s Program Area on Radiation Measurements and Dosimetry. In 2018, he completed 25 continuous years as an Associate Editor of <i>Health Physics</i>.</p>
<h2 id="research">Research Interests</h2>
<ul>
<li>Radiation dosimetry and dose reconstruction methods</li>
<li>Dose estimation for cohorts exposed to environmental, medical, or occupational radiation</li>
<li>Analysis of uncertainty of radiation exposure models</li>
<li>Health risks from radiation exposure</li>
<li>Doses received from nuclear testing worldwide</li>
<li>Radioactivity in man and the environment and quantitative transfer of radioactive materials to organisms</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349596</field_image_promotional>
  </row>
  <row term_id="302006" id="349599" title="Debra Silverman, Sc.D." langcode="en" field_short_title="Debra Silverman, Sc.D." field_page_description="Debra T. Silverman, Sc.D., biographical sketch and research interests " field_feature_card_description="Debra T. Silverman, Sc.D., biographical sketch and research interests " field_list_description="Debra T. Silverman, Sc.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2015-07-09" field_pretty_url="silverman-debra" field_browser_title="Debra T. Silverman, Sc.D., biographical sketch and research interests " field_card_title="Debra Silverman, Sc.D." field_email_address="silvermd@mail.nih.gov" field_first_name="Debra" field_last_name="Silverman" field_phone_number="240-276-7174" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E142">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=silverman%20d&amp;authorOption=exact&amp;pi=0010057641">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_relationshipid="7252489" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Silverman is chief of the Occupational and Environmental Epidemiology Branch within the Division of Cancer Epidemiology and Genetics, NCI. She received an Sc.D. in epidemiology from the Harvard School of Public Health and an Sc.M. in biostatistics from the Johns Hopkins Bloomberg School of Hygiene and Public Health. She joined the NCI as a biostatistician in 1972, and has served as a cancer epidemiologist since 1983.</p>
<p class="first-graf">Dr. Silverman has received numerous awards, including the Harvard School of Public Health Alumni Award of Merit for the scientific importance and public health impact of her research; the PHS Special Recognition Award for research on environmental determinants of bladder and other cancers; the American Occupational Medical Association Merit in Authorship Award for her contributions to a paper on a job/exposure linkage system; the NIH Director&rsquo;s Award, the NCI Special Act Award, the NIOSH Alice Hamilton Science Award for Occupational Safety and Health, and the British Occupational Hygiene Society Award in recognition of her work on the Diesel Exhaust in Miners Study; the NIH Merit Award for her contributions to pancreatic cancer research; and the DCEG Exemplary Service and Investigator Award. She was a finalist for the NIOSH Alice Hamilton Science Award for Occupational Safety and Health for her research on diesel exhaust exposure and lung cancer in truck drivers. Dr. Silverman is an elected member of the American Epidemiological Society and a Fellow of the American College of Epidemiology.</p>
<h2 id="research">Research Interests</h2>
<h3>Occupational, Environmental and Host Determinants of Cancer</h3>
<p class="first-graf">Dr. Silverman&rsquo;s research involves the design and conduct of epidemiologic investigations to evaluate occupational, environmental, and host determinants of cancer. She and her colleagues closely monitor new findings from clinical observations, experimental studies, and descriptive and analytic epidemiology for leads as to causes of cancer. Her research focuses particularly on the etiology of cancers of the bladder and pancreas and on the carcinogenic effects of diesel exhaust.</p>
<h3>Carcinogenicity of Diesel Exhaust and Outdoor Air Pollutants</h3>
<p class="first-graf">The International Agency for Research on Cancer (IARC) classified diesel exhaust as a human carcinogen in 2012, based in large part on the findings from the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303672" sys_contentid="303672" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="303672" rxinlineslot="103" sys_relationshipid="7252487" sys_variantid="1418">Diesel Exhaust in Miners Study (DEMS)</a>, which was designed and directed by Dr. Silverman and her colleagues at the National Institute for Occupational Safety and Health.</p>
<p class="first-graf">Diesel exhaust is a general airborne contaminant. Exposure is ubiquitous in cities and among commuters who regularly use highways. Occupational exposures are higher than those of the general population, especially among miners, transportation workers and other operators of diesel powered equipment.&nbsp;</p>
<p class="first-graf">Outdoor air pollution also causes lung cancer but the specific pollutant driving the risk is unknown.&nbsp; Dr. Silverman, in collaboration with Dr. Rena Jones, is conducting a study in the LA Basin (Los Angeles Ultrafines Study) to determine the role of ultrafine particles in lung cancer etiology.&nbsp; This study employs state-of-the-art exposure assessment to determine historical ultrafine exposure in members of the AARP cohort in LA.</p>
<h3>Bladder Cancer</h3>
<p class="first-graf">Bladder cancer is recognized as an occupationally-related tumor. During the past three decades, scores of bladder cancer studies have suggested more than 40 high-risk occupations, yet the specific exposures responsible for most of the excess risks remain largely unknown. Known and suspect occupational bladder carcinogens include aromatic amines, diesel exhaust, cutting oil mist, polycyclic aromatic hydrocarbons, aryl hydrocarbons, and their derivatives.</p>
<p>Dr. Silverman heads the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=32&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=438648" sys_contentid="438648" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="438648" rxinlineslot="103" sys_relationshipid="7252488" sys_variantid="1418">New England Bladder Cancer Study</a>, which was designed to determine the reasons for excess bladder cancer risk in northern New England. This complex multidisciplinary investigation includes both an environmental component, with detailed exposure assessment for arsenic and disinfection by-products in drinking water, and a biologic component.</p>
<p>She is also the NCI principal investigator of a hospital-based case-control study of bladder cancer in Spain to clarify the etiologic role of suspected occupational carcinogens and to evaluate a variety of non-occupational exposures, including genetic susceptibility markers, and gene-environment interactions. Biologic specimens have been collected to examine genetic susceptibility in relation to risk of bladder cancer.</p>
<h3>Pancreatic Cancer</h3>
<p class="first-graf">Dr. Silverman has carried out numerous studies of pancreatic cancer to identify risk factors that play a role in the etiology of this malignancy. Her research has helped to establish the causal relationships for smoking, heavy alcohol consumption, obesity, diabetes, and family history of the array of tumors associated with hereditary nonpolyposis colorectal cancer. In particular, her work has also focused on factors contributing to the high rates experienced by African Americans. She continues her research in this area by following up earlier case-control findings on obesity, diabetes, heavy alcohol consumption, smoking habits, and pesticide use.</p>
</div>
</div>]]></body>
    <field_image_promotional>349599</field_image_promotional>
  </row>
  <row term_id="302006" id="349607" title="Aaron Blair, Ph.D., M.P.H. " langcode="en" field_short_title="Aaron Blair, Ph.D., M.P.H. " field_page_description="Aaron Blair, Ph.D., M.P.H., Biographical sketch and research interests" field_feature_card_description="Aaron Blair, Ph.D., M.P.H., Biographical sketch and research interests" field_list_description="Aaron Blair, Ph.D., M.P.H., Scientist Emeritus - biographical sketch and research interests" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-02-01" field_pretty_url="blair-aaron" field_browser_title="Aaron Blair, Ph.D., M.P.H., Biographical sketch and research interests" field_card_title="Aaron Blair, Ph.D., M.P.H. " field_email_address="blaira@mail.nih.gov" field_first_name="Aaron" field_last_name="Blair" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul>
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=blair%20a&amp;authorOption=exact&amp;pi=0010165137">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7252391">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="biography"><a id="Biography"></a>Biography</h2>
<p>Dr. Blair received a Ph.D. in genetics from North Carolina State University and an M.P.H. in epidemiology from the University of North Carolina. He joined the NCI as a staff fellow in 1976, and was appointed to head the Occupational Studies Section in 1978. He was appointed Chief of the group when it became a branch in 1996. At NIH, he received the NIH Director's Award, PHS Special Recognition Award, NIH Merit Award, the DHHS Quality of Work Life Award, and the NIH Director's Award for the Deepwater Horizon Gulf Oil Spill Study. Other awards include the University of North Carolina H.A. Tyroler Distinguished Alumni Award, John Goldsmith Award for Outstanding Contributions to Environmental Epidemiology from the International Society for Environmental Epidemiology, the Harriet Barr Distinguished Alumnus Award from the Public Health Alumnus Association of the University of North Carolina, NIOSH Alice Hamilton Award for Excellence in Occupational Safety and Health, Kansas Wesleyan University Alumni Achievement Award, EPICOH Award for Outstanding Contributions to Occupational Epidemiology, and APHA Epidemiology Section Wade Hampton Frost Annual Lectureship Award. He has served on numerous review groups for IARC, EPA, and other agencies, organizations, and institutions.</p>
<p>Dr. Blair currently serves as an advisor on the Chlordecone Scientific Committee (Institute National du Cancer, France), Pesticide Advisory Committee (Carex Canada), and Independent Advisory Board for Exposure Assessment (Institute of Occupational Medicine, Scotland). He has authored/coauthored more than 500 papers on occupational and environmental causes of cancer, other diseases, and epidemiologic methodology.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Blair&rsquo;s research focuses on evaluating cancer and other disease risks associated with agricultural exposures, chemicals in the workplace and the general environment, and methodologic issues in occupational epidemiology.</p>
<h3>Pesticides</h3>
<p>Studies of pesticides have been a major focus throughout&nbsp;Dr. Blair's&nbsp;career. Pesticides are widely used chemicals, specifically designed to have toxic effects to some species. A number are carcinogenic in laboratory animals. The toxic nature of these agents raises questions about their possible impact on human health, although not specifically designed for this purpose. Dr. Blair&rsquo;s early studies focused on farmers because they have heavier and more frequent exposures to pesticides than the general population and because they are able to describe their pesticide usage. Despite an overall lower mortality than the general population, farmers have excess cancers of the lip, stomach, brain, prostate, skin, and the lymphatic and hematopoietic system, as well as some nonmalignant chronic diseases. Ongoing studies in agriculture are designed to identify risk factors that account for these excesses.</p>
<p>Dr. Blair&rsquo;s early mortality studies of agricultural populations, death certificate case-control studies, and cancer incidence case-control studies of lymphatic and hematopoietic indicated that pesticide exposures were likely to contribute to the development of cancer. Previous biomarker studies found urinary levels of 2,4 D resulted in increased lymphocyte replication levels were greater after exposure than before. This body of work provided much of the background for the launch of the Agricultural Health Study (AHS), a major prospective investigation of farmers and their families in 1992. Since its initiation, the AHS has provided, and continues to provide, critical new information on the role of pesticides and other agricultural exposures in the development of cancer and diseases of the respiratory, neurologic, and reproductive systems, as well as other outcomes and conditions. Dr. Blair continues to participate in the AHS as a member of the Executive Committee, Scientist Emeritus,&nbsp;and as a coauthor on selected papers. He is also a collaborator in the North American Pesticide Project that pools case-control studies of lymphatic and hematopoietic cancers from the United States and Canada to evaluate the etiologic role of pesticides.</p>
<p></p>
</div>
</div>]]></body>
    <field_image_promotional>349607</field_image_promotional>
  </row>
  <row term_id="302006" id="349624" title="Mary H. Ward, Ph.D. " langcode="en" field_short_title="Mary H. Ward, Ph.D. " field_page_description="Mary H. Ward, Ph.D.m=, biographical sketch and research interests " field_feature_card_description="Mary H. Ward, Ph.D.m=, biographical sketch and research interests " field_list_description="Mary H. Ward, Ph.D.m=, biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2015-07-20" field_pretty_url="ward-mary" field_browser_title="Mary H. Ward, Ph.D.m=, biographical sketch and research interests " field_card_title="Mary H. Ward, Ph.D. " field_email_address="wardm@mail.nih.gov" field_first_name="Mary" field_last_name="Ward" field_phone_number="240-276-7172" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E138">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=ward%20m&amp;authorOption=exact&amp;pi=0010147002">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_relationshipid="7252642" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Ward received an M.S. in ecology from the University of Tennessee and a Ph.D. in epidemiology from The Johns Hopkins School of Hygiene and Public Health. She completed post-doctoral work in the Occupational and Environmental Epidemiology Branch within the Division of Cancer Epidemiology and Genetics, was appointed as a tenure-track investigator in 1999, and received tenure in 2008.&nbsp;Dr. Ward&nbsp;received a DCEG Intramural Research Award in 1999 and an NIH Merit Award in 2000 for her work using geographical information systems for exposure assessment of environmental contaminants. She received the DCEG Mentoring Award in 2011 and the NCI Women Scientist Advisors' Mentoring and Leadership Award in 2016. Dr. Ward is a Fellow of the American College of Epidemiology.</p>
<h2 id="research">Research Interests</h2>
<p>Dr. Ward&rsquo;s research focuses on environmental and occupational causes of cancer, with special emphasis on <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=24&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303673" sys_contentid="303673" inlinetype="rxhyperlink" sys_relationshipid="7252643" sys_dependentvariantid="1418" sys_dependentid="303673" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">drinking water contaminants,</a> pesticides, and other chemicals in relation to the etiology of childhood leukemia, gastrointestinal cancers, and thyroid cancer. She is examining nitrate in drinking water and the diet with respect to cancers of the bladder, colon, stomach, esophagus, ovary, and thyroid. Dr. Ward is responsible for developmental work using geographic information systems for exposure assessment of environmental contaminants.</p>
<h4>Nitrates, Pesticides and Cancer and Environmental Exposure Assessment</h4>
<p class="first-graf">Dr. Ward&nbsp;uses <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1075341" sys_contentid="1075341" inlinetype="rxhyperlink" sys_relationshipid="7252644" sys_dependentvariantid="1424" sys_dependentid="1075341" rxinlineslot="103" sys_siteid="475" sys_variantid="1424">innovative methods such as geographic information systems (GIS)</a> to display and analyze environmental exposure data. Using GIS and remote sensing data, she is&nbsp;participating in interdisciplinary collaborations to develop new methods of exposure assessment for epidemiologic studies of cancer risk in relation to drinking water contaminants, agricultural pesticides, and other environmental contaminants.</p>
<h4>Nitrates, Nitrite, and N-nitroso Compounds</h4>
<p>The endogenous formation of carcinogenic N-nitroso compounds (NOC) can occur following ingestion of nitrate from drinking water. Certain foods are also sources of nitrate and nitrite. Nitrate can also inhibit iodide uptake by the thyroid. Only a limited number of analytic epidemiologic studies have evaluated these exposures with respect to diet and drinking water. Dr. Ward&nbsp;conducted case-control studies that found an increased risk of colon and kidney cancer associated with prior exposure to elevated nitrate in drinking water among those who also had lower intakes of vitamin C and higher intakes of red meat, inhibitors and precursors in the endogenous formation of NOC. Increasing intake of dietary nitrite, a major source of which is processed meats, was associated with increased risk of colorectal adenomas, colon, rectum, pancreas, thyroid, and ovarian cancers in case-control and/or cohort studies. Drinking water nitrate increased the risk of thyroid, bladder, kidney, and ovarian cancers in a cohort of older women in Iowa.</p>
<p>To follow up upon these findings, Dr. Ward led interdisciplinary collaborations to develop GIS-based random forest models to estimate nitrate levels in the drinking water wells of participants of the Agricultural Health Study, a cohort of pesticide applicators and their spouses with high exposure to nitrate through their private wells.&nbsp;</p>
<h4>Pesticides and Other Chemicals</h4>
<p>A feasibility study using remote sensing data and a GIS to estimate indirect exposure to pesticides demonstrated that using available data, accurate historical crop maps could be produced and that these could be linked to pesticide use data to estimate probabilities of indirect exposure to agricultural pesticides. This was the first study to estimate the prevalence of potential indirect exposure to agricultural pesticides in the general population. A validation study in Iowa found that increasing acreage of corn and soybean fields within 750 m of homes was associated with significantly elevated concentrations of agricultural herbicides compared with homes with no crops within 750 m even after accounting for the presence of an occupational exposed worker. Dr. Ward and colleagues are applying this exposure assessment approach to estimate residential exposures to agricultural pesticides in studies of childhood cancers in California and Denmark.</p>
<p>In a <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303596" sys_contentid="303596" inlinetype="rxhyperlink" sys_relationshipid="7252645" sys_dependentvariantid="1418" sys_dependentid="303596" rxinlineslot="103" sys_siteid="475" sys_variantid="1418">case-control study of childhood leukemia in California</a>, Dr. Ward and colleagues&nbsp;analyzed carpet dust samples for pesticides and other chemicals. Analyses of persistent organochlorine pesticides, polychlorinated biphenyls (PCB), and polybrominated diphenyl ethers (PBDE) in carpet dust samples revealed an increased risk of acute lymphocytic leukemia among children living in homes with higher levels of PCB and specific PBDE congeners. In a nested-case control study of in the Norwegian Janus Serum Bank cohort, early life exposures to specific organochlorine chemicals were associated with increased risk of thyroid cancer.&nbsp;</p>
</div>
</div>]]></body>
    <field_image_promotional>349624</field_image_promotional>
  </row>
  <row term_id="302006" id="349628" title="Charles Rabkin, M.D." langcode="en" field_short_title="Charles Rabkin, M.D." field_page_description="Charles Rabkin, M.D., biographical sketch and research interests " field_feature_card_description="Charles Rabkin, M.D., biographical sketch and research interests " field_list_description="Charles Rabkin, M.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-03-12" field_pretty_url="rabkin-charles" field_browser_title="Charles Rabkin, M.D., biographical sketch and research interests " field_card_title="Charles Rabkin, M.D." field_email_address="rabkinc@mail.nih.gov" field_first_name="Charles" field_last_name="Rabkin" field_phone_number="240-276-7105" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E110">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=rabkin%20c&amp;authorOption=exact&amp;pi=0010080121">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=56&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" sys_relationshipid="7280127" sys_dependentvariantid="1422" sys_dependentid="302590" rxinlineslot="103">Infections and Immunoepidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Rabkin earned an Sc.B. and M.D. from Brown University and an M.Sc. in epidemiology from the London School of Hygiene and Tropical Medicine. He received postgraduate training at the University of Colorado and is board certified in internal medicine and preventive medicine. Before coming to the NCI, he was an Epidemic Intelligence Service Officer and a medical epidemiologist at the Centers for Disease Control and Prevention. He has received Public Health Service (PHS) Commendation and Unit Commendation Medals for his studies of non-Hodgkin lymphoma and Kaposi sarcoma and the Outstanding Service Medal for the molecular epidemiology of <i>Helicobacter pylori</i> and HIV-related malignancies.</p>
<h2 id="research">Research Interests</h2>
<p class="first-graf">Chronic infection and inflammation are associated with increased risk of many types of cancer. My research is directed toward understanding the molecular mechanisms underlying these associations, particularly for gastric cancer and non-Hodgkin lymphoma. The overarching objective is to increase etiologic understanding and diminish burden of disease.</p>
<h3>Gastric cancer</h3>
<p class="first-graf">My work in gastric cancer encompasses&nbsp;four sub-projects on the pathogenic microbes, modifying host factors, molecular pathologic features, and intermediate markers with potential for screening of gastric cancer and pre-neoplastic lesions. I have a particular focus on the Epstein-Barr virus (EBV) as a co-factor with <i>Helicobacter pylori,</i> the established cause of most cancers of the noncardia stomach. Viral coinfection is present in 8-10 percent&nbsp;of gastric cancers worldwide, and I lead an<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=5&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=827356" sys_contentid="827356" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" sys_relationshipid="7280126" sys_dependentvariantid="1418" sys_dependentid="827356" rxinlineslot="103">&nbsp;international consortium studying EBV's etiologic and clinicopathologic significance</a>.&nbsp;</p>
<p class="first-graf">Another major effort is the <em></em><a href="/Rhythmyx/assembler/render?sys_contentid=1141200&amp;sys_revision=1&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="1141200" rxinlineslot="103" sys_folderid="" sys_relationshipid="7280128"><em>H. pylori</em> Genome Project (HpGP)</a>, a collaboration with the Metabolic Epidemiology Branch and an international team of experts to comprehensively catalog genetic and epigenetic variation of this important pathogen. Our goal is to identify bacterial characteristics associated with long-term outcome by comparing isolates from patients with gastric cancer or advanced premalignant lesions with isolates from controls with benign infection (superficial gastritis) from high- and low-incidence populations in multiple countries. In other studies, I have implicated <a href="/Rhythmyx/assembler/render?sys_contentid=1141199&amp;sys_revision=1&amp;sys_variantid=1418&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_folderid=" inlinetype="rxhyperlink" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="1141199" rxinlineslot="103" sys_folderid="" sys_relationshipid="7280129">autoimmune gastritis</a> as an emerging etiology underlying changing trends in cancer incidence.&nbsp;I am currently pursuing this novel hypothesis using multiple approaches, including examinations of administrative databases and testing for autoantibodies in prospective cohort studies.</p>
<h3>Non-Hodgkin lymphoma</h3>
<p class="first-graf">Non-Hodgkin lymphoma is a neoplasm of the effector cells that mediate adaptive immunity. I study the acquired and inherited abnormalities of immune cells that may contribute to their malignant transformation.&nbsp;AIDS-related lymphoma represents a particularly informative model, given its high incidence in defined populations under close medical supervision. To advance research efforts in this area, we have launched AIDSLymph, a consortium investigating associations and risk factors for lymphoma in patients with advanced HIV infection, in collaboration with the North American AIDS Cohorts Collaboration on Research &amp; Design (NA-ACCORD).</p>
<p>&nbsp;</p>
</div>
</div>]]></body>
    <field_image_promotional>349628</field_image_promotional>
  </row>
  <row term_id="302006" id="349636" title="Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D." langcode="en" field_short_title="Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D." field_page_description="Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D., biographical sketch and research interests " field_feature_card_description="Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D., biographical sketch and research interests " field_list_description="Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-23" field_pretty_url="stolzenberg-solomon-rachael" field_browser_title="Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D., biographical sketch and research interests " field_card_title="Rachael Stolzenberg-Solomon, Ph.D., M.P.H., R.D." field_email_address="stolzenr@dcpcepn.nci.nih.gov" field_first_name="Rachael" field_last_name="Stolzenberg-Solomon" field_phone_number="240-276-7224" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E420">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=stolzenberg-solomon%20r&amp;authorOption=exact&amp;pi=0010408847">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_relationshipid="7276645" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Stolzenberg-Solomon received a B.S. in nutrition and dietetics at the University of California, Davis in 1984, followed by a dietetic internship and M.Ed. in health science (nutrition) education at Vanderbilt University Medical Center and George Peabody School of Education, respectively. After this training she worked as a registered dietitian for 10 years. In 1994, she completed an M.P.H. with concentrations in epidemiology and nutrition at the Johns Hopkins School of Hygiene and Public Health. Dr. Stolzenberg-Solomon joined the NCI in 1996 as a predoctoral fellow in the Cancer Prevention Studies Branch of the former Division of Cancer Prevention and Control and later the Center for Cancer Research, and subsequently earned a Ph.D. in epidemiology from the Johns Hopkins School of Hygiene and Public Health in 1999. As a Cancer Prevention Fellow, she continued postdoctoral research in the Division of Cancer Prevention and DCEG. She became an investigator in the Nutritional Epidemiology Branch in December 2002, and was awarded NIH scientific tenure and promoted to senior investigator in 2011.</p>
<p>Dr. Stolzenberg-Solomon has won several awards in recognition of her contributions to cancer research, including the 2008 NIH Merit Award for sustained and innovative work in elucidating nutritional, genetic, infectious, and other determinants of pancreatic cancer. She is an active mentor, working with graduate students, as well as postdoctoral fellows. She serves on the editorial board of the <em>American Journal of Epidemiology</em> and <em>Cancer Epidemiology, Biomarkers, and Prevention</em>. Dr. Stolzenberg-Solomon also holds a position as an adjunct Associate Professor at the Yale University School of Public Health and is a fellow of the American College of Epidemiology.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Dietary, lifestyle, genetic and other risk factors for pancreatic cancer</li>
<li>Nutritional, molecular, and other biomarkers (i.e. metabolomics) and cancer</li>
</ul>
<p class="first-graf">Dr. Stolzenberg-Solomon has focused much of her research on elucidating the etiology of pancreatic cancer. She has examined dietary, other lifestyle, genetic, and infectious factors, including biomarkers that may help reveal underlying mechanisms of carcinogenesis. In addition to her major work on pancreatic cancer, she has pursued, on a limited basis, other nutrition-related hypotheses including biomarkers in nutritional intervention studies.</p>
<p>Although relatively rare, pancreatic cancer is a leading cause of cancer deaths and one whose incidence is increasing. In the United States, pancreatic cancer is the third leading cause of cancer mortality. Pancreatic ductal adenocarcinoma (PDAC) is the most common histologic type. There is no effective screening test for the malignancy; therefore, it is often diagnosed at an advanced stage, which contributes to its poor five-year survival rate of approximately 8.2%. Cigarette smoking, diabetes mellitus, and adiposity (overweight and obesity) are among the few consistent and modifiable risk factors for pancreatic cancer. Additional environmental and nutritional factors likely play a role; however, the evidence for specific exposures is often only suggestive due to the cancer&rsquo;s low incidence and inherent methodological issues related to collecting data for this rapidly fatal gastrointestinal cancer. PDAC cases often have gastrointestinal problems, weight loss, or diabetes prior to being diagnosed due to sub-clinical cancer which can influence dietary intake and biomarkers. Cohort studies with prediagnostic measures of exposures are less prone to these problems. Most of Dr. Stolzenberg-Solomon&rsquo;s research is conducted using prospective data and through pooled consortia efforts including the international <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=459581" sys_dependentvariantid="1418" sys_dependentid="459581" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276646" sys_variantid="1418" sys_contentid="459581">Genome-wide Association Study of Pancreatic Cancer (PanScan)</a>.</p>
</div>
</div>]]></body>
    <field_image_promotional>349636</field_image_promotional>
  </row>
  <row term_id="302006" id="349639" title="Marianne K. Henderson, M.S. CPC" langcode="en" field_short_title="Marianne K. Henderson, M.S. CPC" field_page_description="Marianne K. Henderson, M.S., biographical sketch and research interests " field_feature_card_description=" Marianne K. Henderson, M.S., biographical sketch and research interests " field_list_description=" Marianne K. Henderson, M.S., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="henderson-marianne" field_browser_title="Marianne K. Henderson, M.S., biographical sketch and research interests " field_card_title="Marianne K. Henderson, M.S. CPC" field_email_address="hendersm@mail.nih.gov" field_first_name="Marianne" field_last_name="Henderson" field_phone_number="240-276-7362" field_org_name_1="National Cancer Institute" field_org_name_2="Office of the Director" field_campus="300" field_office_location="Room 7E590">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<h2>Biography</h2>
<p>Ms. Henderson is the Senior Advisor for Division Resources for the National Cancer Institute&rsquo;s Division of Cancer Epidemiology and Genetics (DCEG). She also lends her expertise as Senior Advisor on biobanking to the NCI Center for Global Health. From 1999-2015, she served as Chief of DCEG's Office of Division Operations and Analysis. Ms. Henderson trained in zoology and marine ecology at the University of Maryland, College Park studying fish communities in the Red Sea. She has post graduate training in molecular biology, histology and genetics. Ms. Henderson is responsible and involved in project operations and contract management, fiscal and scientific reporting; strategic planning; technology transfer; and laboratory/biorepository infrastructure planning for large&shy;scale molecular epidemiology studies for the Division. She is a founding member of the NCI Biospecimen Coordinating Committee and participated in the development and revision of the first and second editions of NCI&rsquo;s Best Practices for Biospecimen Resources.</p>
<p>Since 1999, Ms. Henderson has been a member of the International Society for Biological and Environmental Repositories (ISBER) and served as ISBER President 2011&ndash;2012. She is currently the chair of the ISBER Organizing Advisory Committee. She is also a member of the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)&ndash;Large Prospective Cohorts Scientific and Ethical Advisory Board, and the BBMRI.se (Sweden Node) Advisory Board; a member of the U.S. Interagency Working Group on Scientific Collections; Chair of the Education and Training subcommittee and Steering committee member of the International Agency on Cancer&rsquo;s Low and Middle Income Country Biobank and Cohort Network; and the U.S.&shy;France Working Group on Large Scale Infrastructure for Life Sciences. Ms. Henderson is actively involved in human biospecimen management process improvements in processing, handling, technology transfer, and repository automation.</p>
</div>
</div>]]></body>
    <field_image_promotional>349639</field_image_promotional>
  </row>
  <row term_id="302006" id="349651" title="Blanche P. Alter, M.D., M.P.H." langcode="en" field_short_title="Blanche P. Alter, M.D., M.P.H." field_page_description="Blanche P. Alter, M.D., M.P.H., Biographical sketch and research interests" field_feature_card_description="Biographical sketch and research interests of Blanche P. Alter, M.D., M.P.H." field_list_description="Biographical sketch and research interests of Blanche P. Alter, M.D., M.P.H." field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2017-08-11" field_pretty_url="alter-blanche" field_browser_title="BBlanche P. Alter, M.D., M.P.H., Biographical sketch and research interests" field_card_title="Blanche P. Alter, M.D., M.P.H." field_email_address="alterb@mail.nih.gov" field_first_name="Blanche" field_last_name="Alter" field_phone_number="240-276-7239" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E452">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=alter%20bp&amp;authorOption=exact&amp;pi=0010848375">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_relationshipid="7252379" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Alter received a B.A. from Radcliffe College and an M.D. from Johns Hopkins University School of Medicine. She did an internship and residency in Pediatrics at Johns Hopkins, and a fellowship in Pediatric Hematology/Oncology at Boston Children's Hospital, as well as a postdoctoral fellowship at the Massachusetts Institute of Technology. She is board certified in Pediatrics and in Pediatric Hematology/Oncology, and is a fellow of the American Academy of Pediatrics. Her previous faculty appointments include:</p>
<ul>
<li>Assistant and Associate Professor of Pediatrics at Harvard Medical School (1974-79)</li>
<li>Professor of Medicine and of Pediatrics at Mount Sinai School of Medicine (1979-92)</li>
<li>Professor of Pediatrics and of Obstetrics and Gynecology, and Chief of Pediatric Hematology/Oncology at the University of Texas Medical Branch (1992-1999)</li>
</ul>
<p>In 1999, Dr. Alter returned to Johns Hopkins to obtain an M.P.H. and then joined the Clinical Genetics Branch in September 2000. Her research interests are in cancer-prone genetic syndromes, particularly the hematologic bone marrow failure disorders. She has published more than&nbsp;300 peer-reviewed articles, books and book chapters.</p>
<h2 id="research">Research Interests</h2>
<p>Dr. Alter developed an interdisciplinary clinical research program, conducting systematic investigations of cancer in the inherited bone marrow failure syndromes (<a href="http://marrowfailure.cancer.gov/">http://marrowfailure.cancer.gov/</a>). The prototype disorder for this program is Fanconi anemia, in which there is a large excess of unusual cancers that occur at atypically early ages, including myelodysplastic syndrome, acute myeloid leukemia, and cancers of the oral cavity and oropharynx, esophagus, cervix and vulva, and liver. Other hematologic conditions with increased occurrences of specific and early cancers include dyskeratosis congenita, Diamond-Blackfan anemia, and Shwachman-Diamond syndrome. This set of disorders serves as a model for the study of mechanisms of cancer development in human populations.</p>
<p>This project involves active, protocol-driven clinical research. Investigations include surveys to determine the incidence and characteristics of cancer in each of the syndromes; case-control studies to identify additional risk factors and perhaps new cancer pathways; genotype/phenotype correlations with reference to cancer susceptibility; heterozygote surveys with regard to the possible relation between the carrier state and cancer; and biologic studies of the tumors to determine their resemblance to their counterparts in the general population. The patients who have these syndromes comprise a group at high risk of cancer which may be suitable for studies of cancer screening and prevention modalities.</p>
<p>This study is open for enrollment.</p>
</div>
</div>]]></body>
    <field_image_promotional>349651</field_image_promotional>
  </row>
  <row term_id="302006" id="349665" title="Joseph F. Fraumeni, Jr., M.D. " langcode="en" field_short_title="Joseph F. Fraumeni, Jr., M.D. " field_page_description="Joseph F. Fraumeni, Jr., M.D., biographical sketch" field_feature_card_description="Joseph F. Fraumeni, Jr., M.D., biographical sketch" field_list_description="Joseph F. Fraumeni, Jr., M.D., biographical sketch&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2017-07-27" field_pretty_url="fraumeni-joseph" field_browser_title="Joseph F. Fraumeni, Jr., M.D., biographical sketch" field_card_title="Joseph F. Fraumeni, Jr., M.D. " field_email_address="fraumeni@nih.gov" field_first_name="Joseph" field_last_name="Fraumeni" field_org_name_1="National Cancer Institute" field_org_name_2="Office of the Director" field_campus="300">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Fraumeni+JF&amp;authorOption=exact&amp;pi=0010037247">Scientific Publications</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Joseph Fraumeni received an A.B. degree from Harvard College, an M.D. from Duke University, and an M.Sc. in epidemiology from the Harvard School of Public Health. After completing a medical residency at Johns Hopkins Hospital and the Memorial Sloan-Kettering Cancer Center, he joined the Epidemiology Branch of the National Cancer Institute as a commissioned officer in the U.S. Public Health Service in 1962.&nbsp; He became head of the Ecology Studies Section in 1966, Chief of the Environmental Epidemiology Branch in 1975, Director of the Epidemiology and Biostatistics Program in 1979, and founding Director of the Division of Cancer Epidemiology and Genetics in 1995. He retired in 2017 and was named Scientist Emeritus. Dr. Fraumeni has authored or co-authored more than 900 scientific publications, and was an editor with David Schottenfeld of the first three editions of <em>Cancer Epidemiology and Prevention,</em> Oxford University Press.</p>
<p>In recognition of his research accomplishments, Dr. Fraumeni has received numerous honors, including the Abraham Lilienfeld Award from the American College of Epidemiology, John Snow Award from the American Public Health Association, James D. Bruce Award from the American College of Physicians, Nathan Davis Award from the American Medical Association, Charles S. Mott Prize from the General Motors Cancer Research Foundation, Medal of Honor from the International Agency for Research on Cancer and the American Cancer Society, as well as a Lifetime Achievement Award from the American Association for Cancer Research. Recently, the American Society of Preventive Oncology renamed its Distinguished Career Achievement Award as the Joseph F. Fraumeni, Jr., Award for Distinguished Achievement. Dr. Fraumeni is also an elected member of the National Academy of Sciences, the National Academy of Medicine, the Association of American Physicians, and the American Academy of Arts and Sciences.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Over a career spanning more than 50 years at NIH, Dr. Fraumeni shaped and directed a national and international research program designed to identify the environmental and genetic determinants of cancer and the means of prevention. His personal research focused on genetic susceptibility to cancer, particularly by investigating familial aggregations of various malignancies. Most notable was his discovery in 1969, with fellow NCI researcher Frederick P. Li, of a rare, inherited syndrome featuring an array of multiple cancers in young people that came to be known as Li-Fraumeni syndrome. This observation eventually led to collaborative molecular studies that uncovered inherited mutations in the <em>TP53</em> tumor suppressor gene.</p>
<p>Another theme of Dr. Fraumeni&rsquo;s research has been the search for lifestyle and other environmental causes of cancer. In 1975, he led the development of the first in a series of computer-generated maps depicting the geographic variation of U.S. cancer mortality at the county level. This work allowed Dr. Fraumeni and his colleagues to identify previously undetected exposures driving the distinctive patterns of certain malignancies, such as lung, oral, and bladder cancers, followed by preventive interventions in high-risk populations. This strategy was later applied in China, where a series of collaborative studies were conducted in areas with exceptionally high mortality from esophageal, stomach, lung, and other cancers.</p>
<p>Dr. Fraumeni&rsquo;s more recent work has centered on the integration of genomic, metabolomic and other high-throughput technologies in large-scale consortial studies with replication strategies designed to identify with some precision the carcinogenic risks and biological underpinnings that may inform new clinical and public health interventions.</p>
<div class="callout-box center">
<h3>Insights and Views on Cancer Epidemiology by Dr. Fraumeni</h3>
<p><b>Read:</b> <a href="http://www.ncbi.nlm.nih.gov/pubmed/24076995">A conversation with Joseph F. Fraumeni, Jr. - interviewed by Robert N. Hoover</a><br />From the <i>VOICES</i> project of <i>Epidemiology</i>, November 2013</p>
<p><b>Watch:</b> <a href="http://dceg.cancer.gov/news-events/events/fraumeni-schottenfeld-panel-discussion-video">Cancer Epidemiology over the Last Half-Century and Thoughts on the Future</a><br />A Panel Discussion with Dr. David Schottenfeld</p>
<p><b>View:</b> <a href="http://videocast.nih.gov/summary.asp?Live=12184&amp;bhcp=1">Genes and the Environment in Cancer Causation</a><br />3rd Annual Alan S. Rabson Award Lecture for Intramural Research</p>
</div>
</div>
</div>]]></body>
    <field_image_promotional>349665</field_image_promotional>
  </row>
  <row term_id="302006" id="349678" title="Ethel S. Gilbert, Ph.D. " langcode="en" field_short_title="Ethel S. Gilbert, Ph.D. " field_page_description="Ethel S. Gilbert, Ph.D., biographical sketch and research interests" field_feature_card_description="Ethel S. Gilbert, Ph.D., biographical sketch and research interests" field_list_description="Ethel S. Gilbert, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-06" field_pretty_url="gilbert-ethel" field_browser_title="Ethel S. Gilbert, Ph.D., biographical sketch and research interests" field_card_title="Ethel S. Gilbert, Ph.D. " field_email_address="gilberte@mail.nih.gov" field_first_name="Ethel" field_last_name="Gilbert" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=gilbert%20e&amp;authorOption=exact&amp;pi=0010141178">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7252414" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103" sys_siteid="475">Radiation Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Ethel S. Gilbert received a B.A. in mathematics from Oberlin College and an M.P.H. and Ph. D. in biostatistics from the University of Michigan. She spent several years as a senior staff scientist at Battelle Pacific Northwest National Laboratory, where her research focused on epidemiologic studies of nuclear workers and on analyzing data from experimental animal studies, and also spent a year at the Radiation Effects Research Foundation in Hiroshima, Japan. Dr. Gilbert joined the NCI in 1996 as an Expert and received the NIH Merit Award in 2003. Dr. Gilbert is a fellow of the American Statistical Association and an honorary member of the National Council on Radiation Protection and Measurements. She was a member of the National Academy of Sciences BEIR VII Committee on Health Risks from Exposure to Low Levels of Ionizing Radiation, and was also a member of the study group for the 15-country nuclear worker study. Dr. Gilbert became a special volunteer in 2018.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Evaluating carcinogenic risk from protracted radiation exposure in nuclear workers including those at the Mayak nuclear facility in the Russian Federation</li>
<li>Developing risk models for estimating the carcinogenic risk from exposure to radiation</li>
<li>Analyzing data from both case-control and cohort studies of second cancers after radiotherapy and chemotherapy</li>
</ul>
<h3>Nuclear Worker Studies</h3>
<p class="first-graf">In most countries, exposure to nuclear workers has been deliberately limited as a protection to the worker. Thus, studies of these workers offer a direct assessment of risks from exposure to radiation at low doses and dose rates, and provide a check on A-bomb survivor-based estimates that form the basis of radiation protection standards. I have served on the main study group and also on the epidemiology and dosimetry subgroups for the planning and implementing of the 15-country nuclear worker study, which combined data on about 400,000 nuclear workers in 15 countries. Risk estimates for leukemia (excluding chronic lymphatic leukemia) and all cancers excluding leukemias were compatible with those that provide the basis for radiation protection standards, but confidence intervals were wide.</p>
<p>In collaboration with Russian scientists, NCI is conducting epidemiologic studies of workers at the Mayak weapons production plant in the South Ural Mountains in the Russian Federation. These studies provide information on protracted radiation exposure at much larger doses than in worker studies in other countries, and also provide the only reliable direct information on risks from plutonium exposure. Dose-response relationships for exposure to plutonium were demonstrated for mortality from cancers of the lung, liver, and bone, the three major sites of plutonium deposition. Dose-response relationships for external radiation exposure were demonstrated for mortality from leukemia; lung cancer, and all cancers other than lung, liver, and bone cancer. Further analyses of other site-specific cancers are underway.</p>
<h3>Radiation Risk Assessment</h3>
<p class="first-graf">I have been involved in several efforts to estimate radiation risks and their dependence on dose, gender, age, and other factors. These include serving as a member of the National Research Council&rsquo;s BEIR VI Committee (concerned with risks from exposure to radon), of the National Research Council&rsquo;s BEIR VII Committee (concerned with low dose exposure to low-LET radiation), and of the NCI-CDC Working Group to revise the 1985 NIH Radioepidemiological Tables.</p>
<h3>Second Cancer Studies</h3>
<p class="first-graf">I have analyzed data from both cohort and case-control studies to evaluate risk of second cancers in cancer survivors. In an international case-control study of lung cancer following Hodgkin lymphoma (HL), lung cancer risk increased with both increasing radiation dose, and with increasing number of cycles of chemotherapy involving alkylating agents. In addition, the combined effects of radiation dose and therapy with alkylating agents were estimated to be almost exactly additive whereas the combined effect of radiation and smoking was better described by a multiplicative relationship. In a similarly designed international case-control study of breast cancer following HL that was diagnosed under age 30, risk increased with increasing radiation dose, but treatment with either alkylating agent chemotherapy or receiving a dose to the ovaries that exceeded 5 Gy reduced both the overall risk of breast cancer and the slope of the radiation dose-response. I have also analyzed data from cohort studies of both testicular cancer and HL survivors. Although these cohorts lack detailed treatment information, they provide information on which site-specific cancers show elevated rates, and also on the temporal patterns of risk and the dependence of risk on sex, age at exposure, and attained age. I am currently involved in planning and analysis for an international study of second primary gastrointestinal cancers among survivors of Hodgkin lymphoma and cancers of the testis, breast, and cervix.</p>
</div>
</div>]]></body>
    <field_image_promotional>349678</field_image_promotional>
  </row>
  <row term_id="302006" id="349681" title="Susan Shaw Devesa, M.H.S., Ph.D. " langcode="en" field_short_title="Susan Shaw Devesa, M.H.S., Ph.D. " field_page_description="Susan Shaw Devesa, M.H.S., Ph.D., biographical sketch and research interests " field_feature_card_description="Susan Shaw Devesa, M.H.S., Ph.D., biographical sketch and research interests " field_list_description="Susan Shaw Devesa, M.H.S., Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-02" field_pretty_url="devesa-susan" field_browser_title="Susan Shaw Devesa, M.H.S., Ph.D., biographical sketch and research interests " field_card_title="Susan Shaw Devesa, M.H.S., Ph.D. " field_email_address="devesas@mail.nih.gov" field_first_name="Susan" field_last_name="Devesa" field_phone_number="240-276-7410" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 6E216">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=devesa%20s&amp;authorOption=exact&amp;pi=0010114240">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302568" sys_dependentvariantid="1422" sys_relationshipid="7252749" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Devesa received a M.H.S. and Ph.D. in epidemiology from The Johns Hopkins School of Hygiene and Public Health. She joined the NCI in 1966, and was appointed chief of the Descriptive Studies Section in 1993. She is a Fellow of the American College of Epidemiology. She received the PHS Special Recognition Award for descriptive studies of the changing patterns of cancer in the United States, which have provided new clues to etiologic risk factors, and the NCI Division of Cancer Epidemiology and Genetics Exemplary Service Award in recognition of sustained research accomplishments and outstanding service to the Division and the National Cancer Intstitute, resulting in the advancement of the goals of the National Cancer Program.</p>
<h2 id="research">Research Interests</h2>
<p class="first-graf">We plan and conduct descriptive studies of cancer incidence and mortality in the United States and other countries, including analyses of trends in cancer rates and variations by age, sex, race and other demographic factors. Databases on deaths are used to produce maps of cancer mortality. The maps and associated descriptive and correlational studies are utilized by researchers at NCI and elsewhere to generate etiologic leads and test hypotheses through targeted studies into causes of cancer.</p>
</div>
</div>]]></body>
    <field_image_promotional>349681</field_image_promotional>
  </row>
  <row term_id="302006" id="349683" title="Maureen Hatch, M.P.H., Ph.D." langcode="en" field_short_title="Maureen Hatch, M.P.H., Ph.D." field_page_description="Maureen Hatch, M.P.H., Ph.D., biographical sketch and research interests " field_feature_card_description="Maureen Hatch, M.P.H., Ph.D., biographical sketch and research interests " field_list_description="Maureen Hatch, M.P.H., Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-06" field_pretty_url="hatch-maureen" field_browser_title="Maureen Hatch, M.P.H., Ph.D., biographical sketch and research interests " field_card_title="Maureen Hatch, M.P.H., Ph.D." field_email_address="hatchm@mail.nih.gov" field_first_name="Maureen" field_last_name="Hatch" field_phone_number="240-276-7382" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E508">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=hatch%20m&amp;authorOption=exact&amp;pi=0011253721">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7252574" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103" sys_siteid="475">Radiation Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Hatch received an M.P.H. and Ph.D. in epidemiology from Columbia University, and was on the faculty of the Columbia School of Public Health and the Mount Sinai School of Medicine. She joined NCI in May 2002, serving on the Chernobyl Research Unit and conducting research on the nuclear power plant accident at Three Mile Island. She is an elected member of the American Epidemiological Society and a Fellow of the American College of Epidemiology.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Cancer risks among workers and residents exposed to radiation as a result of the 1986 accident at the Chernobyl Nuclear Power Plant.</li>
<li>In particular, Dr. Hatch is interested in studying thyroid disease among those who were <i>in utero</i> when the accident occurred.</li>
<li>Women's health (reproduction, thyroid disease).</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349683</field_image_promotional>
  </row>
  <row term_id="302006" id="349690" title="Kiyohiko Mabuchi, M.D., Dr.P.H. " langcode="en" field_short_title="Kiyohiko Mabuchi, M.D., Dr.P.H. " field_page_description="Kiyohiko Mabuchi, M.D., Dr.P.H., biographical sketch and research interests " field_feature_card_description="Kiyohiko Mabuchi, M.D., Dr.P.H., biographical sketch and research interests " field_list_description="Kiyohiko Mabuchi, M.D., Dr.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-07" field_pretty_url="mabuchi-kiyohiko" field_browser_title="Kiyohiko Mabuchi, M.D., Dr.P.H., biographical sketch and research interests " field_card_title="Kiyohiko Mabuchi, M.D., Dr.P.H. " field_email_address="km221v@nih.gov" field_first_name="Kiyohiko" field_last_name="Mabuchi" field_phone_number="240-276-7392" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E534">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=mabuchi%20k&amp;authorOption=exact&amp;pi=0010388656">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_contentid="302459" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7252591">Radiation Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Mabuchi, senior scientist in REB, is engaged in epidemiological studies of thyroid disease and leukemia risks following the Chernobyl nuclear reactor accident and the continuing follow-up studies of cancer in the Japanese atomic-bomb survivors. He received an M.D. from Osaka University Medical School, and an M.P.H. / Dr.PH. from the John Hopkins University School of Hygiene and Public Health. He joined the DCEG Radiation Epidemiology Branch in 2000 after serving as Chief of the Department of Epidemiology at the Radiation Effects Research Foundation, Hiroshima, Japan, where he led the long-term epidemiological studies of health effects of radiation exposure in cohorts of atomic bomb survivors and their children. Dr. Mabuchi then served as Deputy Branch Chief from 2002&ndash;2014. He has been a member of several international radiation committees, including the International Commission of Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), UK National Radiological Protection Board&rsquo;s Advisory Group on Ionizing Radiation and also formerly a member of the Executive Committee of the International Association of Cancer Registries.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Cancer risks associated with exposure to ionizing radiation and how the radiation-related risks are modified by modes of exposure and other factors including age, gender, time as well as other host and carcinogenic factors.</li>
<li>The risk and dose-response for chronic diseases other than cancer associated with exposure to ionizing radiation.</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349690</field_image_promotional>
  </row>
  <row term_id="302006" id="349694" title="Allan Hildesheim, Ph.D. " langcode="en" field_short_title="Allan Hildesheim, Ph.D. " field_page_description="Allan Hildesheim, Ph.D., biographical sketch and research interests" field_feature_card_description="Allan Hildesheim, Ph.D., biographical sketch and research interests" field_list_description="Allan Hildesheim, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-12" field_pretty_url="hildesheim-allan" field_browser_title="Allan Hildesheim, Ph.D., biographical sketch and research interests" field_card_title="Allan Hildesheim, Ph.D. " field_email_address="hildesha@mail.nih.gov" field_first_name="Allan " field_last_name="Hildesheim" field_phone_number="240-276-7101" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E102">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=hildesheim%20a&amp;authorOption=exact&amp;pi=0010163561">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=56&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_contentid="302590" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302590" sys_dependentvariantid="1422" sys_relationshipid="7280835">Infections and Immunoepidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Hildesheim received his Ph.D. in epidemiology from The Johns Hopkins School of Hygiene and Public Health in 1991 and has been at the NCI since 1987. He was Chief of the Infections and Immunoepidemiology Branch from 2008&ndash;2017. Dr. Hildesheim's research focuses on understanding host and viral factors involved in the pathogenesis of DNA virus-related tumors and in translating etiological findings to practical public health measures aimed at reducing morbidity and mortality associated with virus-related tumors.</p>
<h2 id="research">Research Interests</h2>
<p class="first-graf">Dr. Hildesheim conducts large-scale population studies to investigate exogenous and host factors involved in the pathogenesis of DNA virus-related tumors. He investigates two groups of tumors&mdash;nasopharyngeal cancer (NPC) linked to Epstein-Barr virus (EBV) and female gynecological cancers linked to human papillomavirus (HPV). Both viral and non-viral factors hypothesized to be involved in the pathogenesis of EBV- and HPV-related cancers are examined, since infection alone is rarely sufficient for the development of cancer. Dr. Hildesheim is also the co-lead on studies to evaluate the long-term impact of HPV vaccination and the immunological markers of long-term vaccine efficacy.</p>
<h3><strong>Nasopharyngeal Cancer</strong></h3>
<p class="first-graf">Nasopharyngeal cancer has a very distinct geographic and ethnic distribution, occurring at high rates among ethnic Chinese from southeastern China and at much lower rates among Caucasians. While infection with EBV is believed to be necessary for development of the cancer, both genetic and exogenous factors are also thought to be important. Dr. Hildesheim is the lead NCI investigator on several studies of NPC in Taiwan and collaborates with investigators in China and other countries on studies of NPC.&nbsp; His recent focus in this area has been on the evaluation of EBV-based markers that might be useful to risk stratify individuals at high risk of familial and sporadic NPC and to better understand specific genetic factors associated with the development of NPC.</p>
<h3>HPV Vaccines</h3>
<p>HPV vaccines designed to prevent infection and associated lesions associated with oncogenic HPV types 16 and 18 have been licensed in many countries. These vaccines have the potential to profoundly impact cervical cancer prevention strategies, and if applied wisely, to reach underserved populations that have historically not benefited from secondary prevention programs based on Pap smears. Dr. Hildesheim is the co-lead NCI investigator on a 7,465 women community-based HPV 16/18 vaccine trial in Costa Rica. Initiated in 2004, this trial is designed to evaluate the safety and efficacy of the HPV 16/18 vaccine, to examine broader questions of long-term population impact of vaccination, and to explore cost-effective ways in which HPV-based vaccination and screening might be applied in the future. The trial involves active follow-up of participants and includes a rich biological specimen collection component that allows for the added evaluation of numerous scientific questions of etiological and immunological interest.</p>
<p>Dr. Hildesheim is also a co-investigator on a 24,000 women community-based trial underway in Costa Rica to formally evaluate whether a single dose of two commercially available vaccines (GARDASIL<sup>&reg;</sup> 9 and Cervarix<sup>&reg;</sup>) is non-inferior to a multi-dose regimen for these same vaccines. The results of this later trial have the potential to simplify HPV vaccine delivery programs, thereby making cervical cancer control more achievable in low resource countries with high cervical cancer burden.</p>
</div>
</div>]]></body>
    <field_image_promotional>349694</field_image_promotional>
  </row>
  <row term_id="302006" id="492224" title="Bin Zhu, Ph.D." langcode="en" field_short_title="Bin Zhu, Ph.D." field_page_description="Bin Zhu, Ph.D., biographical sketch and research interests" field_feature_card_description="Bin Zhu, Ph.D., biographical sketch and research interests" field_list_description="Bin Zhu, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2013-01-17" field_date_reviewed="2013-01-17" field_date_updated="2013-01-17" field_pretty_url="bin-zhu" field_browser_title="Bin Zhu, Ph.D., biographical sketch and research interests" field_card_title="Bin Zhu, Ph.D." field_email_address="zhub@mail.nih.gov" field_first_name="Bin" field_last_name="Zhu" field_phone_number="240-276-7420" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E618">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=BB&amp;searchTxtAuth=Zhu+B&amp;authorOption=exact&amp;pi=2001038043">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_relationshipid="7252389" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<a id="Biography"></a>
<h3>Biography</h3>
<p>Dr. Zhu received a Ph.D. in biostatistics from the University of Michigan in 2010 and then spent two years as a post-doctoral associate at the Department of Statistical Science and the Center for Human Genetics at Duke University. He joined the Biostatistics Branch of DCEG in 2012 as a tenure-track investigator.</p>
<a id="Research Interests"></a>
<h3>Research Interests</h3>
<p>Developing and applying novel statistical methods to increase understanding of biological mechanisms underlying complex diseases, and studing the pattern and determinants of disease in human population. The primary foci of current research include:</p>
<ul>
<li>Functional data analysis for time series and longitudinal data, and its applications to oncology, proteomics and epidemiology</li>
<li>Statistical genetics in admixture mapping, copy number variation, recombination hotspot identification, genome-wide association study and next-generation sequencing data</li>
<li>Nonparametric Bayes and Bayesian variable selection for large-scale and high-dimensional complex data</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>492224</field_image_promotional>
  </row>
  <row term_id="302006" id="936140" title="Jennifer K. Loukissas, M.P.P." langcode="en" field_short_title="Jennifer K. Loukissas, M.P.P." field_page_description="Jennifer K. Loukissas, M.P.P., biosketch and professional background" field_feature_card_description="Jennifer K. Loukissas, M.P.P., biosketch and professional background" field_list_description="Jennifer K. Loukissas, M.P.P., biosketch and professional background&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-04-13" field_date_reviewed="2015-04-13" field_date_updated="2015-04-13" field_pretty_url="loukissas-jennifer" field_browser_title="Jennifer K. Loukissas, M.P.P., biosketch and professional background" field_card_title="Jennifer K. Loukissas, M.P.P." field_email_address="loukissj@mail.nih.gov" field_first_name="Jennifer" field_last_name="Loukissas" field_phone_number="240-276-7367" field_org_name_1="National Cancer Institute" field_org_name_2="Office of the Director" field_campus="300" field_office_location="Room 7E-434">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<p>Jennifer Loukissas serves as the Chief of the Communications&nbsp;team&nbsp;in&nbsp;the National Cancer Institute&rsquo;s Division of Cancer Epidemiology and Genetics. Ms. Loukissas helps DCEG investigators and trainees to transmit their research findings to a variety of lay audiences including news media, research advocates, general public, the United States Congress, and other governmental agencies.</p>
<p>Ms. Loukissas manages the Division&rsquo;s web and social media presence, and serves as senior managing editor for the <i>Linkage</i> newsletter. Equally important is her management of crisis communications for the Division. She also regularly delivers training on communicating science to investigators and trainees in NIH and academia. Ms. Loukissas is an award-winning science writer with 15 years of experience in public affairs. She came to the NIH in 2002 as Presidential Management Intern following receipt of a Master's Degree in Public Policy from Duke University; she holds a Bachelor of Arts in English from Haverford College.</p>
<p>Follow Ms. Loukissas on Twitter: <a href="https://twitter.com/jloukissas">@jloukissas</a>.</p>
</div>
</div>]]></body>
    <field_image_promotional>936140</field_image_promotional>
  </row>
  <row term_id="302006" id="974580" title="Sarah Locke, M.S., M.S.P.H." langcode="en" field_short_title="Sarah Locke, M.S., M.S.P.H." field_page_description="Sarah Locke, M.S., M.S.P.H., biographical sketch and research interests " field_feature_card_description="Sarah Locke, M.S., M.S.P.H., biographical sketch and research interests " field_list_description="Sarah Locke, M.S., M.S.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-07-08" field_date_reviewed="2015-07-08" field_date_updated="2015-07-08" field_pretty_url="sarah-locke" field_browser_title="Sarah Locke, M.S., M.S.P.H., biographical sketch and research interests " field_card_title="Sarah Locke, M.S., M.S.P.H." field_email_address="lockesj@mail.nih.gov" field_first_name="Sarah" field_last_name="Locke" field_phone_number="240-276-7263" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E608">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research">Research Interests</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7252800" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p class="first-graf">Ms. Locke received a Master&rsquo;s of Science in entomology from the University of California, Davis, and a Master&rsquo;s of Science in Public Health from the University of Utah. She became a board-certified industrial hygienist in 1996.&nbsp;Ms. Locke&nbsp;joined the Occupational and Environmental Epidemiology Branch (OEEB) in 2010 as an occupational hygiene specialist and became Assistant Branch Chief in 2016. Ms. Locke&rsquo;s research focuses on characterizing occupational exposure for participants in epidemiologic studies of cancer. Before joining NCI, she spent 10 years as a senior industrial hygienist and project manager at the research corporation, Westat. Prior to that, she worked as an industrial hygiene consultant and field industrial hygienist, where she conducted exposure assessments in manufacturing, mining, construction, commercial, and residential settings.<o:p></o:p></p>
<h2><a id="Research"></a>Research Interests</h2>
<ul>
<li>Identifying, extracting, and synthesizing exposure-related information from the published and grey literature for use in reconstructing occupational exposures to lead in U.S. industry. This information includes historical changes in lead production, consumption and use patterns.</li>
<li>Developing novel retrospective exposure assessment methods to efficiently evaluate and estimate historical workplace exposures in epidemiologic studies of cancer.</li>
<li>Working on the design and implementation of field sampling strategies for prospective studies characterizing exposures and identifying key exposure determinants.</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>974580</field_image_promotional>
  </row>
  <row term_id="302006" id="1027736" title="Michael L. Nickerson, Ph.D." langcode="en" field_short_title="Michael L. Nickerson, Ph.D." field_page_description="Michael Nickerson, Ph.D., biographical sketch and research interests " field_feature_card_description="Michael Nickerson, Ph.D., biographical sketch and research interests " field_list_description="Michael Nickerson, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-11-25" field_date_reviewed="2015-11-25" field_date_updated="2015-11-25" field_pretty_url="nickerson-michael" field_browser_title="Michael Nickerson, Ph.D., biographical sketch and research interests " field_card_title="Michael L. Nickerson, Ph.D." field_email_address="nickersonml@od.nih.gov" field_first_name="Michael" field_last_name="Nickerson" field_phone_number="301-451-2724" field_org_name_1="National Cancer Institute" field_org_name_2="Laboratory of Translational Genomics" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield"><a id="Top"></a>
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Nickerson+ML&amp;authorOption=exact&amp;pi=0010299609&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302432" sys_dependentvariantid="1422" sys_relationshipid="7252614" sys_variantid="1422" sys_contentid="302432">Laboratory of Translational Genomics</a></li>
</ul>
<h2 id="Biography"><a id="Biography"></a>Biography</h2>
<p>Dr. Nickerson obtained a bachelor&rsquo;s degree in biology with honors from the St. Mary&rsquo;s College of Maryland in 1985; a master&rsquo;s degree in biochemistry from the State University of New York at Stony Brook in 1987; and a Ph.D. in molecular medicine from the George Washington University, Washington, D.C. in 2010. He has studied families with inherited clear cell, papillary, and chromophobe kidney cancer with Berton Zbar, M.D., at the National Cancer Institute (NCI) in Frederick, in collaboration with Marston Linehan, M.D., NCI in Bethesda. He left the NIH to serve as Director of the Genome Research Division at Transgenomic, Inc., where he conducted genetic analyses of <em>KRAS</em> and <em>EGFR</em> in tumors from lung cancer patients participating in clinical trials examining targeted therapy treatment. He joined DCEG in 2015.</p>
<p>Dr. Nickerson has received awards from the Center of Excellence in Cancer Biology and Genomics, two NCI Major Opportunities for Clinical Cancer Research, and an NCI Director&rsquo;s Intramural Innovation Award in 2013.</p>
<h2 id="Research-Interests"><a id="Research-Interests"></a>Research Interests</h2>
<h3>Urologic Cancer Genetics</h3>
<p>My goal is to comprehensively identify clinically relevant variation associated with urologic cancers (bladder, kidney, and prostate) that improves our understanding and diagnosis of disease and&nbsp;that can be utilized as clinical biomarkers in clinical trials. Seminal research accomplishments to date include:</p>
<ul>
<li>Lead author on the discovery of the <i>Birt-Hogg-Dub&eacute;</i> gene altered in families with inherited chromophobe kidney cancer, pneumothorax, and Birt-Hogg-Dub&eacute; Syndrome, characterized by benign fibrofolliculomas in hair follicles.</li>
<li>Developed a Sanger sequencing and analysis pipeline utilized to successfully identify a mutation in the <em>Dead-end</em> gene causal for testicular teratomas (germ cell tumors) in the Ter (teratoma) mouse; and mutations in the <i>MET</i> oncogene and fumarate hydratase in families with inherited papillary type I and II kidney cancer.</li>
<li>Senior author on the discovery of alterations in the UbiA prenyltransferase domain 1 (<i>UBIAD1</i>) gene in families with Schnyder Corneal Dystrophy.</li>
<li>Lead author on a study demonstrating improved detection of von Hippel-Lindau (<i>VHL</i>) gene alterations in 91% of sporadic clear cell kidney tumors that identified distinct tumor subsets with <i>VHL</i> sequence alterations or promoter hypermethylation.</li>
<li>Lead author on an exome sequencing study of prostate tumors that identified germline and somatic cancer gene alterations that were sequentially acquired during progression to metastatic disease.&nbsp;Led efforts to identify somatic and rare germline alterations in the methylcytosine dioxygenase <em>TET2</em> in families with prostate cancer and in sporadic patient tumors.</li>
<li>Lead author on an exome sequencing study of bladder tumors that identified somatic, nonsynonymous <em>BRCA1</em>-associated protein 1 (<em>BAP1</em>) alterations&nbsp;that contributed&nbsp;to a high prevalence of <em>BRCA</em> pathway defects in bladder cancer. These findings have since been confirmed by additional laboratories and the TCGA project and form the basis for a clinical trial that will be initiated in 2016.</li>
</ul>
<h4>Genetics of Bladder Cancer</h4>
<p>Lead or co-author on four publications describing next-generation sequencing (NGS) of bladder tumors in U.S. and Chinese patients. A 2014 study showed somatic, nonsynonymous alterations in the deubiquitinating enzyme, BAP1, were correlated with papillary tumor histology and contributed to a high frequency of <em>BRCA</em> pathway alterations and showed telomerase (<em>TERT</em>) was the most frequently altered gene by somatic and germline promoter mutations in 69% and 56% of tumors, respectively. Another study describes cancer gene alterations in 25 bladder cell lines and frequent, homozygous loss of the MTA phosphorylase, <em>MTAP</em>.</p>
<h4>Genetics of Prostate Cancer</h4>
<p>In an NGS study of prostate cancer (PCa), I characterized the accumulation of somatic alterations during progression of disease. An index patient inherited a deleterious <em>BRCA1</em> p.E23Rfs (rs80357713) and the remaining wild-type allele was lost in metastatic tumors. Copy number analysis of whole genome Helicos NGS identified a somatic deletion between <em>TMPRSS2</em> and <em>ERG</em>, which gave rise to a <em>TMPRSS2</em>-<em>ERG</em> fusion transcript.&nbsp;Additionally in metastatic tumors, an additional somatic frameshift truncated the remaining <em>TMPRSS2</em> allele. Somatic missense mutations were observed in epigenetic-associated <em>polybromo 1</em> (<em>PBRM1</em>) and the <em>ten-eleven translocation 2</em> (<em>TET2</em>) in the primary tumor and metastatic tumors, respectively. Additional somatic <em>TET2</em> sequence and copy number alterations were observed in metastatic tumors from additional patients, which were accompanied by complex combinations of nonsynonymous germline alterations. More recent work with collaborators has identified <em>TET2</em> binding partners with roles in androgen signaling and the enrichment of rare germline variants in families with inherited PCa.</p>
<h4>Genetics of Kidney Cancer</h4>
<p>Studies of kidney cancer genetics initiated by Dr. Nickerson have been conducted with collaborators from the NCI Urologic Oncology Branch and the NCI DCEG that examined somatic alterations associated with clear cell RCC. Current studies are in progress to examine somatic cancer gene alterations that may be associated with exposure, lifestyle, clinical factors, response to therapy and overall survival (manuscript in preparation). I am a member of the Cancer Genome Atlas (TCGA) pan-kidney and pan-urology working groups.</p>
<h4>Clinical Trials</h4>
<ol>
<li>A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer. Study Director: Paula O'Connor, M.D., Genentech. My team conducted molecular genetics analyses to characterize mutations in the <em>epidermal growth factor receptor</em> (<em>EGFR</em>) and <em>KRAS</em> in ~550 tumors, and their association with response to therapy. ClinicalTrials.gov Identifier: NCT00130728.</li>
<li>A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS). Study Director: Donald Strickland, M.D., Genentech. My team conducted molecular genetics analyses to characterize mutations in <em>EGFR</em> and <em>KRAS</em> in ~650 non-small cell lung cancer tumors and their association with response to therapy. ClinicalTrials.gov Identifier: NCT00257608.</li>
<li>Examined cancer gene alterations in ~350 clear cell kidney tumors for an association with response to Avastin, in collaboration with the Cancer and Leukemia Group B, Phil Febbo, M.D. (Chief Scientific Officer, Genomic Health; and the University of California, San Francisco) and the NCI DCEG Cancer Genomics Research Laboratory.</li>
<li>Initiated a clinical trial examining the efficacy of a PARP inhibitor, Olaparib (Astra Zeneca), in patients with BRCA pathway-defective bladder tumors in collaboration with Drs. Andrea Apollo, NCI, and Tom Flaig and Dan Theodorescu, University of Colorado at Denver. Patient recruitment should begin in 2016.</li>
</ol>
</div>
</div>]]></body>
    <field_image_promotional>1027736</field_image_promotional>
  </row>
  <row term_id="302006" id="1034208" title="Roni Falk, M.S." langcode="en" field_short_title="Roni Falk, M.S." field_page_description="Roni Falk, M.S., biographical sketch and research interests " field_feature_card_description="Roni Falk, M.S., biographical sketch and research interests " field_list_description="Roni Falk, M.S., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-01-21" field_date_reviewed="2016-01-21" field_date_updated="2016-01-21" field_pretty_url="falk-roni" field_browser_title="Roni Falk, M.S., biographical sketch and research interests " field_card_title="Roni Falk, M.S." field_email_address="falkr@mail.nih.gov" field_first_name="Roni" field_last_name="Falk" field_phone_number="240-276-7329" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E344">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=Falk+R&amp;authorOption=exact&amp;pi=0010046508">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7252751" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2 id="Biography"><a id="Biography"></a>Biography</h2>
<p>Ms. Falk joined the Epidemiology and Biostatistics Program in 1983 after receiving a M.S. degree in epidemiology and biostatistics from Georgetown University. Since that time, she has been involved in efforts to incorporate the study of molecular markers into large-scale epidemiologic studies, particularly in the area of hormonal carcinogenesis.&nbsp;Ms. Falk's&nbsp;early efforts to systematically evaluate the performance of laboratory assays influenced the direction of the program&rsquo;s research efforts in hormonal carcinogenesis. Her methods have since been used as a model to evaluate the feasibility of incorporating new molecular markers into epidemiologic studies.</p>
<p>With her longstanding interest in the role of steroid sex hormones in carcinogenesis, Ms. Falk has been involved in many studies throughout the Division evaluating circulating hormones and cancer risk. She has also played a key role in establishing a laboratory dedicated to developing reliable methods for measuring unique panels of estrogen, androgen and progesterone metabolites using state-of-the-art technology. Ms. Falk has guided all aspects of the design, implementation, and oversight of the laboratory component of many large epidemiologic studies of biomarkers such as estrogens, androgens, growth factors, vitamin D, cytokines, angiogenic factors and adipokines. She received an NIH Merit Award in 2009.</p>
<h2 id="Research-Interests"><a id="Research-Interests"></a>Research Interests</h2>
<ul>
<li>Understand the underlying biologic mechanisms linking sex hormones to cancer risk</li>
<li>Clarify whether known preventive measures/behaviors that reduce risk do so by favorably altering the hormonal milieu</li>
<li>Identify new preventive efforts or behaviors that favorably alter circulating hormones</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>1034208</field_image_promotional>
  </row>
  <row term_id="302006" id="1052539" title="Maria Constanza Camargo, Ph.D." langcode="en" field_short_title="Maria Constanza Camargo, Ph.D." field_page_description="Maria Constanza Camargo, Ph.D., biographical sketch and research interests" field_feature_card_description="Maria Constanza Camargo, Ph.D., biographical sketch and research interests" field_list_description="Maria Constanza Camargo, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-06-13" field_date_reviewed="2016-06-13" field_date_updated="2016-06-13" field_pretty_url="Camargo-Maria" field_browser_title="Maria Constanza Camargo, Ph.D., biographical sketch and research interests" field_card_title="Maria Constanza Camargo, Ph.D." field_email_address="camargomc@mail.nih.gov" field_first_name="Maria Constanza" field_last_name="Camargo" field_phone_number="240-276-7175" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E338">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Camargo%20MC&amp;authorOption=exact&amp;pi=0013919339%20">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7252519" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422">Metabolic Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Camargo earned an M.S. in epidemiology from the School of Public Health in Mexico, an M.H.A degree from the Pontificia Universidad Javeriana in Colombia, and a Ph.D. in public health with concentration in epidemiology from the University of Illinois at Chicago. She conducted her dissertation work at the Infections and Immunoepidemiology Branch (IIB) on the role of Epstein-Barr virus infection in gastric carcinogenesis. She joined IIB as a postdoctoral fellow in 2010 and became an Earl Stadtman Tenure-Track Investigator in the Metabolic Epidemiology Branch (MEB) in 2016.</p>
<p>Prior to joining NCI, Dr. Camargo was a member of the research group led by Dr. Pelayo Correa, first at Louisiana State University and then at Vanderbilt University, studying gastric cancer and its primary risk factor, <em>Helicobacter pylori</em> infection.</p>
<h2><a id="Research Interests"></a>Research Interests</h2>
<h3><em>H. pylori</em> and Gastric Cancer</h3>
<p>Gastric cancer is the third leading cause of cancer death worldwide. Dr. Camargo maintains a robust research program with a multidisciplinary team of international collaborators applying cutting edge molecular epidemiology to the study of <em>H. pylori</em>, premalignant and malignant gastric lesions.</p>
<p>As a co-PI with <a href="http://dceg.cancer.gov/about/staff-directory/biographies/A-J/rabkin-charles"></a><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349628" sys_contentid="349628" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7252520" sys_siteid="475" rxinlineslot="103" sys_dependentid="349628" sys_dependentvariantid="1965">Charles Rabkin, M.D.</a>, senior investigator in IIB, Dr. Camargo recently launched the <em>H. pylori</em> Genome Project (HpGP). The HpGP will establish a large-scale international biobank of clinically annotated <em>H. pylori</em> strains for molecular studies addressing the role of bacterial diversity in the gastric cancer cascade. For this important initiative, Dr. Camargo has partnered with investigators from the Division of Gastroenterology at Vanderbilt University.</p>
<p>Dr. Camargo is currently planning a new field effort aimed to elucidate the risk factors for advanced premalignant lesions, and potential non-invasive biomarkers for risk stratification in high-risk populations in Latin America, Eastern Europe and Eastern Asia.</p>
<h3>Esophageal Squamous Cell Carcinoma (ESCC)</h3>
<p>As a smaller research effort, Dr. Camargo is collaborating with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349670" sys_contentid="349670" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7252522" sys_siteid="475" rxinlineslot="103" sys_dependentid="349670" sys_dependentvariantid="1965">Sandy Dawsey, M.D.</a> and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=49&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349612" sys_contentid="349612" inlinetype="rxhyperlink" sys_variantid="1965" sys_relationshipid="7252521" sys_siteid="475" rxinlineslot="103" sys_dependentid="349612" sys_dependentvariantid="1965">Christian Abnet, Ph.D., M.P.H.</a>, in MEB to design and conduct studies of ESCC in endemic Asian and African populations. Her research focuses on the evaluation of infections and potential biomarkers for screening.</p>
</div>
</div>]]></body>
    <field_image_promotional>1052539</field_image_promotional>
  </row>
  <row term_id="302006" id="1055695" title="Maria Isabel Achatz, M.D., Ph.D." langcode="en" field_short_title="Maria Isabel Achatz, M.D., Ph.D." field_page_description="Maria Isabel Achatz - biography and research interests" field_feature_card_description="Biography and Research Interests of Maria Isabel Achatz, M.D., Ph.D." field_list_description="Biography and Research Interests of Maria Isabel Achatz, M.D., Ph.D." field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-07-15" field_date_reviewed="2016-07-15" field_date_updated="2016-07-15" field_pretty_url="achatz-maria-isabel" field_browser_title="Maria Isabel Achatz, M.D., Ph.D. - Biography" field_card_title="Maria Isabel Achatz, M.D., Ph.D." field_email_address="mariaisabel.achatz@nih.gov " field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Achatz%20MI&amp;authorOption=exact&amp;pi=2002100012">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=42&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_relationshipid="7276796" sys_siteid="475" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<p><strong><a id="Biography"></a>Biography</strong></p>
<p>Maria Isabel Achatz received her medical degree at Faculdade de Medicina do ABC, S&atilde;o Paulo, Brazil, and completed residency training in Medical Genetics. She received a Master&acute;s Degree in Science (Oncology) at Funda&ccedil;&atilde;o Antonio Prudente, S&atilde;o Paulo, and completed her doctorate at the Universidade de S&atilde;o Paulo. Dr. Achatz joined the A.C. Camargo Cancer Center in 2003, as a clinician and researcher in oncogenetics. She is currently an adjunct investigator in the DCEG Clinical Genetics Branch, working on the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303694" sys_dependentvariantid="1418" sys_dependentid="303694" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276798" sys_variantid="1418" sys_contentid="303694">Li-Fraumeni syndrome (LFS) Study</a>.</p>
<p><strong><a id="Research Interests"></a>Research Interests</strong></p>
<p>Dr. Achatz's work as a physician-scientist is translational; she works both in clinical settings and the laboratory. In 2007, she described the high prevalence of LFS patients in Brazil due to the the founder p.R337H <em>TP53</em> germline mutation. Her primary research interests include:</p>
<ul>
<li>Clinical diagnosis and molecular basis of LFS, in particular the prevalence of the Brazilian founder mutation</li>
<li>Early detection and innovative screening methods for LFS</li>
<li>Genomic pattern and expression profile in tumors developed by carriers of germline <em>TP53</em> mutations</li>
<li>Clinical and molecular diagnosis of Xeroderma Pigmentosum syndrome</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>1055695</field_image_promotional>
  </row>
  <row term_id="302006" id="1090448" title="Jason Hoskins, Ph.D." langcode="en" field_short_title="Jason Hoskins, Ph.D." field_page_description="Jason Hoskins, Ph.D., biographical sketch and research interests" field_feature_card_description="Jason Hoskins, Ph.D., biographical sketch and research interests" field_list_description="Jason Hoskins, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-07-26" field_date_reviewed="2017-07-26" field_date_updated="2017-07-26" field_pretty_url="hoskins-jason" field_browser_title="Jason Hoskins, Ph.D., biographical sketch and research interests" field_card_title="Jason Hoskins, Ph.D." field_email_address="jason.hoskins@nih.gov" field_first_name="Jason" field_last_name="Hoskins" field_phone_number="240-760-6495" field_org_name_1="National Cancer Institute" field_org_name_2="Laboratory of Translational Genomics" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul>
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=hoskins%20j&amp;authorOption=exact&amp;pi=2000641644">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" sys_dependentvariantid="1422" sys_dependentid="302432" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252426" sys_variantid="1422" sys_contentid="302432">Laboratory of Translational Genomics</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Hoskins earned his B.S. in biochemistry in 2002 and his Ph.D. in biochemistry in 2007, both from the University of Rochester, New York. His thesis work helped establish the RNA-based toxicity of the chemotherapeutic drug 5-fluorouracil, and proposed a model mechanism for these RNA-based effects in <em>Saccharomyces cerevisae</em>. Prior to joining NCI, Dr. Hoskins served as a postdoctoral fellow in the laboratory of Charles Thornton at the University of Rochester, studying candidate compounds for the treatment of myotonic dystrophy. <br /><br />Dr. Hoskins joined the Laboratory of Translational Genomics (LTG) as a postdoctoral fellow in 2011, and became a research fellow in 2014, under the mentorship of Laufey Amundadottir, Ph.D., senior investigator, LTG. In these roles, he identified a new putative pancreatic tumor suppressor gene (<em>HNF1A</em>), and developed a molecular model explaining the risk altering effects of a germline pancreatic cancer risk variant in a large gene desert on chr13q22.1. In 2017, Dr. Hoskins was appointed as a staff scientist in the LTG, where he continues his pancreatic cancer post-GWAS functional work with an interest in applying systems biology approaches to understanding the effects of risk altering alleles in the context of complex gene regulatory programs.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<ul>
<li>Pancreatic cancer genetics</li>
<li>Gene regulatory networks</li>
<li>Systems biology</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>1090448</field_image_promotional>
  </row>
  <row term_id="302006" id="1100189" title="Tongwu Zhang, Ph.D." langcode="en" field_short_title="Tongwu Zhang, Ph.D." field_page_description="Tongwu Zhang, Ph.D., biographical sketch and research interests " field_feature_card_description="Tongwu Zhang, Ph.D., biographical sketch and research interests " field_list_description="Tongwu Zhang, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-11-14" field_date_reviewed="2017-11-14" field_date_updated="2017-11-14" field_pretty_url="zhang-tongwu" field_browser_title="Tongwu Zhang, Ph.D., biographical sketch and research interests " field_card_title="Tongwu Zhang, Ph.D." field_email_address="tongwu.zhang@nih.gov" field_first_name="Tongwu" field_last_name="Zhang" field_phone_number="240-760-6563" field_org_name_1="National Cancer Institute" field_org_name_2="Integrative Tumor Epidemiology Branch" field_campus="300" field_office_location="Room 7E218">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<p><a href="#Biography">Biography</a><br /><a href="#Research Interests">Research Interests</a><br /><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Zhang%20t&amp;authorOption=exact&amp;pi=2001062665">Scientific Publications</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_dependentvariantid="1422" sys_dependentid="302506" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252831" sys_variantid="1422" sys_contentid="302506">Integrative Tumor Epidemiology Branch</a></p>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Tongwu Zhang received his Ph.D. in bioinformatics from Zhejiang University, China, in June 2012. He conducted part of his doctoral research at the Beijing Institute of Genomics, Chinese Academy of Science, where he worked on whole-genome assembly and RNA-sequencing analysis. Prior to joining NCI, he was a visiting scholar at the King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia. Dr. Zhang joined the Laboratory of Translational Genomics (LTG) as a visiting postdoctoral fellow in July 2012, under the mentorship of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349626" sys_dependentvariantid="1965" sys_dependentid="349626" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252832" sys_variantid="1965" sys_contentid="349626">Kevin M. Brown, Ph.D</a>. He became a staff scientist in the Integrative Tumor Epidemiology Branch (ITEB) in October 2017.</p>
<p>Dr. Zhang has received several awards, including an NCI Director&rsquo;s Innovation Award in 2013, a Fellowship Achievement Award for Excellence in 2014, a 2015 DCEG Intramural Research Award, a DCEG Fellow Award for Research Excellence (DFARE) in 2016, and a winning entry in the 2016 DCEG Informatics Tool Challenge.</p>
<h2><a id="Research Interests"></a>Research Interests</h2>
<p>As a bioinformatician, Dr. Zhang has been involved in the design, application, and evaluation of new statistical methods and bioinformatics pipelines. He also performs data mining and visualization of large genetic and genomic datasets (TCGA, ICGC, GTEx, ENCODE, ExAC etc.).</p>
<p>Dr. Zhang has been conducting expression/methylation/miRNA quantitative trait loci analyses of primary cultured human melanocytes to identify and characterize susceptibility genes for nevi, pigmentation, and melanoma using data from genome-wide association studies (GWAS). In addition, he works with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=278&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302640#Choi" sys_dependentvariantid="1418" sys_dependentid="302640" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252833" sys_variantid="1418" sys_contentid="302640#choi">Jiyeon Choi, Ph.D.</a>, in Dr. Brown&rsquo;s lab, to identify functional risk variants from melanoma GWAS data using the massively-parallel reporter assays (MPRA). Future work will include the development and analysis of a GWAS of non-sun-exposed melanoma in a non-Caucasian population.</p>
<p>In collaboration with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=492224" sys_dependentvariantid="1965" sys_dependentid="492224" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252834" sys_variantid="1965" sys_contentid="492224">Bin Zhu, Ph.D.</a>, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349594" sys_dependentvariantid="1965" sys_dependentid="349594" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252835" sys_variantid="1965" sys_contentid="349594">Jianxin Shi, Ph.D.</a>, <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=21&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349649" sys_dependentvariantid="1965" sys_dependentid="349649" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252836" sys_variantid="1965" sys_contentid="349649">Joshua Sampson, Ph.D.</a>, and <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349623" sys_dependentvariantid="1965" sys_dependentid="349623" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252837" sys_variantid="1965" sys_contentid="349623">Maria Teresa Landi, Ph.D</a>., Dr. Zhang studies spatial intratumoral heterogeneity and temporal clonal evolution of non-clear-cell renal cell carcinoma, lung squamous cell carcinoma and neuroendocrine tumors via multiple region whole-genome sequencing approaches. In addition, he utilizes genomic and genetic data to characterize potential exposure-associated mutation signatures.</p>
</div>
</div>]]></body>
    <field_image_promotional>1100189</field_image_promotional>
  </row>
  <row term_id="302006" id="1113673" title="Nan Hu, M.D., Ph.D." langcode="en" field_short_title="Nan Hu, M.D., Ph.D." field_page_description="Nan Hu, M.D., Ph.D., biographical sketch and research interests" field_feature_card_description="Nan Hu, M.D., Ph.D., biographical sketch and research interests" field_list_description="Nan Hu, M.D., Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2018-04-23" field_date_reviewed="2018-04-23" field_date_updated="2018-04-23" field_pretty_url="hu-nan" field_browser_title="Nan Hu, M.D., Ph.D., biographical sketch and research interests" field_card_title="Nan Hu, M.D., Ph.D." field_email_address="Nan.Hu@nih.gov" field_first_name="Nan" field_last_name="Hu" field_phone_number="240.276.7231" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 7E236">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul>
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=hu%20n&amp;authorOption=exact&amp;pi=0010148466">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_dependentvariantid="1422" sys_dependentid="1033171" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252576" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Nan Hu received her medical degree from the Shanxi Medical College in Taiyuan China in 1976, followed by a master&rsquo;s degree in cytogenetics and medical genetics from the Beijing Medical College in 1982. After completing a doctorate in cancer genetics from the Peking Union Medical College in 1987 under the mentorship of Dr. Wu Min, she served as a postdoctoral fellow with Dr. Janet Rowley at the University of Chicago from 1987 to 1989. Dr. Hu went on to serve at NCI&mdash;first as a visiting associate from 1990 to 1991, and then as a postdoctoral fellow with Dr. Dean Hamer of NCI from 1992 to 1994. She joined the Cancer Prevention Fellowship program in 1994, earning an M.P.H. in epidemiology and biostatistics from the George Washington University in the process. Dr. Hu joined DCEG as a staff scientist in 1998, and is currently serving in the Metabolic Epidemiology Branch (MEB).</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Hu integrates her training, experience, and skill in widely-varied but complementary disciplines&mdash;molecular genetics bench work, epidemiologic field studies, and statistical analysis&mdash;to play a fundamental role in MEB&rsquo;s research on the etiology, prevention, and early detection of upper gastrointestinal cancers.</p>
</div>
</div>]]></body>
    <field_image_promotional>1113673</field_image_promotional>
  </row>
  <row term_id="302006" id="349591" title="Neil E. Caporaso, M.D. " langcode="en" field_short_title="Neil E. Caporaso, M.D. " field_page_description="Neil E. Caporaso, M.D., biographical sketch and research interests " field_feature_card_description="Neil E. Caporaso, M.D., biographical sketch and research interests " field_list_description="Neil E. Caporaso, M.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-01-30" field_pretty_url="caporaso-neil" field_browser_title="Neil E. Caporaso, M.D., biographical sketch and research interests " field_card_title="Neil E. Caporaso, M.D. " field_email_address="caporasn@mail.nih.gov" field_first_name="Neil" field_last_name="Caporaso" field_phone_number="240-276-7228" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 7E102">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=caporaso%20ne&amp;authorOption=exact&amp;pi=0010062217">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252524" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="biography"><a id="Biography"></a>Biography</h2>
<p>Dr. Caporaso received his undergraduate degree in chemistry and cell biology research and an M.S. in environmental science&nbsp;from Rutgers University, and his M.D. from the University of Medicine and Dentistry of New Jersey in 1980. After completing a residency in internal medicine in 1983, he joined the NCI as an oncology fellow in the Medicine Branch and a research fellow and biotechnology fellow in the Environmental Epidemiology Branch of NCI. In 1996, he became Chief of the Pharmacogenetics Section of the DCEG Genetic Epidemiology Branch (GEB). He served as Chief of GEB from 2011 to 2016.</p>
<p class="first-graf">Dr. Caporaso serves on the DCEG Biorepository Planning Group, the Research Evaluation Panel and Biomarker Advisory Committees of the American College of Radiology Imaging Network (ACRIN), the Steering Committee for the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Cohort Study, the Technology Planning Group for the Next Generation Cohort for DCEG, the Steering Committee of the International Lung Cancer Consortium, and the&nbsp;NCI&nbsp;Data Access Committee charged with implementing sharing of available NCI genome-wide association study data with the scientific community. Dr. Caporaso is the Genetic Epidemiology Editor of <em>Cancer Biomarkers Epidemiology and Genetics</em> and teaches at the George Washington Milken School of Public Health and the University of Maryland, as well as the Molecular Epidemiology Course in DCEG, and the Translational Research in Clinical Oncology (TRACO) course for oncology fellows at NIH.</p>
<h2 id="research"><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Caporaso has focused his research on understanding the molecular and population determinants of lung cancer and smoking. To that end, he and his colleagues designed the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=10&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303605" sys_contentid="303605" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="303605" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252525" sys_variantid="1418">EAGLE (Environment And Genetics in Lung cancer Etiology) Study, a large, population-based case-control study of lung cancer in Italy,</a> to provide a resource for descriptive, molecular, clinical outcome, and genetic/genomic studies. He incorporated novel behavioral aspects such as nicotine dependency, which has made possible a series of studies involving Time To First Cigarette (TTFC), in which he showed that short TTFC constituted a risk factor for lung cancer and later for COPD. Also, Dr. Caporaso and his colleagues have conducted a series of studies exploring biomarkers (microbiome, cytokines, metabolomics) in relation to smoking and lung cancer and plan to consolidate this work in risk model studies.</p>
<p>Dr. Caporaso&rsquo;s second major research focus involves <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302601" sys_contentid="302601" inlinetype="rxhyperlink" sys_dependentvariantid="1418" sys_dependentid="302601" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252526" sys_variantid="1418">studying the etiology of chronic lymphocytic leukemia (CLL) in familial kindreds</a>, and related hematologic and lymphoproliferative conditions including Hodgkin lymphoma, non-Hodgkin lymphoma, and Waldenstr&ouml;m macroglobulinemia, among others. Dr. Caporaso, along with his colleagues and long-time collaborators, created an international consortium that identified monoclonal B-cell lymphocytosis (MBL) as a precursor condition to CLL. Within this group, he has been conducting follow-up studies of MBL as well as other investigations involving genetic analyses (GWAS and linkage), chromosome mosaic biomarker studies, single cell analyses, and planned studies of somatic mutations.</p>
<p>In addition, Dr. Caporaso has recently begun investigating the impact of circadian disruption on cancer&nbsp;with recent publications on social jetlag and cancer, a diurnal influence on metabolomic markers, sleep studies. A study of insulin levels in relations to health markers in National Health and Nutrition Examination Survey (NHANES) is in preparation.&nbsp;</p>
</div>
</div>]]></body>
    <field_image_promotional>349591</field_image_promotional>
  </row>
  <row term_id="302006" id="349593" title="Xiaohong Rose Yang, Ph.D., M.P.H. " langcode="en" field_short_title="Xiaohong Rose Yang, Ph.D., M.P.H. " field_page_description="Xiaohong Rose Yang, Ph.D., M.P.H., biographical sketch and research interests " field_feature_card_description="Xiaohong Rose Yang, Ph.D., M.P.H., biographical sketch and research interests " field_list_description="Xiaohong Rose Yang, Ph.D., M.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-23" field_pretty_url="yang-rose" field_browser_title="Xiaohong Rose Yang, Ph.D., M.P.H., biographical sketch and research interests " field_card_title="Xiaohong Rose Yang, Ph.D., M.P.H. " field_email_address="royang@mail.nih.gov" field_first_name="Rose" field_last_name="Yang" field_phone_number="240-276-7226" field_org_name_1="National Cancer Institute" field_org_name_2="Integrative Tumor Epidemiology Branch" field_campus="300" field_office_location="Room 7E104">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=yang%20x&amp;authorOption=exact&amp;pi=0010848756">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302506" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276885" sys_variantid="1422" sys_contentid="302506">Integrative Tumor Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Yang received a Ph.D. in physiology from the Lombardi Cancer Center, Georgetown University in 1999 and an M.P.H. in epidemiology from the Johns Hopkins Bloomberg School of Public Health in 2003. She joined the Genetic Epidemiology Branch (GEB) in 2000 as a postdoctoral fellow, became a tenure-track investigator in 2006, and was appointed senior investigator upon receiving NIH scientific tenure in 2014. She received NCI Director&rsquo;s Intramural Innovation Awards in 2007 and 2009. &nbsp;Dr. Yang serves on the editorial board for <i>Cancer Epidemiology, Biomarkers &amp; Prevention</i>, and is an adjunct associate professor at the Chinese University of Hong Kong. Her research interests include the genetics of familial cutaneous malignant melanoma/dysplastic nevi syndrome and chordoma, and etiologic heterogeneity of breast cancer.</p>
</div>
<!--  - - - - - - - - - - - - - - - - - - - - /about/directory bio main content ends  - - - - - - - - - - - - - - - - - - - -  -->
<div class="dceg-bio-content">
<h2 id="research">Research Interests</h2>
<p>In her research on familial cancers&mdash;including melanoma and dysplastic nevi syndrome, and chordoma&mdash;Dr. Yang employs cutting-edge genomic technologies and novel statistical approaches to evaluate copy number and exome sequencing variants, as well as mRNA expression, miRNA expression, DNA methylation, chromatin modification, and telomere length in disease susceptibility. Most recently, Dr. Yang and her colleagues identified a rare inherited mutation in a gene involved in maintaining telomere stability in melanoma families, further supporting a role for abnormal telomeres in the development of melanoma.</p>
<p>In her investigation of etiologic heterogeneity of breast cancer, Dr. Yang characterizes the molecular signature of tumors using tissue microarray and integrated tumor profiling analyses to identify risk factors for specific cancer subtypes. She is leading breast cancer studies in mainland China, Hong Kong, and Malaysia to identify distinct molecular alterations in tumors and adjacent normal tissues among Asian women, and to examine the associations of these molecular changes with genetic and environmental risk factors, breast tissue composition and density, and breast cancer subtypes.</p>
</div>
</div>]]></body>
    <field_image_promotional>349593</field_image_promotional>
  </row>
  <row term_id="302006" id="349604" title="Mark Little, D.Phil. " langcode="en" field_short_title="Mark Little, D.Phil. " field_page_description="Mark LIttle, D.Phil., biographical sketch and research interests " field_feature_card_description="Mark LIttle, D.Phil., biographical sketch and research interests " field_list_description="Mark LIttle, D.Phil., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="little-mark" field_browser_title="Mark LIttle, D.Phil., biographical sketch and research interests " field_card_title="Mark Little, D.Phil. " field_email_address="mark.little@nih.gov" field_first_name="Mark" field_last_name="Little" field_phone_number="240-276-7375" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E450">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=Little+MP&amp;authorOption=exact&amp;pi=2000486528">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=110&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302459" sys_dependentvariantid="1422" sys_relationshipid="7276829" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Little studied mathematics at Trinity College, Cambridge and obtained his doctorate in mathematics at New College, Oxford. Over the last two decades he has analyzed dose response for cancer and cardiovascular disease risks in populations exposed to ionizing radiation and cigarette smoke. Dr. Little has developed statistical models to elucidate mechanisms of carcinogenesis and cardiovascular disease in various irradiated populations, and to highlight the effects of measurement error on regression estimates. He currently serves on a National Committee on Radiation Protection and Measurements (NCRP) committee, and has previously been a member of the United Kingdom (UK) Health Protection Agency&rsquo;s Advisory Group on Ionising Radiation. He has also served as consultant to the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), the International Atomic Energy Agency (IAEA), and to the UK Committee on Medical Aspects of Radiation in the Environment (COMARE).</p>
<h2 id="research">Research Interests</h2>
<h3>Low-dose radiation and cancer risk</h3>
<p class="first-graf">Dr. Little has quantified radiation-cancer dose-response relationship at low and very low doses and examined the likelihood of dose thresholds. He has evaluated the relationship of radiation levels with breast, thyroid, and other solid cancers and hematopoietic malignancies in populations exposed to environmental, occupational and medical sources of radiation. Dr. Little has also developed and fit statistical models to account for the effects of dose measurement error on the shape of the dose-response curve. In light of the continued controversy about in utero radiation effects, Dr. Little is particularly interested in associations of low-level radiation in utero, postnatally, or preconception with risk of pediatric leukemia. He has spearheaded novel work on postnatal radiation exposures that suggests close to 15-20% of childhood leukemia could be caused by natural background exposures. Since joining NCI, Dr. Little is the lead statistician in the UK-NCI study of cancer risk following pediatric CT exposure, and assessment of thyroid cancer risk in persons exposed in childhood to radiation fallout following the Chernobyl accident &ndash; in each case taking account of errors in dose.</p>
<h3>High-dose radiation and cancer risk</h3>
<p class="first-graf">Dr. Little has also investigated radiation effects at the much higher doses characteristic of radiotherapy, and potential modification by chemotherapy and genetic factors. Dr Little&rsquo;s work suggests that in general cancer relative risks in patients treated with radiotherapy are lower than in comparable (age-, sex-, time-since-exposure-matched) subsets of the Japanese atomic bomb survivors. He has developed mechanistic models that explain these lower risks.</p>
<h3>Low and moderate dose radiation and cardiovascular risk</h3>
<p class="first-graf">Although excess radiation-associated circulatory disease risk is associated with high-dose radiotherapy, evidence of circulatory disease at low doses of radiation is inconsistent. Dr. Little has analyzed cardiovascular risk in a number of moderate- and low-dose radiation exposed groups, in particular the Japanese atomic bomb survivors, in a group exposed for treatment of peptic ulcer, and in a cohort given diagnostic X-rays as part of the treatment for tuberculosis. He has also conducted a number of systematic reviews and meta-analyses of low-dose radiation and cardiovascular disease risk, which add to the weight of evidence for moderate- and low-dose associations and recently proposed a promising candidate mechanism, which may explain these associations.</p>
<h3>Modeling of radio-biological processes</h3>
<p class="first-graf">Dr. Little has developed novel quasi-biological (mechanistic) models of carcinogenesis and related radiobiological endpoints to account for time variation in latency and other patterns of radiation-induced cancer risk. A model developed by Dr. Little to assess the potential role of transmissible genomic instability, when applied to NCI Surveillance Epidemiology and End Results population-based colon cancer incidence data, revealed little evidence that genomic instability was responsible for initiation of colon cancer. These models, when fitted to both human and animal data, have shown promise in explaining the interaction of ionizing radiation and cigarette smoke as causes of lung cancer. Dr. Little has also recently extended his work on statistical fitting of these models of carcinogenesis to describe methods for assessing the number of estimable parameters.</p>
</div>
</div>]]></body>
    <field_image_promotional>349604</field_image_promotional>
  </row>
  <row term_id="302006" id="349606" title="Shahinaz Gadalla, M.D., Ph.D. Biography" langcode="en" field_short_title="Shahinaz Gadalla, M.D., Ph.D. Biography" field_page_description="Shahinaz Gadalla, M.D., Ph.D., biographical sketch and research interests " field_feature_card_description="Shahinaz Gadalla, M.D., Ph.D., biographical sketch and research interests " field_list_description="Shahinaz Gadalla, M.D., Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="gadalla-shahinaz" field_browser_title="Shahinaz Gadalla, M.D., Ph.D., biographical sketch and research interests " field_card_title="Shahinaz Gadalla, M.D., Ph.D. Biography" field_email_address="gadallas@mail.nih.gov" field_first_name="Shahinaz" field_last_name="Gadalla" field_phone_number="240-276-7254" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E534">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=gadalla%20s&amp;authorOption=exact&amp;pi=0013132418">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302430" sys_dependentvariantid="1422" sys_relationshipid="7252753" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2 id="Biography">Biography</h2>
<p>Dr. Shahinaz Gadalla earned her medical degree from Ain Shams University School of Medicine in Cairo, Egypt, and an M.S. and a Ph.D. in epidemiology from the University of Maryland, Baltimore. She joined the Clinical Genetics Branch within the NCI Division of Cancer Epidemiology and Genetics as a Cancer Prevention Fellow in 2008, and was promoted to a Staff Scientist in 2011. In 2014, she was appointed as an Earl Stadtman Tenure-Track Investigator. Dr. Gadalla&rsquo;s research interests focus on the role of genetic factors in cancer etiology, as well as identifying genetic and environmental risk factors among individuals at high risk of developing cancer. She has received numerous awards for her work, including a Fellows&rsquo; Intramural Research Award and an NCI Director&rsquo;s Intramural Innovation Award.</p>
<h2 id="Research">Research Interests</h2>
<h3>Cancer Predisposition in Patients with Myotonic Dystrophy</h3>
<p>Myotonic Dystrophy (DM) is an inherited disorder that represents the most common type of adult onset muscular dystrophy group of diseases. In 2011, Dr. Gadalla and colleagues were the first to report epidemiological evidence of excess cancer risk in DM patients. Dr. Gadalla analyzed data from population registries in Sweden and Denmark and observed a high risk of endometrial, ovarian, brain and colon cancer among DM patients. This work identified DM as a new cancer susceptibility syndrome. Dr. Gadalla plans to build on this work, and her future research in this area aims at understanding the cancer risk factors and the molecular mechanisms behind this observation.</p>
<h3>Telomere Biology and Human Diseases &nbsp;</h3>
<p>Telomeres are specialized structures at the ends of chromosomes that are essential for maintaining chromosomal integrity. Germline mutations in telomere biology genes cause diverse phenotypes including classic dyskeratosis congenita, aplastic anemia, acute myeloid leukemia, and others. Dr. Gadalla is interested in elucidating factors that contribute to this phenotypic variation. In addition, she is leading studies to understand how telomere length may contribute to transplant outcomes in patients who receive hematopoietic stem cell transplantation for aplastic anemia. Her future work in this area will focus on the role of telomere dysfunction in cancer risk following transplantation.</p>
</div>
</div>]]></body>
    <field_image_promotional>349606</field_image_promotional>
  </row>
  <row term_id="302006" id="349613" title="Qing Lan, M.D., Ph.D., M.P.H." langcode="en" field_short_title="Qing Lan, M.D., Ph.D., M.P.H." field_page_description="Qing Lan, M.D., Ph.D., M.P.H., biographical sketch and research interests " field_feature_card_description="Qing Lan, M.D., Ph.D., M.P.H., biographical sketch and research interests " field_list_description="Qing Lan, M.D., Ph.D., M.P.H., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2019-02-07" field_pretty_url="lan-qing" field_browser_title="Qing Lan, M.D., Ph.D., M.P.H., biographical sketch and research interests " field_card_title="Qing Lan, M.D., Ph.D., M.P.H." field_email_address="qingl@mail.nih.gov" field_first_name="Qing" field_last_name="Lan" field_phone_number="240-276-7171" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E136">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=lan%20q&amp;authorOption=exact&amp;pi=%200010413627">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_relationshipid="7252776" sys_dependentvariantid="1422" sys_dependentid="302610" rxinlineslot="103" sys_siteid="475" sys_variantid="1422">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p class="first-graf">Dr. Lan received her M.D. at Weifang Medical University and her Ph.D. in molecular epidemiology at the Chinese Academy of Preventive Medicine in Beijing, as part of a joint training program with the U.S. Environmental Protection Agency and the University of North Carolina at Chapel Hill, and her M.P.H. at Johns Hopkins University. She was awarded NIH scientific tenure in 2008. Dr. Lan uses classic epidemiologic methods, detailed exposure assessment approaches, and state-of-the-art biomarker platforms to evaluate relationships between important exposures and cancer, and to obtain mechanistic insight.</p>
<p class="first-graf">Dr. Lan has received multiple awards, including the NIH Merit Award for her pioneering research on lung cancer and indoor air pollution that led to interventions that reduced cancer risk; the U.S. EPA Scientific and Technological Achievement Award, and the DCEG intramural research award.</p>
<h2 id="research"><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Lan&rsquo;s research focuses on the molecular epidemiology of indoor air pollution and lung cancer and occupational exposures to known or suspected carcinogens, as well as the etiology of hematopoietic malignancies. She has conducted molecular epidemiologic studies of populations exposed to well-defined classes of chemical compounds that are known or suspected carcinogens, including polycyclic aromatic hydrocarbons (PAHs), benzene, formaldehyde, trichloroethylene, diesel, carbon black, nanoparticles, and others. Dr. Lan and her colleagues apply "omic" technologies in their studies including metabolomics, genomics, epigenetics, transcriptomics, proteomics, and whole genome sequencing, as well as conduct genome-wide association studies (GWAS).</p>
<h3>Molecular Epidemiology Studies of Lung Cancer Among Never Smokers</h3>
<p class="first-graf">Lung cancer rates for never-smoking women in Asia are among the highest in the world. The histological distribution and molecular characteristics of lung cancer in this population have patterns that are distinctly different from lung cancer among smokers. Although the etiology remains mostly unexplained, it may be due in part to the contribution of environmental exposures such as the use of coal for cooking, secondhand smoke, and exposure to exhaust from cooking. Dr. Lan has conducted a series of studies to investigate the relationship between environmental exposures, genetic susceptibility, and risk of lung cancer in Xuanwei, China, where lung cancer rates are among the highest in the world for never-smoking women.&nbsp;Dr. Lan formed and leads the Female Lung Cancer Consortium in Asia to study both environmental and genetic risk factors for lung cancer and has led the largest GWAS of lung cancer among never-smokers.</p>
<h3 class="first-graf">Molecular Epidemiology Studies of Known or Suspected Carcinogenic Combustion-Derived Particulates</h3>
<p>There is increasing evidence that particulate matter exposure from multiple sources of indoor and outdoor pollution causes lung cancer; however, the carcinogenic components of particulates have not been clearly identified (e.g., organic vs. elemental carbon core). Dr. Lan conducted a series of cross-sectional molecular epidemiology studies of populations exposed to particulates that are known or suspected carcinogens including diesel exhaust, carbon black, and multi-walled carbon nanotubules.</p>
<h3>Molecular Epidemiology Studies of Benzene, Trichloroethylene, and Formaldehyde</h3>
<p class="first-graf">Benzene is known to have toxic effects on the blood and bone marrow and is a known leukemogen and suspect lymphomagen, but its impact at levels below the U.S. occupational standard of 1 part per million (ppm) remains uncertain. Dr. Lan and her colleagues carried out a cross-sectional molecular epidemiology study with detailed exposure assessment to investigate the effect of benzene exposure below 1 ppm and found that white blood cell and platelet counts were significantly lower among workers exposed to benzene compared to unexposed workers. She and her colleagues are evaluating additional hematologic changes, cytogenetic abnormalities, altered proteomic and mRNA expression, and genetic susceptibility in workers exposed to benzene.</p>
<p>Trichloroethylene (TCE) is a ubiquitous environmental contaminant and is present in many EPA Superfund sites. TCE is a recognized kidney carcinogen, but its carcinogenicity is still unclear for other cancer sites (e.g., non-Hodgkin lymphoma (NHL), liver). To address questions about TCE&rsquo;s mechanism of action, Dr. Lan has conducted a molecular epidemiology study of biomarkers related to immune function and kidney toxicity as well as alterations in methylation, the metabolome, and microRNA to evaluate the biologic plausibility of carcinogenicity related to occupational exposure to TCE.</p>
<p>Epidemiological studies have shown that occupational exposure to formaldehyde is associated with increased risk of leukemia, particularly myelogenous leukemia. Dr. Lan carried out a molecular epidemiological study analyzing chromosomal aberrations and alterations of immune markers to explore the biologic plausibility of this association.</p>
<h3>Molecular Epidemiology Study of Non-Hodgkin Lymphoma</h3>
<p>The incidence rates of NHL in the United States steadily increased over the last half of the 20th century. Despite many studies into this malignancy, there are still questions about the etiology of NHL and its subtypes.</p>
<p>Dr. Lan generated a series of novel findings from her studies of occupational, environmental, and genetic factors and risk of NHL among non-Hispanic whites. However, the ability to follow-up, confirm, and extend those observations is limited by several factors: relatively low exposure to several suspected chemical carcinogens, and low allele frequency, and/or high to complete linkage disequilibrium for multiple candidate genetic loci in Western populations. To address these issues Dr. Lan and her colleagues conducted a case-control study of lymphoma and leukemia in East Asia (i.e., AsiaLymph). The study takes advantage of the higher prevalence and greater range of certain key risk factors in Asia compared to the West, as well as differences in genetic background. It will provide new insights into the etiologies of lymphoma and leukemia.</p>
</div>
</div>]]></body>
    <field_image_promotional>349613</field_image_promotional>
  </row>
  <row term_id="302006" id="349626" title="Kevin Brown, Ph.D." langcode="en" field_short_title="Kevin Brown, Ph.D." field_page_description="Kevin Brown, Ph.D., biographical sketch and research interests " field_feature_card_description="Kevin Brown, Ph.D., biographical sketch and research interests " field_list_description="Kevin Brown, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="1980-01-01" field_pretty_url="brown-kevin" field_browser_title="Kevin Brown, Ph.D., biographical sketch and research interests " field_card_title="Kevin Brown, Ph.D." field_email_address="brownkm2@mail.nih.gov" field_first_name="Kevin" field_last_name="Brown" field_phone_number="240-760-6463" field_org_name_1="National Cancer Institute" field_org_name_2="Laboratory of Translational Genomics" field_campus="301" field_office_location="ATC Room 134F">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/44385086/?sort=date&amp;direction=descending">Scientific Publications in PubMed</a></li>
<li><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;amp;searchTxtAuth=brown+km&amp;amp;authorOption=exact&amp;amp;pi=0010391572">NCI-DCEG Publications</a></li>
<li><a href="#Laboratory Members">Brown Lab Members</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=29&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" sys_contentid="302432" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302432" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7276190" sys_variantid="1422">Laboratory of Translational Genomics</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<div class="callout-box right">
<h3>Spotlight on Investigator</h3>
<p><img class="left" alt="" src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=4&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1482&amp;sys_contentid=606673" inlinetype="rximage" sys_siteid="475" sys_relationshipid="7276196" sys_dependentvariantid="1482" sys_dependentid="606673" rxinlineslot="104" />Read about Kevin Brown's research in <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1955&amp;sys_contentid=380875" inlinetype="rxhyperlink" sys_siteid="475" sys_relationshipid="7276197" sys_dependentvariantid="1955" sys_dependentid="380875" rxinlineslot="103" sys_variantid="1955" sys_contentid="380875">"Unraveling Susceptiblity to Melanoma"</a>, <i>Linkage</i> newsletter, March 2012 .</p>
</div>
<p>Dr. Brown received a Ph.D. in genetics from the George Washington University in Washington, D.C., in 2003. He conducted his postdoctoral training in the Laboratory of Dr. Jeffrey Trent at the Translational Genomic Research Institute (TGen) in Phoenix, Arizona.&nbsp;He subsequently went on to direct his own research program at TGen as an investigator from 2005 to 2010, and served as an adjunct professor in basic medical sciences at the Mayo Clinic Cancer Center, the University of Arizona College of Medicine, and Arizona State University from 2008 to 2010.&nbsp;His work at TGen involved the application of whole-genome familial linkage, candidate gene, and genome-wide association study (GWAS) approaches to identify genetic variants associated with melanoma susceptibility. In 2010, Dr. Brown joined the Laboratory of Translational Genomics (LTG) in the Division of Cancer Epidemiology and Genetics (DCEG) as a tenure-track investigator. He was awarded NIH scientific tenure in 2018. His research largely focuses on the genetic underpinnings of melanoma susceptibility.</p>
<h2><a id="Research"></a>Research Interests</h2>
<h3>Discovery of Germline Cancer Susceptibility Genes</h3>
<p>My research is focused on identifying the genetic contributions and functional pathways associated with cancer risk with a primary focus on melanoma. While early-stage melanoma is largely curable via surgical resection, late-stage melanoma remains nearly incurable despite decades of research. Much of the effort in my laboratory is directed towards better understanding the genetic factors contributing to melanoma risk, with a goal of ultimately facilitating prevention and early-detection efforts in at-risk individuals.&nbsp;We are actively involved in ongoing melanoma GWAS efforts within DCEG, and as members of the <a href="http://www.genomel.org/">International Melanoma Genetics Consortium (GenoMEL)</a>, we collaborate on melanoma GWAS meta-analyses as well as family studies. We also work with GenoMEL member groups to better understand the genetics of melanoma susceptibility in melanoma-prone families using whole-genome and -exome sequencing approaches. Lastly, we are actively involved in ongoing renal cell cancer GWAS at the NCI, as well as meta-analyses with international teams working in the same area.</p>
<h3>Functional Characterization of Cancer Susceptibility Loci</h3>
<p>Beyond susceptibility gene/locus discovery, a major focus of our laboratory is in the functional characterization of such loci. While significant strides have been made towards cataloging loci involved in cancer risk, elucidation of how risk variants influence susceptibility remains a significant challenge, with progress in this area lagging far behind. Our approach focuses both on better understanding the molecular consequences of specific risk variants on gene regulation and function, and on the phenotypic effects of allele-specific gene functions. Work in the laboratory involves fine-mapping of risk-associated regions, targeted and genome-wide expression analysis, gene regulation and epigenetic work, and bioinformatic analysis of large genomic datasets.</p>
<p>Current projects in the laboratory include a large-scale study of the&nbsp;influences of germline genetic variation on both gene regulation and cellular phenotypes in melanocytes and melanoma cells, functional genomic screens to identify genes that mediate phenotypes associated with early stage tumor progression, large-scale reporter screens to identify risk-associated genetic variants conferring allele-specific gene regulatory potential, and directed analyses applied to specific susceptibility regions and genes, presently including chromosome bands 1q21.3 (multi-gene), 1q42.12 (<em>PARP1</em>), 2q33.1 (<em>CASP8</em>), 5p15.33 (<em>TERT-CLPTM1L</em>), 7p21.1 (<em>AGR3/AHR</em>), 22q13.1 (<em>PLA2G6</em>), and 22q22.3 (<em>MX2</em>).</p>
<h3>Consortia</h3>
<p>Member of the <a href="http://www.genomel.org/">International Melanoma Genetics Consortium (GenoMEL)</a></p>
<h3><a id="Laboratory Members"></a>Laboratory Members</h3>
<p>Mai Xu, Ph.D. &ndash; Biologist and Lab Manager<br /><a href="https://dceg.cancer.gov/fellowship-training/what-our-fellows-do/meet-current-fellows/ltg-fellows#Brown-Lab">Current fellows</a></p>
<p><a href="#top">Back to Top</a></p>
</div>
</div>]]></body>
    <field_image_promotional>349626</field_image_promotional>
  </row>
  <row term_id="302006" id="349627" title="Ruth Pfeiffer, Ph.D. " langcode="en" field_short_title="Ruth Pfeiffer, Ph.D. " field_page_description="Ruth Pfeiffer, Ph.D., biographical sketch and research interests " field_feature_card_description="Ruth Pfeiffer, Ph.D., biographical sketch and research interests " field_list_description="Ruth Pfeiffer, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2018-05-31" field_pretty_url="pfeiffer-ruth" field_browser_title="Ruth Pfeiffer, Ph.D., biographical sketch and research interests " field_card_title="Ruth Pfeiffer, Ph.D. " field_email_address="pfeiffer@mail.nih.gov" field_first_name="Ruth" field_last_name="Pfeiffer" field_phone_number="240-276-7317" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E142">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=pfeiffer%20r&amp;authorOption=exact&amp;pi=0010656430">Scientific Publications</a></li>
<li><a href="#book">Books</a></li>
<li><a href="#software">Software</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_relationshipid="7252796" sys_siteid="475" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p class="first-graf">Dr. Pfeiffer is a tenured senior investigator in the Biostatistics Branch of the Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI). She received an M.S. degree in applied mathematics from the Technical University of Vienna, Austria, and an M.A. degree in applied statistics and a Ph.D. in mathematical statistics&mdash;both from the University of Maryland, College Park. At NCI she is an active collaborator on many research projects and mentors several fellows and junior investigators. Her research focuses on statistical methods for absolute risk prediction, problems arising in molecular and genetic epidemiologic studies, and the analysis of data from electronic medical records.&nbsp;She is the recipient of a Fulbright Fellowship, an elected Member of the International Statistical Institute, and an elected Fellow of the American Statistical Association.</p>
<h2 id="research"><a id="Research-Interests"></a>Research Interests</h2>
<ul class="grey-bullets">
<li>Mixture models and applications</li>
<li>Methods for high-dimensional data</li>
<li>Absolute risk modeling</li>
</ul>
<h2 id="book"><a id="book"></a>Book</h2>
<ul class="grey-bullets">
<li>Absolute Risk: Methods and Applications in Clinical Management and Public Health. Pfeiffer RM, Gail MH. Chapman &amp; Hall. Boca Raton, FL 2018.</li>
</ul>
<h2 id="software"><a id="Software"></a>Software</h2>
<ul class="grey-bullets">
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=595704" inlinetype="rxhyperlink" sys_relationshipid="7252795" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="595704" rxinlineslot="103" sys_variantid="1418" sys_contentid="595704">Breast, Endometrial, and Ovarian Risk Assessment Macros</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=13&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302539" inlinetype="rxhyperlink" sys_relationshipid="7252791" sys_dependentvariantid="1418" sys_dependentid="302539" rxinlineslot="103" sys_variantid="1418" sys_contentid="302539">Colon Cancer Risk Assessment SAS Macro</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_variantid=1418&amp;sys_contentid=302628" inlinetype="rxhyperlink" sys_relationshipid="7252792" sys_dependentvariantid="1418" sys_dependentid="302628" rxinlineslot="103" sys_variantid="1418" sys_contentid="302628">Colon Cancer Risk Assessment Gauss Program</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=501305" inlinetype="rxhyperlink" sys_relationshipid="7252794" sys_siteid="475" sys_dependentvariantid="1418" sys_dependentid="501305" rxinlineslot="103" sys_variantid="1418" sys_contentid="501305">Thyroid Cancer Risk Assessment R Package</a></li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349627</field_image_promotional>
  </row>
  <row term_id="302006" id="349635" title="June A. Peters, M.S., C.G.C., L.M.F.T. " langcode="en" field_short_title="June A. Peters, M.S., C.G.C., L.M.F.T. " field_page_description="June A. Peters, M.S., C.G.C., L.M.F.T., biographical sketch and research interests " field_feature_card_description="June A. Peters, M.S., C.G.C., L.M.F.T., biographical sketch and research interests " field_list_description="June A. Peters, M.S., C.G.C., L.M.F.T., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-16" field_pretty_url="peters-june" field_browser_title="June A. Peters, M.S., C.G.C., L.M.F.T., biographical sketch and research interests " field_card_title="June A. Peters, M.S., C.G.C., L.M.F.T. " field_email_address="petersju@mail.nih.gov" field_first_name="June" field_last_name="Peters" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=peters%20j&amp;authorOption=exact&amp;pi=%200010633394">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_relationshipid="7252467" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">June Peters received an M.S. degree in genetic counseling in 1973 from Rutgers University and an M.S. in psychological counseling in 1986 from California State University at San Bernardino. Over a four decade career, she has held a wide variety of genetic counseling and academic positions in tertiary care medical centers, universities, private community hospitals, county, state and federal government. She is board certified by both the American Board of Genetic Counseling and the American Board of Medical Genetics and is a founding member of both the National Society of Genetic Counselors, and the American College of Medical Genetics. Ms. Peters is also a Marriage and Family Therapist, licensed in California and the District of Columbia.&nbsp;</p>
<p class="first-graf">Within DCEG's Clinical Genetics Branch (CGB), June Peters served as the senior genetic counselor, involved in genetic education, counseling and research in various CGB clinical research protocols. She and sociologist collaborator Regina Kenen have conceived and introduced the Colored Eco-Genetic Relationship Map (CEGRM) into clinical research for assessing social exchanges. They applied the CEGRM to assessing high risk families and, with NHGRI collaborators, their social networks.&nbsp;</p>
<p class="first-graf">Ms. Peters' research efforts explored the dynamic personal, family and social implications of hereditary cancers and gene-environmental interactions focusing on biological mechanisms &ndash; &nbsp;such as inflammation and telomere biology &ndash; that interact with psychological and social well-being and health. She retired from government service in 2017.</p>
</div>
</div>]]></body>
    <field_image_promotional>349635</field_image_promotional>
  </row>
  <row term_id="302006" id="349637" title="Katherine A. McGlynn, Ph.D., M.P.H. " langcode="en" field_short_title="Katherine A. McGlynn, Ph.D., M.P.H. " field_page_description="Katherine A. McGlynn, Ph.D., M.P.H., biographical sketch and research interests" field_feature_card_description="Katherine A. McGlynn, Ph.D., M.P.H., biographical sketch and research interests" field_list_description="Katherine A. McGlynn, Ph.D., M.P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2014-10-23" field_pretty_url="mcglynn-katherine" field_browser_title="Katherine A. McGlynn, Ph.D., M.P.H., biographical sketch and research interests" field_card_title="Katherine A. McGlynn, Ph.D., M.P.H. " field_email_address="mcglynnk@mail.nih.gov" field_first_name="Katherine" field_last_name="McGlynn" field_phone_number="240-276-7297" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E446">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=mcglynn%20ka&amp;authorOption=exact&amp;pi=0010119391">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=23&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_relationshipid="7276836" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p>Dr. McGlynn received an M.P.H. in population studies from Tulane University and a Ph.D. in epidemiology from the University of Pennsylvania. She conducted postdoctoral research on liver cancer at the Fox Chase Cancer Center, where she subsequently served as a faculty member before coming to the NCI in 1998. Dr. McGlynn has been the recipient of an NIH Merit Award for her study of testicular cancer among military servicemen and an NCI Outstanding Mentor Award.</p>
<h2><b>Research Interests</b></h2>
<h3><b>Epidemiology of Testicular and Liver Cancers</b></h3>
<p>The incidence of both testicular cancer and primary liver cancer are increasing in many populations, although there is wide geographic and ethnic variability in their incidence.&nbsp;Dr. McGlynn has been using a variety of study designs to investigate environmental and genetic risk factors that may contribute to the increasing rates.</p>
<h3><b>Testicular Cancer and Testicular Dysgenesis Syndrome</b></h3>
<p>Testicular germ cell tumors (TGCT) are the most frequently occurring tumors among U.S. men between the ages of 15 and 40 years. Although the incidence has been increasing for decades, the etiology remains poorly understood. TGCT is part of a constellation of male reproductive disorders known as the Testicular Dysgenesis Syndrome (TDS) which also includes cryptorchidism, hypospadias, and impaired spermatogenesis. Because of the interrelationship of these conditions, Dr. McGlynn has been studying a number of TDS outcomes in complementary studies. Her TDS research is currently oriented around several areas of investigation: maternal/son hormonal effects, endocrine-disrupting chemicals, and perinatal factors. One of her principal interests in TDS is the relationship of steroid hormones and gonadotropins to the development of TDS outcomes. Thus far, her studies have found little evidence that maternal hormone levels are associated with risk of TDS. Her studies suggest, however, that lower androgen levels during adolescence may predispose risk of developing TGCT. &nbsp;</p>
<p>Ongoing analyses of pre-diagnostic serum samples should provide information on whether hormone levels in adulthood are similarly associated with TGCT. As endocrine disrupting chemicals may affect hormone levels and be related to TGCT, Dr. McGlynn has been studying the relationship of organochlorine compounds to several TDS outcomes. She has identified relationships between TGCT and some pesticides, but has not seen these same relationships with cryptorchidism and hypospadias, suggesting that post-natal, rather than pre-natal, exposure to these compounds may be critical to increasing risk of TGCT. She is currently broadening her research to include endocrine-disrupting chemicals currently in use, and certain medications.</p>
<h3><b>Liver Cancer</b></h3>
<p>Incidence rates of primary liver cancer and its most common histologic type, hepatocellular carcinoma (HCC), have been increasing in the U.S. for more than 30 years.&nbsp;Although hepatitis C virus (HCV) has certainly played a role in the increase, Dr. McGlynn&rsquo;s research has sought to understand the role of other risk factors.&nbsp;Among the factors in which she has a particular interest are the related conditions of diabetes, obesity and metabolic syndrome.&nbsp;Her research has shown that the risk of HCC attributable to diabetes and/or obesity is larger than that of any other risk factor, and that risk of liver cancer among men with diabetes is greater than the risk of any other cancer. As diabetes, obesity and metabolic syndrome are often treated pharmacologically, Dr. McGlynn has also been studying whether medications such as non-steroidal anti-inflammatory drugs, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors,&nbsp;diabetes medications and other drugs affect risk of HCC. To examine the large gender discrepancy in risk of HCC, Dr. McGlynn is focusing on examining hormonal and reproductive factors and endogenous hormone levels. &nbsp;</p>
<p>&nbsp;</p>
</div>
</div>]]></body>
    <field_image_promotional>349637</field_image_promotional>
  </row>
  <row term_id="302006" id="349660" title="Mary L. McMaster, M.D." langcode="en" field_short_title="Mary L. McMaster, M.D." field_page_description="Mary L. McMaster, M.D., biographical sketch and research interests " field_feature_card_description="Mary L. McMaster, M.D., biographical sketch and research interests " field_list_description="Mary L. McMaster, M.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-14" field_pretty_url="mcmaster-mary" field_browser_title="Mary L. McMaster, M.D., biographical sketch and research interests " field_card_title="Mary L. McMaster, M.D." field_email_address="mcmastem@mail.nih.gov" field_first_name="Mary" field_last_name="McMaster" field_phone_number="240-276-7248" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E516">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=mcmaster%20ml&amp;authorOption=exact&amp;pi=0010129987">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252600" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. McMaster received an M.D. from the Bowman Gray School of Medicine of Wake Forest University in 1984, then trained in Internal Medicine and Medical Oncology at Vanderbilt University. Following a postdoctoral fellowship in cellular biology, she came to NIH in 1996, where she completed training in Clinical Medical Genetics. She joined NCI in 1998 to pursue clinical research in cancer genetics with an emphasis on familial cancer syndromes.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Clinical and genetic characterization of familial Waldenstr&ouml;m&rsquo;s macroglobulinemia</li>
<li>Clinical, genetic and epidemiologic characterization of families at high risk of chronic lymphoproliferative disorders</li>
<li>Epidemiologic studies in familial testis cancer: histopathologic correlates and risk of cancers other than germ cell tumors in relatives of testis cancer patients</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>349660</field_image_promotional>
  </row>
  <row term_id="302006" id="349672" title="Louise A. Brinton, Ph.D., M.P.H." langcode="en" field_short_title="Louise A. Brinton, Ph.D., M.P.H." field_page_description="Louise A. Brinton, Ph.D., M.P.H. biographical sketch and research interests" field_feature_card_description="Louise A. Brinton, Ph.D., M.P.H. biographical sketch and research interests" field_list_description="Louise A. Brinton, Ph.D., M.P.H. biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2014-10-14" field_pretty_url="brinton-louise" field_browser_title="Louise A. Brinton, Ph.D., M.P.H. biographical sketch and research interests" field_card_title="Louise A. Brinton, Ph.D., M.P.H." field_email_address="brintonl@mail.nih.gov" field_first_name="Louise" field_last_name="Brinton" field_org_name_1="National Cancer Institute" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield"><a id="top"></a>
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=brinton%20l&amp;authorOption=exact&amp;pi=0010170180">Scientific Publications</a></li>
</ul>
<a id="Biography"></a>
<h2>Biography</h2>
<p>After receiving an M.P.H. in epidemiology from the University of North Carolina at Chapel Hill, Dr. Brinton joined the NCI as a staff fellow in 1976. She earned a Ph.D. in epidemiology from The Johns Hopkins School of Hygiene and Public Health in 1979, and subsequently conducted postdoctoral research at Oxford University in the United Kingdom. Dr. Brinton was appointed Acting Chief of the Environmental Studies Section in 1984, and in 1996 became Chief of the Environmental Epidemiology Branch (later called the Hormonal and Reproductive Epidemiology Branch). In 2016 she was named Scientific Advisor for International Activities. She retired from federal service in 2017.&nbsp;She served on the Executive Board of the Society for Epidemiologic Research, and was elected president of the organization in 1990. Dr. Brinton has received the PHS Special Recognition Award and the NIH Director's Award for innovative leadership in women's health research. She has also been honored by receipt of the H.A. Tyroler Distinguished Alumni Award from the University of North Carolina and the American College of Epidemiology&rsquo;s Abraham Lilienfeld Award and the 2015 Society for Epidemiologic Research Career Accomplishment Award.</p>
</div>
</div>]]></body>
    <field_image_promotional>349672</field_image_promotional>
  </row>
  <row term_id="302006" id="349675" title="Jennifer T. Loud, R.N., C.R.N.P., D.N.P." langcode="en" field_short_title="Jennifer T. Loud, R.N., C.R.N.P., D.N.P." field_page_description="Jennifer Loud, R.N., C.R.N.P., D.N.P., biographical sketch and research interests" field_feature_card_description="Jennifer Loud, R.N., C.R.N.P., D.N.P., biographical sketch and research interests" field_list_description="Jennifer Loud, R.N., C.R.N.P., D.N.P., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-14" field_pretty_url="loud-jennifer" field_browser_title="Jennifer Loud, R.N., C.R.N.P., D.N.P., biographical sketch and research interests" field_card_title="Jennifer T. Loud, R.N., C.R.N.P., D.N.P." field_email_address="loudj@mail.nih.gov" field_first_name="Jennifer" field_last_name="Loud" field_phone_number="240-276-7255" field_org_name_1="National Cancer Institute" field_org_name_2="Clinical Genetics Branch" field_campus="300" field_office_location="Room 6E536">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=loud%20j&amp;authorOption=exact&amp;pi=0010172249">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=40&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302430" inlinetype="rxhyperlink" sys_relationshipid="7252453" sys_dependentvariantid="1422" sys_dependentid="302430" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302430">Clinical Genetics Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Loud received her B.S. in Nursing from Old Dominion University in 1981, followed by an M.S. in Nursing from George Mason University in 1992 and a Doctor of Nursing Practice from the University of Maryland, Baltimore in 2008. She has been a board-certified Adult Nurse Practitioner since 1992. She spent six years as a Nurse Practitioner with NCI's Medical Oncology Branch, working with individuals enrolled in clinical trials of new cancer treatments. During that time, she was a Clinical Trials Coordinator, and an Associate Investigator on two chemoprevention trials for women at increased risk of breast cancer. This led to an interest in cancer genetics, in pursuit of which she has taken both the Basic and the Advanced Course for Nurses in Genetic Cancer Risk Counseling at the Fox Chase Cancer Center. She joined the Clinical Genetics Branch in 2000, where she is currently involved in multiple clinical and epidemiologic studies aimed at understanding hereditary cancer and at better understanding the psychosocial impact of individuals identified as being at high genetic risk of cancer. In September 2008, Dr. Loud was appointed Assistant Branch Chief, Clinical Genetics Branch. She is also a member of NCI's Clinical Center Institutional Review Board and of the Gynecologic Oncology Group Nursing Committee.</p>
<h2 id="research">Research Interests</h2>
<p class="first-graf">Current research interests include assessing the impact of risk identification and risk management as they affect various aspects of an at-risk individual's life, with a particular focus on hereditary breast and ovarian cancer. Dr. Loud is also a co-investigator on CGB's Familial Testicular Cancer study, and the National Ovarian Cancer Prevention and Early Detection study (GOG-199). As CGB investigates the clinical implications of carrying mutations in cancer susceptibility genes, and develops novel approaches to risk management, she also hopes to learn how these strategies affect individuals and their families. She is studying how specific factors impact complex decisions related to cancer risk assessment, cancer risk communication, and activities of cancer prevention and control made by individuals at increased risk of cancer.</p>
</div>
</div>]]></body>
    <field_image_promotional>349675</field_image_promotional>
  </row>
  <row term_id="302006" id="349679" title="Ruth A. Kleinerman, M.P.H., Ph.D." langcode="en" field_short_title="Ruth A. Kleinerman, M.P.H., Ph.D." field_page_description="Ruth A. Kleinerman, M.P.H., Ph.D., biographical sketch and research interests " field_feature_card_description="Ruth A. Kleinerman, M.P.H., Ph.D., biographical sketch and research interests " field_list_description="Ruth A. Kleinerman, M.P.H., Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-07" field_pretty_url="kleinerman-ruth" field_browser_title="Ruth A. Kleinerman, M.P.H., Ph.D., biographical sketch and research interests " field_card_title="Ruth A. Kleinerman, M.P.H., Ph.D." field_email_address="kleinerr@mail.nih.gov" field_first_name="Ruth" field_last_name="Kleinerman" field_phone_number="240-276-7393" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E456">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=kleinerman%20r&amp;authorOption=exact&amp;pi=0010089661">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_relationshipid="7252772" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2>Biography</h2>
<p class="first-graf">Dr. Kleinerman received a B.A. from Washington University, an M.P.H. from Boston University School of Public Health, and a Ph.D. from the University of London, U.K. Dr. Kleinerman joined the NCI Epidemiology and Biostatistics Program in 1979. Currently, she is Deputy Branch Chief of the Radiation Epidemiology Branch. As lead of the large follow-up study of late effects in adult survivors of retinoblastoma with a focus on the risk of second cancers, Dr. Kleinerman identified for the first time that hereditary retinoblastoma survivors with an inherited germline <i>RB1</i> mutation are at higher risk of a second cancer, especially melanoma, compared to hereditary retinoblastoma survivors with a <i>de novo</i> germline <i>RB1</i> mutation. She has received the NIH Merit Award as well as two NCI DCEG awards for Outstanding Research Paper by a Staff Scientist based on her research on retinoblastoma survivors. Through her research, she has identified new risks of specific second cancers in retinoblastoma survivors. Her interest in second cancers has led her to collaborate on a large study of second gastrointestinal cancers following radiotherapy for cervical cancer, which builds on her earlier research on second cancers following radiation for cervical cancer.</p>
<h2 id="research">Research Interests</h2>
<ul class="grey-bullets">
<li>Gene-environment interaction in retinoblastoma patients</li>
<li>Interventional radiation and fluoroscopically-guided procedures</li>
<li>Second gastrointestinal cancers following radiotherapy</li>
</ul>
<h3>Retinoblastoma</h3>
<p class="first-graf">Children with hereditary retinoblastoma (Rb) are at exceptionally high risk of sarcomas, melanoma and brain tumors due to a germline mutation in their <i>RB1</i> gene,especially those with an inherited germline mutation. Radiotherapy used to treat these patients has enhanced the risk of these cancers. In collaboration with the Human Genetics Program, we continue to investigate cancer incidence and mortality in a series of 1,850 one-year survivors of RB to learn whether these patients continue to be at risk of sarcomas as they age as well as typical epithelial tumors of adulthood. We identified a striking excess of leiomyosarcomas in patients 35 years and later after Rb diagnosis. Efforts are underway to identify specific mutations in the <i>Rb1</i> gene in hereditary patients who develop sarcomas and melanomas. We created a website to inform study participants about the risks of second cancers and provide cancer screening recommendations. <a href="http://rbstudy.cancer.gov/">Retinoblastoma Follow-Up Study</a></p>
<h3><b>Cancer mortality in physicians conducting fluoroscopically-guided procedures</b></h3>
<p class="first-graf">During the past few decades, there has been dramatic growth in the number of high-dose diagnostic x-ray examinations and fluoroscopically&ndash;guided (FG) procedures, primarily performed by interventional cardiologists and interventional radiologists. These complex procedures use long and on-time radiological imaging, resulting in high radiation exposure not only to patients but also to physicians. Cancer mortality has not been investigated in physicians exposed to radiation from FG procedures We are conducting the first comprehensive mortality study of radiologists, cardiologists and other physicians performing these procedures to determine their risk of dying from cancer. A large cohort of radiologists and other physicians exposed to radiation has been assembled to determine cause of death compared to physicians who are not exposed to radiation.</p>
</div>
</div>]]></body>
    <field_image_promotional>349679</field_image_promotional>
  </row>
  <row term_id="302006" id="349685" title="Margaret A. Tucker, M.D. " langcode="en" field_short_title="Margaret A. Tucker, M.D. " field_page_description="Margaret Tucker, M.D., DCEG Scientist Emerita, biographical sketch and research interests " field_feature_card_description="Margaret Tucker, M.D., DCEG Scientist Emerita, biographical sketch and research interests " field_list_description="Margaret Tucker, M.D., DCEG Scientist Emerita, biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-21" field_pretty_url="tucker-margaret" field_browser_title="Margaret Tucker, M.D., DCEG Scientist Emerita, biographical sketch and research interests " field_card_title="Margaret A. Tucker, M.D. " field_email_address="tuckerp@mail.nih.gov" field_first_name="Margaret" field_last_name="Tucker" field_phone_number=" 240-276-7396" field_org_name_1="National Cancer Institute" field_org_name_2="Human Genetics Program" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=tucker%20m&amp;authorOption=exact&amp;pi=0010126495">Scientific Publications</a></li>
</ul>
<h2 id="biography">Biography</h2>
<div class="callout-box right">
<h3>Moles to Melanoma: Recognizing the ABCDE Features</h3>
<div sys_dependentvariantid="2088" sys_dependentid="1050433" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="475" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7276267">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=302271&amp;sys_siteid=475&amp;sys_contentid=1050433&amp;sys_command=edit" alt="" /><!--Comment--></div>
</figure>
</div>
<p>This online tool contains serial photographs of pigmented lesions: common moles, dysplastic nevi, and melanomas, taken over time. Includes associated clinical descriptors. &nbsp;<a href="http://analysistools.nci.nih.gov/nevustool/?page=home">Explore the Moles to Melanoma website</a>.</p>
</div>
<p class="first-graf">Dr. Margaret A. Tucker received her M.D. from Harvard Medical School and completed training in internal medicine and medical oncology at Stanford University Medical Center. In her over 40 years at NCI, Dr. Tucker led the Institute&rsquo;s research program on familial cancers, serving as Director of the DCEG Human Genetics Program.&nbsp;Dr. Tucker's landmark scientific contributions have substantively improved our understanding of the mechanisms underlying familial cancers, the etiology of melanoma, and predisposition to multiple malignancies.&nbsp;Her research team and collaborators identified the first major susceptibility genes for melanoma. Dr. Tucker and her team published a melanoma atlas, created training videos for the clinical examination of members of high-risk families, developed the first <a href="https://mrisktool.cancer.gov/">calculator to estimate an individual&rsquo;s risk of developing melanoma</a>, and&nbsp;more recently launched a website with the <a href="https://analysistools.nci.nih.gov/nevustool/">first-ever serial collection of dysplastic nevi and melanomas</a><span>,</span> documenting skin changes over nearly four decades of clinical follow-up. <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1424&amp;sys_contentid=1117025" sys_contentid="1117025" inlinetype="rxhyperlink" sys_variantid="1424" sys_relationshipid="7276265" sys_siteid="475" rxinlineslot="103" sys_dependentid="1117025" sys_dependentvariantid="1424">Dr. Tucker retired in June 2018</a>&nbsp;and was named as a Scientist Emerita by the NIH Scientific Directors. She remains committed to DCEG, providing crucial scientific advice for ongoing studies in several important research areas, mentoring junior investigators, and offering valuable management insights to DCEG&rsquo;s leadership team.</p>
</div>
</div>]]></body>
    <field_image_promotional>349685</field_image_promotional>
  </row>
  <row term_id="302006" id="349686" title="Philip R. Taylor, M.D., Sc.D. " langcode="en" field_short_title="Philip R. Taylor, M.D., Sc.D. " field_page_description="Philip R. Taylor, M.D., Sc.D., biographical sketch and research interests " field_feature_card_description="Philip R. Taylor, M.D., Sc.D., biographical sketch and research interests " field_list_description="Philip R. Taylor, M.D., Sc.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-23" field_pretty_url="taylor-philip" field_browser_title="Philip R. Taylor, M.D., Sc.D., biographical sketch and research interests " field_card_title="Philip R. Taylor, M.D., Sc.D. " field_email_address="ptaylor@mail.nih.gov" field_first_name="Philip" field_last_name="Taylor" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=ALL&amp;searchTxtAuth=Taylor+PR&amp;authorOption=exact&amp;pi=0010161793">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" inlinetype="rxhyperlink" sys_relationshipid="7252820" sys_dependentvariantid="1422" sys_dependentid="1033171" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="1033171">Metabolic Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p class="first-graf">Dr. Taylor received his medical degree from the University of Iowa in 1973 and completed his residency in internal medicine at Vanderbilt University in 1976. He joined the Centers for Disease Control in 1976 as an Epidemic Intelligence Service officer and while there, completed a residency in preventive medicine. He received his master&rsquo;s and doctoral degrees in epidemiology from the Harvard School of Public Health, and came to the NCI in 1983. He was Chief of the Cancer Prevention Studies Branch from 1987 &ndash; 2004 before joining the Genetic Epidemiology Branch in 2005. Dr. Taylor retired from federal service in 2017.</p>
<p class="first-graf">Dr. Taylor&nbsp;has a long-standing interest in developing cancer prevention strategies. His recent research emphasized (1) identifying germline variants of susceptibility to upper gastrointestinal (UGI) cancers through genome-wide association studies (GWAS) and family studies, (2) evaluating tissue alterations in UGI cancers and premalignancy, and (3) integrating germline and somatic data with functional genomics to understand etiology and identify biomarkers for early detection and prognosis.</p>
</div>
</div>]]></body>
    <field_image_promotional>349686</field_image_promotional>
  </row>
  <row term_id="302006" id="349696" title="Lynn R. Goldin, Ph.D. " langcode="en" field_short_title="Lynn R. Goldin, Ph.D. " field_page_description="Lynn R. Goldin, Ph.D., biographical sketch and research interests " field_feature_card_description="Lynn R. Goldin, Ph.D., biographical sketch and research interests " field_list_description="Lynn R. Goldin, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="1980-01-01" field_date_updated="2007-03-09" field_pretty_url="goldin-lynn" field_browser_title="Lynn R. Goldin, Ph.D., biographical sketch and research interests " field_card_title="Lynn R. Goldin, Ph.D. " field_email_address="goldinl@mail.nih.gov" field_first_name="Lynn" field_last_name="Goldin" field_org_name_1="National Cancer Institute" field_org_name_2="Integrative Tumor Epidemiology Branch" field_campus="301">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=goldin&amp;authorOption=exact&amp;pi=0010145672">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" inlinetype="rxhyperlink" sys_relationshipid="7252570" sys_dependentvariantid="1422" sys_dependentid="302506" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302506">Integrative Tumor Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Goldin received a Ph.D. in genetics from the University of North Carolina at Chapel Hill. She joined the&nbsp;DCEG in 1998 as a senior investigator in the Genetic Epidemiology Branch&nbsp;after conducting genetics research at the NIH National Institute of Mental Health. Dr. Goldin retired from federal service in 2017.&nbsp;Her major research interests are in developing and evaluating methods and study designs for detecting susceptibility genes for complex diseases, quantifying familial aggregation of disease, and applying these methods to familial cancer studies. Her specific focus is on solving the underlying genetics of hematologic malignancies.</p>
<strong></strong></div>
</div>]]></body>
    <field_image_promotional>349696</field_image_promotional>
  </row>
  <row term_id="302006" id="983937" title="Biographical sketch and research interests of Mark Purdue, Ph.D. " langcode="en" field_short_title="Biographical sketch and research interests of Mark Purdue, Ph.D. " field_page_description="Mark Purdue, Ph.D., biographical sketch and research interests" field_feature_card_description="Mark Purdue, Ph.D., biographical sketch and research interests" field_list_description="Mark Purdue, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2015-08-06" field_date_reviewed="2015-08-06" field_date_updated="2015-08-06" field_pretty_url="purdue-mark" field_browser_title="Mark Purdue, Ph.D., biographical sketch and research interests" field_card_title="Biographical sketch and research interests of Mark Purdue, Ph.D. " field_email_address="purduem@mail.nih.gov" field_phone_number="240-276-7265" field_org_name_1="National Cancer Institute" field_org_name_2="Occupational and Environmental Epidemiology Branch" field_campus="300" field_office_location="Room 6E140">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=purdue%20mp&amp;authorOption=exact&amp;pi=0011600195">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=50&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302610" sys_contentid="302610" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="302610" sys_dependentvariantid="1422" sys_relationshipid="7252621">Occupational and Environmental Epidemiology Branch</a></li>
</ul>
<h2 id="Biography"><a id="Biography"></a>Biography</h2>
<p>Dr. Purdue received a Ph.D. in epidemiology from the University of Toronto, Canada. He joined DCEG in 2004 as a postdoctoral fellow within the Occupational and Environmental Epidemiology Branch, was appointed as a tenure-track investigator in 2009, and was awarded NIH scientific tenure in 2017. He has received several awards for his research in molecular epidemiology, including DCEG and NIH Fellowship Achievement awards, the&nbsp;DCEG Intramural Research Award, and the NIH Merit Award.</p>
<h2 id="Research Interests"><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Purdue&rsquo;s interests center on applying molecular and classical epidemiologic methods to study the causes of cancer and improve exposure assessment. He is particularly interested in evaluating the potential carcinogenicity of chlorinated solvents and investigating the etiology of kidney cancer and lymphomas.</p>
<h3>Chlorinated Solvents</h3>
<p>Chlorinated solvents are manmade compounds widely used across different industries for a variety of applications. The International Agency for Research on Cancer (IARC) has classified trichloroethylene (TCE), commonly used in vapor degreasing in the past, as a (Group 1) human carcinogen affecting kidney cancer, and the widely used dry cleaning solvent perchloroethylene (&ldquo;Perc&rdquo;, also known as tetrachloroethylene) as a probable human carcinogen (Group 2A).</p>
<p>Dr. Purdue is leading case-control and cohort investigations to clarify whether TCE is a human carcinogen at sites other than the kidney, and whether Perc and other chlorinated solvents are human carcinogens at any site.&nbsp; He is also conducting molecular epidemiologic research to elucidate exposure-related biologic mechanisms relevant to cancer.</p>
<h3>Kidney Cancer</h3>
<p>Investigations of kidney cancer etiology make up a large part of Dr. Purdue&rsquo;s research program. His leadership in organizing genome-wide association studies have produced seminal contributions to our understanding of genetic susceptibility for this malignancy. In other kidney cancer research, Dr. Purdue has been evaluating suspected occupational risk factors, investigating possible factors underlying the excess of this disease among Black vs. White Americans, and exploring the existence of etiologic heterogeneity across histologic and molecular subtypes.</p>
<h3>Lymphomas</h3>
<p>While severe immune dysregulation is an established risk factor for non-Hodgkin lymphoma (NHL), it is unclear whether subtle, subclinical immune system function influences lymphomagenesis in the general population. Dr. Purdue has been conducting investigations of serum immune markers and NHL within prospective cohorts to address this research question. He is also conducting research to better understand serum markers associated with risk of multiple myeloma (MM), a highly lethal B-cell malignancy, including investigations into markers predictive of future progression to MM from its asymptomatic precursor, monoclonal gammopathy of undetermined significance.</p>
</div>
</div>]]></body>
    <field_image_promotional>983937</field_image_promotional>
  </row>
  <row term_id="302006" id="1033924" title="Gwen A. Murphy, Ph.D., M.P.H." langcode="en" field_short_title="Gwen A. Murphy, Ph.D., M.P.H." field_page_description="Gwen A Murphy, Ph.D., biographical sketch and research interests " field_feature_card_description="Gwen A Murphy, Ph.D., biographical sketch and research interests " field_list_description="Gwen A Murphy, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-01-14" field_date_reviewed="2016-01-14" field_date_updated="2016-01-14" field_pretty_url="murphy-gwen" field_browser_title="Gwen A Murphy, Ph.D., biographical sketch and research interests " field_card_title="Gwen A. Murphy, Ph.D., M.P.H." field_email_address="murphygw@mail.nih.gov" field_first_name="Gwen" field_last_name="Murphy" field_phone_number="240-276-7199" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiology Branch" field_campus="300" field_office_location="Room 6E428">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Murphy+G&amp;authorOption=exact&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_relationshipid="7252465">Metabolic Epidemiology Branch</a></li>
</ul>
<h2 id="Biography"><a id="Biography"></a>Biography</h2>
<p>Dr. Gwen Murphy earned a Ph.D. in clinical medicine from Trinity College, Dublin, Ireland in 2005, and an M.P.H. from University College, Dublin in 2006. She joined DCEG as an NCI Cancer Prevention Fellow in the Infections and Immunoepidemiology Branch in 2006, where she worked with <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=16&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349628" sys_contentid="349628" inlinetype="rxhyperlink" sys_variantid="1965" sys_siteid="475" rxinlineslot="103" sys_dependentid="349628" sys_dependentvariantid="1965" sys_relationshipid="7252461">Charles Rabkin, Ph.D.</a>, to initiate the NCI International Epstein-Barr virus (EBV)-Gastric Cancer Consortium. During her fellowship, she also collaborated with Dr. Amanda Cross on a series of molecular epidemiology studies within the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=303703" sys_contentid="303703" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" rxinlineslot="103" sys_dependentid="303703" sys_dependentvariantid="1418" sys_relationshipid="7252462">Polyp Prevention Trial</a>. In 2009, Dr. Murphy moved to the Nutritional Epidemiology Branch as a research fellow, becoming a staff scientist in 2012.</p>
<h2 id="Research-Interests"><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Murphy&rsquo;s research explores the role of hormones produced within the gastrointestinal tract in the etiology of gastrointestinal cancers. She also investigates the role of <em>Helicobacter pylori</em> infection and its sequelae in relation to gastric and other cancers. In recognition of her research, Dr. Murphy has received a Cancer Prevention Research Training Merit Award, a Fellows Award for Research Excellence, an Intramural Research Award, and in 2012 an award for Outstanding Research Paper by a DCEG Fellow. She currently chairs the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=14&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=302410" sys_contentid="302410" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" rxinlineslot="103" sys_dependentid="302410" sys_dependentvariantid="1418" sys_relationshipid="7252460">Upper Gastrointestinal Cancer Research Group</a><span>&nbsp;</span>at DCEG and sits on the DCEG Tech Transfer Committee.</p>
<p>In the&nbsp;<a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_variantid="1422" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422" sys_relationshipid="7252463">Metabolic Epidemiology Branch</a>, Dr. Murphy coordinates a number of large field studies of upper gastrointestinal cancers in high-incidence areas (China, Iran, Kenya, Brazil) and continues to coordinate the Polyp Prevention Trial.</p>
<p>Dr. Murphy is a member of the <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=7&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1418&amp;sys_contentid=1090903" sys_contentid="1090903" inlinetype="rxhyperlink" sys_variantid="1418" sys_siteid="475" rxinlineslot="103" sys_dependentid="1090903" sys_dependentvariantid="1418" sys_relationshipid="7252466">African Esophageal Cancer Consortium (AfrECC)</a>.</p>
</div>
</div>]]></body>
    <field_image_promotional>1033924</field_image_promotional>
  </row>
  <row term_id="302006" id="1037044" title="Olusegun Onabajo, Ph.D." langcode="en" field_short_title="Olusegun Onabajo, Ph.D." field_page_description="Olusegun Onabajo, Ph.D., biographical sketch and research interests" field_feature_card_description="Olusegun Onabajo, Ph.D., biographical sketch and research interests" field_list_description="Olusegun Onabajo, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-02-11" field_date_reviewed="2016-02-11" field_date_updated="2016-02-11" field_pretty_url="onabajo-olusegun" field_browser_title="Olusegun Onabajo, Ph.D., biographical sketch and research interests" field_card_title="Olusegun Onabajo, Ph.D." field_email_address="olusegun.onabajo@nih.gov" field_first_name="Olusegun" field_last_name="Onabajo" field_phone_number="301-594-7631" field_org_name_1="National Cancer Institute" field_org_name_2="Laboratory of Translational Genomics" field_campus="301" field_office_location="ATC Room 127">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=onabajo+o&amp;authorOption=exact&amp;pi=2001248510&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302432" inlinetype="rxhyperlink" sys_dependentvariantid="1422" sys_dependentid="302432" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252789" sys_variantid="1422" sys_contentid="302432">Laboratory of Translational Genomics</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Olusegun (Segun) Onabajo received a Bachelor of Pharmacy degree from the Obafemi Awolowo University, Nigeria and a Ph.D. in cell biology and molecular genetics from the University of Maryland, College Park in 2008. He received postdoctoral training at the University of Maryland Medical School in Baltimore and the Uniformed Services University for the Health Sciences in Bethesda. In May 2013, Dr. Onabajo joined the group of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=34&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=349662" inlinetype="rxhyperlink" sys_dependentvariantid="1965" sys_dependentid="349662" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252788" sys_variantid="1965" sys_contentid="349662">Ludmila Prokunina-Olsson, Ph.D.</a>, in the Laboratory of Translational Genomics (LTG), DCEG as a postdoctoral fellow. He has been instrumental in establishing functional studies to explore the role of the newly discovered interferon lambda 4 (<em>IFNL4</em>) in cancer and infection. Dr. Onabajo has received the NCI Director&rsquo;s Career Development Award, the DCEG Fellows Award for Research Excellence, and the DCEG Fellowship Achievement Award. He also received an award from the International Cytokine and Interferon Society. He was promoted to staff scientist in LTG in 2016.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Onabajo&rsquo;s research interests are focused on understanding the biology of <em>IFNL4</em>, a novel interferon that was discovered by the Prokunina-Olsson group in LTG and collaborators in 2013. He is defining how <em>IFNL4</em> is associated with the pathogenesis of hepatitis C virus (HCV) infection, which is a leading cause of liver cancer. Dr. Onabajo showed that <em>IFNL4</em> has a strong anti-proliferative effect in a hepatoma cell line and is currently defining the mechanism of this effect. He is evaluating the anti-proliferative effect of <em>IFNL4</em> on other cancer cell lines, which may have translational potential. Dr. Onabajo also explores the association of <em>IFNL4</em> with cancers of viral origin as well as viral infections in general. For example, he is exploring the role of <em>IFNL4</em> in Burkitt lymphoma, a major pediatric cancer in Africa.</p>
</div>
</div>]]></body>
    <field_image_promotional>1037044</field_image_promotional>
  </row>
  <row term_id="302006" id="1045242" title="Sara Schonfeld, Ph.D." langcode="en" field_short_title="Sara Schonfeld, Ph.D." field_page_description="Sara Schonfeld, Ph.D., biographical sketch and research interests" field_feature_card_description="Sara Schonfeld, Ph.D., biographical sketch and research interests" field_list_description="Sara Schonfeld, Ph.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-04-15" field_date_reviewed="2016-04-15" field_date_updated="2016-04-15" field_pretty_url="schonfeld-sara" field_browser_title="Sara Schonfeld, Ph.D., biographical sketch and research interests" field_card_title="Sara Schonfeld, Ph.D." field_email_address="schonfes@mail.nih.gov" field_first_name="Sara" field_last_name="Schonfeld" field_phone_number="240-276-6474 " field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E540">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Schonfeld+S&amp;authorOption=exact&amp;pi=0011796735">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" inlinetype="rxhyperlink" sys_relationshipid="7252808" sys_dependentvariantid="1422" sys_dependentid="302459" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Schonfeld received her M.P.H. from the&nbsp;George Washington University and a Ph.D. in epidemiology from the Johns Hopkins Bloomberg School of Public Health.&nbsp;She completed both a predoctoral and postdoctoral fellowship in the Radiation Epidemiology Branch. During this time, Dr. Schonfeld received a DCEG Fellowship Achievement Award and an award for Outstanding Research Paper by a DCEG Fellow. From 2012-2015, she worked at the International Agency for Research on Cancer in Lyon, France where she worked primarily on developing a retrospective cohort study of occupational asbestos exposure and cancer mortality.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Schonfeld currently supports research to elucidate the relationship between cancer treatment and the development of second malignancies. She has broad expertise in environmental and occupational causes of cancer, with a particular focus on exposure to ionizing radiation.</p>
</div>
</div>]]></body>
    <field_image_promotional>1045242</field_image_promotional>
  </row>
  <row term_id="302006" id="1061744" title="Thomas U. Ahearn, Ph.D., M.P.H." langcode="en" field_short_title="Thomas U. Ahearn, Ph.D., M.P.H." field_page_description="Thomas U. Ahearn, Ph.D., M.P.H., biographical sketch and research interests" field_feature_card_description="Thomas U. Ahearn, Ph.D., M.P.H., biographical sketch and research interests" field_list_description="Thomas U. Ahearn, Ph.D., M.P.H., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-09-14" field_date_reviewed="2016-09-14" field_date_updated="2016-09-14" field_pretty_url="ahearn-thomas" field_browser_title="Thomas U. Ahearn, Ph.D., M.P.H., biographical sketch and research interests" field_card_title="Thomas U. Ahearn, Ph.D., M.P.H." field_email_address="thomas.ahearn@nih.gov" field_first_name="Thomas" field_last_name="Ahearn" field_phone_number="240-276-7587" field_org_name_1="National Cancer Institute" field_org_name_2="Integrative Tumor Epidemiology Branch" field_campus="300" field_office_location="Room 7E228">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=%28%22Ahearn%2C%20Thomas%20U%22%5bFull%20Author%20Name%5d%20OR%20%22Ahearn%20TU%22%5bAuthor%5d%29%20OR%20%2824828990%5buid%5d%20OR%2021724580%5buid%5d%29&amp;cmd=DetailsSearch">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=28&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302506" sys_dependentvariantid="1422" sys_dependentid="302506" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252729" sys_variantid="1422" sys_contentid="302506">Integrative Tumor Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Ahearn received an M.P.H in epidemiology from the Rollins School of Public Health, Emory University, in&nbsp;2006 and a Ph.D. in nutrition and health sciences,&nbsp;epidemiology track, from the Graduate Division Biological and Biomedical Sciences, Emory University, in 2012.&nbsp;His dissertation was titled &ldquo;The investigation and development of dietary and life-style modifiable, pre-neoplastic biomarkers of risk for colorectal neoplasms.&rdquo; Upon completion of his Ph.D., he became a postdoctoral fellow and most recently, a research associate in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health. Dr. Ahearn joined DCEG as a staff scientist in 2016 and supports integrative molecular epidemiology research&nbsp;under the direction of <a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=8&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1965&amp;sys_contentid=1004366" inlinetype="rxhyperlink" sys_relationshipid="7252728" sys_dependentvariantid="1965" sys_dependentid="1004366" rxinlineslot="103" sys_siteid="475" sys_variantid="1965" sys_contentid="1004366">Dr. Montserrat Garc&iacute;a-Closas</a>.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>My overall research interests include utilizing integrative molecular epidemiology methods to illuminate pathways and risk factors for cancer, and to develop translational capacity of etiological research to inform on prevention and treatment efforts. The purpose of my research is to provide epidemiological data that could guide the development of primary and secondary cancer prevention, identify novel treatment strategies, and improve quality of life.</p>
</div>
</div>]]></body>
    <field_image_promotional>1061744</field_image_promotional>
  </row>
  <row term_id="302006" id="1063061" title="Rebecca J. Troisi, Sc.D." langcode="en" field_short_title="Rebecca J. Troisi, Sc.D." field_page_description="Rebecca Troisi, Sc.D., biographical sketch and research interests" field_feature_card_description="Rebecca Troisi, Sc.D., biographical sketch and research interests" field_list_description="Rebecca Troisi, Sc.D., biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2016-09-30" field_date_reviewed="2016-09-30" field_date_updated="2016-09-30" field_pretty_url="troisi-rebecca" field_browser_title="Rebecca Troisi, Sc.D., biographical sketch and research interests" field_card_title="Rebecca J. Troisi, Sc.D." field_email_address="troisir@mail.nih.gov" field_phone_number="603-276-0132" field_org_name_1="National Cancer Institute" field_org_name_2="Epidemiology and Biostatistics Program" field_campus="300" field_office_location="9609 Medical Center Drive, MSC #9773">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Troisi+R&amp;authorOption=and&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=50&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=12&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302673" inlinetype="rxhyperlink" sys_siteid="475" rxinlineslot="103" sys_dependentid="302673" sys_dependentvariantid="1422" sys_relationshipid="7252821" sys_variantid="1422" sys_contentid="302673">Epidemiology &amp; Biostatistics Program</a></li>
</ul>
<h3><a id="Biography"></a>Biography</h3>
<p>Dr. Troisi received a Sc.D. from the Harvard School of Public Health in 1994 and joined NCI the same year.&nbsp;Her research has focused on the hormonal etiologies of reproductive cancers and the role of maternal, gestational, neonatal and early life factors in breast cancer risk, including endocrine disruptors such as diethylstilbestrol, a drug previously given to pregnant women. Dr. Troisi and colleagues Dr. Marlene Goldman and Dr. Kathryn Rexrode edited the second edition of <em>Women and Health</em>, a comprehensive review of the behavioral, social, and biological determinants of health and well-being in women, published in late 2012 by Elsevier. She received NIH Merit Awards in 2011 and 2012.</p>
<h3><a id="Research-Interests"></a>Research Interests</h3>
<ul>
<li>Hormonal etiologies of reproductive cancers</li>
<li>The role of maternal, gestational, neonatal and early life factors in breast cancer risk, including endocrine disruptors such as diethylstilbestrol (DES)</li>
<li>The biology of early life risk factors and implications for cancer risk</li>
</ul>
<h4>DES Follow-up Study</h4>
<p>Since 1992, Dr. Troisi, other NCI investigators, and collaborators from five field study centers have been actively following DES exposed and unexposed mothers, daughters and sons, and granddaughters for adverse health effects resulting from this exposure. As DES-exposed offspring are currently reaching the age when cancer rates begin to rise, it is important to continue to monitor long-term risk of cancer and other adverse health outcomes in this unique population. The study also provides a model for assessing a number of hypotheses that address concerns about prenatal hormonal influences on disease risk, both an intriguing area of science and an increasingly controversial environmental issue that affects a substantial proportion of the population.</p>
<p>To date the study has identified excess female breast cancer after age 40 that shows a dose-response effect, as well as increased risk for high-grade lesions of the cervix and vagina. Concern over other hormone-related cancers remains; though to date analyses have been limited due to small numbers of cases. In the sons, investigators observed an excess risk for urogenital anomalies and infertility, and a likely excess of testicular cancer. To examine the effects in the third generation (the daughters of the prenatally exposed daughters), investigators assembled a small cohort in 2000. Given their average age, there have been few relevant disease outcomes. However, investigators noted an elevated risk for infertility&mdash;though not statistically significant, this outcome was also seen in DES-daughters. In addition, there were three cases of ovarian cancer in the granddaughters, even though substantially less than one had been expected. While both of these observations remain difficult to interpret, they have added some urgency to expand the cohort and continue to follow-up. <a href="http://www.desfollowupstudy.org/index.asp">More on the DES Follow-up Study</a>.</p>
</div>
</div>]]></body>
    <field_image_promotional>1063061</field_image_promotional>
  </row>
  <row term_id="302006" id="1071068" title="Sung Duk Kim, Ph.D." langcode="en" field_short_title="Sung Duk Kim, Ph.D." field_page_description="Sung Duk Kim, Ph.D., biographical sketch and research interests " field_feature_card_description="Sung Duk Kim, Ph.D., biographical sketch and research interests " field_list_description="Sung Duk Kim, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-01-17" field_date_reviewed="2017-01-17" field_date_updated="2017-01-17" field_pretty_url="kim-sung-duk" field_browser_title="Sung Duk Kim, Ph.D., biographical sketch and research interests " field_card_title="Sung Duk Kim, Ph.D." field_email_address="kims2@mail.nih.gov" field_first_name="Sung Duk" field_last_name="Kim" field_phone_number="240-276-6930" field_org_name_1="National Cancer Institute" field_org_name_2="Biostatistics Branch" field_campus="300" field_office_location="Room 7E-606">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Kim%2C%20Sungduk%5bFull%20Author%20Name%5d&amp;cmd=DetailsSearch">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=37&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302568" inlinetype="rxhyperlink" sys_relationshipid="7252770" sys_dependentvariantid="1422" sys_dependentid="302568" rxinlineslot="103" sys_siteid="475" sys_variantid="1422" sys_contentid="302568">Biostatistics Branch</a></li>
</ul>
<h3><a id="Biography"></a>Biography</h3>
<p>Dr. Sung Duk Kim joined the Biostatistics Branch as a staff scientist in September 2016. He previously served as a staff scientist in the Biostatistics and Bioinformatics Branch in the Division of Intramural Population Health Research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Prior to joining the NIH, Dr. Kim spent three years as a postdoctoral fellow at the Department of Statistics at the University of Connecticut. He received a Ph.D. in statistics from the Pusan National University, Korea, in 2004.</p>
<h3><a id="Research-Interests"></a>Research Interests</h3>
<ul>
<li>Bayesian statistical methodology, Bayesian computation, Bayesian hierarchical modeling</li>
<li>Bayesian variable selection, categorical data analysis, cure rate model, latent class model</li>
<li>Longitudinal data analysis, missing data analysis, Monte Carlo methodology</li>
<li>Multivariate meta-analysis, structural equation model, survival data analysis</li>
</ul>
</div>
</div>]]></body>
    <field_image_promotional>1071068</field_image_promotional>
  </row>
  <row term_id="302006" id="1074447" title="Kelly Yu, Ph.D., M.P.H." langcode="en" field_short_title="Kelly Yu, Ph.D., M.P.H." field_page_description="Kelly Yu, Ph.D. - biographical sketch and research interests" field_feature_card_description="Kelly Yu, Ph.D. - biographical sketch and research interests" field_list_description="Kelly Yu, Ph.D. - biographical sketch and research interests&#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-03-01" field_date_reviewed="2017-03-01" field_date_updated="2017-03-01" field_pretty_url="yu-kelly" field_browser_title="Kelly Yu, Ph.D. - biographical sketch and research interests" field_card_title="Kelly Yu, Ph.D., M.P.H." field_email_address="yuke@mail.nih.gov" field_first_name="Kelly" field_last_name="Yu" field_phone_number="(240) 276-7041" field_org_name_1="National Cancer Institute" field_org_name_2="Infections and Immunoepidemiology Branch" field_campus="300" field_office_location="Room 6E230">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<p><a href="#Biography">Biography</a><br /><a href="#Research-Interests">Research Interests</a><br /><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=Yu%20kj&amp;authorOption=exact&amp;pi=0011086480">Scientific Publications</a><br /><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=47&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302590" sys_dependentvariantid="1422" sys_dependentid="302590" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252662" sys_variantid="1422" sys_contentid="302590">Infections and Immunoepidemiology Branch</a></p>
<h2><a id="Biography"></a>Biography</h2>
<p>Kelly J. Yu received a B.S. in biology from the University of Maryland, College Park, an M.P.H. from Yale University, and a Ph.D. from Johns Hopkins Bloomberg School of Public Health. She focused her doctoral dissertation on evaluating early risk factors and prevention of nasopharyngeal carcinoma in high-risk families, and continued her postdoctoral work in the same area under the mentorship of Allan Hildesheim, Ph.D. In January 2011, she joined the Early Detection Research Group in the Division of Cancer Prevention as an epidemiologist and project officer for the Prostate, Lung, Colorectal, and Ovarian Screening Trial. She returned to DCEG/IIB in November 2015 as a staff scientist.</p>
<p>Dr. Yu has received several awards for her research, including the AACR Scholar-in-Training Award and NCI Award of Merit.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>Dr. Yu&rsquo;s research has been focused primarily on screening as a mode of cancer prevention. Her interest is in evaluating the utility of the Epstein-Barr virus as a biomarker for early detection of nasopharyngeal carcinoma (NPC) in general and high-risk populations. To that end, she has maintained a long collaboration with researchers at the National Taiwan University and Academia Sinica, Taiwan, to evaluate the genetic and environmental risk factors of NPC. In addition, she is involved with a longitudinal study that aims to investigate the early natural history of head and neck cancer precursor lesions and evaluate the predictive ability of biomarkers for progression. This study is important because there are currently no consensus guidelines for follow-up and treatment of patients with precursor lesions. Successful completion of this study will provide critical information regarding 1) the most optimal screening intervals for follow-up of patients with precursor lesions and 2) the ideal way to identify patients for treatment.</p>
</div>
</div>]]></body>
    <field_image_promotional>1074447</field_image_promotional>
  </row>
  <row term_id="302006" id="1087122" title="Elizabeth K. Cahoon, Ph.D." langcode="en" field_short_title="Elizabeth K. Cahoon, Ph.D." field_page_description="Elizabeth K. Cahoon, Ph.D., biographical sketch and research interests " field_feature_card_description="Elizabeth K. Cahoon, Ph.D., biographical sketch and research interests " field_list_description="Elizabeth K. Cahoon, Ph.D., biographical sketch and research interests &#xA;" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2017-06-09" field_date_reviewed="2017-06-09" field_date_updated="2017-06-09" field_pretty_url="Cahoon-Elizabeth" field_browser_title="Elizabeth K. Cahoon, Ph.D., biographical sketch and research interests " field_card_title="Elizabeth K. Cahoon, Ph.D." field_email_address="cahoonek@mail.nih.gov" field_first_name="elizabeth" field_last_name="cahoon" field_phone_number="240-276-7401" field_org_name_1="National Cancer Institute" field_org_name_2="Radiation Epidemiology Branch" field_campus="300" field_office_location="Room 7E524">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul class="dceg-blue-bullets-lrg">
<li><a href="#biography">Biography</a></li>
<li><a href="#research">Research Interests</a></li>
<li><a href="https://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?branch=&amp;searchTxtAuth=Khaykin+Cahoon&amp;authorOption=or&amp;searchTxtTitle=&amp;titleOption=or&amp;searchTxtYearBegin=&amp;searchTxtMonthBegin=&amp;searchTxtYearEnd=&amp;searchTxtMonthEnd=&amp;searchOption=and&amp;EntryLimit=0&amp;sortOrder=date%2Cauthor%2Ctitle">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=97&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=302459" sys_dependentvariantid="1422" sys_dependentid="302459" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="475" sys_relationshipid="7252395" sys_variantid="1422" sys_contentid="302459">Radiation Epidemiology Branch</a></li>
</ul>
<h2 id="biography">Biography</h2>
<p>Dr. Cahoon received her B.S.E. in bioengineering from the University of Pennsylvania, her S.M. from the Engineering Systems Division at the Massachusetts Institute of Technology, and her M.H.S. in biostatistics and Ph.D. in epidemiology from the Johns Hopkins Bloomberg School of Public Health. She joined the Radiation Epidemiology Branch (REB) as a postdoctoral fellow in 2010 and was promoted to research fellow in 2014. She was appointed to the position of Earl Stadtman Tenure-Track Investigator in 2017. Dr. Cahoon has received numerous awards for her work, including the DCEG Intramural Research Award, the DCEG Outstanding Research Paper by a Fellow, and the NIH Award of Merit.</p>
<h2 id="research">Research Interests</h2>
<p>Dr. Cahoon&rsquo;s research focuses on cancer and precancer risks conferred by environmental sources of radiation exposure.</p>
<h3>Ultraviolet Radiation and Skin Cancer</h3>
<p>Solar radiation is the primary environmental risk factor for most types of skin cancers, which occur in 5 million people and result in more than ten thousand deaths each year in the United States. Sensitivity to sunlight is influenced by constitutional characteristics such as skin complexion and potentially external factors such as use of photosensitizing medications. Dr. Cahoon is working to identify medications that modify the relationship between UV radiation and skin cancer risk.</p>
<p>For skin cancer prevention, information on the timing of UV radiation exposure over the life course is important. In addition, despite a shift in our relative exposure to different UV radiation wavelengths due to use of sunscreens, tanning beds, and even window glass, the relative roles of UV radiation wavelengths and skin cancer risks are not known. Dr. Cahoon is evaluating the UV radiation dose-response relationship for skin cancer risk by wavelength, age at exposure, and anatomic site.</p>
<p>In addition, Dr. Cahoon is evaluating the role of UV radiation in viral activation, immune modulation, and other mediators of skin (and other) cancer risk. Her previous work identified a relationship between ambient UV radiation and risk of Kaposi sarcoma, possibly through reactivation of the causative virus, human herpesvirus 8. Dr. Cahoon is working to confirm these findings in independent populations.</p>
<h3>Ionizing Radiation</h3>
<p>Ionizing radiation exposure from occupational, accidental, and medical sources continues to be of public health significance and regulatory concern. Quantification of radiation-related risks provides important information for risk assessment models and risk/benefit analyses of cancer screening programs that rely on radiation for early cancer ascertainment. Dr. Cahoon examines radiation-related risk of various cancer types in the Lifespan Study of Japanese atomic bomb survivors and is also leading a thyroid cancer case-control study nested in a cohort of Chernobyl liquidators (i.e., emergency clean-up workers) who were exposed to a large range of external radiation.</p>
Few studies have evaluated the relationship between I-131 exposure and thyroid nodules, which are potential precursors for thyroid cancer. Dr. Cahoon is examining incidence of new thyroid nodules in Belarus and Ukraine and progression of prevalent nodules. Potentially providing a rare window into multistage carcinogenesis, these will be the first studies to evaluate whether nodule characteristics associated with increased risk of thyroid cancer, such as size and vascularization, are apparent at clinical diagnosis or whether these characteristics emerge and evolve over time.</div>
</div>]]></body>
    <field_image_promotional>1087122</field_image_promotional>
  </row>
  <row term_id="302006" id="1114015" title="Arash Etemadi, M.D., Ph.D." langcode="en" field_short_title="Arash Etemadi, M.D., Ph.D." field_page_description="Arash Etemadi, M.D., Ph.D.-Biographical Sketch and Research Interest" field_feature_card_description="Arash Etemadi, M.D., Ph.D.-Biographical Sketch and Research Interest" field_search_engine_restrictions="IncludeSearch" field_public_use="1" field_date_posted="2018-04-27" field_date_reviewed="2018-04-27" field_date_updated="2018-04-27" field_pretty_url="etemadi-arash" field_browser_title="Arash Etemadi, M.D., Ph.D., biographical sketch and research interests" field_card_title="Arash Etemadi, M.D., Ph.D." field_email_address="arash.etemadi@nih.gov" field_first_name="Arash" field_last_name="Etemadi" field_phone_number="240-276-7197" field_org_name_1="National Cancer Institute" field_org_name_2="Metabolic Epidemiolgy Branch" field_campus="300" field_office_location="Room 6E328">
    <body><![CDATA[<div class="rxbodyfield">
<div class="dceg-bio-content">
<ul>
<li><a href="#Biography">Biography</a></li>
<li><a href="#Research-Interests">Research Interests</a></li>
<li><a href="http://dceg2.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl?EntryLimit=0&amp;branch=ALL&amp;searchTxtAuth=etemadi%20a&amp;authorOption=exact&amp;pi=2000483639">Scientific Publications</a></li>
<li><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=17&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=475&amp;sys_variantid=1422&amp;sys_contentid=1033171" sys_contentid="1033171" inlinetype="rxhyperlink" sys_variantid="1422" sys_relationshipid="7252403" sys_siteid="475" rxinlineslot="103" sys_dependentid="1033171" sys_dependentvariantid="1422">Metabolic Epidemiology Branch</a></li>
</ul>
<h2><a id="Biography"></a>Biography</h2>
<p>Dr. Arash Etemadi received an M.D., an M.P.H., and a Ph.D. in epidemiology from Tehran University of Medical Sciences. As a postdoctoral fellow at the University of Maastricht in the Netherlands, he worked on polymorphisms in the genes responsible for the metabolism of polycyclic aromatic hydrocarbons (PAHs) and DNA repair. Dr. Etemadi was appointed as an Assistant Professor of Epidemiology at Tehran University of Medical Sciences, before joining DCEG as a postdoctoral visiting fellow in 2010. He was promoted to research fellow in 2015 and became a staff scientist in the Metabolic Epidemiology Branch (MEB) in 2018.</p>
<p>Dr. Etemadi has been the recipient of multiple awards, including an Intramural Research Award, the DCEG Fellows Award for Research Excellence, the NCI Director&rsquo;s Career Development Innovation Award, the DCEG Fellowship Achievement Award, and the Outstanding Research Paper by a Fellow Award.</p>
<h2><a id="Research-Interests"></a>Research Interests</h2>
<p>As a molecular epidemiologist, Dr. Etemadi&rsquo;s main research focus is population-based studies on the molecular basis of etiology, early detection, and prevention of chronic diseases, especially cancer.</p>
<h4>Emerging exposures</h4>
<p>Dr. Etemadi is studying exposures to carcinogens from tobacco and non-tobacco sources in a number of studies and research collaborations. As part of these studies, he is working on health outcomes associated with alternative tobacco products (such as waterpipe or hookah, and smokeless tobacco), using questionnaires and biomarkers.</p>
<p>Another example is his evaluation of the effects of long-term opioid use. With the increasing number of people using opioids over extended periods of time, their long-term health effects pose important concerns. However, studying these health effects is particularly challenging because of the lack of longitudinal data, difficulties in following opioid users over extended periods of time, and the lack of information about the best way to characterize and measure long-term opioid use. Dr. Etemadi&rsquo;s research is using unique resources and collaborations to overcome these challenges.</p>
<h4>Upper gastrointestinal cancers</h4>
<p>Dr. Etemadi has a track record of studying upper gastrointestinal tract cancers (i.e. cancers of the esophagus and stomach). He is a member of the&nbsp;<a href="https://dceg.cancer.gov/research/how-we-study/dceg-working-groups/ugcrg-upper-gastrointestinal-group">DCEG Upper Gastrointestinal (UGI) Cancer Research Group</a>. He is also a member of several large field studies of UGI cancers in high-incidence areas and helps coordinate MEB&rsquo;s broad portfolio of international field studies across Asia and Africa. In addition, Dr. Etemadi is an investigator in the <a href="https://dceg2.cancer.gov/gemshare/">GEMINI project</a> and the <a href="https://epi.grants.cancer.gov/Consortia/members/gcs.html">Golestan Cohort Study</a>.</p>
<p></p>
<p></p>
</div>
</div>]]></body>
    <field_image_promotional>1114015</field_image_promotional>
  </row>
</rows>